Non-Injectable Naloxone for the Prevention of Opioid Overdose Deaths by McDonald, Rebecca Silvia
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 




















NON-INJECTABLE NALOXONE FOR THE 














Thesis submitted to King’s College London for the degree of 














Background and Aims: Naloxone is the standard treatment for reversal of opioid 
overdoses. Due to risk of needle-stick injury, licensed injectable naloxone products are 
not well suited for layperson administration or take-home naloxone distribution. The aims 
of this thesis are threefold: Aim 1) assess the effectiveness and limitations of take-home 
naloxone provision (any naloxone formulation); Aim 2) compare the pharmacokinetic 
profiles of non-injectable naloxone formulations; Aim 3) identify non-injectable 
formulations that provide early naloxone exposure similar to a 0.4mg intramuscular dose. 
Methods: Primary and secondary data analyses were conducted in two stages. The first 
stage involved evidence syntheses (including two systematic reviews), with secondary 
data retrieval from the peer-reviewed literature and international patent applications. The 
second stage involved pharmacokinetic data analysis of two clinical trials (n=12 and 38 
healthy volunteers; open-label randomized cross-over design) of concentrated intranasal 
naloxone formulations (1mg/0.1mL–16mg/0.4mL range). 
Results: Re Aim 1: Take-home naloxone meets the Bradford Hill criteria. The 
intervention is effective at reducing opioid overdose mortality and has a low rate of 
adverse events.  
Re Aim 2: Improvised nasal kits using non-concentrated spray (1mg/ml per nostril) have 
low bioavailability of FIM ≤ 10% (relative to intramuscular administration). Concentrated 
intranasal spray (≥10mg/ml; administered as ≤0.2mL per nostril) has good bioavailability 
of FIM = 26-57%. 
Re Aim 3: Relative to the 0.4mg intramuscular reference, a 2mg/0.1mL nasal spray 
provided equal naloxone exposure in the first 10-minutes post-dosing and then exceeded 
blood levels for two hours. 
Conclusions: Take-home naloxone distribution to opioid users should be introduced as 
standard of care for the community-based prevention of overdose-related deaths and 
injury. In the presence of licensed alternatives, continued off-label use of improvised 
nasal kits is not justified. If approved by relevant regulatory agencies, the 2mg/0.1mL 
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In 1960, Dr. Jack Fishman was the first person to synthesize the naloxone compound. 
In 2006, his son Jonathan died of a heroin overdose in front of a Miami hospital, where 
his dealers had reportedly left him (Fishman, 2016). Perhaps like few others, the case of 
Dr. Fishman’s son illustrates that “[m]ost people who die from an overdose do so before 
reaching hospital” (ACMD, 2000). This highlights the urgent need for technology transfer 
of naloxone from the Emergency Department (ED) into the community as well as the 
largely unexploited potential for user-friendly, non-injectable naloxone products that can 
facilitate bystander intervention. 
My interest for this PhD project developed during my previous role as Senior Research 
Assistant at the National Center on Addiction and Substance Abuse in New York. 
Between 2010 and 2013, I was involved in a number of projects that aimed to improve 
treatment access for individuals with substance use disorders in the Bronx and other 
underserved communities in New York and New Jersey, including the evaluation of a 
mobile opioid substitution treatment program for homeless and uninsured users. Working 
together with providers across both states, I became acutely aware of the growing 
concern of opioid overdose deaths. I was thus immensely grateful for the opportunity of 
a PhD project that tackled what I consider to be one of the most pressing current public 
health issues. I began my PhD studies in October 2013, at a time when research interest 
in naloxone was intensifying (see Figure 1). This allowed me to publish the six first-
authored papers which I incorporate in this thesis. 
 
 
Figure 1 Web of Science citation report for "naloxone AND overdose" (Jan 1998 - May 2017)1 
                                               
1 Source: Web of Science 
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However, the rapid increase in research activity also mirrors the escalating opioid crisis 
in the United States (US) and, to a lesser extent, in the United Kingdom (UK). The 
prevalence rates of opioid overdose mortality show similar upwards trends in both 
countries, though the affected populations differ, with a higher proportion of women dying 
from prescription opioid overdose in the US (see Figure 2 & Figure 3). 
 
 
Figure 2 US overdose deaths (2001-14) from prescription opioids (left) and heroin (right)2 
 
US overdose fatalities began to rise from the mid-1990s onwards, spurred by a 
significant increase in prescription opioid abuse (Compton & Volkow, 2006; Paulozzi & 
Ryan, 2006). Between 1999 and 2010, there was a greater than fourfold increase in 
overdose deaths from prescription opioids (Volkow, Frieden, Hyde, & Cha, 2014), 
paralleled by increased prescribing of these medications for the treatment of pain 
(SAMHSA, 2013) and facilitated by new access through online pharmacies (Jena & 
Goldman, 2011). Accounting for 16,651 deaths in 2010, prescription opioid overdose 
fatalities surpassed the number of overdose deaths from heroin and cocaine combined 
(CDC, 2012a; Volkow et al., 2014). However, more recent evidence suggests an 
overlapping more acute epidemic of heroin with potential transition toward heroin use as 
of the mid-2000s, with nationwide hospital data (Unick, Rosenblum, Mars, & Ciccarone, 
2013) showing a 44% increase in heroin overdose admissions between 2005 and 2009. 
The US opioid epidemic has led to a demographic shift in heroin users, from urban 
minority populations to predominantly white suburban and rural men and women (Cicero, 
                                               
2 Source: National Center for Health Statistics (2014) 
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Ellis, Surratt, & Kurtz, 2014). Overdose mortality rates (any substance) have increased 
among men and women of non-Hispanic white and black ethnicity (CDC, 2016b). A total 
of 33,091 opioid overdose deaths were recorded in the US in 2015 (CDC, 2016b). 
 
 
Figure 3 Heroin and morphine deaths in England and Wales (2011-15)3 
 
In the UK, latest numbers reveal that heroin and morphine accounted for 1,201 deaths 
in England and Wales in 2015, reflecting a 102% 5-year increase since 2011 (ONS, 
2016). Similarly, a 68% increase in heroin and morphine deaths has been recorded for 
Scotland, with 349 deaths in 2015 (up from 207 in 2011) (NRS, 2016). Heroin and 
morphine are main contributors to drug-related deaths in the UK (PHE, 2017), despite 
representing only a small proportion of the use of illicit drugs. For example, prevalence 
rates among the general population (adults aged 16-59) were reported to be 0.1% for 
heroin (past-year use), relative to 1.9% and 6.4% for cocaine and cannabis, respectively 
(Home Office, 2013). Opiate overdose accounts for nearly half of all deaths among 
heroin injectors, exceeding human immunodeficiency virus (HIV) and other disease-
related deaths (Hickman et al., 2003). According to public estimates, nearly three 
quarters (74%) of current drug overdose deaths in the UK occur in men (PHE, 2017). 
Moreover, the proportion of older heroin users, aged ≥40 years, of any drug treatment 
                                               
3 Source: ONS (2016) 
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status has been steadily increasing (PHE, 2017), and their risk of overdose death is 
presumed to be increased due to physical comorbidity and complex health needs. 
From 2000 onwards, the possibly greater suitability of a non-injectable form of naloxone 
was occasionally mooted (Strang, 1999), and improvised nasal naloxone kits began to 
be constructed in some parts of the world, using existing injectable formulations and their 
administration through simple attachment of an atomizer spray device. However, no 
approved nasal naloxone products existed, and no data were available on the extent of 
absorption of naloxone from these improvised nasal kits, apart from a concerning report 
of extremely poor bioavailability reported from one investigative group (Dowling, Isbister, 
Kirkpatrick, Naidoo, & Graudins, 2008). 
An important step forward occurred when, in April 2012, the US Food and Drug 
Administration (FDA) and partner agencies convened a public meeting to encourage the 
development of non-injectable naloxone formulations. 
The overarching research objective of my PhD project has thus been to study novel 
injection-free naloxone formulations with potential to deliver rapid overdose reversal. In 
order to operationalize this goal, I have developed the following three aims: 
• Aim 1: Assess the effectiveness and limitations of take-home naloxone provision 
(any naloxone formulation) 
• Aim 2: Compare the pharmacokinetic profiles of non-injectable naloxone 
formulations 
• Aim 3: Identify non-injectable formulations that provide early naloxone exposure 
similar to a 0.4mg intramuscular dose 
To address these aims, I have applied a two-stage test strategy. The first stage involves 
evidence syntheses (Chapters 2-6), including secondary data retrieval from the peer-
reviewed literature and international patent applications. The second stage (Chapters 
7-8) involves pharmacokinetic data analysis of clinical trials of naloxone nasal spray in 
healthy volunteers. 
The structure of the thesis is as follows: In the two opening chapters, I present a review 
of the literature that follows the journey of the naloxone from its first synthesis in a Long 
Island laboratory in 1960 into emergency rooms and ambulances (Chapter 1) and, from 
1996 onwards, into the community through provision of take-home naloxone to opioid 
users and family members (Chapter 2). I describe the pharmacological properties of the 
antidote and address current and past limitations of take-home naloxone implementation 
(Aim 1) as backdrop for my empirical work in the following chapters. 
20 
 
In Chapter 3, I conduct a systematic review of the effectiveness of take-home naloxone 
programs (Aim 1). The rationale is straightforward: If take-home naloxone provision has 
no impact on opioid overdose mortality, then there is little reason to invest in the study 
and development of new non-injectable formulations. If, however, take-home naloxone 
is effective and safe, then reformulation of naloxone needs to be explored so as to 




Figure 4 Thesis outline 
 
In Chapter 4, I then assess the evidence base for existing improvised nasal naloxone 
kits, which are already in use in the US and parts of Scandinavia. Having established 
that take-home naloxone is effective (Aim 1) but that the pharmacokinetic profile and 
safety of the improvised kits are uncertain (Aim 2), I conclude that study of novel non-
injectable formulations is needed. 
I thus proceed to the next stage of testing in Chapter 5 where I conduct a second 
systematic review by applying the FDA’s regulatory criteria for naloxone products to all 
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routes of drug administration listed by the FDA (n=112) in order to identify injection-free 
routes with potential suitability for naloxone delivery in the overdose emergency.  
Given the limited data availability in the peer-reviewed literature, I then extend my search 
for human pharmacokinetic data for non-injectable naloxone formulations to industry 
sources through exploratory review of international patent applications – which I report 
in Chapter 6. Integration of the evidence reported in the patent documents allows me to 
determine the key characteristics for a naloxone nasal spray for treatment of opioid 
overdose, with concentrated formulations and low volumes of administration being 
essential for efficient nasal mucosal absorption (Aim 2). 
Working together with industry, I then move towards the development and study of new 
purpose-made naloxone nasal spray in this second part of my PhD project. I analyze an 
archived dataset from a 2004 clinical trial (n=12; cross-over design), of high-dose (8mg, 
16mg) naloxone nasal spray in Chapter 7 in order to inform target doses (1mg, 2mg, 
4mg) for the design of the new clinical trial of concentrated naloxone nasal spray in 
healthy volunteers (n=38; cross-over design) – undertaken specifically for the purpose 
of potential future application as emergency medicine for opioid overdose reversal by 
non-medical personnel. I present my pharmacokinetic data analysis of the new clinical 
trial in Chapter 8, identifying a 2mg/0.1mL intranasal dose as providing equal early 
naloxone exposure as a 0.4 intramuscular injection (Aim 3). 
In Chapter 9, I introduce a more recent alternative to injectable naloxone that, with 
colleagues at the Institute of Pharmaceutical Science, my supervisors, and I have jointly 
developed: an instant-dissolving buccal naloxone tablet. I attach a copy of the patent, 
which lists me as co-inventor, in Appendix C. 
In Chapter 10, I integrate the findings from Chapters 2 to 9 and address their implications 
for clinical practice, policy, and future research. 
A nasal naloxone spray product is now licensed in North America, and the arrival of a 
first non-injectable naloxone product in Europe is anticipated for late 2017 or early 2018. 
This thesis incorporates my six first-authored publications in the leading specialty 
journals, including Addiction, Drug and Alcohol Dependence, and Drug and Alcohol 
Review which report the work which has comprised much of my PhD studies. I include 
copies of these publications in Appendix B. For convenience, I provide the references of 
the publications along with the study aims by thesis chapter in Table 1. A graphic outline 




Table 1 Aims and first-authored publications by thesis chapter 
Chapter  Aims Publication  
Ch. 1  
“The Discovery of 
Naloxone” 
• Describe the discovery of 
naloxone and its use in clinical 
practice  
• Describe the pharmacokinetics 





“Twenty Years of Take-home 
Naloxone” 
• Identify key events in the 
emergence and evolution of 
take-home naloxone 
McDonald, R., Campbell, N.D, & 
Strang, J (in press).  
Twenty years of take-home 
naloxone for the prevention of 
overdose deaths from heroin and 
other opioids – conception and 
maturation.  
Drug and Alcohol Dependence.   
Ch. 3 
“Bradford Hill Analysis of 
Take-home Naloxone” 
• Describe the impact of take-
home naloxone provision on 
overdose-related mortality in 
opioid users 
• Assess the safety of take-
home naloxone provision by 
quantifying adverse events 
associated with naloxone 
administration 
McDonald, R., & Strang, J. 
(2016).  
Are take‐home naloxone 
programmes effective? 
Systematic review utilizing 
application of the Bradford Hill 
criteria.  
Addiction, 111(7), 1177-1187. 
Ch. 4 
“The Insufficiency of 
Improvised Nasal Naloxone 
Kits” 
• Assess the provision of 
improvised nasal naloxone in 
clinical practice 
• Examine published evidence 
of pharmacokinetics and 
effectiveness of naloxone by 
nasal administration relative to 
injection 
Strang, J.*, McDonald, R.*, Tas, 
B., & Day, E. (2016). (* joint first 
authors) 
Clinical provision of improvised 
nasal naloxone without 
experimental testing and without 
regulatory approval: imaginative 
shortcut or dangerous bypass of 
essential safety procedures?  
Addiction, 114(04), 574-82. 
Ch. 5 
“Non-injectable Routes of 
Naloxone Administration” 
 
• Identify candidate routes of 
injection-free naloxone 
administration potentially 
suitable for emergency 
overdose reversal 
• Consider pathways for 
developing and evaluating 
novel naloxone formulations 
Strang, J.*, McDonald, R.*, 
Alqurshi, A., Royall, P., Taylor, 
D., & Forbes, B. (2016). (* joint 
first authors) 
Naloxone without the needle− 
systematic review of candidate 
routes for non-injectable naloxone 
for opioid overdose reversal.  
Drug and Alcohol 




Chapter  Aims Publication  
Ch. 6 
“Patent Applications for Non-
Injectable Naloxone” 
• Trace the concept and product 
development by route of 
administration 
• Describe the non-injectable 
naloxone formulations for 
which human in vivo data are 
available 
• Compare human 
pharmacokinetic data reported 
in the patent applications 
McDonald, R.*, Glende, Ø.D.*, 
Dale, O, & Strang, J. (in press). (* 
joint first authors) 
International patent applications 
for non-injectable naloxone for 
opioid overdose reversal: 
Exploratory search and retrieve 
analysis of the PatentScope 
database.  
Drug and Alcohol Review. 
Ch. 7 
“Early Study of 
Concentrated Nasal 
Naloxone”  
• Describe the pharmacokinetic 
properties of two high-
concentration intranasal 
naloxone formulations 
• Assess naloxone absorption in 
the clinically-relevant period of 
the first 30 minutes post-
administration 
• Assess dose proportionality of 
the two intranasal naloxone 
formulations 
Mundin, G.*, McDonald, R.*, 
Smith, K., Harris, S., & Strang, J. 
(2017).   (* joint first authors) 
Pharmacokinetics of concentrated 
naloxone nasal spray over first 30 
minutes post‐dosing: analysis of 







“New Study of Concentrated 
Nasal Naloxone” 
• Assess the pharmacokinetic 
profile of intranasal naloxone 
• Compare its early partial 
systemic exposure to the 
intramuscular reference.  
• Determine intranasal 
bioavailability 
(manuscript under review) 
Ch. 9 
“Beyond Nasal: The 
Exploration of Buccal 
Naloxone” 
• Develop a buccal tablet that 
contains a clinically relevant 
naloxone dose and dissolves 
instantly (e.g. ≤ 30 s) 
• Test the stability and 
dissolution of the tablet in vitro 
• Test the pharmacokinetics of 
buccal naloxone 





• Integrate findings 
• Discuss implications for 







Chapter 1 The Discovery of Naloxone 
 
Preface 
In this opening chapter, I present a review of the remarkable properties of naloxone and 
its application for the reversal of opioid overdose. 
Naloxone is a potent antidote. Antidotes are defined as “therapeutic substance[s] used 
to counteract the toxic action(s) of a specified xenobiotic” (WHO/CEC, 1993). The prompt 
administration of antidotes can reduce patient morbidity and mortality as well as the 
burden placed on healthcare systems, and their availability is essential, particularly in 
areas or countries with limited access to emergency medical care. Examples of other 
emergency medicines include glucagon (for severe acute hypoglycemia in treated 
diabetes) and flumazenil (for benzodiazepine overdose). While there is substantial 
variation in the efficacy of antidotes in general, the clinical effect of naloxone is 
considered “both rapid and dramatic” (WHO/CEC, 1993).  
The first part of this chapter describes the discovery of naloxone and its 
pharmacokinetics and explains why, almost 60 years after its original synthesis, 
naloxone remains the opioid antagonist of choice for the treatment of acute opioid 
overdose. 
The second part summarizes how heroin and other opioids impact the respiratory system 
and reviews the pharmacodynamics of naloxone, i.e. how naloxone reverses respiratory 
depression during opioid overdose. 
A third and final part describes the shift from intravenous to intramuscular naloxone 
administration that occurred in ambulance care in the 1990s and effectively set the scene 





1.1 What is Naloxone? 
Naloxone (N-allylnoroxymorphone, N-allyl-14-hydroxydihydro-nor-morphinone; see 
Figure 5) is an antidote that counters the effects of heroin and other opioids. It can 
reverse any potentially life-threatening respiratory depression that the opioid agonists 
have caused by blocking their ability to occupy receptor sites and displacing opioids 
which are already occupying receptors. Naloxone is a specific opioid antagonist (Martin, 
1976) with affinity for all three opioid receptors (mu > kappa ≥ delta) (Rang, Dale, Ritter, 
Flower, & Henderson, 2012). It is a semi-synthetic antagonist that is made from thebaine, 
an alkaloid component that is extracted from the opium poppy plant and has no direct 
therapeutic uses itself (EMCDDA, 2016a). At least three synthetic routes have been 
reported to produce naloxone (Hassan, Mohamed, & Mian, 1985). The main clinical use 
of naloxone is to treat respiratory depression caused by opioid overdose (Rang et al., 
2012). Naloxone has no abuse potential due to lack of euphoriant effect (Brunton, 
Chabner, & Knollman, 2010), and it is associated with only a small rate of adverse effects 
(Buajordet, Næss, Jacobsen, & Brørs, 2004).  
 
 
Figure 5 The molecular structure of naloxone4 
 
1.1.1  The early development of naloxone 
Naloxone was first synthesized in 1960 by Dr. Jack Fishman (see Figure 6). Born Jacob 
Fiszman in Krakow, Poland, in 1930, Dr. Fishman had fled Nazi occupation with his 
family at 8 years of age and, after spending his youth in Shanghai, China, immigrated to 
                                               
4 Source: EMCDDA (2016a) 
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the US in 1948 (The New York Times, 2013). He trained in chemistry in New York in the 
late 1940s and early 1950s, and his subsequent PhD thesis at Wayne State University 




Figure 6 Dr. Jack Fishman (1930-2013)5 
 
By the late 1950s, Dr. Fishman held a position in steroid research at the Sloan Kettering 
Institute for Cancer Research, New York, and was also working on alkaloid opioid 
research in the private laboratory of Dr. Mozes J. Lewenstein. One of the goals of his 
research at Dr. Lewenstein’s laboratory was to find a potent opioid antagonist without 
major adverse side effects (Garfield, 1983). Among other compounds, Dr. Fishman 
synthesized naloxone in 1960 (see Table 2), which would prove to be the solution to his 
search for the specified antagonist. 
It is interesting to note that the original synthesis of naloxone was first disclosed in a 
patent rather than as journal article (see also Chapter 6). 
Drs. Lewenstein and Fishman submitted a patent application in March 1961 stating that 
naloxone was a “more potent antagonist to the respiratory depressive effects of potent 
analgesics than the antagonists hitherto known” (Garfield, 1983). The patent was issued 
in May 1966 (Lewenstein & Fishman, 1966). 
                                               
5 Source: The New York Times 
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Outside of his private research laboratory, Dr. Lewenstein headed the Narcotics Division 
at Endo Laboratories (New York), and he licensed naloxone to Endo for evaluation 
(Garfield, 1983). At Endo, the director of biological laboratories, Dr. Harold Blumberg, 
who was a biochemist and toxicologist by training, soon started testing the new 
compound’s properties in animals. In a 1961 abstract in Federation Proceedings, Dr. 
Blumberg and colleagues introduced naloxone as a “potent, rapid-acting, and relatively 
pure narcotic antagonist”, which counteracted the effects of a range of opioid agonists, 
including morphine and methadone (Blumberg, Dayton, George, & Rapaport, 1961). 
The first full-length journal article on naloxone was published by the Japanese 
pharmaceutical company Sankyo in 1962 (Minakami et al., 1962). While it is not possible 
to delineate what share Sankyo had in the early investigation of naloxone, the company’s 
impact on future naloxone research was limited: Over the course of the next two 
decades, over 100 patents and journal articles cited the 1961 patent and abstract by Drs. 
Fishman, Blumberg, and Lewenstein, acknowledging their role as the early developers 
of naloxone, whereas the 1962 Sankyo paper was only cited once (Garfield, 1983). 
Following their pioneering work around naloxone in 1960/61, Dr. Fishman carried on his 
work at Dr. Lewenstein’s laboratory and synthesized over a dozen related opioid 
agonists and antagonists. He also explored ways to prolong the duration of action of 
naloxone (Fishman, Hahn, & Norton, 1975; Heilman, Hahn, & Fishman, 1975; Linder & 
Fishman, 1973) and studied its disposition (i.e. absorption, distribution, metabolism, and 
excretion) in humans (Fishman et al., 1975; Fishman, Roffwarg, & Hellman, 1973). 
Meanwhile, Dr. Blumberg continued to publish on naloxone and on two closely related 
opioid compounds, the agonist-antagonist nalbuphine and the longer-acting antagonist 
naltrexone (half-life about 10 hours) (Rang et al., 2012). Dr. Blumberg applied for 
regulatory review of naltrexone, which received its original FDA approval for opioid 
addiction in 1984. From 1974 onwards, Dr. Blumberg served as a consultant to the U.S. 
National Institute on Drug Abuse (NIDA). 
In 1982, Drs. Fishman and Blumberg received the prestigious John Scott Award in 
recognition of their “useful invention”, i.e. the original synthesis of naloxone by Dr. 
Fishman and its significant biological investigation by Dr. Blumberg. To quote the speech 
that Dr. Eugene Garfield, a member of the John Scott Award Advisory Committee, 
delivered at the award ceremony (Garfield, 1983): “While no one at the time could have 
recognized how important naloxone would become, the story reveals once again the way 




1.1.2  The predecessors of naloxone and more recent alternatives 
Although not the first opioid antagonist, naloxone is regarded as the first pure opioid 
antagonist free of agonist effects (Martin, 1976; Rang et al., 2012). As such, naloxone 
constitutes a safer and more powerful opioid antagonist with fewer side effects than its 
predecessors, nalodeine and nalorphine. 
Both nalodeine and nalorphine were only partial antagonists, acting as agonists of the 
kappa-opioid receptor. Nalodeine (N-allyl-norcodeine) was discovered in 1915 as the 
first-ever opioid antagonist – but it was never marketed. Nalorphine (N-allyl-normorphine; 
trade name: Nalline), a morphine derivative, entered clinical practice in 1954 and was 
commonly used as an antidote to reverse opioid overdose and as opioid challenge test 
(“Nalline test”) (Terry & Braumoeller, 1956; Wikler, Fraser, & Isbell, 1953). The latter 
involves injecting an individual with nalorphine to test if its antagonistic effects precipitate 
withdrawal symptoms, indicating the presence of opioids and potential opioid 
dependence of the individual (Grupp, 1970). While nalorphine effectively reversed opioid 
overdoses in most cases, its activation of the kappa-opioid receptor could produce strong 
side effects, including hallucinations and, paradoxically, reduced respiration (Garfield, 
1983).  
A breakthrough which established naloxone as the superior opioid antagonist was Dr. 
Blumberg’s study (1966) of naloxone’s action against the analgesic (i.e. agonist) activity 
of nalorphine. Naloxone reversed the agonist activity of nalorphine while showing no 
agonist activity of its own. 
In the early 1970s, nalmefene, an opioid antagonist related to naltrexone, was developed 
as a potential alternative to naloxone. Nalmefene exceeded naloxone in its biological 
half-life (11±5 hours versus 1±0.5 hours) and oral bioavailability. Immediate-release 
injectable nalmefene (trade name: Revex), manufactured by Baxter Healthcare 
Corporation, received FDA-approval for opioid overdose reversal in 1995. However, 
Baxter discontinued Revex in 2008 (FDA, 2008), presumably because Revex was more 
expensive than naloxone and its sales volume limited accordingly. (In the UK, nalmefene 
is only licensed, as an oral tablet medication, for the reduction of alcohol consumption in 
patients with alcohol dependence (NICE, 2014)). 
To summarize, naloxone – due to its unique effectiveness and safety profile, paired with 
its relatively low cost – has been the opioid antagonist of choice since its regulatory 




1.1.3  Regulatory approval 
The US FDA approved naloxone in 1971 as prescription-only medication for intravenous, 
intramuscular, and subcutaneous administration for reversing the effects of opioids. 
Naloxone entered clinical practice in Europe in the following years. Injectable naloxone-
hydrochloride solution is commercially available in formulations ranging from 0.4mg/mL 
to 1mg/mL. Initially marketed under the trade name Narcan in the US, injectable 
naloxone now exists off-patent as a generic medicine. 
In 2015, a naloxone nasal spray (4mg/0.1mL) also received FDA approval (see Chapter 
4). However, in the remainder of this chapter, “naloxone” refers to naloxone-
hydrochloride solution for injection, unless otherwise specified. 
 
1.1.4  Inclusion in the WHO Model List of Essential Medicines 
In 1983, naloxone (0.4mg in 1mL-ampoules) was included as specific antidote in the 
WHO (World Health Organization) Model List of Essential Medicines, which lists “the 
most efficacious, safe and cost-effective medicines for priority conditions” (WHO, 2011a, 
2015). The shelf-life of injectable naloxone is three years in temperate as well as tropical 
countries, which makes the antidote well suited for global use. 
 
Table 2  Key events in the original development of naloxone 
Year Month Country Event  
1915   Nalodeine is discovered as the first opioid antagonist 
1954   Nalorphine is development and introduced  
1960  USA Naloxone is first synthesized by Dr. Jack Fishman  
1961 March USA Drs. Jack Fishman and Mozes J. Lewenstein apply for first 
US patent for naloxone (issued in May 1966)  
  USA Dr. Harold Blumberg and colleagues publish abstract on 
naloxone in Federation Proceedings 
1962 March UK Sankyo Company Ltd. applies for British patent for naloxone 
(issued in October 1963) 
  Japan Minakami et al. of Sankyo publish first full-length journal 
article on naloxone in Life Sciences 
1966  USA Blumberg et al. paper demonstrates naloxone’s superior 
safety profile compared to nalorphine 
1971  USA FDA licenses naloxone as prescription-only medication 
1983  Int’l Naloxone is added to the WHO List of Essential Medicines 
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1.2  Pharmacokinetics  
I now describe how the human body handles naloxone, i.e. how the concentration of 
naloxone in human blood changes over time following dosing. This section only relates 
to parenteral injection of naloxone. The pharmacokinetics of non-injectable (i.e. nasal, 
sublingual) naloxone are presented in Chapters 4 to 8. 
Dhillon and Gill (2006) define pharmacokinetics as “a mathematical basis to assess the 
time course of drugs and their effects on the body. It enables the processes [of 
absorption from the site of administration, distribution within the body, metabolism, and 
excretion] to be quantified.” 
The study of pharmacokinetics generally focuses on concentrations of a drug (i.e. 
naloxone) in blood plasma, which is obtained from intravenous blood samples. The 
rationale is that “plasma concentrations are assumed usually to bear a clear relation to 
the concentration of drug in extracellular fluid surrounding cells that express the 
receptors or other targets with which drug molecules combine” (Rang et al., 2012). To 
put it simply, blood plasma concentrations of naloxone are representative of naloxone 
availability at the therapeutic target site, i.e. opioid receptors in the brain. 
The pharmacokinetics of naloxone were first studied in the years following its original 
synthesis in 1960 (see below), but assay methods were not very advanced at the time. 
Radioimmunoassay (RIA) for naloxone assay was first reported in the 1970s (Berkowitz, 
Ngai, Hempstead, & Spector, 1975) but was challenging, because availability of the 
required antibody was limited. Gas-liquid chromatography (GLC) and high-performance 
liquid-chromatography (HPLC) for naloxone assay followed in the 1980s (Asali, Nation, 
& Brown, 1983; Meffin & Smith, 1980; Terry, Hisayasu, Kern, & Cohen, 1984), of which 
HPLC was considered the more reliable method. Modern liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) method, as used for the chemical analysis of the results 
presented in Chapters 7 and 8, exceeds these earlier assay methods in sensitivity, as it 
combines the physical separation capabilities of HPLC with the mass analysis 
capabilities of mass spectrometry, but has only become widely available since the mid-
1990s (Grebe & Singh, 2011). 
 
1.2.1   Absorption 
Absorption describes the passage of naloxone from its site of administration into the 
blood plasma (Rang et al., 2012). Naloxone appears to be readily absorbed after oral 
administration, but only a small proportion reaches the systemic circulation. In an early 
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study in healthy volunteers, Fishman et al. found that orally administered radiolabelled 
naloxone underwent extensive first-pass hepatic metabolism (Fishman et al., 1973). Its 
low bioavailability (≤ 2%) makes the oral route unreliable for naloxone administration 
(Smith et al., 2012). For maximum effectiveness, naloxone must consequently be given 
by a route that bypasses ingestion and first-pass metabolism (Brunton et al., 2010). 
When given intravenously, naloxone reaches peak plasma concentrations almost 
immediately. The peak plasma concentration is slightly delayed (at approximately 10-12 
minutes) when administered intramuscularly (WHO, 2014), see Figure 7. 
 
Figure 7 Naloxone plasma concentration from 0.4mg parenteral dose: intravenous (IV) versus 
intramuscular (IM) administration (see also Chapter 8) 
 
1.2.2  Distribution 
Naloxone is highly lipid soluble (Rang et al., 2012). Once absorbed, naloxone is rapidly 
distributed throughout the body and crosses the blood-brain barrier (NIH, 2007a). In an 
experimental study in rats, Fishman et al. observed that the distribution of naloxone was 
not altered by a 25-fold morphine (Fishman et al., 1975). The fact that the distribution of 
naloxone was not compromised by the presence of opioid agonists lent further support 
to the unique suitability of naloxone for the reversal of opioid overdose. 
1.2.3  Metabolism 
When naloxone reaches the liver, it is rapidly metabolized to its two metabolites 
naloxone-3-glucuronide and 6-alpha-naloxol. While inactive, naloxone-3-glucuronide 
can be used as a marker when measuring the levels of naloxone in the body (Smith et 
al., 2008). In a rodent study, naloxone was found to be 65-fold more potent than 6-alpha-
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naloxol to precipitate opioid withdrawal (Schulteis, Chiang, & Archer, 2009). 6-alpha-
naloxol is thus not considered to be clinically relevant. 
The half-life of naloxone (i.e. the time required for the naloxone plasma concentration to 
be reduced to half) is variable and averages around 1±0.5 hours (NIH, 2007). 
 
1.2.4  Excretion 
After an oral or intravenous dose, about 25-40% of naloxone is excreted as metabolites 
in urine within 6 hours, about 50% in 24 hours, and 60-70% in 72 hours (WHO/CEC, 
1993). 
 
1.3  Pharmacodynamics 
In the following sections, I describe the pharmacodynamics of naloxone, i.e. how 
naloxone reverses opioid overdose, after a summary of how opioid overdose leads to 
respiratory depression. 
 
1.3.1  Opioid-induced respiratory depression 
Opioid overdose causes respiratory and central nervous system depression. 
Understanding the significance of naloxone requires some knowledge of respiratory 
depression. To review briefly, mu-opioid receptors are the most widespread opioid 
receptor group in the body and the primary target for many analgesic drugs, but they can 
also produce adverse effects including respiratory depression (Pasternak, 2006). While 
normal lung function serves to maintain high concentrations of oxygen and low 
concentrations of carbon dioxide in body tissues (Levitzky, 2013), consumption of 
opioids interrupts the feedback loop between the lungs and the respiratory centers in the 
brain and reduces the respiratory rate. Heroin or opioid metabolites bind to the mu-opioid 
receptors in the respiratory centers in the brain (see Figure 8). The drug and also active 
metabolites dampen brain activity in areas associated with inspiration, whereas brain 
areas associated with expiration are unaffected. This can lead also to hypercapnia 





Figure 8 Heroin metabolite attaches to a mu-opioid receptor (triangle)6 
 
The effect of opioid consumption on oxygen levels is illustrated by Figure 9, which shows 




Figure 9 Oxygen saturation levels after intravenous opioid injection78 
 
                                               
6 Source: EMCDDA (2016a) 
7 Source: idem 
8 SpO2: peripheral capillary oxygen saturation 
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During overdose, the respiratory rate drops and becomes irregular, with temporary 
cessation of breathing (“apnea”) (Leino, Mildh, Lertola, Seppaelae, & Kirvelä, 1999). If 
the respiratory rate is reduced for an extended time, breathing will eventually stop 
(“respiratory arrest”). Respiratory arrest and the collapse of oxygen supply to the lungs, 
heart and brain (“hypoxia”) can lead to opioid-induced organ failure, injury, coma or 
overdose death (EMCDDA, 2016a). 
 
1.3.2 How does naloxone reverse opioid overdose? 
Pharmacodynamics describe how naloxone affects the body, capturing “events 
consequent on interaction of [naloxone] with its receptor or other primary site of action” 
(Rang et al., 2012).  
Naloxone has no significant effects of its own. However, if opioids are present in the 
body at the time of naloxone administration, naloxone will rapidly reverse any opioid-
induced effects (incl. respiratory depression and decreased consciousness) by 
competing and displacing opioid metabolites at the opioid receptors (see Figure 10). 
Reversal of respiratory depression mainly occurs at the mu-opioid receptor (Pazos & 
Florez, 1984). The extent of this reversal will depend on the dose of naloxone and its 
route of administration as well as on the dose of the opioids consumed and their receptor 
affinity (EMCDDA, 2016a). 
In the treatment of respiratory depression, the effects of naloxone should be visible 
within 1–2 minutes of intravenous administration (Nguyen et al., 2012; NIH, 2007) and 






Figure 10 Naloxone competing with heroin metabolites for mu-opioid receptors9 
 
In this same time interval post-dosing, naloxone administration can also precipitate 
moderate to severe withdrawal symptoms in opioid-dependent patients (McEvoy, 2012). 
Although rarely life-threatening, possible withdrawal symptoms include: abdominal 
cramps, body aches and weakness, diarrhea, fever, increased blood pressure irritability, 
nausea, nervousness, restlessness, runny nose, shivering, sweating, tachycardia, 
trembling, and vomiting (Martindale, 2013). The onset and severity of opioid withdrawal 
symptoms is more pronounced with higher naloxone doses and with intravenous 
administration (BMJ, 2016; Clarke, Dargan, & Jones, 2005; McEvoy, 2012). Symptoms 
typically subside within 1-2 hours (BMJ, 2016; McEvoy, 2012). 
 
1.3.3 Duration of action 
The duration of action of naloxone depends on its dose and route of administration. The 
effect of parenteral naloxone injection is typically described as lasting for up to 2-4 hours 
(Rang et al., 2012), with intravenous administration leading to a shorter duration of action 
than intramuscular administration. Kaufman et al. (1981) reported a 1.5 hours’ duration 
of action for intravenous naloxone in volunteers who had received morphine pre-
treatment. The cause of the relatively short duration of action of naloxone following 
                                               
9 Source: EMCDDA (2016a) 
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intravenous administration is the ease with which naloxone enters the brain and the 
subsequent rapid redistribution, elimination and fall in brain naloxone levels 
(Berkowitz, 1976).  
 
1.3.4 Naloxone dosing 
Since naloxone is a competitive antagonist, the dose required to reverse the effects of a 
specific opioid will depend on the opioid dose and its pharmacological properties, 
particularly on its receptor affinity and duration of action and (Martin, 1976). The half-
lives of different opioids vary greatly, ranging from less than 10 minutes to more than 24 
hours (see Table 3). In general, injection of 0.4–0.8mg of naloxone can produce a prompt 
reversal of opioid effects. While dosing guidelines vary at national level, the 2014 World 
Health Organization guidelines noted that this parenteral dose range was effective in 
most cases, adding that initial naloxone doses above 0.8mg increased the likelihood of 
significant withdrawal symptoms (WHO, 2014). The overdose victim’s response should 
be closely monitored, and naloxone may need to be given repeatedly, since its duration 
of action is shorter than that of many opioids. 
 
Table 3 Half-life of the opioids 
Opioid Approximate half-life value 
Heroin (diamorphine) 6 minutes 
Morphine 120 minutes 
Hydromorphone 150 minutes 
Oxymorphone  150 minutes 
Codeine 180 minutes 
Fentanyl 220 minutes 
Tramadol (immediate release) 6 hours 
Methadone 24 hours 
Buprenorphine 37 hours 
Source: Pasternak (2006) 
 
The British National Formulary (BNF) differentiates between the administration of 
naloxone in medical versus non-medical settings. For medical settings, the BNF 
recommends the intravenous administration – or, alternatively, subcutaneous or 
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intramuscular administration (only if intravenous access is not feasible) – of an initial 
dose of 0.4mg. In case of non-response after 1 minute, dosing may be escalated as 
follows: “Give [0.8mg], and if still no response after another 1 minute, repeat dose of 
[0.8mg]; if still no response, give 2mg (4mg may be required in a seriously poisoned 
patient), then review diagnosis; further doses may be required if respiratory function 
deteriorates”. For non-medical settings, the BNF only recommends intramuscular 
injection, with doses of 0.4mg to be given at 2-3 minute intervals into the deltoid muscle 
or the anterolateral thigh until normal breathing and consciousness are restored (BNF, 
2017). 
 
1.4  The shift from intravenous to intramuscular naloxone 
administration  
As discussed above, naloxone became the treatment of choice for reversing opioid 
overdose in emergency medicine. For the quickest absorption into the bloodstream and 
onset of action, naloxone was recommended for intravenous administration, which 
became standard clinical practice for nearly two decades. A 1993 publication by the 
World Health Organization and the Commission of the European Communities 
(WHO/CEC, 1993) recommended: “In patients with [ … ]  opiate poisoning, naloxone 
[of up to 2mg] should be given by the intravenous route until an improvement in 
conscious level and respiration is observed.” Hospital emergency departments 
routinely used naloxone intravenously for the antidote’s three indications: to reverse 
respiratory and central nervous system depression in opioid overdose, to reverse the 
therapeutic effects of opioids in medical use (e.g. after general anesthesia) and as a 
diagnostic tool (i.e. opioid challenge test, see above). 
In the 1990s, US ambulance services started to train staff in the management of 
suspected opioid overdose to improve the prevention of overdose deaths in the 
community. Training included intramuscular naloxone administration in combination with 
bag–valve–mask ventilation (Sporer, Firestone, & Isaacs, 1996). Stocking ambulances 
with naloxone enabled staff to administer naloxone at the scene of the overdose 
emergency and constituted an example of ‘technology transfer’, i.e. the transfer of a 
development established in a specialist setting (e.g. the emergency department) to new 
locations (e.g. scene of overdose in the community) for more effective implementation. 
However, spurred by the acquired immune deficiency syndrome (AIDS) epidemic, 
clinicians became increasingly wary of the risk of needle-stick injury associated with 
the difficulty of establishing intravenous access in people who inject drugs. The 1993 
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joint publication of the World Health Organization and Commission of the European 
(WHO/CEC, 1993) warned: “Appropriate protective precautions need to be taken by 
[ … ]  staff in the case of opiate addicts, bearing in mind the risk of infection from 
blood-borne diseases such as hepatitis B and HIV.” 
As a result, there was also interest in non-injecting routes of naloxone administration as 
a safer alternative for use in the high-risk opioid user population. Loimer et al (1994) 
began to explore the feasibility of intranasal administration of naloxone (in the context of 
sedated detoxification and initiation onto oral naltrexone). Similarly, a Vancouver-based 
ambulance study by Wanger et al. (1998) compared time to recovery (interval from crew 
arrival to reversal of respiratory depression) between intravenous and subcutaneous 
administration. The study found that the slower absorption rate from subcutaneous 
administration was offset by the delay in establishing intravenous access in overdose 
victims, thus resulting in equal clinical efficacy for both routes. In addition, Horowitz 
(1998) noted that subcutaneous (or intramuscular) administration led to a more gradual 
patient recovery from overdose, compared to intravenous administration. Intramuscular 
naloxone administration is also associated with less rapid onset of opioid withdrawal 
(BMJ, 2016; McEvoy, 2012).This shift in clinical practice from intravenous towards 
subcutaneous and intramuscular administration of naloxone, along with the growing 
awareness that most overdoses are witnessed by others, set the scene for the 




Chapter 2  Twenty Years of Take-Home Naloxone 
 
Preface 
In this chapter I reconstruct historical and conceptual sequence of the development of 
take-home naloxone from its conception through to the present. Technology transfer of 
naloxone supply from standard medical settings (i.e. ambulance and emergency rooms) 
to layperson use constitutes the foundation of take-home naloxone distribution. Training 
opioid users and their peers, and also family members in overdose prevention and 
emergency management along with pre-provision of naloxone for emergency use (take-
home naloxone) was first proposed in 1996 as a previously overlooked opportunity to 
prevent deaths by reducing the time between overdose onset and naloxone 
administration, while awaiting the arrival of an ambulance. The chapter reviews two 
decades of take-home naloxone research in chronological order, from its first mention in 
the peer-reviewed literature in 1996 up to its inclusion in the scientific summary of the 
United Nations General Assembly Special Session on Drugs in 2016.  
Between October 2014 and December 2015, I had the opportunity to co-edit the 
twentieth edition of the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) Insights series, entitled “Preventing Opioid Overdose Deaths with Take-
home Naloxone”, which EMCDDA had commissioned my first supervisor and me to 
author, in collaboration with colleagues from the Addictions Department at King’s College 
London. This chapter draws on content from my first-authored Chapter 4 (“Historical 
summary of the development and spread of take-home naloxone provision”, p. 49-68) of 
the Insights monograph (EMCDDA, 2016a). Contents of this chapter have also been 
published as first-authored manuscript in Drug and Alcohol Dependence (“Twenty years 
of take-home naloxone for the prevention of overdose deaths from heroin and other 
opioids – conception and maturation”; in press), in co-authorship with my first supervisor 
and the US historian Professor Nancy D. Campbell. 
This chapter sets the scene for the systematic review of the effectiveness of take-home 
naloxone programs which I present in the next chapter.   
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2.1  Introduction 
Over the past two decades, take-home naloxone has moved from its initial 
conceptualization as a possible harm reduction measure for preventing opioid overdose 
deaths to becoming an evidence-based public health strategy with organized 
implementation (UNODC/WHO, 2013).   
In addition to naloxone, take-home naloxone programs provide overdose prevention 
training which may cover overdose risk factors, signs of an opioid overdose, first aid, and 
aftercare procedures (McAuley, Lindsay, Woods, & Louttit, 2010; Seal et al., 2005; 
Strang, Manning, Mayet, Best, et al., 2008). 
Strong advocacy by local early adopters has enabled emergence of take-home naloxone 
initiatives around the world. In Italy, a harm reduction service on the outskirts of Turin 
reportedly provided naloxone access to clients as early as 1991 (ForumDroghe, 2016). 
Today, formal take-home naloxone programs exist in Australia, Canada, at least nine 
European countries (EMCDDA, 2016a), and the US; as well as pilots in low- and middle-
income countries, including Afghanistan, China, India, Kazakhstan, Kyrgyzstan, Russia, 
Tajikistan, Thailand, Ukraine, and Vietnam (UNODC/WHO, 2013). 
The World Health Organization issued new guidelines for community-based overdose 
management, suggesting that “[p]eople likely to witness an opioid overdose should have 
access to naloxone and be instructed in its administration” (WHO, 2014).  
Despite these recent advances, dissemination of take-home naloxone remains 
remarkably slow. Twenty years after take-home naloxone was first proposed in 1996, 
only Scotland and Wales have national programs. Opioid overdose continues to account 
for approximately 68,000-104,000 annual deaths worldwide (UNODC, 2016b), with 
sharp increases reported for the UK (ISD, 2016; ONS, 2016) and US (CDC, 2016c). 
Many of these deaths could possibly be prevented if take-home naloxone was available. 
However, adequate intervention is only possible where witnesses recognize the opioid 
overdose. In addition to naloxone supply, it is thus essential for THN programs to teach 
awareness of overdose risk factors (e.g. using alone, street injection), crisis detection 
(e.g. snoring following opioid use may signal overdose), interim emergency care aid, and 
need for continued care (McAuley et al., 2010; Seal et al., 2005; Strang et al., 2008a; 
Strang et al., 2008b). 
Take-home naloxone is now widespread in some countries, but minimal or absent 
elsewhere. Take-home naloxone provision is often restricted by legal and regulatory 
barriers. In most countries, naloxone is a prescription-only medicine and its use restricted 
to medical personnel or to patients to whom it is prescribed. In many countries, the 
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introduction of take-home naloxone provision would therefore require adjustments to 
current medico-legal regulations, as has occurred in the UK and elsewhere. One of the 
main challenges for existing take-home naloxone programs is to provide sufficient 
coverage of at-risk populations, so that substantial reductions in opioid overdose deaths 
can be achieved. Reasons for inertia and poor implementation have not been well 
explored.  
This chapter chronicles the limitations as well as milestones and events in the 
emergence and evolution of take-home naloxone, from speculative harm reduction 
proposal to public health strategy.   
 
 
2.2  Methods 
2.2.1 Literature search 
Medline and PsycINFO were searched for take-home naloxone-related peer-reviewed 
literature published between January 1990 and December 2016 using the Boolean 
queries: 1) “naloxone OR Narcan”; 2) “(opioid OR opiate) AND overdose AND 
prevention”. Database entries were not limited to English-language results. Specialist 
websites and databases of Public Health England, the European Monitoring Centre for 
Drugs and Drug Addiction, US National Institute on Drug Abuse, and United Nations 
agencies were also searched for take-home naloxone-related entries. Additional 
materials from the non-peer-reviewed literature were consulted to reconstruct the 
historical timeline. Information on current take-home naloxone-provision and naloxone-
related legislation in Europe was gathered at the EMCDDA event “Take-home naloxone 
to reduce fatalities: scaling up a participatory intervention across Europe” (Lisbon, 14 
October 2014). Additional information was provided by the Health Consequences and 
Responses Sector at EMCDDA, following consultation with EMCDDA national focal 
points in member states.  
 
2.2.2 Data extraction and evidence synthesis 
Take-home naloxone-related evidence was extracted and synthesized as narrative 
review. Relevant events were considered according to occurrence in one of four 
developmental phases of constructed quinquennia (with some overlap naturally 




2.3  Results 
I present the results in four sections which discuss the following themes. Firstly, the 
formal articulation of the need for take-home naloxone is examined, along with 
preliminary testing and implementation (1996-2001). I then document early take-home 
naloxone schemes and challenges (2001-06). I then explore new national or state-level 
naloxone programs made possible through the identification and response to legal 
concerns (2006-11). Finally, I review the examine emergence of research studies 
meeting higher evidentiary standards and examine efforts to widen take-home naloxone 
availability (2011-16). Key events are also summarized as a chronological timeline (see 
Table 4). 
 
2.3.1  1996-2001 circa: Conception and early implementation  
Original articulation 
Naloxone was FDA-approved in 1971 for intravenous, intramuscular, and subcutaneous 
administration for partial or complete reversal of opioid overdose (Garfield, 1983; 
Yardley, 2013) (see Table 4) and became the standard rescue medication in the 
emergency management of heroin overdose in hospital and ambulance settings (see 
Chapter 1). 
However, the idea to enable opioid users and/or family and friends to take naloxone 
home did not arise until more than two decades after initial FDA-approval. It was first 
mooted at the 3rd International Harm Reduction Conference in March 1992 (Strang, 
1992, 1993; Strang & Farrell, 1992) as a mere throwaway example of potential harm 
reduction alternatives that were being overlooked.  
The first serious consideration was in the 1996 BMJ editorial (Strang, Darke, Hall, Farrell, 
& Ali, 1996) which identified key elements for making take-home naloxone a serious 
possibility, noting that take-home naloxone schemes would need to include provision to:  
1) individuals at high risk of overdose, e.g. those leaving emergency care following 
overdose and those who lost tolerance due to detoxification, incarceration, or 
abstinence-based treatment; 
2) patients enrolled in treatment programs (despite the protective benefits of 
treatment, they remain at risk); and 
3) active users.  
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The editorial also described the poor suitability of existing naloxone products (ampoules, 
vials) compared to pre-filled syringes and identified medico-legal challenges raised by 
the prospect of third parties, such as family members, requesting or administering 
naloxone. Finally, the editorial urged reconsideration of naloxone’s prescription-only 
medication status. These central points of the editorial shaped implementation and 
research in the subsequent years. 
 
Early implementation 
The introduction of take-home naloxone was made possible through user advocates 
working with physicians willing to prescribe naloxone despite medico-legal barriers. First 
take-home naloxone provision occurred in the late 1990s, in the US (Chicago, San 
Francisco), Germany (Berlin), the UK (Jersey), and Italy (Turin, Bologna, Padua).  
 
United States 
The Chicago Recovery Alliance began obtaining and distributing naloxone in 1996. Due 
to high user demand during a fourfold increase in drug-related deaths from 1996 to 2000, 
distribution by mobile van was introduced in 1998 and converted into a formal training 
curriculum in 2001 (Bigg, 2002; Maxwell, Bigg, Stanczykiewicz, & Carlberg-Racich, 
2006).  
During the late 1990s, the Chicago Recovery Alliance began discussions with harm 
reduction advocates in other places around starting take-home naloxone-programs and 
served as central clearinghouse for take-home naloxone across the US. 
San Francisco Needle Exchange introduced a small-scale take-home naloxone pilot for 
youth in the Haight-Ashbury district in 1999 (Bigg, 2000; Giuliano, 2000; Seal et al., 
2001). The pilot was later scaled up in conjunction with the DOPE (Drug Overdose 
Prevention and Education) project (Giuliano, 2000; Seal et al., 2001; Seal et al., 2005) 




Multiple sources point to undocumented or minimally documented early community-
based naloxone availability in parts of Italy, notably Turin (1991) and the Emilia Romagna 
region (incl. Bologna, 1998) (ForumDroghe, 2016; Simini, 1998). There were reports of 
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take-home naloxone distribution in Padua in 1996, where a methadone clinic distributed 
150 naloxone vials within 18 months. However, while overdose deaths decreased 
citywide, there was no formal evaluation of take-home naloxone usage (Schifano, 2001). 
Two pilot schemes in Berlin and the British island of Jersey (Dettmer, Saunders, & 
Strang, 2001) constitute the first published outcomes report on take-home naloxone 
provision. Between 1998 and 2000, 101 clients of a community-based drug clinic in 
Jersey were trained in overdose management and received take-home naloxone kits, 
with five reported overdose reversals (Dettmer et al., 2001). In Berlin, take-home 
naloxone was introduced at a mobile needle and syringe exchange scheme (“Fixpunkt”) 
in 1999. Within 16 months, 124 take-home naloxone kits had been issued; 22 users 
reported administering naloxone for a total of 29 overdose reversals. The pilot was 
discontinued after 2002 due to lack of funding (AIDS-Hilfe, 2013; Dettmer, 2014).  
 
Testing the notion: is the intervention necessary?  
Several studies in the late 1990s and early 2000s identified situations in which naloxone 
should be made available: 
 
Injecting use 
In a London-based community sample of heroin users, the vast majority of reported 
overdoses occurred among injection users (Gossop, Griffiths, Powis, Williamson, & 
Strang, 1996). Injection bears a much higher risk of fatal overdose than ‘chasing the 
dragon’, snorting or oral use. It was later estimated that each year one in four injecting 
drug users would experience an overdose (Darke, Mattick, & Degenhardt, 2003). 
 
Return into the community 
Several international studies identified the period following release from prison as the 
most striking high-risk situation, with 1 in 200 prisoners with history of heroin use dying 
from an opioid overdose within a month of release (Bird & Hutchinson, 2003; Farrell & 
Marsden, 2008; Merrall et al., 2010; Seaman, Brettle, & Gore, 1998; WHO, 2010). Similar 
but less intense concentration of overdose deaths was observed among patients who 
complete in-patient detoxification (Strang et al., 2003), residential rehabilitation (Davoli, 
Bargagli, Perucci, Schifano, Belleudi, Hickman, Salamina, Diecidue, Vigna‐Taglianti, et 





Opioid substitution treatment 
The first weeks on oral methadone treatment are associated with a transient increase in 
risk of overdose death (Caplehorn & Drummer, 1999; Cornish, Macleod, Strang, 
Vickerman, & Hickman, 2010; Davoli, Bargagli, Perucci, Schifano, Belleudi, Hickman, 
Salamina, Diecidue, Vigna-Taglianti, et al., 2007; Degenhardt et al., 2009). 
 
Testing the notion: is the intervention acceptable for those involved?  
Parallel to early take-home naloxone implementation, research assessed the feasibility 
and acceptability among users, carers, and providers. 
 
Opioid users  
The 1996 BMJ editorial identified opiate users as the primary target group for take-home 
naloxone because they are at risk of future overdose themselves and highly likely to 
witness and intervene in someone else’s overdose. Users have expressed strong 
support of take-home naloxone. A London-based survey of injecting drug users (Strang 
et al., 1999) estimated that two-thirds of witnessed overdose deaths could have been 
avoided with take-home naloxone. Most respondents had already witnessed at least one 
overdose; 89% expressed willingness to administer naloxone in the event of an 
overdose; 70% agreed with the proposal that naloxone should be provided; and nearly 
90% of those who had witnessed an overdose stated that they would have used the 
medication had it been available.  
Subsequent surveys reported willingness among users to be trained in overdose 
management and naloxone administration (Bennett & Higgins, 1999; Best et al., 2002; 
Kerr, Dietze, Kelly, & Jolley, 2008; Lagu, Anderson, & Stein, 2006; Seal et al., 2003; 
Strang, Best, Man, Noble, & Gossop, 2000; Worthington, Markham Piper, Galea, & 
Rosenthal, 2006).  
In the first published evaluation of take-home naloxone training, Seal and colleagues 
(2005) assessed knowledge of overdose management by asking participants to name 
risk factors, signs of overdose, and overdose prevention and management strategies. A 
significant increase in overdose-related knowledge was maintained at 6-month follow-up 
(Seal et al., 2005).  
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However, opioid users also expressed concerns about take-home naloxone, such as 
fear of experiencing withdrawal symptoms, enabling further drug use, risk of blood-borne 
virus infection, and potentially having to manage agitation and hostility in those revived 
(Kerr, Dietze, Kelly, et al., 2008; Seal et al., 2003; Worthington et al., 2006). Service 
users also expressed concerns about the risk of confiscation of the antidote and its 
potential role in escalating already delicate relationships with law enforcement (Richert, 
2015; Seal et al., 2003; Worthington et al., 2006). 
 
Carers 
Most opiate overdoses occur at private homes and/or in presence of peers, family 
members, and partners (Best et al., 2002; McGregor, Darke, Ali, & Christie, 1998). 
Constituting a potential intervention resource, close contacts of users are thus the 
second target group for take-home naloxone and training. In an England-based postal 
survey of family members (Strang, Manning, Mayet, Titherington, et al., 2008), the 
majority reported strong interest in take-home naloxone. A recent waiting-list randomized 
trial (Williams, Marsden, & Strang, 2014) demonstrated good improvements in the 
knowledge and competence of carers in overdose management, which were maintained 
at 3-month follow-up. 
 
Health care providers 
Early US-based studies explored health care providers’ attitudes to take-home naloxone. 
A postal survey (Coffin et al., 2003) of New York-based clinicians with prescribing 
authority showed that over a third were willing to prescribe naloxone. Negative attitudes 
were revealed in surveys of Baltimore-based emergency service providers (Tobin, 
Gaasch, Clarke, MacKenzie, & Latkin, 2005) and physicians throughout the US who 
were likely involved in treatment of opioid users (Beletsky et al., 2007): most believed 
take-home naloxone would not reduce drug-related deaths and reported they would 
never consider prescribing naloxone. Common concerns included potential promotion of 
drug use (Ashworth, 2006; Tobin et al., 2005), risk of unsafe needle disposal (Tobin et 
al., 2005), and users’ competency in administration (Ashworth, 2006; Byrne, 2006; Tobin 
et al., 2005). Providers voiced strong concerns over uncertain medico-legal status and 
potential liability issues (Burris, Norland, & Edlin, 2001). 
In the coming years, community-based naloxone would be adopted by firefighters and 
the police. The unanticipated uptake by these workforces may have positively influenced 




2.3.2 2001-2006 circa: Modest progress amidst legal and safety concerns  
Following the pioneering Chicago Recovery Alliance program, early adopters in the US 
included New Mexico, which began take-home naloxone distribution in early 2001 (Baca, 
2001; Baca & Grant, 2005).  
In 2004, the Baltimore Staying Alive Drug Overdose Prevention Program was launched, 
sponsored by the Baltimore City Health Department and Open Society Institute, and the 
Lower East Side Harm Reduction Coalition in New York conducted a pilot in 2004, which 
was expanded to all city-funded Syringe Exchange Programs in 2005 (Heller & Stancliff, 
2007). 
There were also reports of take-home naloxone distribution in Barcelona as early as 
2001, which led to around 60 successful overdose reversals (Trujols, 2001). In mainland 
UK, take-home naloxone was first introduced in South London in 2002 (McDonald et al., 
2016).  
Support was rarely encountered in the treatment field, where the take-home naloxone 
debate was dominated by legal and safety concerns, such as: (i) might naloxone 
availability encourage heroin use?; (ii) could it discourage users from calling an 
ambulance; and (iii) would naloxone’s short half-life result in rebound overdose after the 
initial dose wore off?  
Early surveys of drug users found that take-home naloxone was unlikely to lead to 
increased heroin consumption (Strang, 1999), a finding recently confirmed in a large US 
retrospective cohort study (n=4,926) (Doe-Simkins et al., 2014). Similarly, in a Danish 
study, death from (presumed) ‘rebound’ overdose toxicity occurred only in 3 out of 3,245 
cases of naloxone administration (Rudolph et al., 2011). Low rates of ambulance calls 
after take-home naloxone administration have been observed (Bennett & Holloway, 
2012); but use of emergency medical services can be encouraged in take-home 
naloxone training (Bennett & Holloway, 2012; Strang, Manning, Mayet, Best, et al., 
2008).  
 
Legal analyses of Take-Home Emergency Naloxone provision 
An early US legal analysis (Burris et al., 2001) found that providers’ risk of malpractice 
liability associated with prescribing take-home naloxone was no greater than for general 
health care provision. Nonetheless, many prescribers have remained wary of prescribing 
take-home naloxone (NPHL, 2014). 
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Prescribing take-home naloxone to an at-risk patient for administration by a trained 
partner/family member is analogous to the pre-provision of anti-epileptic medication or 
injectable adrenaline/epinephrine (EpiPen). However, in situations where naloxone is 
being prescribed without specific knowledge of who will administer or be administered 
naloxone, the legal situation becomes murky. Professionals have expressed anxieties 
about patients’ ‘deputation’ as health care providers when injecting naloxone (Burris et 
al., 2001); medical providers and service users alike raised concerns about civil or 
criminal liability (Lenton & Hargreaves, 2000).  
 
2.3.3  2006-2011 circa: Identification of legal pathways for THN 
 
Responses to legal barriers 
Because take-home naloxone has come about so recently, most medico-legal barriers 
to it were unintended consequences of prior legislation passed for other purposes 
(NPHL, 2016). About ten years after the original take-home naloxone proposal, some 
jurisdictions began to pass laws to facilitate take-home naloxone implementation. 
Policies are typically of two kinds: those that enable naloxone access either via broad 
standing orders, or amendment of Good Samaritan legislation that widens immunity to 
encompass not only physicians but also first responders, bystanders, or witnesses who 
extend care in emergency situations.   
 
United Kingdom  
In the UK, parenteral (injectable) medicines can be administered only by patients 
themselves, or by ‘an appropriate practitioner or a person acting in accordance with the 
directions of an appropriate practitioner’ (s.58(2)(b) Medicines Act 1968), (Government, 
1968). However, following endorsement of take-home naloxone provision by the 
Advisory Council on the Misuse of Drugs (ACMD, 2000), naloxone was incorporated into 
the Schedule 7 of the UK Medicines Act in 2005, which allowed any member of the 
general public to administer naloxone with the aim of saving a life. Thereby, naloxone 
was placed alongside other rescue medications, such as glucagon, adrenaline and 
snake antivenin (Strang, Kelleher, Best, Mayet, & Manning, 2006). Naloxone could then 
lawfully be given by a witness to an overdose victim to whom it was not prescribed, 
opening doors to naloxone administration by layperson first-responders. At least 16 sites 
then implemented take-home naloxone pilots in England (NTA, 2011). 
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However, naloxone remained a prescription-only medication. The UK Department of 
Health 'Orange Guidelines' (DOH, 2007) stated: “naloxone […] must be prescribed to 
named patients or supplied to an individual by means of a patient group direction.”  
In 2012, ACMD urged the Department of Health to review naloxone’s prescription-only 
status (ACMD, 2012). Triggered by this request, the Medicines and Healthcare Products 
Regulatory Agency (MHRA) released a consultation in 2013, asking for feedback on a 
proposal to increase community-based naloxone access (MHRA, 2013). Thus, new UK 
legislation was passed in late 2015 which explicitly enabled wider availability to drug 
users, family members, other carers, and staff working in relevant treatment and social 
care agencies. New Public Health England (PHE) guidelines exempted naloxone from 
the usual prescription requirement when it is supplied by a drug service commissioned 
by a local authority or NHS (PHE, 2015).  
 
United States  
In the US, naloxone is a prescription-only-medication at federal level, although there is 
considerable variation due to state-level legislation and lower-court rulings. New Mexico 
became the first state to remove legal barriers to take-home naloxone prescribing and 
distribution in 2001 (Alcorn, 2014) and to grant legal immunity to bystanders in 2007 via 
a “Good Samaritan” law. New York and Connecticut followed with laws that granted 
immunity from civil liability to healthcare providers with prescribing authority (Sporer & 
Kral, 2007). 
Established in 2006, the Massachusetts take-home naloxone pilot program used a 
standing order to enable public health care workers to provide take-home naloxone 
without a prescription (Doe-Simkins, Walley, Epstein, & Moyer, 2009). The standing 
order model allows a lead physician within a given jurisdiction to issue a written order 
that naloxone can be distributed by designated pharmacists or other qualified 
professionals (OSF, 2013).  
At the end of the 2000s, there were fewer than three dozen take-home naloxone 
programs in the US, but the number had increased more than fivefold by 2014 (OSF, 
2013) – operated by community-based organizations, public health departments, and 
Veterans Health Administration facilities (Humphreys, 2015).  
Amid growing public support, organizations including the US Conference of Mayors, the 
American Medical Association, the American Public Health Association, and the National 
Association of Boards of Pharmacy urged states to remove legal barriers to take-home 
naloxone (Alcorn, 2014; NPHL, 2016). As of June 2016, forty-eight states had amended 
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laws to relieve provider liability when prescribing or dispensing naloxone, and thirty-
seven states had passed Good Samaritan laws (both including the District of Columbia) 
(Burris et al., 2001; DOJ, 2014; NPHL, 2014, 2016). Sustainability has been achieved in 
several states (CDC, 2012b). 
As of mid-2014, 136 take-home naloxone programs were providing naloxone kits to 
laypersons at 644 sites across the country, with naloxone kits supplied to a total of 
152,283 clients and 26,463 reported overdose reversals since 1996 (CDC, 2015).  
 
First national and state-wide programs 
In the late 2000s, first take-home naloxone programs expanded coverage from a local 
to a state-wide or national level.  
 
Catalonia 
Following underground distribution of naloxone in the early 2000s, the public health 
agencies of Barcelona and the autonomous region of Catalonia formally launched a take-
home naloxone program in 2008 (EMCDDA, 2016a). Barcelona is considered to have 
the highest mortality rate in Spain (EMCDDA, 2016a). 
The Catalonian take-home naloxone program was integrated into the Catalan Drug 
Abuse Care Centers Network (XADC), which covers drug-treatment centers, therapeutic 
communities, detox units, and drug-consumption rooms. At participating sites, staff and 
clients could receive training in overdose prevention and naloxone kits. Clients received 
a financial incentive to attend training. As of December 2013, 1,007 professionals and 
4,738 injecting drug users had been trained, with 5,830 naloxone kits distributed since 
2008. Among those who received naloxone and witnessed an overdose, 40% reported 
using the naloxone kit. In a cross-sectional study of 306 opioid users in Catalonia, 44% 
reported having participated in an overdose prevention program (Arribas-Ibar, Sánchez-
Niubò, Majó, Domingo-Salvany, & Brugal, 2014), suggesting substantial coverage of the 
target population. However, the impact of take-home naloxone provision on overdose 
mortality rates could not be determined, since overdose deaths in Catalonia had been 





Three local take-home naloxone pilots were launched in Glasgow, Lanark and Inverness 
during or after 2007 (McAuley, Best, Taylor, Hunter, & Robertson, 2012). In 2011, the 
Scottish Procurator Fiscal issued a “Letter of Comfort”, granting immunity to pharmacists 
who supplied naloxone without prescription to staff working at services with a high rate 
of overdoses (e.g. hostels) (Angiolini, 2011). By allowing naloxone storage in non-
medical facilities for emergency use, these so-called ‘Lord Advocate’s guidelines’ 
facilitated introduction of the Scottish National Naloxone Programme in 2011 (ACMD, 
2012). 
The program involves take-home naloxone distribution in the community and to prisoners 
on release. Services can issue take-home naloxone to staff, persons at risk of overdose, 
family members, and peers (with documented consent of the person at risk). The 
Scottish government has funded the program centrally, reimbursing all service providers 
for the number of naloxone kits issued. Scotland has its own registry for drug-related 
deaths, which enables the Scottish National Naloxone Programme to track the number 
of opioid overdose deaths in relation to the number of take-home naloxone kits in 
circulation. 
The Scottish National Naloxone Programme issued a total of 8,146 naloxone kits during 
a 12-month period in 2015/16; 7,214 (89%) in the community and 932 (11%) to prisoners 
on release (ISD, 2016). 
Among Scottish prisoners supplied with take-home naloxone, mortality within 4 weeks 
after release had decreased to 4.7% by 2015, compared with the pooled 2006–10 
baseline of 9.8% (ISD, 2016). The reduction of heroin-related deaths within 4 weeks of 
prison release coincides with a steady increase in the number of take-home naloxone 
kits provided since start of the Scottish National Naloxone Programme. The significance 
of this reduction has been examined (Bird, McAuley, Perry, & Hunter, 2016), with study 
rationale as described by (Bird, Parmar, & Strang, 2015).  
Despite more than doubling of the volume of take-home naloxone kits in Scotland (i.e. 
from 52 kits per 1,000 problem drug users in 2011/12 to 132 per 1,000 in 2015/16), the 
percentage of all opioid-related deaths occurring among people who had been 
discharged from hospital in the previous four weeks has remained largely unchanged at 
around 10% (ISD, 2016).  
 
Wales 
Following the 2007 introduction of a take-home naloxone pilot, Wales launched a 
national naloxone program in 2011 (Bennett & Holloway, 2012). Between mid-2009 and 
52 
 
early 2014, 4,579 take-home naloxone kits were issued and reportedly used in 375 
overdose events (McDonald et al., 2016). In an effort to increase the volume of take-
home naloxone kits in circulation, 1,802 kits were issued in Wales in 2013/14 alone; with 
150 overdose reversals recorded in the same period. The Welsh take-home naloxone 
program tracks overdose prevention training and the provision of take-home naloxone 
kits in a national Harm Reduction Database, which subsumes local data from 37 
registries across Wales. 
Massachusetts  
The Massachusetts Department of Public Health has conducted the most 
comprehensive U.S. program evaluation to date. Boston-based harm reduction activists 
began take-home naloxone distribution in the early 2000s without formal approvals and 
documented the number of naloxone vials distributed and overdose events reversed in 
a 2005 letter to the mayor of Boston who facilitated a joint meeting between the activists 
and the Department of Public Health. As a result, Boston Public Health Commission 
authorized development of a take-home naloxone program via its mobile needle-
exchange scheme in 2006. The Massachusetts take-home naloxone program was the 
first to involve distribution of intranasal naloxone and to allow non-medical public health 
workers to issue naloxone. By 2009, the Massachusetts Department of Public Health 
had expanded the program to seven more communities, operating out of needle-
exchange sites, methadone clinics, homeless shelters, inpatient detoxification programs, 
community meetings, outpatient and residential addiction-treatment programs, and 
emergency departments. By 2014, the Massachusetts take-home naloxone program had 
trained 4,926 drug users, of whom 373 reported administering naloxone (Doe-Simkins 
et al., 2014). 
 
2.3.4  2011-2016 circa: Emergence of stronger data and expansion 
Encouraged by the WHO Guidelines and the emergence of more robust evidence, many 
countries began to introduce take-home naloxone projects in the early and mid -2010s. 
 
Dissemination and expansion 
Australia 
Despite immediate endorsement of the original take-home naloxone proposal by 
Australian researchers (Darke & Hall, 1997; Fry, Dietze, & Crofts, 2000; Lenton & 
Hargreaves, 2000), funding for an early naloxone trial in Victoria was affected by the 
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2000 Australian heroin drought (Dietze, 2016). Intranasal naloxone was explored in 
ambulance-based trials (Kelly et al., 2005; Kerr, Kelly, Dietze, Jolley, & Barger, 2009), 
but take-home naloxone was halted by medico-legal concerns.  
Following the emergence of findings from take-home naloxone schemes overseas, 
Australian researchers reiterated the case for take-home naloxone (Dietze & Lenton, 
2010; Lenton, Dietze, Degenhardt, Darke, & Butler, 2009), which ultimately led to the 
launch of I-ENNAACT, the first Australian take-home naloxone program in Canberra, in 
late 2011.  
A preliminary evaluation in late 2014 showed that over 200 injecting drug users had been 
trained in overdose prevention (including 18 inmates) and reported 57 successful 
overdose reversals (Dietze, 2016). Naloxone access in Australia was facilitated by the 
2012 addition of the antidote to the government Pharmaceutical Benefit Scheme which 
subsidizes prescription drugs. Australian residents can now obtain naloxone at a 
concession rate of AUD 5.90, rather than the previous AUD 60 (Fowlie, 2013). The 
Australian Medical Association endorsed take-home naloxone in 2013 (Anex, 2013), and 
naloxone was re-classified / scheduled as over-the-counter medication in 2016 (Lenton, 
Dietze, & Jauncey, 2016). Take-home naloxone scale-up in New South Wales is 
currently underway (Dietze, 2016). 
 
Europe 
In the early 2010s, several northern European countries launched take-home naloxone 
projects:  Denmark and Estonia in 2013, with Norway following in 2014 and Ireland in 
2015 (EMCDDA, 2016a).  
 
Denmark: During the 1990s and 2000s, an average 250–275 drug overdose deaths 
were registered in Denmark annually, mostly from methadone and heroin. 
Because of the high number of opioid-related overdoses, the Danish Ministry of Health 
decided in 2012 to introduce a take-home naloxone program which launched in March 
2013 (EMCDDA, 2016a) and was implemented out in four municipalities (Copenhagen, 
Aarhus, Odense and Glostrup) with high prevalence of opioid use. 
The Danish take-home naloxone kits are unique in that they contain a 2mg/2ml pre-filled 
naloxone syringe in combination with both the mucosal atomizer device for nasal 
administration (i.e., similar to the Massachusetts program) as well as a needle for 
intramuscular injection in case of non-response to the nasal spray (EMCDDA, 2016a). 
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Trainees are instructed to regard the 2-mg/2ml formulation as five doses of 0.4mg each: 
the first three doses are for intranasal administration and, in case of non-response, the 
fourth and fifth doses should be used for intramuscular administration. As of October 
2014, 121 take-home naloxone kits had been distributed, with seven reported overdose 
reversals. While there has been a downward trend in drug-related deaths in Denmark, 
the uncontrolled evaluation design of the Danish take-home naloxone program does not 
allow for assessment of its impact on mortality outcomes. 
Estonia: Estonia has the highest drug-related mortality rate in the European Union, with 
111 deaths per million adult inhabitants in 2013. Unlike other European countries, most 
drug overdose fatalities are associated with the use of fentanyl (EMCDDA, 2012). In 
September 2013, the National Institute for Health Development launched a government-
funded take-home naloxone program in Harju and East-Viru, i.e. the two counties with 
the highest prevalence of injection drug use. Based on the model of the Scottish National 
Naloxone Programme, patient lists are generated (instead of individual prescriptions) 
and the distribution of naloxone kits is logged to comply with national legislation. As of 
October 2014, 552 naloxone kits had been distributed, which led to 72 repeat 
prescriptions and 71 overdose reversals (EMCDDA, 2016a). 
 
Norway: In response to some of the highest per capita overdose mortality rates in 
Europe with 70 overdose deaths per million adult inhabitants (EMCDDA, 2012), the 
Norwegian Minister for Health launched the national overdose-prevention campaign in 
April 2014. The campaign covers a 5-year overdose-prevention strategy, including take-
home naloxone distribution. The Norwegian take-home naloxone pilot, which launched 
in June 2014, is run out of low-threshold health and care facilities in Bergen and Oslo, 
as well as housing facilities, drop-in day centers and mobile services. Similar to the 
Massachusetts take-home naloxone program, participants receive a 2-mg/2ml pre-filled 
syringe equipped with a mucosal atomization device. Unlike the Danish pilot, the 
Norwegian naloxone kit does not contain a needle for naloxone injection, and only 
intranasal administration is possible. Since no needles are provided, no individual 
prescription is needed. Special approval from the Norwegian drugs regulatory authority 
was required to distribute the off-label naloxone nasal spray formulation. Between 
program start in mid-2014 and late 2015, the Norwegian take-home naloxone program 
distributed 2,056 nasal kits, with 277 overdose reversals reported (Madah-Amiri, 




Ireland: In Ireland, the number of drug-related deaths increased from 105 in 2003 to 181 
in 2012. Most overdose fatalities registered in 2012 were opioid-related, and toxicology 
results revealed that methadone was present in more cases than heroin (EMCDDA, 
2012). More than a decade after the Irish National Advisory Committee on Drugs (NACD) 
explored of the feasibility of take-home naloxone implementation in Ireland which was 
not pursued at the time (NACD, 2003), the Irish Health Service Executive announced In 
October 2014 that it would fund a take-home naloxone demonstration project with an 
initial target sample size of 600 opioid users (Sheehan, 2014). The launch of the project 
took place in May 2015 (Health, 2015). As of 2016, a total of 95 naloxone prescriptions 
had been issued, of which two-thirds in Dublin in one third Limerick, with a total of five 
overdose reversals reported (A. Clarke & Eustace, 2016). 
 
Exploration of new settings and workforces 
Community-based harm reduction teams have been the ‘default’ resource for take-home 
naloxone provision, with users and their primary carers the main target populations. The 
CDC survey (2015) of current take-home naloxone programs in the US reported that 
most program participants are people who use drugs (82%), with friends and family 
members being the second most common group (12%). Over the past five years, 
researchers have sought to study whether expansion of the take-home naloxone 
intervention to new settings and workforces could enhance its impact. 
 
Police and firefighters 
In the US, several jurisdictions have passed legal provisions to authorize nonmedical 
first responders to administer naloxone (Banta-Green, Beletsky, Schoeppe, Coffin, & 
Kuszler, 2013). In 2010, Massachusetts was the first state to pioneer equipping 
firefighters and police with naloxone (Davis, Ruiz, Glynn, Picariello, & Walley, 2014), and 
the Obama administration’s National Drug Control Strategy (ONDCP, 2010) urged 
expansion of law enforcement professionals and firefighters “who are trained in how to 
recognize an overdose and who further know how to administer […] naloxone.” Law 
enforcement officers can be successfully trained to respond to overdose (Saucier, Zaller, 
Macmadu, & Green, 2016; Wagner, Bovet, Haynes, Joshua, & Davidson, 2016) and 
report positive attitudes (Goodman & Hartocollis, 2014; Ray, O'Donnell, & Kahre, 2015). 
Over 220 law enforcement agencies across 24 U.S. states carry naloxone (Davis, Carr, 
Southwell, & Beletsky, 2015). Equipping Ohio police with naloxone nasal spray was 
associated with a decline in opioid overdose deaths (Rando, Broering, Olson, Marco, & 
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Evans, 2015). A New York-based program reported over 100 overdose rescues within a 
year (NYAG, 2015). However, studies reveal geographical disparities, with naloxone 
equipment of emergency responders more common in urban than rural settings (Rando 
et al., 2015). In Europe, police officers have been included as target population in the 
Norwegian take-home naloxone program (EMCDDA, 2016a). 
 
Primary care 
U.S. primary care providers have described insufficient time during patient appointments 
and inability to follow up with patients as main organizational barriers to take-home 
naloxone (Binswanger et al., 2015). However, a San Francisco study of primary care 
patients receiving long-term opioid pain therapy found that naloxone co-prescribing was 
feasible and associated with significantly reduced opioid-related emergency department 
visits at 1-year follow-up (Coffin et al., 2016). 
 
Emergency care 
The Massachusetts take-home naloxone program provides naloxone at emergency 
departments, and feasibility has recently also been explored elsewhere. A British 
Columbia survey of emergency department patients at risk of opioid overdose (Kestler 
et al., 2017) found that two-thirds accepted take-home naloxone kits when offered to 




Take-home naloxone provision on prison release was the focus of the N-ALIVE 
randomized trial in England and Wales, which assessed its impact on overdose mortality 
in the month post-release (Bird & Hutchinson, 2003; Farrell & Marsden, 2008; Strang, 
Bird, & Parmar, 2013). N-ALIVE pilot with its target recruitment of 2,800 subjects yielded 
a marked decrease in opioid-related deaths, a subsequent large-scale trial involving 
28,000 prisoners on release was scheduled. However, the pilot was ended prematurely 
in December 2014 (total enrolment: 1,685 subjects) (Parmar, Strang, Choo, Meade, & 
Bird, 2017) after it became clear that many of the overdoses being reversed by naloxone 
were not among the study subjects being followed up, and after separate monitoring of 
the Scottish National Naloxone Programme showed a significant reduction in the 
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proportion of opioid-related deaths in the month following prison release (see above) 
(Bird et al., 2016).  
Prison-based take-home naloxone has also been introduced and studied in New York 
City, California, and Rhode Island (Green et al., 2015; Jordan, 2015; Rosner, 2015). 
 
A growing evidence base 
By the 2010s intervention studies typically reported the number of overdoses reversed 
with naloxone as a central outcome; high naloxone usage rates confirmed the 
‘trainability’ of heroin users to adequately respond to overdose (Green, Heimer, & Grau, 
2008; Lopez-Gaston, Best, Manning, & Day, 2009; Markham-Piper et al., 2008; McAuley 
et al., 2010; Strang, Manning, Mayet, Best, et al., 2008; Tobin, Sherman, Beilenson, 
Welsh, & Latkin, 2009; Wagner et al., 2010). However, methodological limitations such 
as small sample sizes, uncontrolled designs, lack of randomization and systematic 
follow-up made it difficult to quantify the impact of take-home naloxone provision on 
overdose mortality.  
In 2012, the United Nations Commission on Narcotic Drugs passed Resolution 55/7 
(UNODC, 2012), which identified need for more effective prevention of drug overdose 
and “[e]ncourage[d] all Member States to include effective elements for the prevention 
and treatment of drug overdose, in particular opioid overdose, in national drug policies, 
including the use of opioid receptor antagonists such as naloxone.” The same year, N-
ALIVE, i.e. the first large-scale randomized trial of take-home naloxone provision, started 
recruitment (Strang et al., 2013). 
In 2013, two cost-effectiveness analyses presented modelling data from the US and 
Russia, concluding that take-home naloxone was cost-effective even when the cost of 
naloxone increased and the rate of observed overdoses decreased (Coffin & Sullivan, 
2013a, 2013b). Another 2013 study addressed the impact of take-home naloxone 
provision on local overdose rates using an interrupted-time series analysis, finding that 
Massachusetts-based communities with take-home naloxone provision had significantly 
lower overdose mortality rates than communities without (Walley, Xuan, et al., 2013). 
These results were among the key evidence included in a WHO review of community-
based naloxone, which led to the November 2014 launch of the WHO Guidelines on the 
Community Management of Opioid Overdose (WHO, 2014).  
The key recommendation was that “[p]eople likely to witness an opioid overdose should 
have access to naloxone and be instructed in its administration” (WHO, 2014). 
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Subsequently, a BMJ editorial was published, arguing that there is “[n]ow enough 
experience to justify [take-home naloxone implementation]” (Strang, Bird, Dietze, Gerra, 
& McLellan, 2014). Following release of the WHO Guidelines, three systematic reviews 
(Clark, Wilder, & Winstanley, 2014; EMCDDA, 2015; McDonald & Strang, 2016) reached 
similar conclusions. Clark et al. (2014) found that participation in take-home naloxone 
programs led to improved overdose-related knowledge and appropriate use and 
administration of naloxone. The EMCDDA (2015) concluded: ‘there is evidence that 
educational and training interventions with provision of take-home naloxone decrease 
overdose-related mortality’ (p. 11). The most recent systematic review (McDonald & 
Strang, 2016) assessed the safety of take-home naloxone programs as well as their 
impact on opioid overdose-related mortality using the Bradford Hill criteria (Hill, 1965) 
(see Chapter 3). 
Finally, in April 2016, the United Nations General Assembly Special Session on Drugs 
(UNGASS 2016) included “naloxone distribution to prevent overdose deaths associated 




2.4  Discussion  
2.4.1  Statement of principal findings 
This chapter traces the development of take-home naloxone over twenty years, from its 
conception up to its current role. 
 
2.4.2  Strengths and weaknesses of the chapter 
To allow for the wide scope of this literature review, a broad search strategy was applied. 
While the search strategy was not limited to English-language entries, it is possible that 
relevant international sources (published in other languages) may have been 
overlooked. Take-home naloxone initiatives in non-English speaking countries may thus 
be underrepresented in this literature review. Apart from a program description of take-
home naloxone provision in Kyrgyzstan and Tajikistan (Kan et al., 2014), take-home 
naloxone initiatives in low and middle-income countries largely missing from the peer-
reviewed literature. A second limitation concerns the possibility that that the 
chronological timeline (see also Table 4) may include minor inaccuracies due to 




2.4.3  Questions for future research 
After two decades of take-home naloxone research, many questions still remain 
unanswered about the intervention, including questions about suitable non-injectable 
routes of naloxone administration and optimal dose range (FDA, 2016b). These 
questions are discussed in more detail in Chapters 4 to 9. 
 
2.5  Conclusion 
Twenty years ago, the very idea of take-home naloxone was a radical speculative 
proposal to extend harm reduction beyond needle and syringe exchange. Take-home 
naloxone has subsequently overcome legal barriers in many jurisdictions and is 
increasingly accepted as an effective public health strategy to reduce overdose fatalities. 
In the next chapter, I will present my systematic review of the effectiveness of take-home 




Table 4 Key events in the emergence and evolution of THN 
Year Month Country Event  
1961 March USA Drs. Jack Fishman and Mozes J. Lewenstein apply for first US 
patent for synthesis of naloxone (issued in May 1966)  
  USA Dr. Harold Blumberg and colleagues publish abstract in Federation 
Proceedings in which he introduces naloxone as “potent, rapid-
acting, and relatively pure narcotic antagonist.” 
1962 March UK Sankyo applies for British patent for naloxone (issued in October 
1963) 
  Japan Minakami et al. of Sankyo Company Ltd. Publish first full-length 
journal article on naloxone in Life Sciences 
1971  USA FDA licenses naloxone as prescription-only medication; naloxone 
enters clinical practice in Europe in subsequent years  
1983  Int’l Naloxone is included in the 1983 WHO List of Essential Medicines 
(and subsequent editions)   
1991  Italy Report of community-based naloxone access in Turin suburb 
1992 March Australia Notion of THN provision to at-risk populations is mooted at 3rd 
International Harm Reduction Conference in Melbourne 
1996 June UK BMJ editorial by Strang et al. states ‘home-based supplies of 
naloxone would save lives’  
ca. June USA Chicago Recovery Alliance (CRA) distributes first THN kits  
 Italy Ministry of Health classifies naloxone as over-the-counter 
medication 
 Italy Reports of THN distribution in Padua  
1998 September Italy Simini announces plans to distribute THN in Bologna and 
surrounding Emilia Romagna region in The Lancet  
 October UK Island of Jersey starts THN distribution  
1999 January Germany Fixpunkt Berlin starts THN distribution  
 March USA San Francisco Needle Exchange starts THN distribution  
2001 April Germany/  
UK 
First published report of THN distribution by Dettmer et al. in BMJ  
 
 Spain Reports of underground THN distribution in Barcelona  
 USA New Mexico launches THN program  
  UK Introduction of first mainland THN scheme (south London)  
2002 March USA Dan Bigg of CRA reports first lives saved using THN in BMJ  
2003  USA San Francisco Public Health Dept. starts THN program 
2004 June USA Lower East Side Harm Reduction Coalition in New York starts THN 
distribution 




Year Month Country Event  
2005 November UK Legal status of naloxone changed to permit emergency 
administration of naloxone by any member of the general public 
(Schedule 7 of the Medicines Act) 
2006 August USA Boston Public Health Commission authorizes start of THN 
program, including provision of intranasal naloxone kits 
2006  UK National Treatment Agency for Substance Misuse (NTA) funds 
THN training pilot in 16 sites in England  
2007  UK Scotland and Wales establish THN pilots  
2008  UK Medical Research Council funds N-ALIVE trial  
 Spain Formal THN program launched in Barcelona  
2010  USA ONDCP National Drug Control Strategy endorses community use 
of naloxone 
 November UK Scotland launches national THN program 
2011  UK Scottish Lord Advocate issues new guidelines  
 UK Wales launches national THN program  
 Australia First Australian THN program starts in Canberra  
2012 March Int’l UNODC Resolution 55/7 states ‘opioid overdose treatment, 
including the provision of opioid receptor antagonists such as 
naloxone, is part of a comprehensive approach to services for drug 
users’  
April USA FDA, CDC, NIDA, and HHS convene naloxone meeting  
 May UK Advisory Council on the Misuse of Drugs urges Department of 
Health to review naloxone prescription-only status 
 December Australia Naloxone is added to the Pharmaceutical Benefit Scheme 
2013 March Denmark THN program starts (dual kits: intranasal and injectable)  
 Estonia Harju and East-Viru counties start THN distribution 
2014 July Norway THN program starts (intranasal)  
November Int’l WHO releases guidelines on the community management of opioid 
overdose 
2015 May Ireland Health Services Executive approves THN by prescription, THN 
project starts 
 October UK Public Health England release guidelines allowing drug services to 
issue THN without prescription 
 November USA FDA approves a first naloxone nasal spray product 
2016 February Australia Injectable naloxone becomes available over-the-counter 
 April Int’l UNGASS 2016 includes naloxone in its scientific summary 
 October Canada Health Canada approves naloxone nasal spray product without 
prescription requirement 




Chapter 3  Bradford Hill Analysis of Take-Home Naloxone 
 
Preface 
In this chapter, I review the evidence for take-home naloxone programs by means of a 
Bradford-Hill analysis. Due to the current lively debate around take-home naloxone and 
associated public health implications, I considered it important for the data from take-
home naloxone programs to be reported in their entirety. 
The idea for this chapter emerged in 2013 when the Australian researcher Dr. Alex 
Wodak published a blog post (Wodak, 2013), wherein he voiced skepticism regarding 
the effectiveness and safety of take-home naloxone. Despite his roots in the harm 
reduction movement, Dr. Wodak argued that – in the absence of results from randomized 
controlled trials – the “existing evidence for the effectiveness and safety [of take-home 
naloxone] was weak” and suggested that implementation of THN should be delayed until 
stronger evidence became available. Dr. Wodak called on the research community to 
provide the lacking evidence by conducting a Bradford Hill analysis, having previously 
himself applied this method to the study of needle-and-syringe programs.  
I used the contents of this Bradford Hill analysis as the basis of a first-authored paper 
entitled “Are take-home naloxone programmes effective? Systematic review utilizing 
application of the Bradford Hill criteria” that was published in Addiction in March 2016. In 
addition, prior to publication of the paper, I was invited to present the results of my study 
as part of a naloxone symposium at the annual meeting of the Society for the Study of 
Addiction (SSA) in November 2015. After accessing the PowerPoint slides and audio 
recording of my presentation on the SSA website, Dr. Wodak issued a public statement 
to the effect that, with my SSA presentation of the Bradford-Hill analysis, he considered 
that the scientific case had now adequately been made. Dr. Wodak’s email to me 
(December 17, 2015) stated: “[I am] even more delighted (but not surprised) to read that 
your assessment is that the available evidence meets all but two of the criteria”. As 
recently as January 2016, Dr. Wodak has been quoted as “welcom[ing] the increased 
availability of the antidote” in Australia (Davey, 2016).  
According to the Addiction editorial office, my Bradford Hill analysis ranks among the top 
0.1% of most downloaded papers in the journal in the year 2016. The US FDA also 
presented my analysis as key evidence for the effectiveness of take-home naloxone at 
their public meeting in October 2016 (FDA, 2016a).  
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3.1  Introduction 
As discussed in Chapter 2, take-home naloxone (THN) programs have over the past 20 
years been implemented in Europe, Northern America, Asia, and Australia 
(UNODC/WHO, 2013). However, the vast majority of evaluations have been pilot 
schemes with uncontrolled study design. 
The evaluation of THN programs is challenging: randomized controlled trials (RCTs) are 
often considered the gold standard of scientific study of clinical impact, but conducting 
such trials in this context would often be unethical and fraught with methodological difficulties 
given the infrequency and unpredictability of overdose.  
Critics of THN programs argue that the existing observational data are not strong enough 
to infer causation from naloxone provision to the reduction of overdose deaths (Byrne, 
2006; Wodak, 2013). A counter-argument may be that similar reservations initially 
blocked other harm reduction strategies, including needle exchange programs and 
opioid substitution therapy (Des Jarlais, Paone, Friedman, Peyser, & Newman, 1995) 
that are now evidence-based practice (Bazazi, Zaller, Fu, & Rich, 2010) (and would still 
be absent if the precautionary principle had been strictly applied). 
A better understanding of the potential benefits and risks of THN provision is essential. 
If concerns are valid, they need to be identified and considered in context. But mere 
assertions of hypothetical disadvantages must not prohibit access to a life-saving 
medication. A previous systematic review (Clark et al., 2014) found that participation in 
THN programs led to improved overdose-related knowledge as well as appropriate use 
and administration of naloxone, but the impact on overdose mortality was not assessed. 
The goal of this Bradford Hill analysis is to assess the effectiveness of THN programs 
by rigorously following a well-recognized process (i.e. the Bradford Hill criteria) to 
evaluate the data within eligible studies. The analysis was conducted with two specific 
aims:  
• Aim 1: to describe the impact of THN provision on overdose-related mortality in 
opioid users;  
• Aim 2: to assess the safety of THN provision by quantifying adverse events 
associated with naloxone administration.  
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3.2  Methods 
A systematic literature search was performed following PRISMA guidance (see Figure 
11for PRISMA flow diagram).  
 
 
Figure 11 PRISMA flow diagram of study selection process 
 
3.2.1  Identification of eligible studies 
Electronic databases were searched to identify relevant peer-reviewed articles published 
between January 1946 and June (3rd week) 2015. Replicating the search strategy 
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reported by Clark et al. (Clark et al., 2014), the following Boolean search query was used: 
(opioid OR opiate) AND overdose AND prevention (see Table 5 for search protocol).  
Electronic database searching generated 1,397 records: 150 on Medline, 772 on 
PsycINFO (both via OVID), and 475 on PubMed. Five studies (Bennett & Holloway, 
2012; Lopez-Gaston et al., 2009; McAuley et al., 2010; Seal et al., 2005; Strang, 
Manning, Mayet, Best, et al., 2008) were added after manually searching the reference 
lists of recent literature reviews (Clark et al., 2014; EMCDDA, 2015; Mueller, Walley, 
Calcaterra, Glanz, & Binswanger, 2015). 
Original quantitative (or mixed-method) studies of randomized or observational trials of 
THN programs that trained opioid users in overdose prevention AND reported on 
overdose outcomes were included in the study. Several exclusion criteria were applied: 
reporting on buprenorphine/ naloxone; case reports; not reporting primary research data; 
not reporting on heroin/opioid users, naloxone, or overdose (see Table 11 for a list of 
excluded studies).  
Under guidance of my first supervisor, I extracted data using the STROBE-checklist (Von 
Elm et al., 2007), assessed study eligibility, and conducted quality appraisal using an 
eight-item scale (Jinks, Cotton, & Rylance, 2011), which had previously been applied by 
Clark et al. (2014) (see Table 9). 
All 22 studies that met the inclusion criteria were entered into the analysis. Among these, 
one was an interrupted-time series analysis that provided quasi-experimental data. 
Sixteen were pre-post studies (nine with systematic follow-up), three were case-series, 
and two were cross-sectional. None of the studies involved randomization to the 
intervention (i.e. THN distribution), although two studies were controlled (Bennett & 
Holloway, 2012; Walley, Xuan, et al., 2013). Of the 22 included studies, 15 were carried 
out in the US, two in Canada, four in the UK, and one in the UK and Germany (multi-





Table 5 Search protocol 
Research question Are take-home naloxone programs effective at reducing overdose deaths 
among opioid users? 
Aim 1: To assess the impact of take-home naloxone provision on overdose-
related mortality in opioid users. 
Sub-questions Do take-home naloxone programs lead to adverse events among opioid 
users? 
 Aim 2: To assess the safety of take-home naloxone provision among opioid 
users 
Search strategy Electronic Databases:  
Medline, PsycINFO (both accessed via OVID SP), and PubMed to identify 
relevant peer-reviewed articles published in English language between January 
1946 and June (3rd week) 2015.  
 
Medline: 
1. (opioid or opiate).mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier] 
2. prevention.mp. 
3. Drug Overdose/ or overdose.mp. 
4. 1 and 2 and 3 
 
PubMed: 
(((opioid) OR opiate) AND prevention) AND overdose 
 
PsycINFO: 
1. opioid.mp. or exp Opiates/ 
2. overdose.mp./or exp Naloxone/ or exp Drug Therapy/ or exp Drugs/ or or exp 
Drug Abuse/ or exp Heroin/ or exp Opiates/ or exp Drug Overdoses/ or exp 
Methadone/ 
3. prevention.mp. or exp Prevention/ 
4. 1 and 2 and 3 
 
Web:  
UK Advisory Council on the Misuse of Drugs 
Public Health England 
US National Institute on Drug Abuse 
European Monitoring Centre for Drugs and Drug Addiction 
databases of United Nations agencies 
 
Hand-searching (snowballing method): 
Reference lists of recent literature reviews (Clark et al., 2014; EMCDDA, 2015; 
Mueller et al., 2015); ToC for key journals (Addiction, BMJ, Journal of Urban 
Health, Harm Reduction Journal).  
Existing systematic reviews Clark AK, Wilder CM, Winstanley EL. A systematic review of community opioid 
overdose prevention and naloxone distribution programs. Journal of Addiction 
Medicine. 2014;8(3):153-63. 
EMCDDA. Preventing fatal overdoses: a systematic review of the effectiveness 




General search filter used Identify records from title, abstract, keywords; Map term to Medical Subject 
Heading 
Publication Year: 1946 – Current 
Duplicate articles to be removed using EndNote software version X6 for 
Windows. 
Question specific search 
filter 
(none) 
Amendments to filter/ search 
strategy 
(none) 
Search Date 1 January 1946 to June (3rd week) 2015 
Eligibility criteria  
• Population  Opioid users (any treatment status)  
• Intervention Take-home naloxone 
• Comparison Standard care (no take-home naloxone) 
• Outcomes Adverse reactions 
Deaths 
Follow-up 
Inappropriate naloxone administration (e.g. cocaine intoxication) 
Survived after take-home naloxone administration 
Take-home naloxone kits distributed 
Take-home naloxone kits used 
Unknown outcomes 
Secondary outcomes (not specified) 
• Study design Randomized clinical trials (RCTs) and observational studies (quantitative or 
mixed-method studies) 
• Publication status Original studies published in peer-reviewed journals 
Exclusion criteria Case reports 
Qualitative studies 
Reporting on naloxone/ buprenorphine 
Indication: not reporting on heroin or opioid users, e.g. use of naloxone to treat: 
- dysmenorrhea (ICD-10 N94.4-94.6; naloxone used to treat uterine 
contractions) 
- restless legs syndrome (ICD-10 G25.8) 
- chronic pain condition (e.g. in cancer patients) 
- opioid‐induced bowel dysfunction 
Not reporting on naloxone 
Not reporting on overdose 
Not reporting primary research data 
Quality assessment Eight-item checklist (Jinks et al., 2011) 
The eight items are each dichotomised to ‘yes’ (1 point) or ‘no’ (0 points) and 
address the relevance of the study aims, appropriateness of methods used, 
transparency of data analysis and results, and soundness of interpretive 
approach. 




3.2.2  Analysis 
Meta-analysis was dismissed for two reasons. Firstly, there was large variability in the 
size and quality of the THN intervention studies identified: many were merely descriptive 
reports. While valuable communications to other practitioners, these reports 
nevertheless lacked study design and analytical rigor. Secondly, while nine studies 
involved systematic follow-up, they were not considered necessarily representative of 
the majority of included studies due to small sample sizes. For instance, in the Seal et 
al. (2005) study with systematic follow-up, the 24 program participants received an 8-
hour training in overdose prevention, naloxone use and cardiopulmonary resuscitation, 
whereas training sessions in the Massachusetts take-home naloxone program (n = 
2,912) could be as short as 10 minutes (Walley, Xuan, et al., 2013). A meta-analysis of 
THN programs by Giglio, Li, and DiMaggio (2015) illustrates this dilemma. As central 
outcomes, the authors presented the mean difference in overdose prevention training 
scores and odds ratios of recovery from drug overdose associated with naloxone 
administration by bystanders. However, the authors were only able to determine odds 
ratios of recovery for a total of four studies (Galea, Nandi, et al., 2006; Lankenau et al., 
2013; McAuley et al., 2010; Strang, Manning, Mayet, Best, et al., 2008) across which no 
more than 66 overdose events and 39 naloxone administrations had been reported. This 
number of naloxone administrations is negligible compared to the 2,336 naloxone 
administrations reported across 17 studies in this systematic review (i.e. excluding 4 
studies which may have contained duplicate samples) (see Table 8).  
Therefore, narrative synthesis was chosen as the more appropriate method of analysis 
in lieu of meta-analysis. In this context, the evidence was evaluated using the Bradford 
Hill criteria (Hill, 1965). 
 
The Bradford Hill criteria 
The Bradford Hill criteria (Hill, 1965) are a set of nine criteria (see Table 7) devised in 
1965 by British epidemiologist and statistician Sir Austin Bradford Hill (see Figure 12) to 
assess causality when only correlational data are available: 1) Strength of Association, 
2) Consistency, 3) Specificity, 4) Temporality, 5) Dose-response Relationship, 6) 
Plausibility, 7) Coherence, 8) Experimental Evidence, and 9) Analogy. The Bradford Hill 
criteria are considered a standard tool to assess the impact of broad-based public health 






Figure 12 Sir Austin Bradford Hill (1897-1991)10 
 
Sir Austin Bradford Hill originally applied the criteria to the example of lung cancer related 
to smoking (Hill, 1965). The criteria have since been applied to a wide range of 
indications, from data integration in epigenetics and molecular epidemiology (Fedak, 
Bernal, Capshaw, & Gross, 2015) to regional public health emergencies, for instance the 
association between the outbreak of the Zika virus and microcephaly in Brazil (Frank, 
Faber, & Stark, 2016). 
Within addictions research, the Bradford Hill criteria have been valuably applied in a 
WHO “Evidence for Action” report (authored by Dr. Alex Wodak and Annie Cooney) 
(WHO, 2004) on the effectiveness of needle-exchange interventions in reducing HIV 
among IDUs. The WHO report also considered evidence according to five additional 
criteria relating to feasibility and implementation (see Table 6), which are included as 
supplementary analysis: 10) Cost-effectiveness; 11) Absence of Negative 
Consequences; 12) Feasibility of Implementation, Expansion, and Coverage; 13) 
Unanticipated Benefits; 14) Special Populations. 
Where summary outcome measures (e.g. number of naloxone administrations, overdose 
reversals, adverse events) were calculated across studies, I have sought to avoid 
(partial) duplication of samples by including only the study with the largest participant 
sample per project (Wagner et al., 2010; Walley, Xuan, et al., 2013) for THN projects 
that had produced more than one published study (i.e. Boston/Massachusetts, Los 
Angeles, New York, San Francisco). Vice versa, if the time periods covered by multiple 
studies from the same project could be clearly distinguished and did not overlap, all 
project evaluations entered analysis (Enteen et al., 2010; Galea, Worthington, et al., 
                                               
10 Source: Wikipedia.org 
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2006; Piper et al., 2008; Rowe et al., 2015). All summary statistics are pooled, 
unweighted estimates from the referenced studies. The number of overdose reversals is 
used as proxy for the impact of THN provision on opioid overdose mortality (Aim 1), as 
a ratio of one fatal overdose in every 20 overdose events has been described in the 
literature (Darke et al., 2003), and it is impossible to ascertain for each overdose event 
whether, in the absence of intervention, the outcome would have been fatal or whether 
respiratory function would have recovered. 
 
 
3.3  Results 
I now present the findings from application of the nine original Bradford Hill criteria (Hill, 
1965), followed by consideration of the extra five criteria added in the WHO report (WHO, 
2004; Wodak & Cooney, 2006) (see Table 6).  
 
Table 6 Additional feasibility and implementation criteria 
Criterion Take-home Naloxone (THN) 
Cost-effectiveness Is THN for lay overdose reversal cost-effective compared 
to treatment as usual (no intervention)? 
Absence of Negative Consequences Does the distribution of THN to users bear the risk of 
adverse events? 
Feasibility of Implementation, Expansion, 
and Coverage 
Is it feasible to introduce THN distribution in diverse 
settings, including resource-poor settings, and scale up 
implementation? 
Unanticipated Benefits Does the distribution of THN to users lead to 
unanticipated benefits? 
Special Populations  How successful are THN programs in reaching special 
populations that have been identified as particularly “at 
risk” opioid users? 
 
 
3.3.1  Consideration according to the original Bradford Hill criteria 
1) Strength of Association  
In 21 of the 22 studies, pre-provision of naloxone was followed by use of the naloxone 
to reverse opioid overdose. After exclusion of four studies that possibly contained 
duplicate samples (Doe-Simkins et al., 2009; Dwyer et al., 2015; Lankenau et al., 2013; 
Walley, Doe-Simkins, et al., 2013), a total of 2,336 THN administrations were found 
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across 17 studies (see Table 8). Due the binary outcome (survival/death), the number of 
successful overdose reversals can be estimated by deducting the number of deaths from 
the number of THN administrations. By deducting the 20 confirmed deaths 
(1+1+2+6+10) where overdose victims did not recover following naloxone administration 
(Bennett, Bell, Tomedi, Hulsey, & Kral, 2011; Bennett & Holloway, 2012; Enteen et al., 
2010; Maxwell et al., 2006; Rowe et al., 2015), an upper estimate of 2,316 successful 
overdose reversals11 emerges. If the four deaths where it was unclear if naloxone had 
been administered (Wagner et al., 2010) and 63 cases (8+36+14+5) of naloxone 
administration with ‘unknown outcome’ (Bennett et al., 2011; Enteen et al., 2010; Piper 
et al., 2008; Wagner et al., 2010) are also counted towards fatalities following naloxone 
administration, a conservative, lower estimate of 2,249 successful overdose reversals12 
emerges. In the only study where THN provision did not lead to overdose reversals 
(Lopez-Gaston et al., 2009), nine out of 46 program participants witnessed a total of 16 
overdoses at six-month follow-up, but none administered naloxone to the overdose 
victims. 
The main reason for non-administration was that participants did not have their naloxone 
supply available. 
In summary, there is a strong association between THN programs and overdose survival, 
as evidenced by at least 2,249 successful overdose reversals (96.3%; 95% CI: 95.5, 
97.1) among 2,336 THN administrations. 
 
2) Temporality 
In 21 of the 22 studies, training in overdose prevention and THN provision preceded 
overdose reversals. Two of these studies provide clear evidence in support of the 
temporality criterion. Supportive evidence comes from descriptive accounts of early THN 
distribution in Chicago and surrounding Cooks County (Maxwell et al., 2006): after a 
135% increase in local overdose deaths from 1996-2000, the introduction of THN in 2001 
led to reduction in fatal overdoses by 20% in 2001, 8% in 2002, and 6% in 2003 
(compared to past-year rate). While these data are indicative of a temporal sequence 
between THN introduction and reduced overdose mortality, no definite conclusion can 
                                               
11 2,316 OD reversals equals 2,336 THN administrations minus 20 deaths 




be drawn, as the lack of control group means that other causes may have contributed to 
decreasing overdose mortality rates. 
Stronger evidence comes from Walley, Xuan et al. (2013) who conducted an evaluation 
of a state-funded THN program in Massachusetts. Between 2006 and 2009, the 
Massachusetts Department of Public Health used a phased roll-out to introduce THN in 
19 communities, enrolling 2,912 individuals in total. To evaluate the impact of THN, 
Walley, Xuan et al. (2013) used an interrupted time-series analysis, where each 
community served as its own geographic control and communities without concurrent 
THN availability served as time control. For all 19 participating communities, overdose 
mortality rates in the time periods before and after THN implementation were compared. 
Overdose mortality rates were significantly reduced in communities where THN was 
implemented - compared to pre-implementation rates and to communities without THN.  
 
3) Consistency 
Overdose reversals by means of THN have been documented in the selected studies by 
independent investigators under different circumstances in at least 15 different cities, 
states and countries: in Canada (Toronto & British Columbia), the USA (Baltimore, 
Boston/Massachusetts, Chicago, Los Angeles, San Francisco, New York, Pittsburgh, 
Rhode Island), the UK (England, Jersey, Scotland, Wales), and Germany (Berlin). 
Overdose reversals by THN have also been documented repeatedly in New York (Galea, 
Worthington, et al., 2006; Piper et al., 2008) and San Francisco (Enteen et al., 2010; 
Rowe et al., 2015; Seal et al., 2005). In conclusion, there is substantial support for the 
consistency criterion. 
 
4) Biological Plausibility 
This criterion addresses the therapeutic effect of naloxone. Naloxone is a pure opioid 
antagonist that binds to the μ-opioid receptor and blocks competing agonists, such as 
heroin (NIH, 2007). All but one study (Lopez-Gaston et al., 2009) reported on THN 
administration in cases of suspected opioid overdoses, and the pharmacological effects 
of naloxone led to at least 2,249 overdose reversals. In conclusion, there is strong 






Declining overdose rates in the absence of THN have been reported in the literature. 
The Australian heroin drought constitutes a prominent example, where overdose-related 
mortality rates dropped between 2001 and 2002 in conjunction with a shortage in illicit 
heroin imports. THN could not have accounted for the decline in mortality, as it was only 
introduced in Australia in 2011 (ACT-Health, 2014; Degenhardt, Day, Gilmour, & Hall, 
2006). However, the Australian example does not conflict with the presumed effect of 
THN on reduced overdose mortality. The cause-and-effect interpretation of our data is 
consistent with current understanding of the mechanisms of opioid overdose, and the 21 
studies which reported overdose reversals provide strong support for the coherence 
criterion. 
 
6) Specificity  
The Specificity criterion relates to efficacy of the intervention (same as Biological 
Plausibility), rather than population-wide effectiveness. THN exclusively reverses opioid-
induced overdoses, as illustrated by the following two cases: in the Dettmer et al. study 
(Dettmer et al., 2001), naloxone had zero effect when administered to a person suffering 
from cocaine intoxication. The Chicago Recovery Alliance reported one fatality after 
naloxone administration (Maxwell et al., 2006) where naloxone failed to revive an 
overdose victim with non-opioids in their system. The mooted benefit from naloxone is 
specific to opioid overdose. In practice, THN may be primarily beneficial for the reversal 
of overdoses from heroin and other short-acting opioids. (All 22 studies reported primarily 
on heroin overdoses, and one study specified that the long-acting opioid methadone was 
involved in less than 5% of overdose reversals (Walley, Doe-Simkins, et al., 2013)). 
Overall, the evidence constitutes strong support for this criterion. 
 
7) Dose-response Relationship  
Researchers estimate that THN distribution can only achieve maximum impact on 
overdose reduction if a certain volume of THN kits is available in the community. Among 
the 22 studies, only Walley, Xuan et al. (2013) assessed the impact of varying degrees 
of THN availability on overdose mortality by splitting the 19 participating communities 
into three groups based on volume of THN distribution: zero implementation, low 
implementation (1-100 program enrollments per 100,000 inhabitants), and high 
implementation (>100 enrollments). Both low and high implementers had significantly 
reduced overdose mortality rates compared to communities without implementation, and 
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there was a significant implementation dose-relationship with overdose death rates, with 
greatest effect with greatest implementation. To summarize, there is only this limited 
empirical evidence for a dose-related impact of THN availability, and hence this criterion 
is only partially fulfilled.  
 
8) Experimental Evidence 
While none of the 22 studies deliver experimental evidence, the interrupted time-series 
analysis by Walley, Xuan et al. (2013) provides quasi-experimental evidence in support 
of causation. Importantly, even communities with low-level THN implementation of THN 
(1-100 participants, see above) saw a reduction in overdose mortality, compared to 
communities without THN distribution. Interrupted time-series analysis is considered to 
be the strongest quasi-experimental research design (Penfold & Zhang, 2013). The 
results of the study by Walley, Xuan et al. (2013) thus provide preliminary support for the 
Experimental Evidence criterion. 
 
9) Analogy  
THN is analogous to naloxone treatment for the same clinical indication in emergency 
medical care, and also to the prescription of other emergency medications (typically 
antidotes for overdose or poisoning) for peer administration: THN has been compared 
to the provision of adrenaline injection kits (e.g., EpiPen) to individuals with severe  
allergic  reactions  for  family  members to administer in the event of anaphylactic shock 
(Strang, Manning, Mayet, Best, et al., 2008) or the provision of glucagon for insulin 
overdose (Maxwell et al., 2006). Similarly, THN has been likened to pre-placement of 
defibrillators and CPR training for lay people likely to witness cardiac arrest (Wagner et 
al., 2014). For all these emergency interventions, timely delivery is crucial. The analogy 
criterion is therefore fulfilled. 
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Table 7 Bradford Hill criteria: definition and application to take-home naloxone 
Criterion Definition Take-home naloxone (THN) 
Strength of 
Association  
The stronger the association between the exposure to a treatment and the 
clinical outcome, the less likely it is influenced by an external variable. 
How strong is the association between THN and OD 
reversal? 
Temporality A cause-and-effect hypothesis can only find empirical support if the 
presumed cause precedes the effect in time.  
Did the distribution of THN precede a reduction in OD 
deaths?  
Consistency The credibility of a finding increases if different investigators can replicate it 
across different locations and under different circumstances.  
Have there been multiple observations of OD reversals as a 
result of THN provision? 
Biological 
Plausibility 
There is stronger support for causality if there is a likely biological or 
pharmacological mechanism that can explain the association between 
exposure to a treatment and the outcome.  
Is it biologically plausible that a reduction in OD deaths 




Causality between a treatment and outcome is supported when the 
association is coherent with current knowledge of the disease. Vice versa, 
conflicting or lack of supporting evidence would count against coherence.  
Are there documented examples of opioid OD mortality 
declining without THN availability? If so, does this empirical 
evidence conflict with the assumed association between THN 
and OD prevention? 
Specificity  Causality can be established when one intervention leads to one specific 
outcome. 
Does THN have the unique effect of reversing opioid ODs? 
Dose-Response 
Relationship  
If a dose-response relationship can be observed for the cause-and-effect 
hypothesis, increased exposure to treatment will proportionally impact the 
clinical outcome.  




If experimental manipulation of the exposure-outcome association impacts 
the outcome, (semi) experimental evidence is given. This delivers the 
strongest support for causation.  
Is there (semi-) experimental evidence to support the 
hypothesized impact of THN on OD mortality?  
Analogy  If a treatment/exposure factor similar to A leads to a clinical outcome similar 
to B, then this analogy counts as evidence in support of our hypothesis that 
A causes B.  
Is there a treatment similar to THN that leads to an outcome 
similar to OD reversal? 
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3.3.2  Consideration according to additional feasibility and implementation criteria 
10) Cost-effectiveness 
Separate modelling data from both the U.S. and Russia conclude that THN is cost-effective 
even under conservative circumstances, i.e. when the cost of naloxone increases and the 
rate of observed overdoses decreases (Coffin & Sullivan, 2013a, 2013b). Bearing in mind 
the potential limitation that both studies were conducted by the same authors, there is 
consistent evidence for the cost-effectiveness of THN. 
 
11) Absence of Negative Consequences 
In five of the 17 studies that did not contain duplicate samples, 20 overdose victims did not 
survive naloxone administration (Bennett et al., 2011; Bennett & Holloway, 2012; Enteen et 
al., 2010; Maxwell et al., 2006; Rowe et al., 2015). In addition, Wagner et al. (2010) reported 
four deaths where it was unclear if naloxone had been administered. Based on these 
observations, the following fatality rates emerge: 20 confirmed deaths per 2,336 naloxone 
administrations (0.9%; 95% CI: 0.5, 1.2), or 24 deaths per 2,336 naloxone administrations 
(1.0%; 95% CI: 0.6, 1.4) if the four fatalities are included where it was unclear if naloxone 
had been administered. If the study selection is limited to the nine articles with systematic 
follow-up, a similar ratio of one confirmed death per 123 naloxone administrations (0.8%; 
95% CI: 0.4, 1.2) was observed.  
In six (Dettmer et al., 2001; Enteen et al., 2010; Maxwell et al., 2006; Strang, Manning, 
Mayet, Best, et al., 2008; Tzemis, Al-Qutub, Amlani, Kesselring, & Buxton, 2014; Wagner et 
al., 2010) of the 17 studies, several adverse reactions were reported in conjunction with a 
total of 2,336 naloxone administrations: at least 65 instances of withdrawal symptoms 
(2.8%), 52 cases of vomiting (2.2%), 50 cases of agitation (2.1%), and four seizures (0.1%). 
In conclusion, THN programs have a low rate of adverse events. Where adverse reactions 
occurred, these were most frequently symptoms of opioid withdrawal (incl. nausea/vomiting, 
agitation). 
 
12) Feasibility of Implementation, Expansion, and Coverage 
The 22 studies document THN implementation in a variety of settings across 16 
geographical locations, and naloxone usage rates between 5%-63% are reported. San 
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Francisco is an example of rapid expansion, as the volume of THN kits distributed increased 
from 24 in 2001 to 2,962 kits over the six-year period between 2003-2009 (i.e. approximately 
494 kits/year) (Enteen et al., 2010), and to 2,500 kits from 2010 to 2013 (i.e. approximately 
833 kits/year) (Rowe et al., 2015). Outside of the 22 studies included in this review, 
implementation in resource-poor settings has been achieved in Kyrgyzstan and Tajikistan, 
with reported naloxone usage rates of 47% and 78%, respectively (Kan et al., 2014). These 
studies suggest that THN schemes are capable of implementation across a wide range of 
settings and cultures. 
 
13) Unanticipated Benefits 
Four of the 22 studies reported unanticipated benefits. In THN programs in California, 25% 
of participants in San Francisco entered treatment within 6-month follow-up (Seal et al., 
2005), and 53% of participants in Los Angeles reported decreased drug use at 3-month 
follow-up (Wagner et al., 2010). Similarly, Maxwell et al. reported anecdotal evidence of 
increased willingness among THN recipients to be tested for HIV and HCV (Maxwell et al., 
2006). Strang et al. (2008) found a secondary training effect: within a 3-month follow-up 
period, 28% of THN recipients had trained a family member or peer. 
 
14) Special Populations 
THN provision has successfully been implemented in programs targeting special 
populations with high risk of overdose: detox patients (Lopez-Gaston et al., 2009; Walley, 
Doe-Simkins, et al., 2013), homeless users (Enteen et al., 2010; Piper et al., 2008; Rowe et 
al., 2015; Wagner et al., 2010; Yokell, Green, Bowman, McKenzie, & Rich, 2011), 
methadone patients (Walley, Doe-Simkins, et al., 2013) and prison inmates (Bennett & 
Holloway, 2012). The Massachusetts THN program (Walley, Xuan et al., 2013) also enrolled 
attendees of HIV education centers, and a Los Angeles-based program recruited over 50% 
HCV-positive patients. Both represent particularly vulnerable groups due to their comorbid 
health issues and risk of blood-borne virus transmission by needle-sharing. From the 




Table 8  THN kits distributed and used, overdose reversals, and adverse events 
Study n 
THN kits  
distributed  
THN kits used 
(%) Deaths 
OD Reversal 
after THN**  Unknown Outcomes Adverse Reactions 
Bennett 2011 426 426  249 (58%) 2 ≥ 96% 8 NR 
Bennet 2012 525 NR  28 (NR) 1 96%  NR 
Dettmer 2001a 101 101 5 (5%) 0 100%  Withdrawal (NR) 
Dettmer 2001b 124 124 29 (23%) 0 100%  Withdrawal (10) 
Doe-Simkins 2009* 385 385 74 (19%) 0 100%  Withdrawal (2) 
Dwyer 2015* 415 56 6 (11%) 0 100%  NR 
Enteen 2010 1,942 2,962  399 (13%) 6 ≥ 89% 36 Vomiting (50), Agitation (36), Seizures (3) 
Galea 2006 25 25  10 (40%) 1a 100% 1a None 
Lankenau 2013* 30 30  15 (50%) 0 ≥ 97% 1 NR 
Leece 2013 209 209  17 (8%)  0 100%  None 
Lopez-Gaston 2009 70 70  0 (0%)  1a N/A  N/A 
Markham Piper 2008 122 122  82 (67%)  0 ≥ 83% 14 NR 
Maxwell 2006 1,120 3,500  319 (9%)  1c 99%  Seizures (1), Vomiting (1) 
McAuley 2010 41 19  2 (11%) 1a 100%  NR 
Rowe 2015 2,500 2,500  702 (28%)  10 99%  NR 
Seal 2005 24 24 15 (63%)  0 100%  NR 
Strang 2008 239 239  1 (5%) 1a 100%  Withdrawal  
Tobin 2009 250 250  22 (9%)  0 100%  NR 
Tzemis 2014 692 836  85 (10%)  0 100%  Withdrawal (55), Agitation (9) 
Wagner 2009 66 66  28 (42%)  4b NR 5 Agitation (5), Vomiting (1) 
Walley, Xuan 2013 2,912 2,912  327 (11%) 0 100%  NR 
Walley, Doe-Simk. 2013* 1,553 1,553  92 (6%)  0 100%  NR 
Yokell 2011 120 120  5 (4%) 0 100%  NR 
Annotations: a naloxone not administered; b unclear if naloxone administered; c non-opioids present; N/A: not applicable; NR: not reported; THN: take-home naloxone; * not included in summary 
measures to avoid (partial) duplication of samples; ** where applicable, unknown outcomes were counted towards unsuccessful THN administrations (as indicated by the ‘≥’ sign).  
79 
 
Table 9 Included Studies: Follow-up rate, study design, and quality rating 
Study Location n FU  FU % FU Type Design Score 
Bennett 2011 Pittsburg 426 89 21% non-systematic  pre-post 5 
Bennet 2012 Wales  525 28  5% systematic   pre-post 6 
Dettmer 2001a Jersey 101 NR NR non-systematic  case series 4 
Dettmer 2001b Berlin 124 40  32% non-systematic   case series 4 
Doe-Simkins 2009 Boston 385 278 72% non-systematic  pre-post 5 
Dwyer 2015 Boston 415 51  12% systematic pre-post  6 
Enteen 2010 San Francisco 1,942 310 16% non-systematic  pre-post 6 
Galea 2006 New York  25 22  88% systematic pre-post 7 
Lankenau 2013 Los Angeles 30 N/A N/A N/A cross-sectional 6 
Leece 2013 Toronto  209 NR NR non-systematic  case series 5 
Lopez-Gaston 2009 Birmingham & London  70 46 65% systematic pre-post 7 
Markham Piper 2008 New York  122 NR NR non-systematic  pre-post 6 
Maxwell 2006 Chicago 1,120 NR NR non-systematic  case series 4 
McAuley 2010 Lanarkshire  41 17 89% systematic pre-post 7 
Rowe 2015 San Francisco 2,500 613 25% non-systematic  pre-post 7 
Seal 2005 San Francisco 24  24 100% systematic  pre-post 5 
Strang 2008 England 239 186 78% systematic  pre-post 7 
Tobin 2009 Baltimore 250 85  34% systematic  pre-post 6 
Tzemis 2014 British Columbia 692 N/A N/A N/A cross-sectional  6 
Wagner 2009 Los Angeles 66 47  71% systematic pre-post 7 
Walley, Xuan 2013 Massachusetts  2,912 212 7% non-systematic   ITS 7 
Walley, Doe-Simk. 2013 Massachusetts  1,553 286 18% non-systematic   pre-post 6 
Yokell 2011 Rhode Island  120 10  8% non-systematic  pre-post 5 
Annotations: FU: number of follow-up participants; FU%: FU participants as percentage of study sample; ITS: interrupted time-series analysis; N/A: not applicable; NR: not reported; Score: 





Table 10 Studies cited in support of 9 Bradford Hill and 5 WHO criteria 
























































































































Bennett 2011           †    
Bennet 2012           †    
Dettmer 2001a           AR    
Dettmer 2001b           AR    
Doe-Simkins 2009               
Dwyer 2015               
Enteen 2010           AR,†    
Galea 2006               
Lankenau 2013               
Leece 2013               
Lopez-Gaston 2009*               
Markham Piper 2008               
Maxwell 2006           AR,†    
McAuley 2010               
Rowe 2015               
Seal 2005               
Strang 2008           AR    
Tobin 2009               
Tzemis 2014           AR    
Wagner 2009           AR,†    
Walley, Xuan, 2013               
Walley, Doe-Simk. 2013               
Yokell 2011               
Coffin 2013a               
Coffin 2013b               
Kan 2014               
Annotations:  study cited in support of criterion; * Lopez-Gaston et al. (2009) reported no THN administrations; ** None of the studies explicitly examined the Analogy criterion 
and have not been ticked (by definition, this criterion requires reasoning by analogy); † cited for reporting fatal OD outcome(s) following THN administration; AR: cited for reporting 
adverse reaction(s) following THN administration.   
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3.4   Discussion 
3.4.1  Statement of principal findings 
Empirical evidence from the 22 studies reporting on THN interventions for opioid users 
meets all nine Bradford Hill original criteria. Among these, Sir Austin Bradford Hill 
considered the Experimental Evidence criterion to deliver the strongest support for 
causation (Hill, 1965), but only quasi-experimental evidence from one study (Walley, 
Xuan et al., 2013) is available here. The robustness of empirical support ranges from 
one study per criterion (Dose-Response, Experimental Evidence) to 21 studies per 
criterion (Strength of Association, Coherence) (see Table 10). With regard to the five 
additional criteria assessing feasibility and implementation, THN fully or partially fulfils 
all five criteria. It is found to be cost-effective, and existing projects were able to access 
and train high-risk populations that led to 2,336 layperson naloxone administrations (Aim 
1) with a low rate of adverse effects (Aim 2). 
I conclude that, on the basis of application of the Bradford Hill criteria to the current 
evidence base on THN, there is strong support for the causation hypothesis. While the 
evidence is sometimes based on only one or two studies, I nevertheless conclude that 
this constitutes support for all nine criteria. THN provision reduced fatal outcome of 
overdose among program participants themselves, among fellow opioid users, and in 
the wider community, as evidenced by public vital statistics records (Seal et al., 2005; 
Walley, Xuan et al., 2013). Alternative explanations for this observation are unlikely: in 
control communities that did not implement THN, opioid overdose mortality was 
significantly higher (Walley, Xuan et al., 2013). The risk associated with THN programs 
is relatively low, especially when the life-threatening nature of the emergency situation 
is borne in mind: in studies with systematic follow-up, one death was reported among 
123 overdose victims who were administered THN. Moreover, there is no empirical 
evidence to support the concern that THN programs might encourage heroin use. Two 
studies reported decreased drug use among THN program participants at follow-up  
(Seal et al., 2005; Wagner et al., 2010), whereas a more recent study found no overall 
change in the frequency of heroin use across THN recipients (Doe-Simkins et al., 2014). 
 
3.4.2  Strengths and weaknesses of the chapter 
This is the first published application of the Bradford Hill criteria to assess the 
international evidence base on THN. Our findings extend and substantiate the 2014 
WHO Guidelines as well as the results of the previous systematic reviews by Clark et al. 
(2014) and the EMCDDA (2015). Clark et al. (2014) cautiously concluded “participation 
[in THN programs] is associated with overdose reversals” (p. 162) but avoided 
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statements on the effectiveness of THN, whereas the EMCDDA stated “there is evidence 
that educational and training interventions with provision of take-home naloxone 
decrease overdose-related mortality” (p. 11). 
There are potential limitations to this analysis, which need to be borne in mind. Selection 
bias may have affected the internal validity of the data included. Among 19 studies with 
pre-post and case series designs, 10 relied on unsystematic follow-up to capture 
overdose events and naloxone usage; relying on spontaneous follow-up, with THN 
program participants typically asked to report back on naloxone usage when collecting 
a naloxone refill. This raises scientific analytical doubt about data quality and 
interpretations: first of all, across these 10 studies, less than a quarter (22.9%; i.e. 
1,973/8,602) of THN recipients returned for refills after THN use, and information on the 
majority of participants was consequently lost. Secondly, it is possible that users with 
positive naloxone experiences (e.g. successful overdose reversals) may be more likely 
to return for a refill of their THN kit and complete a follow-up survey, whereas those with 
negative naloxone experiences may not be captured in the follow-up. The lack of 
systematic follow-up in the majority of studies is reflected in the wide range of follow-up 
rates attained across all studies (min. 5%, max. 100%). High levels of dropout can reduce 
the external validity and generalizability of results. A further source of potential bias lies 
in the fact that, for 21 out of the 22 studies, there was an exclusive reliance on self-report 
data for overdose outcomes. Only the interrupted time-series analysis by Walley, Xuan 
et al. (2013) included a public database of vital statistics to calculate overdose fatality 
rates. A further limitation concerns the fact that the Experimental Evidence and Dose-
Response criteria hinge on data from the Walley, Xuan et al. (2013) study. 
 
3.4.3  Possible mechanisms and implications for clinicians 
With regard to clinical implications, it needs to be emphasized that the vast majority of 
studies included in this review reported on heroin overdoses. Consequently, the 
generalizability of my findings to overdoses from long-acting opioids is unclear. Even 
when methadone patients were specifically recruited into a THN program (Walley, Doe-
Simkins, et al., 2013), over 90% of witnessed (and reversed) overdoses were heroin-
induced. The results of this review on the effectiveness of THN are thus limited to impact 
on heroin overdoses, and the effectiveness of the intervention for overdoses from long-




3.4.4  Questions for future research 
More robust studies are needed to confirm these results and assess their applicability to 
other regions internationally, in particular low- and middle-income countries. Moreover, 
the findings from the studies do not inform which distribution model of overdose 
education and THN distribution is preferable. Future studies could formally evaluate the 
impact of program components by providing THN to all subjects and randomizing 
subjects into different training conditions (e.g. ‘overdose education’ versus ‘overdose 
education + CPR training’).  
Despite these methodological limitations, positive reports of overdose reversals following 
THN distribution were reported across 21 studies - regardless of type of follow-up 
(systematic vs. unsystematic) or data source (self-report vs. objective data), suggesting 
that the finding is indeed robust and not an artefact of methodological flaws.  
To control for potential publication bias, I additionally searched the grey literature for 
documents reporting on THN initiatives that are not published in the peer-reviewed 
journal domain. While this search was unlikely exhaustive, the data reported in the grey 
literature are broadly consistent with the results of the studies included in our systematic 
review. For instance, in the Scottish National Naloxone Programme, in the years 2012 
and 2013, the percentage of opioid-related deaths occurring within four weeks of prison 
release (5.5% and 4.7%) was almost half that of the pooled 2006-10 baseline indicator 
(9.8%), suggesting that distribution of naloxone kits on release may reduce the risk of 
fatal overdose among (former) prisoners with history of opioid use (ISD, 2014). 
 
3.5   Conclusion 
To conclude, application of the Bradford Hill criteria to the current evidence base from 
non-randomized studies finds that THN programs have led to improved survival rates 
among program participants and reduced heroin overdose mortality rates in the 
community (Aim 1) and are only accompanied by a low rate of adverse events (Aim 2). 
In the absence of RCTs, I conclude that THN distribution to at-risk users should be 
introduced as standard of care for the community-based prevention of heroin overdose 
deaths.  
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Table 11 Studies excluded after full-text review (n=19) 
Study ID 




Albert et al. (2011) 10.1111/j.1526-
4637.2011.01128.x 
Electronic database Population: no opioid 
users (refugees) 
Arribas-Ibar et al. 
(2014) 
10.1186/1477-7517-11-33 Electronic database  Not relevant (no 
overdose outcomes) 
Bagley et al. (2015) 10.1080/08897077.2014.989352 Electronic database Not relevant (no 
overdose outcomes); 
Population: no opioid 
users (family 
members) 
Behar et al. (2015) 10.1016/j.drugalcdep.2014.12.00
9 
Electronic database Not relevant (no 
overdose outcomes) 
Bird et al. (2015) 10.3109/09687637.2014.981509 Electronic database  Review article 
(protocol) 
Bowman et al. (2008) rimed.org/medhealthri/2008/2008
-09.pdf 
Electronic database  Review article  
Brason et al. (2013) classic.ncmedicaljournal.com/wp
-content/uploads/2013/05/74323-
Brason-Final.pdf 





Electronic database  Review article 
Dahlem et al. (2015) 10.1002/2327-6924.12249 Electronic database  Not relevant (no 
overdose outcomes) 
Jones et al. (2014) 10.1016/j.drugpo.2013.05.006 Electronic database  Not relevant (no 
overdose outcomes) 
Kan et al. (2014) 10.1016/j.drugpo.2014.01.005 Electronic database  Not relevant (no 
overdose outcomes) 
Sherman et al. (2008) 10.1186/1477-7517-5-2 Electronic database Qualitative study 
Wagner et al. (2014) 10.1016/j.drugpo.2013.07.003 Electronic database  Qualitative study 
Wheeler et al. (2015) cdc.gov/mmwr/pdf/wk/mm6423.p
df 
Electronic database  Review article 
Wilder et al. (2014) 10.1097/ADM.000000000000003
2 
Electronic database  Case study 
Williams et al. (2014) 10.1111/add.12360 Electronic database  Population: no opioid 
users (family 
members) 
Worthington et al. 
(2006) 
10.1186/1477-7517-3-19 Electronic database  Not relevant (no 
overdose outcomes), 
qualitative study 
Wright et al. (2006) 10.1186/1747-597x-1-28 Electronic database  Qualitative study 




Chapter 4 The Insufficiency of Improvised Nasal Naloxone Kits 
 
Preface 
In this chapter I raise the question whether it is acceptable for clinicians to supply 
unlicensed, improvised nasal naloxone kits. My idea for this chapter arose from 
comparison of the results of an ambulance-based randomized controlled trial in Australia 
(Kerr, Kelly, Dietze, Jolley, & Barger, 2009) and of naloxone refill data from the 
Massachusetts take-home naloxone program (Doe-Simkins et al., 2009; Walley, Xuan 
et al., 2013). If the Australian ambulance staff observed that about one in five patients 
with suspected heroin overdose needed “rescue naloxone” (i.e. a second naloxone dose, 
this time by injection) following administration of improvised naloxone nasal spray 
(2mg/mL), then how come this non-response rate was not also reported in the 
Massachusetts take-home naloxone programs that distributed similar improvised nasal 
kits (2mg/2mL)? Did the lack of systematic follow-up of the take-home naloxone 
recipients in Massachusetts (see also Chapter 3 Discussion) provide an incomplete 
picture? The content of this chapter was developed between January 2015 and January 
2016 and has been published as a peer-reviewed, first-authored manuscript entitled 
“Clinical provision of nasal naloxone without experimental testing and without regulatory 
approval – imaginative shortcut or dangerous bypass of essential safety procedures?” in 
Addiction, in co-authorship with my first supervisor and two colleagues from the 
Addictions Department at King’s College London, Basak Tas and Dr. Edward Day 
(Strang, McDonald, Tas, & Day, 2016). 
The manuscript was published as a “For Debate” article. This manuscript category 
designates opinion pieces that “synthesize the research literature in a way that adds 
important new insights […] [to] challenge existing thinking” (Addiction, 2017). 
The publication of my manuscript was accompanied by a press release and stirred a 
lively debate among international experts in the field. Researchers from Australia, the 
US, and Norway submitted seven commentaries in total which provided alternative 
opinions on the use of improvised nasal kits, and my first supervisor and I submitted two 
responses to the commentaries. According to the Addiction editorial office, my “For 
Debate” article ranks among the top 1% of most downloaded papers in the journal in the 
year 2016.  
While this chapter highlights the issues associated with the use of improvised nasal kits 
without regulatory approval, alternative routes of administration for non-injectable 
naloxone delivery are explored in Chapter 5. 
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4.1  Introduction 
Naloxone undoubtedly saves lives by reversing respiratory depression caused by 
heroin/opioid overdose. Naloxone is approved for intravenous (IV), intramuscular (IM) or 
subcutaneous injection for treatment of heroin/opiate overdose (WHO, 2014). The 
recommended initial dose for injection is 0.4mg, which may then be increased to 2mg, 
according to response, and may be repeated thereafter in extremis (WHO, 2014) (see 
Chapter 1).  
Systematic reviews conclude that take-home naloxone programs are effective (Clark et 
al., 2014; EMCDDA, 2015; McDonald & Strang, 2016) (see Chapter 3), and recent World 
Health Organization guidelines (WHO, 2014) recommend that anyone likely to witness 
an opioid overdose should have access to the antidote. Take-home naloxone has been 
implemented by early adopters in at least a dozen countries, but has only become more 
mainstream in the past decade with the introduction of the first state-wide program in 
Massachusetts in 2008 (Doe-Simkins et al., 2009) and first national programs in Scotland 
and Wales in 2011 (Strang et al., 2014) (see Chapter 2).  
As of May 2017, a variety of nasal naloxone formulations are currently in development. 
A first tested and approved concentrated naloxone nasal spray product (4mg/0.1mL) by 
Adapt Pharma (hereafter referred to as “Adapt”; NARCAN®) already exists in North 
America, having received regulatory approval in the US in November 2015 (FDA, 2015) 
and in Canada in October 2016 (CBCnews, 2016), and the arrival of a first licensed nasal 
spray in Europe is anticipated for late 2017 or early 2018. It is interesting to note that the 
concentrations of these novel formulations vary greatly, with volumes and single doses 
ranging from 0.1mL to 0.5mL and from 1mg to 4mg, respectively.  
These recent developments can be traced back to 12 April 2012, when a step-change 
occurred with the joint meeting of the US FDA, Centers for Disease Control and 
Prevention (CDC), and National Institute on Drug Abuse (NIDA) to encourage new non-
injectable naloxone formulations, alongside FDA clarification of the regulatory 
benchmark for no-injectable naloxone products (see Chapter 5).  
Prior to the joint CDC/FDA/NIDA initiative in 2012, only one patent application 
(WO/2012/156317) for non-injectable naloxone containing human in-vivo data had been 
filed (see Chapters 6 and 7), highlighting very limited investment from pharmaceutical 
industry. With injectable naloxone-hydrochloride solution available as generic and off-
patent medication, naloxone was of limited commercial value. Moreover, as an antidote, 
naloxone is only prescribed for emergency use (unlike e.g. medications for opioid 
substitution therapy), and its per-patient sales volume limited accordingly. When NIDA 
announced that it would fund development of “user-friendly” naloxone delivery systems 
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(Volkow et al., 2014), industry interest finally appeared. 
The two pharmaceutical companies Adapt and Indivior submitted separate New Drug 
Applications for nasal naloxone to the US FDA in mid-2015, of which only the Adapt 
product (NARCAN®) was approved in November that year. Health Canada approval 
followed in October 2016 (CBCnews, 2016). This product delivers a concentrated nasal 
spray of a 4mg naloxone dose in a 0.1ml volume through a single unit-dose device by 
Aptar Pharma (hereafter referred to as “Aptar) for disposable use (see Figure 13) (FDA, 
2015). The nasal spray has a promising pharmacokinetic profile with good bioavailability 
(Krieter et al., 2016) which met the FDA criteria of comparability of systemic exposure 
to naloxone injection (see Chapter 5 for a description of the criteria). 
 
 
Figure 13 Single unit-dose device (Aptar Pharma)13 
 
The New Drug Application for the competitor product by Indivior (1mg/0.1ml formulation, 
also in the Aptar device) was unsuccessful because the naloxone nasal spray was found 
not to be absorbed sufficiently rapidly relative to the reference product of 0.4mg 
intramuscular naloxone (Indivior, 2015). This accords with the concerns described in this 
chapter. 
Another unsuccessful New Drug Application was submitted by a third company, 
Amphastar Pharmaceuticals (hereafter referred to as “Amphastar”). Amphastar already 
holds the U.S. license for two 2mg/2mL injectable naloxone products (Luer-Jet™ 
Prefilled Syringe; Min-I-Jet™ Fixed Needle Syringe) (Amphastar, 2016). The failed 
Amphastar naloxone nasal spray consisted of a 2mg/0.5mL dose (from 4mg/mL 
formulation), likely administered from a pre-filled syringe with spray device and intended 
to be split across the two nostrils. In February 2017, the FDA issued a Complete 




Response Letter (CRL) to Amphastar, stating that the device and its usability required 
improvement before the New Drug Application could potentially be approved 
(Amphastar, 2017). 
In the UK, Mundipharma Research Ltd. has recently developed a 2mg/0.1mL 
concentrated naloxone nasal spray (see Chapter 9) for delivery by the Aptar device and 
has submitted a product portfolio to the European Medicines Agency for regulatory 
review. The notion of nasal naloxone is unquestionably attractive for layperson use. It is 
quick to administer and reduces risk of needle-stick injury.  
However, at the start of my PhD in October 2013, no licensed naloxone nasal spray 
product existed anywhere in the world. Up until late 2015, naloxone for intranasal (IN) 
administration was not licensed anywhere in the world – neither for addiction or overdose 
treatment nor for any other medical indication. Only improvised nasal naloxone kits, 
consisting of a pre-filled syringe (2mg/2mL) with a nasal mucosal atomizer, see Figure 
14) were available, and some services (parts of the US; Norway; Denmark14; parts of 
Scotland) began to supply the improvised kits for take-home use (CDC, 2015; Greig, 
2012), and they continue to be used, despite not having been formally tested for safety 
or efficacy.  
 
 
Figure 14 Pre-filled syringe with nasal mucosal atomizer device15 
 
                                               
14 The Danish naloxone kit contains the nasal atomizer as well as a needle for injection. 
15 Source: http://www.chrisatwoodfoundation.org/naloxone 
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This follows a practice used by some ambulance teams that administer naloxone off-
label as nasal spray (Barton et al., 2005). Off-label use generally designates the re-
purposing of prescription drugs “for any indication not explicitly prohibited by law” (Doe-
Simkins et al., 2009) or for unapproved age groups, dosages, or routes of administration. 
However, the context of emergency care is fundamentally different from emergency care 
from a family member or peer with a nasal spray naloxone kit. In the ambulance context, 
the paramedic teams can give a naloxone injection when the nasal spray fails. No 
fallback treatment exists in the community setting for the family member or carer with 
only the nasal spray. As a result, the UK Advisory Council on the Misuse of Drugs 
(ACMD) do not view the off-label use of injectable naloxone solution as nasal spray as 
a suitable alternative to licensed naloxone for injection (ACMD, 2012). 
This chapter neither condemns nor condones the pragmatic provision of IN naloxone by 
public health initiatives, particularly in communities where the distribution of injectable 
naloxone is legally or politically not feasible. Rather, the scope of the chapter is to discuss 
the unlicensed use of new drug formulations in the addictions treatment field by raising 
the question whether the bypassing of product testing and efficacy be justified when 
licensed naloxone products already exist. The chapter has two aims: 
• Aim 1: to assess the provision of improvised nasal naloxone in clinical practice 
• Aim 2: to examine published evidence of pharmacokinetics and effectiveness of 
naloxone by nasal administration relative to injection.  
 
4.2  Methods 
4.2.1  Search strategy 
A systematic search was conducted to document existing nasal naloxone distribution 
schemes and published evidence of pharmacokinetics. Replicating an earlier peer-
reviewed search strategy reported by Kerr et al. in their review of intranasal naloxone for 
the treatment of suspected heroin overdose (Kerr, Dietze, & Kelly, 2008), the Cinahl, 
Cochrane, Embase and Medline databases were searched to identify relevant peer-
reviewed English-language articles published between January 1946 and January (4th 
week) 2015 using the terms: ‘naloxone.mp’ or ‘exp naloxone’, ‘narcan.mp.’ or 
‘exp.Narcan’ and ‘exp administration, intranasal/or intranasal.mp’ or ‘nose.mp’. I 
conducted the initial data searches, and the same process was replicated independently 
by a colleague (who was a co-author of the Addiction paper). I then screened papers for 
eligibility and extracted data under supervision of my first supervisor. 388 papers were 
retrieved and screened for original research (including case reports) reporting on 
pharmacokinetics, safety or effectiveness data of IN naloxone administration in healthy 
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volunteers or patients with suspected opioid overdose. Eighteen records matched our 
search criteria (Barton et al., 2005; Barton et al., 2002; Belz, Lieb, Rea, & Eisenberg, 
2006; Doe-Simkins et al., 2009; Dowling et al., 2008; Green, Ray, Bowman, McKenzie, 
& Rich, 2014; Kelly et al., 2005; Kelly & Koutsogiannis, 2002; Kerr, Kelly, Dietze, Jolley, 
& Barger, 2009; Loimer, Hofmann, & Chaudhry, 1992; Loimer, Hofmann, & Chaudhry, 
1994; Merlin et al., 2010; Robertson, Hendey, Stroh, & Shalit, 2009; Sabzghabaee, 
Eizadi-Mood, Yaraghi, & Zandifar, 2014; Walley, Doe-Simkins, et al., 2013; Walley, 
Xuan, et al., 2013; Weber, Tataris, Hoffman, Aks, & Mycyk, 2012; Zuckerman, Weisberg, 
& Boyer, 2014) (see Table 12 & Figure 15).  
 
 
Figure 15 Flowchart of study selection 
 
In addition, the World Health Organization International Clinical Trials Registry Platform 
(ICTRP) and the U.S. National Institutes of Health (NIH) Research Portfolio Online 
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Reporting Tools (RePORT) database were searched for ongoing studies investigating 
nasal naloxone. The ICTRP links national and regional clinical trials registers with the 
aim to facilitate registration of all international clinical trials and public accessibility of the 
trial information (WHO, 2017). The RePORT database captures all research activity 




4.3.1  Current use of intranasal naloxone in clinical practice 
Ambulance use 
Nasal naloxone for treatment of opioid overdose was introduced as regular clinical 
practice (although without licensed approval for this route) into ambulance services in 
parts of the US (Denver, Colorado; Fresno, California; among others) in the 2000s 
(Barton et al., 2002; Belz et al., 2006; Robertson et al., 2009), and in several NHS 
Ambulance Service Trusts in the UK (incl. South Western, Great Western, and East 
Midlands).  
 
Figure 16 Assembly of the Massachusetts take-home naloxone kit16 
 
Take-home supply 
Take-home naloxone as nasal spray only (i.e. without supplementary needle for IM 
injection) was first introduced in the US in Boston/Massachusetts in 2006 (Doe-Simkins 
et al., 2009). Assembly of the Massachusetts take-home naloxone kit for intranasal use 
                                               
16 Source: http://www.bu.edu/today/2013/addiction-research-alexander-walley/ 
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is depicted in Figure 16. In 2013, over a third (i.e. 38%; 51 out of 136) of US organizations 
reported providing only improvised intranasal naloxone kits (CDC, 2015). In Europe, the 
Norwegian take-home naloxone scheme began providing only intranasal naloxone in 
2014 (Clausen, 2014). At the time of writing, it was also proposed that the nasal spray 
would be the only form of naloxone provided in parts of Scotland (Inverness and 
surrounding regions Highland, Argyll and Buke) (Greig, 2012) and in France (EMCDDA, 
2016a). 
 
4.3.2  Evidence-base for non-concentrated intranasal naloxone 
No systematic review exists on nasal naloxone to date, but there is growing evidence of 
IN administration of naloxone reversing opioid overdose: At least 327 overdose reversals 
using nasal naloxone kits were reported in the Massachusetts-based take-home 
naloxone program (4, 28, 29). In ambulance and hospital-based trials, the time from dose 
administration to clinical response often took longer for nasal administration compared 
to injectable routes (18, 24, 25). However, for the comparison of IN and IV routes, this 
time difference disappeared when measuring the time from patient contact to clinical 
response due to the time saved for having to establish IV access (24). Similarly, the time 
to clinical response was no different from IM administration when a less dilute nasal 
spray formulation (2mg/mL) was used (19). 
However, for reasons summarized below, there remains a lack of information about how 
adequately and reliably non-concentrated naloxone is absorbed intranasally.  
 
Lack of simple pharmacokinetics 
Progress with basic pharmacokinetic study of intranasal naloxone has been slow. The 
only pharmacokinetic study (Dowling et al., 2008) published by the time of writing 
(January 2016) reported extremely poor bioavailability (4%) for nasal naloxone 
(2mg/5mL), although the authors acknowledged that the dilute solution probably resulted 
in post-nasal loss or nasal leakage. Despite reports of replication studies (e.g. by 
pharmaceutical companies), no pharmacokinetics data had yet been published at the 
time of writing. 
Non-response rate: The results from ambulance-based studies in Australia (Kelly et al., 
2005; Kerr et al., 2009) and the US (Barton et al., 2002; Belz et al., 2006; Robertson et 
al., 2009) indicate that not all opioid overdose victims respond to nasal naloxone, with 
some needing a rescue dose of IM or IV naloxone (see also Table 12). An ambulance-
based randomized trial in Australia compared IN to IM naloxone: in many instances, the 
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intranasal dose (2mg/5mL) was sufficient. However, it was not equal - the IN group was 
twice as likely to require rescue naloxone (26% IN group versus 13% IM group; p = 
0.056; odds ratio (OR) = 2.4; 95% confidence interval (CI) = 1.0–5.7) (Kelly et al., 2005). 
In a replication trial with a more concentrated nasal spray formulation (2mg/mL), 18% of 
the IN group still needed rescue naloxone, which was significantly higher than the IM 
group (5%) (Kerr et al., 2009). This rate is broadly consistent with 16% of IN non-
responders in a Denver-based observational trial (Barton et al., 2005). Other studies 
have reported non-response rates between 9% and 23% (14, 23, 26). 
 
4.3.3  Ongoing research  
Clinical trials are currently being conducted in the ambulance setting in Cincinnati, US, 
and in a supervised injecting clinic in Sydney, Australia. Pharmacokinetic exploration of 
IN formulations is finally underway by at least three groups in the US and Norway: 
however, no results were published at the time of writing (January 2016). Other potential 
non-injectable routes warrant consideration, which are explored more fully in Chapter 5.  
 
4.4  Discussion  
The concerns raised in this chapter relate to the use of improvised nasal sprays based 
on dilute solutions of naloxone developed for injection and not examined for suitability or 
efficacy as nasal spray.  
 
4.4.1  Statement of principal findings 
While FDA-approval of a concentrated naloxone nasal spray (4mg/0.1mL) in the US 
(Dowling et al., 2008) in late 2015 (FDA, 2015) was a step change, the following reasons 
for caution regarding the use of improvised naloxone nasal sprays remain: Firstly, non-
response rates of between 9% and 26% have been reported for non-concentrated nasal 
naloxone (12, 14, 18, 19, 23, 26). As noted in the Introduction section, there is an 
inherent safety in the use of dilute nasal naloxone in the ambulance or hospital context 
where a naloxone injection can be administered if the initial nasal naloxone does not 
reverse overdose. However, in take-home naloxone schemes that only provide naloxone 
for off-label IN use (Doe-Simkins et al., 2009; Madah-Amiri et al., 2017), the absence of 
a back-up injection is a crucial difference. In this situation, the failure of effect of IN 
naloxone, for whatever reason, can delay the time to naloxone injection until an 
ambulance arrives. In the emergency management of opioid-induced respiratory 
depression, time is of essence. Secondly, there is uncertainty about dose adequacy and 
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comparability of nasal naloxone. For the improvised nasal spray, the only commercially 
available injectable formulations have concentrations from 0.4mg/mL to 1mg/mL (adult 
formulations). Drug administration via nasal spray typically involves giving 0.1mL per 
nostril, with 0.25mL considered the maximum, as any greater volume is likely lost post-
nasally (and then swallowed and consequently inactivated) or by nasal drip (and thereby 
lost) (Dowling et al., 2008). 
 
4.4.2  Possible mechanisms and implications for clinicians 
Some consideration of the practical administration of the naloxone as nasal spray is 
warranted. The most concentrated injectable formulation of naloxone available is 
2mg/2mL. If this concentration of naloxone is administered at 0.25mL per nostril, then, 
even if one discounts the reported nasal bioavailability of 4% (Dowling et al., 2008) and 
optimistically assumes that 40% of naloxone is absorbed, the effective IN dose would be 
only 0.2mg, i.e. equivalent to only half the lower recommended injectable dose. The 
remainder would be lost as nasal drip or as post-nasal drip (and inactivation as part of 
first-pass metabolism). 
Given the small dose that is probably absorbed, reported benefit from improvised nasal 
naloxone devices (see Table 12) is puzzling: this should prompt challenge to 
assumptions about naloxone dose-response. Dose-ranging studies with dependent 
volunteers might explore this sensitively (see Chapter 10).  
Thirdly, at a practical level, uncertainties about the effectiveness of a nasal spray include: 
the need for a spray device to function in horizontal position, the impact of compromised 
nasal mucosa (e.g. chronic ulceration from drug snorting (Peyrière et al., 2013), and the 
risk of obstruction from opioid-induced vomit. Any factors which reduce or delay the nasal 
absorption of naloxone may lessen the overdose victim’s chance of survival.  
Finally, some consideration needs to be given to why a clinician would prescribe 
naloxone for use by an unlicensed route, when a highly effective, licensed injection is 
already in their armamentarium. Perhaps the nasal spray relieves layperson anxiety 
about giving an IM injection. However, families of patients with other disorders 
successfully overcome this fear (e.g., EpiPen, glucagon). Training in technique is 
necessary, but this can be done efficiently and bolsters the confidence of family and 
peers to intervene (Williams et al., 2014).  
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4.4.3  Possible mechanisms and implications for policymakers 
In jurisdictions where laypeople (including family members) are prohibited from 
administering emergency medications by injection, there should be urgent challenge of 
this policy. It cannot be ruled out that medico-professional and medico-legal risks may 
arise when naloxone is prescribed for use by unlicensed route, especially when licensed 
naloxone products are applicable. If death were to occur following nasal administration, 
what reason would justify having provided naloxone for use by an unlicensed route? It 
follows that, wherever possible, clinicians should prescribe medications for use by the 
approved routes of proven effectiveness. 
For any novel non-injectable naloxone products, the cost needs to be considered. The 
pricing of nasal naloxone products that are currently under development or under review 
is uncertain. Affordability relative to existing injectable products will be crucial, 
particularly for the proposed population-wide provision of emergency naloxone, as 
articulated by the World Health Organization (WHO, 2014).  
 
4.4.4  Questions for future research 
What data should be available on nasal naloxone formulations? 
Any novel non-injectable naloxone formulation would need to be absorbed to a sufficient 
extent so as to produce the life-saving reversal of opioid effect (for which emergency 
reason it is being given).  
Pharmacokinetics and study of bioavailability need to be undertaken in healthy 
volunteers and published showing acceptable bioavailability and reliability across 
subjects before incorporation into standard clinical practice.  
Human volunteer data may also need to be supplemented with clinical safety data. It is 
not obvious that nasal administration would be equivalent in healthy volunteers and 
opioid overdose victims. The overdose victim’s past drug use may have caused damage 
to the mucosa and structure of the nose, and the overdose crisis may have resulted in 
vomitus or secretions in the nasal cavity. These challenges need to be examined and 
addressed.  
 
What are the potential specifications for an acceptable naloxone nasal spray?   
From the above analysis of the insufficiencies of improvised naloxone nasal spray, it is 
possible to deduct some of the key features of an acceptable nasal naloxone formulation.  
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Firstly, in view of the emergency context of the resuscitation and the likely unconscious 
state of the overdose victim, the nasal device would need to be functional in all 
orientations (i.e. not just when held vertically, as with many nasal sprays).  
Secondly, putting to one side the Dowling et al. finding of 4% bioavailability (2008), if one 
assumes a more optimistic 40% bioavailability for nasal naloxone as well as an 
absorption volume of up to 0.25mL of fluid per nostril, then a more concentrated solution 
is required – perhaps between 4mg/ml up to 20mg/ml. Fortunately, naloxone is highly 
soluble (Rang et al., 2012) (see Chapter 1), so this should not be a problem, provided 
there are no adverse local effects.  
Thirdly, it needs to be established that the speed of onset is sufficient. In addition to 
adequate overall absorption, it is essential that the absorption occurs rapidly, given the 
emergency of the overdose. A rapid onset of action with detectable effect within 5 
minutes and good effect within 10 minutes will likely be needed. Measures of Tmax (i.e. 
the time at which the maximum blood serum concentration of naloxone is observed) may 
not capture the shape of onset of effect. The time taken to achieve blood levels of 50% 
of those subsequently recorded as Cmax (hereafter referred to as T50%) may constitute an 
alternative pharmacokinetic parameter worth exploring.  
 
4.5  Conclusion 
There are good reasons to want a non-injectable naloxone preparation for treating opioid 
overdose to work. However, wishing for a product is not the same as demonstrating 
efficacy and effectiveness. The benchmark for any non-injectable naloxone product, if 
considered for wider community use, should be that it is, in general terms at least, as 
effective and reliable as the licensed injection. 
Description of use of improvised nasal formulations should not be accepted as evidence 
of effectiveness. Actual data need to be published and need to report not only on whether 
it is effective in some subjects, but also whether it is effective in all subjects. If no licensed 
injectable comparator existed, then a new overdose resuscitation medication that was 
effective for many subjects would be valued, even if it was not effective for all subjects. 
However, as established, licensed injectable naloxone with proven efficacy and good 
safety profile already exists, the expectations for potential new naloxone formulations 
are at a higher bar. 
To conclude, outside clinical trial contexts, clinicians should prescribe take-home 
naloxone only as one of its licensed formulations, since it remains uncertain how 
adequately and reliably the improvised nasal spray is absorbed. Or, if clinicians choose 
to prescribe the improvised naloxone nasal spray off-license, then they should include a 
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needle in the naloxone kit to allow for a back-up injection if the nasal spray is insufficient. 
Evidence of adequate bioavailability and acceptable pharmacokinetic curves are vital 
preliminary steps for non-injectable naloxone formulations, especially when effective 
approved injectable formulations exist. And yet, the clinical and scientific communities 
have failed to ask these basic questions around the use of improvised nasal kits. The 
evidence base for the efficacy of improvised kits is insufficient and highlights the need 
for the development of purpose-made non-injectable naloxone formulations. Chapter 5 
explores candidate routes for non-injectable naloxone administration. 
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Table 12 Summary of included studies 
Author (year) Study design Setting N IN Dose Dose 
comparator 
Outcomes of naloxone administration 
Barton et al. (2002) 
 
 Case series 
 
Pre-hospital (EMS) 30 patients 2mg (as 1mg/ml) 2mg IV if no 
immediate 
response 
11 patients responded to naloxone challenge (IN or 
IV), of which 10 (91%) responded to IN alone, with 
an average response time of 3.4 minutes. 




Pre-hospital (EMS) 95 patients 2mg (as 1mg/ml) 2mg IV if no 
immediate 
response 
52 patients responded to naloxone challenge (IN or 
IV), of which 43 (83%) responded to IN alone, with 
an average response time of 4.2 minutes. 
Belz et al. (2006) Case series Pre-hospital (EMS) 164 patients (108 
IV; 29 IV+IM; 18 
IM; 2 IN; 1 IM+IN; 
6 NR)  
Median 1mg 
(0.2mg-2mg) 
across all routes 
of administration 
IV, IM, IV+IM, 
IM+IN (doses 
NR) 
119 (73%) patients fully or partially responded to 
naloxone (for all routes of administration). 36 (22%) 
cases of death, 25 (15%) cases of agitation, 6 cases 
(4%) of emesis. 






385 opioid users 2mg (2mg/2ml) None Participants reported 74 successful OD reversals; no 
deaths. 








0.8mg, 2mg (as 
0.4mg/ml) 
0.8mg IM, 
0.8mg IV, 2mg 
IV 
The bioavailability was 36% for IM and 4% for IN, 
both relative to IV. 
Green et al. (2014) Case report Take-home 
naloxone 
2 opioid users 2mg (2mg/2ml) None Participants reported 2 successful OD reversals (self-
administration); no deaths. 




Randomized trial  Pre-hospital (EMS) 155 patients (71 
IM, 84 IN) 
2mg/5ml 2mg IM The IM group had more rapid respiratory response 
than IN group (significant group difference in ‘time to 
RR > 10/min’ and ‘spontaneous respiration within 8 
min’). No group difference in GCS scores or need for 




Case report Hospital (ED) 6 patients 0.8mg-2mg None  Across all patients, return of adequate spontaneous 
respiration occurred within a median 50 seconds 
(min. 30 seconds, max. 2 minutes). 
Kerr et al. (2009) 
 
Randomized trial Pre-hospital (EMS) 172 patients (89 
IM, 83 IN) 
2mg (2mg/ml) 2mg IM The rates of response within 10 minutes were similar: 
IN naloxone (60/83, 72.3%) compared with IM 
naloxone (69/89, 77.5%). No group difference in 
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Author (year) Study design Setting N IN Dose Dose 
comparator 
Outcomes of naloxone administration 
mean response time (IN: 8.0, IM: 7.9 minutes). 
Significant group difference in need for rescue 
naloxone: IN 18% vs. IM 5%. 
Loimer et al. (1992) Controlled 
prospective trial 
(non-randomized) 
Hospital (jail-based) 30 (22 opiate-
dependent, 8 
control) 
1mg (1mg/0.4ml)  
 
None After opioid challenge test of IN naloxone 
administration, opiate-dependent patients showed 
significantly higher ratings on withdrawal scale for up 
to 30 minutes (in comparison to controls). 
Loimer et al. (1994) Randomized trial Hospital 17 patients  
(7 IV vs. IM; 10 IV 
vs. IN) 
1mg (1mg/0.4ml)  
 
1mg IM 
(1mg IV as pre-
treatment in 
both groups) 
Both IN and IM groups showed significant withdrawal 
symptoms at 15 and 45 minutes. Only the IN group 
had significant withdrawal symptoms at 5 minutes, 
suggesting that onset of IN naloxone is faster than 
IM. 






Pre-hospital (EMS) 93 (38 IN, 55 IV)  
(analysis of 
subsample of 
total 344 cases) 
2mg (1mg per 
nostril) 
IV naloxone 
titrated to effect 
(average 2mg) 
No group difference in RR or GCS pre-naloxone 
administration. Post naloxone administration, both 
the median RR and GCS scores were significantly 
higher for the IV group than the IN group. 9 IN 
patients (23%) required rescue IV naloxone.  





and hospital (ED) 
154 patients (50 
IN, 104 IV) 




The time from dose administration to clinical 
response (pre-defined change in RR and GCS of 6 
points) took significantly longer for IN route (12.9 vs. 
8.1 min). No group difference in overall time from 
patient contact to response. More IN patients 
received 2 doses of naloxone (34% vs. 18%, p = 
0.05), and 3 IN patients needed a rescue dose of IV 
or IM naloxone.  
 
Sabzghabaee et al. 
(2014) 
Randomized trial Hospital (ED) 100 patients (50 
IN, 50 IV) 
0.4mg 
(0.4mg/2ml, i.e. 
1ml per nostril) 
0.4mg IV Response to naloxone was significantly slower in IN 
group. Patients in IN naloxone had higher GCS 
scores but lower heart rate than IV group. No group 
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Author (year) Study design Setting N IN Dose Dose 
comparator 
Outcomes of naloxone administration 
difference in blood pressure, RR, arterial O2 
saturation, or length of hospital stay. 








2mg (2mg/2ml) Communities 
without take-
home naloxone 
Participants reported 327 successful OD reversals; 
no deaths. OD mortality rates were reduced in 
communities with THN, compared to those without. 
Walley, Doe-








2mg (2mg/2ml) None Methadone clients reported 92 successful OD 
reversals; no deaths. 






Pre-hospital (EMS) 105 patients  2mg (2mg/3ml) None Of all 105 cases, 23 (22%) had complete response, 
62 (59%) partial response, and 20 (19%) no 
response, as indicated by GCS score and RR. 
Eleven cases (10%) received rescue naloxone (6 IV, 
5 IM). No adverse events or deaths occurred.  
Zuckerman et al. 
(2014) 
Case report Pre-hospital (EMS) 
and hospital (ED) 
1 patient 2mg (1mg per 
nostril) 
None; After non-response to IN dose, patient was 
administered 3 IV rescue doses (1mg + 0.4mg + 
0.4mg) by EMS and ED staff. 
Annotations: ED - emergency department; EMS - emergency medical services; GCS – Glasgow Coma Scale; IM - intramuscular, IN – intranasal; IV – intravenous; NR - not reported; 




Chapter 5  Non-injectable Routes of Naloxone Administration 
 
Preface 
In response to rising overdose mortality rates, the US FDA, Centers for Disease Control 
and Prevention (CDC), National Institute on Drug Abuse (NIDA), and Office of the 
Assistant Secretary for Health and Human Services (HHS) sponsored a stakeholder 
meeting on April 12, 2012 to “discuss whether naloxone should be made more widely 
available to trained laypersons in an effort to reduce deaths due to opioid overdose” 
(FDA, 2012). 
The meeting set the scene for novel naloxone products for layperson use. The FDA 
strongly encouraged the development of non-injectable naloxone products and 
presented key regulatory criteria that would apply to any New Drug Application (NDA) 
for naloxone (Hertz, 2012; Nadel, 2016). NIDA subsequently announced that it would 
provide funding for the development of “user friendly delivery systems for naloxone (i.e., 
intranasal rather than injection)” (Volkow et al., 2014). 
To address the need for non-injectable naloxone for layperson use, I conducted a 
systematic review between July 2015 and January 2016, which applied the FDA criteria 
to possible routes of administration to evaluate their suitability for the community-based 
management of opioid overdose. Three candidate routes for injection-free naloxone 
administration were identified: buccal, nasal, and sublingual. My analysis forms the basis 
of this chapter and has been published as co-first-authored paper “Naloxone without the 
needle – systematic review of candidate routes for non-injectable naloxone for opioid 
overdose reversal” in Drug and Alcohol Dependence (Strang, McDonald, Alqurshi, et al., 
2016). The publication was developed in co-authorship with my first and second 
supervisor as well as with colleagues Dr. Abdulmalik Alqurshi, Dr. Paul Royall, and 
Professor Ben Forbes from the Institute at Pharmaceutical Science at King’s College 
London. 
In this chapter, I integrate evidence from the peer-reviewed literature. I capture research 
and development activity within pharmaceutical industry in Chapter 6 where I provide a 





5.1  Introduction 
Naloxone without needles would have many advantages over existing injectable 
products. Firstly, injectable medications are intimidating for laypersons to use (Beletsky, 
Rich, & Walley, 2012) and present logistical barriers: they require product assembly (e.g. 
needle and syringe) and training in administration. Secondly, with use of naloxone by 
injection, there is the risk of needle-stick injury and contraction of blood-borne diseases 
(e.g. hepatitis C, HIV), which are highly prevalent among people who inject drugs 
(Degenhardt et al., 2016). Thirdly, non-injectable naloxone could likely overcome 
regulatory obstacles (e.g. prescription-only status for injectable medications) and be 
more easily provided to a wider intervention workforce (e.g. hostel staff, outreach 
workers, police, etc.).  
New methods of delivery for naloxone need to be suitable for layperson use in 
community-based settings. Furthermore, formulations should be developed with longer 
shelf-life, especially in view of the pre-provision of these naloxone products to community 
and families and other non-hospital settings. Naloxone also needs to be absorbed 
rapidly, given the emergency situation, in quantity sufficient to effect quick reversal of 
opioid-induced respiratory depression. 
The reference for any candidate non-injectable routes is injectable naloxone, 
administered by the licensed intramuscular (IM), intravenous (IV), and subcutaneous 
(S/C) routes (WHO, 2014). When administered by the IM or S/C routes, naloxone 
typically reverses opioid action within 3-7 minutes; whereas the effect from IV 
administration has an onset typically within 2 minutes (UNODC/WHO, 2013). With long-
standing approval for, and experience with, naloxone in injectable form, this sets the 
standard against which possible non-injectable formulations need to be measured 
(Hertz, 2012).  
This chapter examines the options for non-injectable naloxone with potential application 
for wider community-based opioid overdose reversal. The aims are twofold:  
• Aim 1: to identify candidate routes of injection-free naloxone administration 
potentially suitable for emergency overdose reversal;  







Table 13 Second stage of selection process: Search protocol 
Research question What are the results of in vivo naloxone administration by the buccal, 
nasal, and sublingual routes of administration? 
Aim: To assess the feasibility of non-injectable naloxone administration 
Search strategy Electronic Databases:  
PubMed to identify relevant peer-reviewed articles published in English 
language between January 1946 and January (4th week) 2016.  
Buccal naloxone – search details: 
("naloxone"[MeSH Terms] OR "naloxone"[All Fields]) AND buccal[All Fields] 
Nasal naloxone – search details: 
("naloxone"[MeSH Terms] OR "naloxone"[All Fields]) AND (("nose"[MeSH 
Terms] OR "nose"[All Fields]) OR ("nose"[MeSH Terms] OR "nose"[All Fields] 
OR "nasal"[All Fields]) OR intranasal[All Fields]) 
Sublingual naloxone – search details: 
("naloxone"[MeSH Terms] OR "naloxone"[All Fields]) AND ("administration, 
sublingual"[MeSH Terms] OR ("administration"[All Fields] AND "sublingual"[All 
Fields]) OR "sublingual administration"[All Fields] OR "sublingual"[All Fields]) 
Hand-search: 
The reference lists of relevant studies identified via PubMed were manually 
searched for additional studies meeting the below eligibility criteria. 
General search filter 
used 
Identify records from title, abstract, keywords; Map term to Medical Subject 
Heading 
Publication Year: 1946 – Current 
Duplicate articles to be removed using EndNote software version X6 for 
Windows. 
Search Date 1 January 1946 to January (4th week) 2016 
Eligibility criteria  
• Population Non-human animals OR humans (healthy volunteers OR opioid users) 
• Intervention Naloxone administration (in vivo) 
• Comparison Parenteral naloxone administration (if available) 
• Outcomes Pharmacokinetics data 
Pharmacodynamics data 
Overdose outcomes (death vs. successful reversal) 
Adverse reactions 
• Study design Pre-clinical and clinical studies (randomized or observational trials) 
• Publication status Original studies published in peer-reviewed journals 
Exclusion criteria Case reports 
Qualitative studies 
Reporting on naloxone / buprenorphine 
Not reporting on naloxone 
Not reporting primary research data 





5.2  Methods 
A three-stage approach has been taken (see Figure 17). The first stage was an 
examination of all 112 routes of drug administration listed by the FDA (FDA, 1992)- 
updated 2014). For each of the 112 possible routes of administration, the potential 
applicability as a viable non-injectable route for emergency naloxone delivery by non-
medical personnel was considered (see Table 16).  
 





Routes of administration were thus identified as unsuitable according to five exclusion 
criteria:  
i) if the drug administration is by injection (or similar invasive procedure);  
ii) if the route is only relevant to medical procedures or requires medical training; 
iii) if the route is not publicly acceptable for administration by non-medical 
bystanders (e.g. rectal or vaginal administration); 
iv) if the route does not produce adequate systemic drug concentrations; 
v) if the route does not produce sufficiently rapid drug absorption relative to 
parenteral administration (Hertz, 2012). 
The second stage was to systematically search PubMed and the WHO International 
Clinical Trials Registry Platform for the potential candidate routes of administration that 
had emerged from the first stage. The search term “naloxone AND [route of 
administration]” (e.g. “naloxone AND (nose OR nasal OR intranasal)”) was used for each 
route across the electronic databases (see Table 13 for search protocol). I conducted 
the search and assessed retrieved studies for eligibility under supervision of my first 
supervisor. Relevant original research studies that were published in English language 
and reported on the outcomes of in vivo naloxone administration (e.g. overdose 
reversals, pharmacokinetics/-dynamics data) in humans or animals were included in this 
analysis (see Figure 18 for PRISMA diagram). A list of the eleven ineligible studies that 
were excluded after full-text review is provided in Table 14. 
The third stage, for remaining potential non-injectable routes of administration, 
comprised a more rigorous examination of the evidence against the inclusion criteria 
(see also Table 15): 
i) the route is suitable for overdose emergency situation;  
ii) the route does not bear major risk of compromise from overdose complication. 
For the first and third stage, I used the specified exclusion and inclusion criteria to screen 
all relevant routes of administration for potential inclusion, and the same process was 
conducted independently by my first supervisor. In cases of disagreement, a third 
colleague (who was a co-author of the Drug and Alcohol Dependence paper) acted as 













5.3  Results 
5.3.1 Shortlisting potential non-injectable routes of administration 
From examination of all 112 listed routes of administration (FDA, 1992), four were 
excluded on the basis that they held no analytic relevance (‘unassigned’, ‘unknown’, 
‘other’ and ‘not applicable’). From the remaining 108 categories, a further 102 were 
excluded according to the criteria listed in ‘Method’ (see Table 16). For instance, enteral 
delivery (through the gastro-intestinal mucosa) was excluded because of insufficient 
systemic absorption, since naloxone is poorly bioavailable if swallowed due to high first-
pass metabolism (Fishman et al., 1973). After this process, six non-injectable candidate 
routes remained to be considered further (see Table 15). Two of these six routes (see in 
italics at bottom of Table 15) were then removed on the basis that they were overarching 
categories of routes already being considered. Thus ‘oropharyngeal’ was removed as 
substantially overlapping with ‘buccal’ and ‘sublingual’, and ‘transmucosal’ was removed 
and considered under the specific mucosa (‘buccal’, ‘intranasal’, ‘sublingual’). With 
regard to the wider range of possible transmucosal routes, rectal delivery, which has 
replaced administration by injection for several emergency medications in pediatric care 
(Lyon & McIntosh, 1985; NICE, 2009), was specifically not included for further 
consideration, since it is unlikely to be acceptable to family and peers for community-
based naloxone emergency administration to overdose victims. 
 
Table 14 Studies excluded after full-text review (n=11) 
Study ID DOI / URL Search Source Reason for exclusion 
Davis (2015) 10.3109/10903127.2014.942484 PubMed Commentary 
Fareed (2015) 10.1111/ajad.12230 PubMed Case report 
Green (2014) 10.1080/08897077.2013.825691 PubMed Case report 
Kelly (2002) 10.1136/emj.19.4.375 PubMed Commentary 
Kerr (2008) 10.1111/j.1360-0443.2007.02097.x PubMed Review article 
Klimas (2015) 10.1186/s12909-015-0487-y PubMed Not relevant   
Lenton (2015) 10.1111/dar.12198 PubMed Not relevant 
Traynor (2016) 10.2146/news160002 PubMed Commentary 
Wermeling (2010) 10.1592/phco.30.7.627 PubMed Commentary 
Wolfe (2004) 10.1016/j.jen.2004.01.006 PubMed Review article 





5.3.2 Fuller examination of the shortlisted potential non-injectable routes 
As next step, these four potential routes (buccal, nasal, sublingual, 
respiratory/inhalation) were examined more fully based on the literature retrieved from 
the electronic databases. According to the WHO International Clinical Trials Registry 
Platform, nasal naloxone was being investigated in clinical trials by the Norwegian 
University of Science and Technology (NCT02307721, NCT01939444), in the US by the 
University of Cincinnati (NCT01912573) and Lightlake Sinclair Ltd. (NCT01567670), in 
Jordan by Mitovie Pharma Ltd (NCT01622504), and in Australia at the Sydney Medically 
Supervised Injecting Centre (ACTRN12611000852954). No database entries were 
found for study of naloxone via the buccal, sublingual or respiratory/inhalation routes. 
Each of these four routes of administration was then considered in turn:  
 
Respiratory (inhalation)  
The 'Respiratory (Inhalation)' route was excluded as not being suitable for further 
consideration because the victim might no longer be breathing (or breathing only very 
shallowly). Further, current portable devices for drug delivery to the lungs could not be 
used reliably in an emergency situation by non-medical personnel (spray or aerosolized 
naloxone is better considered under the ‘nasal’ category).  
 
Sublingual 
For the sublingual route, I identified one pharmacodynamics study in opioid-dependent 
volunteers (via PubMed), where sublingual naloxone precipitated withdrawal symptoms 
in 5 out of 9 participants (Preston, Bigelow, & Liebson, 1990). Apart from separate work 




PubMed search yielded 18 studies reporting in vivo administration of intranasal 
naloxone. Preclinical data from rodent studies showed complete absorption of nasal 
naloxone (bioavailability relative to IV: F% = 101%) (Hussain, Kimura, Chong-Heng, & 
Kashihara, 1984). In first in-human trials, nasal naloxone was found to elicit withdrawal 




Since the early 2000s, nasal naloxone has been used off-label by ambulance personnel 
(Barton et al., 2005; Barton et al., 2002; Belz et al., 2006; Kelly et al., 2005; Kerr et al., 
2009; Merlin et al., 2010; Robertson, Hendey, Stroh, & Shalit, 2009; Weber, Tataris, 
Hoffman, Aks, & Mycyk, 2012) and in the emergency department (Sabzghabaee, Eizadi-
Mood, Yaraghi, & Zandifar, 2014). More recently, improvised nasal kits (consisting of a 
pre-filled naloxone syringe and an atomizer which fits onto the syringe to generate a 
nasal spray) have been provided to opioid users, peers, and families in take-home 
naloxone trials (Doe-Simkins et al., 2009; Dwyer et al., 2015; Walley, Doe-Simkins, et 
al., 2013; Walley, Xuan, et al., 2013), and successful overdose reversals using 
improvised nasal kits have also been reported for police first responders (Rando et al., 
2015). However, the only published pharmacokinetic study in humans found intranasal 
naloxone (2mg/5ml) had a relative bioavailability of only 4% (Dowling et al., 2008).  
 
Buccal 
PubMed search identified two preclinical studies on buccal naloxone. In rodents, buccal 
naloxone administration led to high bioavailability (F% = 69-71%) and a Tmax (i.e. time 
from dosing to peak concentration) of 24 minutes (Hussain, Aungst, Kearney, & Shefter, 
1987; Hussain, Aungst, Koval, & Shefter, 1988), whereas in dogs, despite buccal Tmax at 
18 minutes, bioavailability was low (16%) (Hussain et al., 1988).  
 
Consequently, only three routes of administration were carried forward for full 
consideration as candidate routes of administration for emergency naloxone by non-
medical personnel: nasal, sublingual and buccal. All three routes were then compared 





Table 15 Third stage of selection: inclusion criteria 
   Inclusion criteria 
NAME DEFINITION FDA CODE Suitable for overdose crisis situation 
No risk of compromise from 
overdose complication 
BUCCAL Administration directed toward the cheek, generally from 
within the mouth. 
030 X X 
NASAL Administration to the nose; administered by way of the 
nose. 
014 X possible impairment due to O/D 
vomit or secretions 
SUBLINGUAL Administration beneath the tongue. 024 X possible impairment due to O/D 




Administration within the respiratory tract by inhaling orally 
or nasally for local or systemic effect. 
136 not viable as O/D victim not 
breathing or only shallowly 
X 
With the following routes subsumed into the above four routes: 
OROPHARYNGEAL Administration directly to the mouth and pharynx. 410 absorption likely too slow possible impairment due to O/D 
vomit or secretions 




5.3.3 Testing requirements: The 2012 FDA criteria 
According to the FDA guidance (Hertz, 2012), pharmacokinetic studies would need to 
“[e]valuate the relative bioavailability of at least two different doses compared to 
parenteral injection of naloxone (IM, IV or SC). […]. [Studies should] [c]ompare a 
parenteral dose of naloxone of at least 0.4mg to dose(s) of the new product that would 
be expected to result in similar or greater drug exposure.”  
The regulatory benchmark is thus that a 0.4mg injectable dose (IM, IV, or SC) and one 
or multiple doses of the new non-injectable naloxone formulation need to result in 
comparable plasma naloxone levels (i.e. area under the curve; AUC).  
The selection of the dose(s) of the new non-injectable product should be based on 
assumptions of its bioavailability, i.e. either based on previous data of naloxone 
bioavailability by the same route of administration, or if unavailable, the bioavailability of 
similar active ingredients by the same route of administration, or – if no human 
pharmacokinetic data is available – bioavailability of naloxone by the same route of 
administration in non-human animals.  
Further, “[t]arget plasma naloxone levels [should be] detectable in all subjects for a 
meaningful duration comparable to approved product.” In the emergency situation of 
opioid overdose, naloxone needs to be absorbed rapidly. Absorption would thus need to 
be at least as rapid as intramuscular injection, whereby onset of effect starts within 3 to 
7 minutes of administration (WHO, 2014). Early naloxone exposure can be quantified by 
means of Tmax and partial areas under the curve (e.g. between dosing and Tmax). In 
addition, the FDA guidance (Hertz, 2012) outlines the following key questions concerning 
bioavailability and usability:  
1) If the bioavailability of the new product compared with the approved intramuscular 
injection is low, then it is unclear if adequate efficacy can be reached. Vice versa, if the 
bioavailability of the new product is unexpectedly high, then this may have implications 
for the safety profile of the novel formulation.  
2) “Can the product be used by the intended population, i.e. [is] administration by 
someone other than the patient [possible]?”  
For all three identified candidate non-injectable routes (nasal, sublingual and buccal), 
investigators and manufacturers need to consider the FDA guidance on development of 
novel naloxone formulations for outpatient use (Hertz, 2012). The FDA proposed this 




receptors, it has no pharmacological effect in individuals who are not opiate-dependent 
and do not have any opioids in their system. Moreover, as it has no potential of abuse 
due to lack of euphoriant effect (Brunton et al., 2010), the pharmacokinetics of novel 
naloxone formulations can thus be safely tested in healthy volunteers. 
For all potential non-injectable naloxone products for use in overdose emergency 
management, naloxone will need to be absorbed rapidly into the bloodstream and thence 
across the blood-brain barrier. This is plausible for the nasal, buccal and sublingual 
routes, since they all involve absorption across a mucous membrane outside the gastro-
intestinal tract. They drain to the peripheral circulation rather than the hepatic portal vein, 
thus avoiding the hepatic portal system and first-pass metabolism in the liver. In addition 
to these anatomical and pharmacological factors, the context of emergency overdose 
reversal needs to be considered. For instance, devices need to be portable, accessible, 
easy to use and also operational on an unconscious supine overdose victim). The impact 
of potential pre-existing physical health impairments in the target population, such as 
damage to, or obstruction of, the relevant mucosa also needs to be considered. 
 
5.3.4  Intranasal naloxone 
The nasal route is characterized by high blood perfusion of the nasal mucosa which 
facilitates transmucosal absorption, and drainage mainly occurs into the facial veins 
(Dale et al., 2006; Standring, 2015). An additional nose-to-brain (N2B) connection has 
been hypothesized. It is mooted that drugs could be transported directly into the 
cerebrospinal fluid via the olfactory and trigeminal nerves (Djupesland, Messina, & 
Mahmoud, 2014) through the olfactory epithelium (on the roof of the nasal cavity) 
projecting directly into the olfactory bulb. However, human evidence of direct drug 
transport from the nose to the cerebrospinal fluid is currently still lacking (Djupesland et 
al., 2014; Merkus, Guchelaar, Bosch, & Merkus, 2003) 
Clinical reports describe use of improvised nasal naloxone kits which indicate life-saving 
benefit in many situations. However, for non-concentrate nasal kits, there remains 
uncertainty with regard to the formulation’s bioavailability and reliability of clinical 
effectiveness (Strang, McDonald, Tas, & Day, 2016). For example, Dowling et al. (2008) 
found that non-concentrate nasal naloxone spray (2mg/5mL) had a bioavailability of only 
4%, although the authors themselves acknowledged that the poor absorption was likely 
due to the insufficiently concentrated formulation. In two ambulance-based clinical trials, 




victims, 26% (using 2mg/5mL nasal formulation) (Kelly et al., 2005) and 18% (using 
2mg/mL nasal formulation) (Kerr et al., 2009) required a second rescue dose of naloxone 
(the second dose given IM). For a purpose-developed nasal naloxone spray, a more 
concentrated formulation of naloxone should be used, e.g. at least 5-10x current 
concentrations, a) to overcome the drug loss associated with administration of excessive 
volumes to the nasal cavity and b) to administer naloxone across the recommended 
dose range (i.e. bioequivalent to 0.4-2mg IV or IM).  
A significant positive development in this regard is the recent FDA approval of a new 
nasal spray formulation of a concentrated naloxone solution (US territory only) (FDA, 
2015). Pharmacokinetics data (including dose-equivalence and constancy) on 
concentrated naloxone nasal spray will hopefully become available, and it will be 
important to field-test the new product to assess the potential significance of practical 
obstacles, e.g., inter-individual variability, impact of airway blockage or apnea, impact of 
vomitus in the nasal passages or mouth, impact of nasal mucosal damage from drug 
abuse. This is necessary because drug users, may have damaged nasal mucosa – for 
example, ulceration, scarring and loss of tissue from repeated cocaine use (Peyrière et 
al., 2013). Absorption may consequently vary substantially between individuals, making 
it difficult to achieve systemic drug levels rapidly and reliably. There is also the possibility 
of interference with nasal absorption from vomiting associated with the overdose, 
thereby rendering the nasal cavity compromised. 
 
5.3.5  Sublingual naloxone 
The sublingual and buccal (from the oral vestibular cavity) routes both drain into the 
internal jugular vein via the facial veins, and thence rapidly to the brain (Pather, 
Rathbone, & Senel, 2008; Standring, 2015; Sudhakar, Kuotsu, & Bandyopadhyay, 
2006). An FDA product application was submitted in 2015 for a sublingual naloxone 
spray (FDAnews, 2015). If the naloxone were to be absorbed rapidly and efficiently, then 
this could be viable. However, there are several concerns regarding the suitability of the 
sublingual route for the emergency administration of naloxone. Access to the mucosa 
under the tongue may be obstructed if the mouth of the overdose victim is closed and/or 
if vomiting has occurred. A sublingual spray would be difficult to administer, as liquid 
may be lost to swallowing. Sublingual tablets are typically small and would be hard to 




naloxone delivery and effect in a pharmacodynamics study in opioid users (Preston et 
al., 1990). 
 
5.3.6  Buccal naloxone 
With buccal administration, a drug is absorbed across the buccal mucosa, a 40-50 cell 
(500-600 µm) thick stratified epithelium (Kulkarni et al., 2009). The vasculature of the 
buccal mucosa drains into the retromandibular, lingual and facial veins, which in turn 
drain directly into the internal jugular vein and, via the superior vena cava, into the 
systemic circulation (Pather et al., 2008; Sattar et al., 2014; Sudhakar et al., 2006). 
No human in vivo data for buccal naloxone has been published to date. However, a 
working prototype lyophilized tablet of naloxone has been developed in collaboration 
between the Addictions Department and the Institute of Pharmaceutical Science at 
King’s College London. The tablet is suitable for application to the buccal mucosa with 
rapid drug release for absorption (e.g. within 30 seconds) (Alqurshi et al., 2016). The 
development of this tablet and its in vitro properties are discussed in Chapter 9. 
 
 
5.4  Discussion 
5.4.1 Statement of principal findings 
The development of non-injectable formulations of naloxone is of major importance 
because of the potential for administration by non-medical people in emergency 
situations. Injectable routes work well and are fit for purpose for use by medical staff in 
hospital settings or by ambulance personnel attending a community emergency 
overdose scenario. However, the consideration is different for emergency administration 
by the general public (i.e. without medical training). While family members can be trained 
and are regularly given such training and emergency injectable medications for other 
potential medical crises (e.g. adrenaline/epinephrine for allergy anaphylaxis, insulin for 
diabetics, etc.), there would nevertheless be greater ease of distribution and comfort with 
emergency administration if an effective and reliable non-injectable formulation of 
naloxone was available.  
Examination of the extensive list of more than 100 different routes of administration 




warrant proper study. If successful, all three routes could become viable, cost-effective 
future alternatives to the licensed naloxone injection and could facilitate effective 
bystander response to opioid-overdose while minimizing associated risk. 
Consideration and investigation of nasal naloxone is the more advanced area. After a 
decade of community provision of improvised naloxone nasal spray, several 
pharmaceutical companies have recently been developing and testing purpose-made 
naloxone nasal sprays, and the FDA approved a first concentrated naloxone nasal spray 
in late 2015 (FDA, 2015) (see Chapter 4). 
Sublingual medications have been used in medicine to great benefit in emergency 
situations, such as glyceryl trinitrate (GTN) sublingual tablets or spray as acute treatment 
of angina or myocardial infarct. However, the sublingual route may be compromised if 
there is vomit or secretions. In October 2015, FDA granted fast-track review to a new 
drug application for a sublingual naloxone spray (FDAnews, 2015).  
No human data exist for buccal naloxone to date, and study of the buccal route for 
naloxone administration is less advanced. However, the buccal route has been 
successfully used to develop non-injectable versions of other medications previously 
available as injection only, such as buccal midazolam (Dale et al., 2006; Knoester et al., 
2002; Schwagmeier, Alincic, & Striebel, 1998; Taylor, Okocha, Paton, Smith, & Connolly, 
2008). There have also been promising experimental results with buccal naltrexone 
delivery in humans (Paderni et al., 2013). The potential of a lyophilized naloxone tablet 
for buccal administration is discussed in Chapter 9. 
 
5.4.2 Strengths and weaknesses of the chapter 
The main strength of this chapter lies in the methodological approach of its exhaustive 
consideration of all FDA-recognized routes of administration. However, it cannot be ruled 
out the possibility that other non-injectable routes that may in future prove feasible for 
naloxone administration due to technological advances. The scope of this chapter is 
further limited by the lack of empirical data from pre-clinical or clinical studies, which 






5.4.3 Possible mechanisms and implications for clinicians 
With regard to feasibility of the three candidate routes (see also Table 15) and their 
suitability for clinical practice, I consider the nasal route to be strong if concentrated 
solutions are used and provided dose-titration schedules can be made possible. I 
consider the sublingual route to be weakest, given that access to the sublingual mucosa 
may be obstructed in at least two scenarios: a) if the mouth of the overdose victim is 
closed and/or b) if vomiting has occurred. I consider the buccal route to hold real potential 
if rapid absorption and good stability can be achieved. 
 
 
5.5  Conclusion 
Take-home naloxone provision is held back by reliance on injectable formulations. 
Improvised nasal naloxone kits have been distributed in many communities, but their 
clinical safety is unknown (see Chapter 4). 
Alternative non-injectable naloxone products need to be explored. From application of 
the FDA criteria and review of all 112 categories for routes of administration, only three 
candidate routes for non-injectable naloxone administration were identified: Nasal, 
sublingual and buccal. A first concentrated nasal spray was granted FDA approval in 
2015.  
Despite these recent advances, my systematic review in this chapter illustrates that only 
limited pharmacokinetic data for non-injectable naloxone have been made available in 
the peer-reviewed domain. In the next chapter, I aim to address this gap by reviewing 
relevant naloxone data published by academia and pharmaceutical industry in 





Table 16 First stage of selection process: FDA list (1992) and exclusion criteria 
   Exclusion criteria 















AURICULAR (OTIC) Administration to or by way of the ear. 013    X X 
BUCCAL Administration directed toward the cheek, generally from within the mouth. 030      
CONJUNCTIVAL Administration to the conjunctiva, the delicate membrane that lines the 
eyelids and covers the exposed surface of the eyeball. 
068    X X 
CUTANEOUS Administration to the skin. 130    X X 
DENTAL Administration to a tooth or teeth. 038    X X 
ELECTRO-OSMOSIS Administration of through the diffusion of substance through a membrane in 
an electric field. 
357  X    
ENDOCERVICAL Administration within the canal of the cervix uteri (synonymous with the 
term intracervical).  
131 X     
ENDOSINUSIAL Administration within the nasal sinuses of the head. 133  ?    
ENDOTRACHEAL Administration directly into the trachea. 401  X    
ENTERAL Administration directly into the intestines. 313    X  
EPIDURAL Administration upon or over the dura mater. 009 X     
EXTRA-AMNIOTIC Administration to the outside of the membrane enveloping the fetus 402 X     
EXTRACORPOREAL Administration outside of the body. 057     X 
HEMODIALYSIS Administration through hemodialysate fluid. 
 




   Exclusion criteria 















INFILTRATION Administration that results in substances passing into tissue spaces or into 
cells. 
361 X     
INTERSTITIAL Administration to or in the interstices of a tissue. 088 X     
INTRA-ABDOMINAL Administration within the abdomen. 056 X     
INTRA-AMNIOTIC Administration within the amnion. 060 X     
INTRA-ARTERIAL Administration within an artery or arteries. 037 X     
INTRA-ARTICULAR Administration within a joint. 007 X     
INTRABILIARY Administration within the bile, bile ducts or gallbladder. 362 X     
INTRABRONCHIAL Administration within a bronchus. 067 X     
INTRABURSAL Administration within a bursa. 025 X     
INTRACARDIAC Administration with the heart. 027 X     
INTRACARTILAGINOUS Administration within a cartilage; endochondral. 363 X     
INTRACAUDAL Administration within the cauda equina. 413 X     
INTRACAVERNOUS Administration within a pathologic cavity, such as occurs in the lung in 
tuberculosis. 
132 X     
INTRACAVITARY Administration within a non-pathologic cavity, such as that of the cervix, 
uterus, or penis, or such as that which is formed as the result of a wound. 
023 X     
INTRACEREBRAL Administration within the cerebrum. 
 




   Exclusion criteria 















INTRACISTERNAL Administration within the cisterna magna cerebellomedularis. 405 X     
INTRACORNEAL Administration within the cornea (the transparent structure forming the 
anterior part of the fibrous tunic of the eye). 
406 X     
INTRACORONAL, DENTAL Administration of a drug within a portion of a tooth which is covered by 
enamel and which is separated from the roots by a slightly constricted 
region known as the neck. 
117 X     
INTRACORONARY Administration within the coronary arteries. 119 X     
INTRACORPORUS 
CAVERNOSUM 
Administration within the dilatable spaces of the corporus cavernosa of the 
penis. 
403 X     
INTRADERMAL Administration within the dermis. 008 X     
INTRADISCAL Administration within a disc. 121 X     
INTRADUCTAL Administration within the duct of a gland. 123 X     
INTRADUODENAL Administration within the duodenum. 047 X     
INTRADURAL Administration within or beneath the dura. 052 X     
INTRAEPIDERMAL Administration within the epidermis. 127 X     
INTRAESOPHAGEAL Administration within the esophagus. 072 X     
INTRAGASTRIC Administration within the stomach. 046 X     
INTRAGINGIVAL Administration within the gingivae. 
 




   Exclusion criteria 















INTRAILEAL Administration within the distal portion of the small intestine, from the 
jejunum to the cecum. 
365 X     
INTRALESIONAL Administration within or introduced directly into a localized lesion. 042 X     
INTRALUMINAL Administration within the lumen of a tube. 310 X     
INTRALYMPHATIC Administration within the lymph. 352 X     
INTRAMEDULLARY Administration within the marrow cavity of a bone. 408 X     
INTRAMENINGEAL Administration within the meninges (the three membranes that envelope the 
brain and spinal cord). 
409 X     
INTRAMUSCULAR Administration within a muscle. 005 X     
INTRAOCULAR Administration within the eye. 036 X     
INTRAOVARIAN Administration within the ovary. 354 X     
INTRAPERICARDIAL Administration within the pericardium. 314 X     
INTRAPERITONEAL Administration within the peritoneal cavity. 004 X     
INTRAPLEURAL Administration within the pleura. 043 X     
INTRAPROSTATIC Administration within the prostate gland. 061 X     
INTRAPULMONARY Administration within the lungs or its bronchi. 414 X     
INTRASINAL Administration within the nasal or periorbital sinuses. 010 X     




   Exclusion criteria 















INTRASYNOVIAL Administration within the synovial cavity of a joint. 019 X     
INTRATENDINOUS Administration within a tendon. 049 X     
INTRATESTICULAR Administration within the testicle. 110 X     
INTRATHECAL Administration within the cerebrospinal fluid at any level of the 
cerebrospinal axis, including injection into the cerebral ventricles. 
103 X     
INTRATHORACIC Administration within the thorax (internal to the ribs); synonymous with the 
term endothoracic. 
006 X     
INTRATUBULAR Administration within the tubules of an organ. 353 X     
INTRATUMOR Administration within a tumor. 020 X     
INTRATYMPANIC Administration within the aurus media. 366    X X 
INTRAUTERINE Administration within the uterus. 028 X     
INTRAVASCULAR Administration within a vessel or vessels. 021 X     
INTRAVENOUS Administration within or into a vein or veins. 002 X     
INTRAVENOUS BOLUS Administration within or into a vein or veins all at once. 138 X     
INTRAVENOUS DRIP Administration within or into a vein or veins over a sustained period of time. 137 X     
INTRAVENTRICULAR Administration within a ventricle. 048 X     
INTRAVESICAL Administration within the bladder. 128 X     




   Exclusion criteria 














IONTOPHORESIS Administration by means of an electric current where ions of soluble salts 
migrate into the tissues of the body. 
055  X    
IRRIGATION Administration to bathe or flush open wounds or body cavities. 032  X  X  
LARYNGEAL Administration directly upon the larynx. 364 X     
NASAL Administration to the nose; administered by way of the nose. 014      
NASOGASTRIC Administration through the nose and into the stomach. 071  X X   
NOT APPLICABLE Routes of administration are not applicable. 312 N/A N/A N/A N/A N/A 
OCCLUSIVE DRESSING 
TECHNIQUE 
Administration by the topical route which is then covered by a dressing 
which occludes the area. 
134    X X 
OPHTHALMIC Administration to the external eye. 012    X X 
ORAL Administration to or by way of the mouth. 001    X  
OROPHARYNGEAL Administration directly to the mouth and pharynx. 410      
OTHER Administration is different from others on this list. 135 N/A N/A N/A N/A N/A 
PARENTERAL Administration by injection, infusion, or implantation. 411 X     
PERCUTANEOUS Administration through the skin. 113 X     
PERIARTICULAR Administration around a joint. 045 X     
PERIDURAL Administration to the outside of the dura mater of the spinal cord.. 050 X     
PERINEURAL Administration surrounding a nerve or nerves. 
 






   Exclusion criteria 















PERIODONTAL Administration around a tooth. 040    X X 
RECTAL Administration to the rectum. 016   X   
RESPIRATORY 
(INHALATION) 
Administration within the respiratory tract by inhaling orally or nasally for 
local or systemic effect. 
136      
RETROBULBAR Administration behind the pons or behind the eyeball. 034 X     
RETROBULBAR Administration behind the pons or behind the eyeball. 034 X     
SOFT TISSUE Administration into any soft tissue. 109 X     
SUBARACHNOID Administration beneath the arachnoid. 066 X     
SUBCONJUNCTIVAL Administration beneath the conjunctiva. 096 X     
SUBCUTANEOUS Administration beneath the skin; hypodermic.   003 X     
SUBLINGUAL Administration beneath the tongue. 024      
SUBMUCOSAL Administration beneath the mucous membrane. 053 X     
TOPICAL Administration to a particular spot on the outer surface of the body. 011    X X 
TRANSDERMAL Administration through the dermal layer of the skin to the systemic 
circulation by diffusion. 
358    X X 
TRANSMUCOSAL Administration across the mucosa. 122      
TRANSPLACENTAL Administration through or across the placenta. 
 
 




   Exclusion criteria 















TRANSTRACHEAL Administration through the wall of the trachea. 355  X X X  
TRANSTYMPANIC Administration across or through the tympanic cavity. 124  X   X 
UNASSIGNED Route of administration has not yet been assigned. 400 N/A N/A N/A N/A N/A 
UNKNOWN Route of administration is unknown. 139 N/A N/A N/A N/A N/A 
URETERAL Administration into the ureter. 112  X  X  
URETHRAL Administration into the urethra. 017  X X X  
VAGINAL Administration into the vagina. 015   X   
Annotations: 1 If a route of administration required injection (or a similar invasive procedure), the route was automatically excluded. Vice versa, if a route did not involve injection (or a similar 





Chapter 6  Patent Applications for Non-Injectable Naloxone 
Preface 
In this chapter, I present a review of international research activity around the exploration 
of non-injectable naloxone formulations. My earlier systematic review of candidate routes 
for non-injectable naloxone administration (see Chapter 5) indicated that only limited 
human pharmacokinetic data of injection-free naloxone administration had been 
published in the peer-reviewed literature. To supplement what appeared to be scarce 
academic research output, I consequently needed to identify additional sources of 
information that would also capture research and development within pharmaceutical 
industry. An initial scoping search of the PatentScope database was promising and 
revealed a plenitude of information: depending on the sensitivity of the search method, 
the search term “naloxone” yielded between 522 and 19,000+ entries. The review 
presented in this chapter constitutes an attempt to access and analyze this information 
contained within the PatentScope database in a systematic and transparent manner to 
allow for potential future replication or application to other subject areas. 
The content of this chapter has been accepted as first-authored manuscript (title: 
“International patent applications for non-injectable naloxone for opioid overdose 
reversal: Search and retrieve analysis of the PatentScope database”) for publication in 
Drug and Alcohol Review (in press) and was developed in collaboration with my PhD 
supervisor Professor Sir John Strang as well as Professor Ola Dale and Øyvind 
Danielsson Glende of The Norwegian University of Science and Technology (NTNU) in 
Trondheim. Professor Ola Dale is an anesthetist and clinical pharmacologist by training 
and heads a group of pain researchers at NTNU. Øyvind Danielsson Glende is a 
pharmacist who, as part of his graduate training, undertook a research visit at the 
National Addiction Centre at King’s College London in March 2016. At the time, he was 
enrolled in the Master of Science in Pharmacy course at NTNU (under supervision of 
Professor Dale). I supervised Øyvind during his research visit, and we jointly conducted 
the database searches, eligibility assessment, and data extraction from relevant records, 
as described in the Methods section of this chapter.  
This chapter integrates pharmacokinetic data for intranasal and sublingual 
administration and reference routes (intramuscular, intravenous, subcutaneous) from 
five peer-reviewed journal articles (identified via PubMed) and three published 
international patent applications (identified via PatentScope). The original dataset of one 




6.1  Introduction 
The previous chapter applied the FDA’s 2012 criteria for non-injectable naloxone to the 
peer-reviewed literature and identified three candidate routes of administration for 
injection-free naloxone delivery: IN, sublingual, and buccal. On November 18, 2015, the 
FDA gave regulatory approval for a concentrated intranasal (IN) naloxone spray 
(NARCAN®) by Adapt (FDA, 2015), which constitutes the first-ever licensed non-
injectable naloxone product (see also Chapter 4). 
However, at the time of the FDA approval of the novel product, no results from clinical 
trials were published, and human PK data were only reported in one peer-reviewed 
publication for an improvised IN naloxone spray formulation (2mg/5ml), with extremely 
low absolute bioavailability (F=4%) relative to the intravenous reference (Dowling et al., 
2008). Uncertainties regarding the viability of improvised, off-label IN spray 
(administered by attaching a mucosal atomizer device to a pre-filled naloxone syringe) 
for opioid overdose reversal have been described in Chapter 4 and primarily concern its 
non-response rate and lack of safety data. 
This chapter attempts to close the gap in the literature by examining published 
international patent applications of non-injectable naloxone formulations and 
contributory PK data. The aims are threefold:  
• Aim 1: To trace the concept and product development by route of administration;  
• Aim 2: To describe the non-injectable naloxone formulations for which human in 
vivo data are available;  
• Aim 3: To compare human PK data reported in the patent applications. 
 
6.2  Methods 
A three-stage approach has been taken.  
 
6.2.1  Stage 1  
The PatentScope database of the World Intellectual Property Organization (WIPO), 
which contains 58 million patent documents including 3 million published international 
patent applications (WIPO, 2016), was searched for patent applications for non-
injectable naloxone formulations. PatentScope was searched for English-language 
patent applications (“Language: EN”) that were registered with any international patent 




(default). Only patent applications for non-injectable naloxone that contained human PK 









Table 17 Search protocol 
Research question What are the pharmacokinetics of naloxone administration by the 
nasal, sublingual, or buccal routes of administration? 
Aim: To assess the absorption of non-injectable naloxone formulations in 
humans 
Search strategy Electronic Databases: PubMed to identify relevant peer-reviewed articles 
published in English language between January 1946 and March (2nd 
week) 2016.  
 
Search query: “(nasal OR intranasal OR nose OR buccal OR sublingual) 
AND naloxone AND pharmacokinetics “ 
 
Query Translation: ("nose"[MeSH Terms] OR "nose"[All Fields] OR 
"nasal"[All Fields]) OR intranasal[All Fields] OR ("nose"[MeSH Terms] OR 
"nose"[All Fields]) OR buccal[All Fields] OR ("administration, 
sublingual"[MeSH Terms] OR ("administration"[All Fields] AND 
"sublingual"[All Fields]) OR "sublingual administration"[All Fields] OR 
"sublingual"[All Fields]) AND ("naloxone"[MeSH Terms] OR "naloxone"[All 
Fields]) AND ("pharmacokinetics"[Subheading] OR "pharmacokinetics"[All 
Fields] OR "pharmacokinetics"[MeSH Terms]) 
 
Hand-search: The reference lists of relevant studies identified via PubMed 
were manually searched for additional studies meeting the below eligibility 
criteria. 
General search filter 
used 
Identify records from title, abstract, keywords; Map term to Medical Subject 
Heading 
Publication Year: 1946 – Current 
Duplicate articles to be removed using EndNote software version X6 for 
Windows. 
Search Date 1 January 1946 to March (2nd week) 2016 
Eligibility criteria  
• Population Humans  
• Intervention Naloxone administration (in vivo) 
• Comparison Parenteral naloxone administration (if available) 
• Outcomes Pharmacokinetics data 
• Study design Clinical studies (randomized or observational trials) 
• Publication 
status 
Original studies published in peer-reviewed journals 
Exclusion criteria Case reports 
Qualitative studies 
Preclinical data 
Not reporting on naloxone 
Not reporting primary research data 




6.2.2 Stage 2  
The pharmaceutical properties of the non-injectable naloxone formulations and human 
PK data were extracted from patent the applications. To improve comparability between 
formulations, dose-adjusted values per 1mg were generated.  
 
6.2.3  Stage 3 
To supplement and cross-check the data obtained in Stages 1 and 2, we also searched 
PubMed for human PK data for non-injectable naloxone using the Boolean search query 
“(nasal OR intranasal OR nose OR buccal OR sublingual) AND naloxone AND 
pharmacokinetics” (see Table 17 for search protocol). These three routes of 
administration were chosen based on the systematic review in Chapter 5 (Strang, 
McDonald, Alqurshi, et al., 2016). 
 
6.3  Results 
 
6.3.1  Stage 1 
A PRISMA flow diagram of the selection process of patent applications is shown in Figure 
20. 522 PatentScope records were identified using the search term “naloxone” for front-
page matches. At this stage, a cross-check was made for known patent applications, 
and it was found that no entry for the FDA-approved Adapt IN spray product (NARCAN®, 
see also Chapter 4) had been captured. We thus additionally searched PatentScope for 
“Adapt OR Lightlake”-related entries. (In late 2014, Adapt had bought the global license 
from Lightlake Therapeutics Inc. to develop and commercialize their IN naloxone spray 
(PRNewsWire, 2014).) After matching for the search term “Lightlake” (front-page search, 
English language, all patent offices), this additional search yielded five patent 
applications, which had not been captured using the search term “naloxone” because 
Lightlake had not included the word ‘naloxone’ on the front page. Consequently, these 
five Lightlake patent applications were manually added (n.b. in the remainder of this 
chapter, I denote these as ‘Lightlake’ unless I refer directly to the licensed Adapt nasal 
spray product).  
Of the 47 records that remained after removing 480 irrelevant records, 10 were excluded 
based on their abstract (e.g. active ingredient other than naloxone). The remaining 37 




14 patent applications that contained relevant PK data, 11 were excluded for the 
following reasons: 5 reported only animal data, and 6 were duplicates (earlier or later 
versions of patents containing the same PK data but different patent claims or country 
of publication). Three published international patent applications were identified as 
eligible for inclusion: WO/2015/136373, WO/2015/095644, and WO/2012/156317. A 
timeline of the publication of all 37 patent applications (including excluded records) is 
provided as Table 20. 
The timeline shows that the concept of IN naloxone (drops, spray, solution, suspension, 
ointment or gel) was first being explored at the University of Kentucky, with first animal 
data reported in 1982. The 1990s showed no activity for IN naloxone except for the 
patent application of a spray dispenser by Britannia Pharmaceuticals in 2000 (n.b. the 
same spray device as in the 2015 FDA-approved Adapt naloxone spray which uses the 
Aptar single unit-dose device, see Chapter 4). In 2005, an IN naloxone powder was 
proposed by the Chinese PLA Academy of Military Science. The first human PK data for 
IN naloxone were filed by Euro-Celtique in 2012 (WO/2012/156317).  
The first patent application describing the concept of sublingual or buccal naloxone was 
published by the Israeli company Pentach Pharmaceuticals in 2004, and patent 
applications covering sublingual naloxone (spray, dripping pills) by two Beijing-based 
companies followed in 2007 and 2011. In 2012, Euro-Celtique included sublingual PK 
data in its patent application on concentrate IN naloxone spray (see above). In June 
2015, INSYS Pharma submitted two patent applications for sublingual naloxone spray 
(no PK data) and was granted FDA fast-track review later that year (FDAnews, 2015).  
 
6.3.2  Stage 2 
Description of intranasal pharmacokinetic data  
The following section summarizes the IN PK data reported in the published international 
patent applications WO/2015/136373 (Lightlake Therapeutics), WO/2015/095644 
(AntiOp), and WO/2012/156317 (Euro-Celtique). All data were obtained using crossover 
study designs, though sample sizes differed from 7 to 35 subjects per arm. For a full 
summary of the PK data (including reference routes), please see Table 19. 
AntiOp described two studies, which are hereby referred to as ‘Trial 1 (Pilot’) and ‘Trial 
2’. AntiOp tested a 10mg/ml IN formulation administered as 0.1ml into one and two 
nostrils, as well as 0.2ml per nostril (0.1+0.1ml with 5-minute interval). Trial 1 (Pilot) also 




to a syringe, thus replicating the improvised IN naloxone distributed off-label in several 
countries.  
Lightlake presented results from two studies: Study 1 assessed a 10mg/ml formulation, 
whereas Study 2 tested 20mg/ml and 40mg/ml formulations, all administered as 0.1ml 
into one and two nostrils (total volume: 0.2ml). 
Euro-Celtique tested IN doses of 8mg (0.2ml per nostril; 20mg/ml concentration) and 
16mg (0.2ml per nostril; 40mg/ml concentration). Euro-Celtique also included a 
sublingual arm (16mg/ml solution), but this route is not described here in detail, as its 
absolute bioavailability was only 1%.  
For IN administration, absolute bioavailability (F; relative to intravenous) as well as 
relative bioavailability (FIM; relative to intramuscular) are presented, as neither measure 
was reported across all three patent applications. (Euro-Celtique only provided F, 
whereas the more recent AntiOp and Lightlake patent applications reported FIM in 
accordance with guidance from FDA). 
F: For the Euro-Celtique data, I calculated F values of 22% (20mg/ml, administered as 
0.2ml per nostril) and 21% (40mg/ml; 0.2ml per nostril) using AUC0-∞ data listed in the 
PK data appendix of the patent application. I was unable to obtain the higher F values of 
32% (20mg/ml formulation) and 27% (40mg/ml) which Euro-Celtique cited in-text for 
lower doses (1.2 and 1.6mg, dose-adjusted from 8 and 16mg) in the body of the patent 
application. AntiOp only reported FIM, but included an IV reference in Trial 1 (Pilot), which 
allowed me to manually determine the following F-values for comparison: 36% (0.1ml, 
one nostril only) and 42% (0.1ml per nostril) for the 10mg/ml formulation, and 11% for 
non-concentrate naloxone (1mg/ml per nostril). 
FIM: Lightlake achieved the highest FIM values across all three patent applications, with 
0.1ml of the 10mg/ml formulation administered into both nostrils (FIM=57%). FIM was 
lower (48%), when the volume of the same formulation was doubled (0.2ml per nostril). 
For the 20mg/ml formulation, FIM was 54% (0.1ml, one nostril only) and 55% (0.1ml per 
nostril). The 40mg/ml formulations achieved 49% and 45% when administered into one 
and both nostrils, respectively. AntiOp reported the following FIM values for a 10mg/ml 
formulation: 34% (0.1ml, one nostril only), 31-39% (0.1ml per nostril), and 26% (0.1ml 
per nostril, with re-administration after 5 minutes; i.e. total volume of 0.2ml per nostril). 
Non-concentrate naloxone (1mg/ml per nostril) had a FIM of 10%.  
t1/2: The terminal half-life (t1/2) is the time it takes for the blood concentration of a 
pharmacological agent to decrease by 50%, which usually translates into the loss of 




(t1/2) for IN administration, with 9.1 (40mg/ml) and 9.5 hours (20mg/ml), though data were 
only available for 4 subjects. In the AntiOp and Lightlake patent applications, t1/2 fell in 
the range of 1.2–2.1 hours.  
tmax: IN tmax values ranged from 0.27 (AntiOp, 1mg/ml, 1ml per nostril) to 0.5 hours 
(AntiOp 10mg/ml, 0.1ml into one nostril and Lightlake 40mg/ml, 0.1ml into one nostril). 
AUC & Cmax: Dose-adjusted Cmax values (per mg) were highest for the Lightlake 20mg/ml 
formulation administered as 0.1ml per nostril (Cmax=1.66ng/ml). The same treatment arm 
achieved AUC0-∞=2.48ng*h/ml. The Euro-Celtique 20mg/ml formulation reached the 
highest AUC0-∞ value (2.76ng*h/ml) and dose-adjusted (per mg) Cmax of 1.60ng/ml. The 
1mg/ml non-concentrate AntiOp treatment (administered as 1ml per nostril) had the 
lowest values (AUC0-∞=0.45ng*h/ml; Cmax=0.27ng/ml). 
Additional exploratory analyses: In order to allow for examination of the potential 
influence of spray concentration on IN absorption, AUC, Cmax, and tmax values have been 
plotted against volume (adjusted by dose for AUC and Cmax) and dose (see Figure 21). 
For both AUC and Cmax, the plots indicate a positive association with dose and a negative 
association with the volume of the IN spray. The graphs do not suggest a clear 
association for tmax. 
 
 





6.3.3 Stage 3 
The PubMed search generated 56 matches, with zero duplicates (see Figure 22). 46 
papers were excluded based on title and abstract (no primary data from in-human 
naloxone studies). The ten remaining records were downloaded for full text, with five 
papers excluded for the following reasons: one was a review article, and four did not 
include naloxone PK data (see Table 18 for a list of excluded studies). The remaining 
eligible five papers included human PK data in two papers for IN naloxone (Dowling et 
al., 2008; Middleton, Nuzzo, Lofwall, Moody, & Walsh, 2011) and three papers for 
sublingual naloxone (Fischer, Jonsson, & Hjelmstrom, 2015; Harris, Mendelson, Lin, 
Upton, & Jones, 2004; Nasser, Heidbreder, Liu, & Fudala, 2015). None of the papers 
contained human PK data for buccal naloxone. 
 
 





Divergent bioavailability values have been reported for IN naloxone. One healthy 
volunteers study (n=6) assessed a non-concentrate formulation of IN naloxone 
(2mg/5ml) and reported an absolute bioavailability of only 4%, which the authors 
attributed as possibly due to the dilute solution (and high volume) used (Dowling et al., 
2008). Higher absorption was reported in a study (Middleton et al., 2011) with 
recreational prescription opioid users (n=10) where absolute bioavailability of IN 
administration of crushed buprenorphine/naloxone (4:1 ratio) of two concentrations 
(0.5mg, 2mg naloxone) was 24% and 30%, respectively.   
Systemic uptake after sublingual naloxone administration was generally found to be low. 
In one healthy volunteers study, naloxone doses of 1.4mg and 2mg were administered 
in combination with buprenorphine, resulting in a median tmax of 0.8h and peak naloxone 
plasma concentrations below 0.4ng/ml for both doses (Fischer et al., 2015). A second 
study in non-dependent opioid users (n=8) (Harris et al., 2004) assessed escalating 
naloxone doses (1mg, 2mg, 4mg) and found that dose-effect comparisons were 
impossible, as many naloxone plasma concentrations were below the level of 
quantification (0.050ng/ml). The highest individual AUC reported was 0.55ng*h/ml.  
A third study (Nasser et al., 2015) suggested that sublingual naloxone bioavailability is 
negatively associated with healthy liver functioning. A sublingual 0.5mg naloxone tablet 
(in combination with 2mg buprenorphine) was administered to forty-three subjects 
stratified by hepatic impairment (mild, moderate, or severe), HCV diagnosis without 
hepatic impairment, and healthy volunteers. Across all groups, the median tmax ranged 
from 0.8-1.1 hours, with mean t1/2 from 1.9-5.5 hours. However, the AUC0-last data 
revealed an approximate 3 to 14-fold increase in total naloxone exposure in subjects 
with moderate and severe hepatic impairment. Likewise, the naloxone Cmax was 3 to 11-
times higher in subjects with hepatic impairment.  
 
Table 18 Excluded studies (n=5) 
Study ID DOI / URL Source Reason for exclusion 
Chiang (2003) 10.1016/S0376-8716(03)00058-9 PubMed Review article 
Ciraulo (2006) 10.1177/0091270005284192 PubMed No naloxone PK data 
Compton (2006) 10.1016/j.drugalcdep.2005.08.005 PubMed No naloxone PK data 
Compton (2007) 10.1097/ADM.0b013e31806dcc3e PubMed No naloxone PK data 





6.4  Discussion 
Human PK data for purpose-made non-injectable naloxone formulations had not been 
reported in peer-reviewed scientific papers at the time of FDA approval of the first IN 
naloxone spray (Krieter et al., 2016). However, recent published international patent 
applications by the companies AntiOp, Euro-Celtique and Lightlake contain data on 
concentrated sublingual and IN spray formulations in the range 10-40mg/ml. This 
chapter integrates data from WIPO PatentScope with scientific publications retrievable 
via PubMed, charting R&D activity over two decades (particularly 2012-present).  
 
6.4.1  Statement of principal findings 
Across all concentrate IN naloxone formulations, bioavailability was 21-42% relative to 
IV and 26-57% relative to IM. Plotting of the AUC0-∞ and Cmax values showed a 
moderately linear relationship with dose (higher dose  higher AUC0-∞, Cmax) and a 
negative association for volume (lower volume  higher AUC0-∞, Cmax). The highest IN 
bioavailability (FIM=57%) was reached when 0.1ml of a 10mg/ml formulation was 
administered into both nostrils. For the same formulation, FIM decreased to 48% when 
volume doubled to 0.2ml per nostril. Volume clearly matters. Dose-concentration linearity 
is also evident. The importance of (low) volume is underlined by the observation that IN 
bioavailability was drastically lower (F=11%) when a non-concentrated formulation of 
1mg/ml was administered into both nostrils. This confirms previous reports of low 
bioavailability (F=4%) for dilute IN spray (0.4mg/ml) (Dowling et al., 2008). A non-
concentrated solution is more likely to lead to a proportion being swallowed, as a larger 
volume would be expected to run out of the nasopharynx, rather than being absorbed 
from the nasal mucosa. This would be expected to lower the systemic availability due to 
first-pass metabolism of naloxone absorbed from the gastrointestinal tract.  
Sublingual naloxone administration of a concentrate solution (16mg/ml) had very low 
bioavailability (F=1%). This is below the range of 7-9% identified by Chiang et al. in their 
review of sublingual buprenorphine-naloxone formulations (Chiang & Hawks, 2003). 
Sublingual is thus unlikely to be a route of administration of clinical value. 
 
6.4.2  Strengths and weaknesses of the chapter 
The methodology of this review of non-injectable concentrate naloxone formulations is 
novel in that it includes examination of public-domain information from patent 




from PubMed and WIPO PatentScope databases, capturing both academic and 
pharmaceutical industry advances in the field.  
The validity of this comparison of IN PK data across different patent applications is 
strengthened by the similarity of the IN spray formulations used. While Euro-Celtique 
only disclosed dose concentrations, all formulations all formulations by Lightlake and 
AntiOp with provided PK data are characterized by absence of absorption enhancers 
(which increase membrane permeation) and viscosity-increasing agents (which increase 
the residence time of naloxone to the nasal mucosa and thus contributes to better 
absorption).  
Potential limitations need to be considered. Firstly, not all research and development 
activity leads to registration of intellectual property or to journal publication, and non-
significant or negative results have low likelihood of getting published. Secondly, data 
published in patent applications has not undergone peer-review, and data quality is thus 
dependent on the patent applicant. Thirdly, the WIPO PatentScope database search was 
unlikely exhaustive. Considering that the search initially failed to capture the Lightlake 
patent applications, the possibility of other false-negatives cannot be ruled out. I 
conducted the default “First Page” search, which identified any patent document with the 
search term (“naloxone”) mentioned on its cover page, generating 522 matches. Had I 
conducted the more comprehensive “Full Text” search (“naloxone” mentioned in any full-
text patent document), PatentScope would have identified over 19,000 matches, which 
would have exceeded my capacity for manual screening. Compared to online literature 
databases such as PubMed or Embase, the functionality of the PatentScope interface is 
less advanced, in that users cannot export full search results to a citation manager. For 
every PatentScope entry, we thus had to associated documents had to be downloaded 
individually to allow for assessment of eligibility for inclusion in the analysis. I considered 
supplementing the PatentScope search with additional query of all national and regional 
patent offices for which our PatentScope “naloxone” search had yielded relevant entries 
(Canada, China, European Union, Germany, Great Britain, Israel, Russia, Singapore, 
South Africa, US; see Table 20). However, I concluded that this was not feasible due to 
their different search and output formats that are not always compatible with 
PatentScope: for instance, the British online database Ipsum of the UK Intellectual 
Property office only permits search by application or publication number (i.e. not by 
keyword, e.g. “naloxone”) (IPO, 2016), and the US Patent and Trademark Office offers 
two separate search modes: one for patent applications (Patent Application Full-Text 




Database; PatFT) (USPTO, 2016), whereas PatentScope does not provide such 
distinction.  
The fourth limitation concerns the quality of the data retrieved: PatentScope records 
typically do not include raw data, and this analysis was reliant upon summary data 
provided by the patent applicants. Consequently, the comparability of the PK results was 
limited by different analytical methods and result formats used in the individual studies 
included in the patent applications (e.g. bioavailability reported as F vs. FIM; central 
tendency expressed as mean vs. median). For instance, the actual concentration of the 
AntiOp formulation (10mg/ml Naloxone HCl or 10mg/ml Naloxone HCl dihydrate) 
remains uncertain, which could have affected calculation of dose-adjusted values in 
Table 19. There was also variability in the sampling periods (8-36 hours), which may 
have impacted AUC-dependent measures (e.g. F%, FIM%). In terms of reliability of the 
mean values reported in Table 19, it also needs to be borne in mind that the crossover 
studies (which comprised pilot and registration trials) differed substantially in sample 
sizes (7-35 subjects per treatment arm).  
 
6.4.3  Possible mechanisms and implications for clinicians 
These findings have multiple implications for clinicians and policymakers. 
IN naloxone: Low spray volume and high concentrations lead to better IN naloxone 
absorption. Concentrated IN naloxone spray is thus a potentially valuable non-injectable 
formulation for opioid overdose reversal. This is likely relevant both in medical settings 
and in the community (take-home naloxone programs). This conclusion accords with the 
first FDA approval of an IN naloxone spray product (FDA, 2015), at 4mg/0.1ml naloxone 
hydrochloride (i.e. 40mg/ml concentration).  
However, further examination is required of the full PK curve and the resulting clinical 
effect: for all doses of the 40mg/ml formulations tested (4-16mg), Cmax (5.34-18.3ng/ml) 
was much higher than for intramuscular (IM) references (Cmax=0.77-1.05ng/ml). 
Consequently, while clinical efficacy of concentrated IN sprays is likely, there is the risk 
of inducing acute opioid withdrawal in overdose victims (Buajordet et al., 2004). A recent 
qualitative analysis of heroin/opioid overdose reversals found instances of apparent 
excessive naloxone dosing and consequent ‘over-antagonism’, sometimes triggering 
discharge and active further drug-seeking (Neale & Strang, 2015). Hepatic impairment 
also increases naloxone bioavailability, particularly relevant when larger fractions of 
buccal/sublingual or IN naloxone are swallowed (Nasser et al., 2015), potentially causing 




Sublingual naloxone: In October 2015, INSYS Therapeutics announced that its 
sublingual naloxone spray (formulation unknown) had been granted FDA fast-track 
review. Considering the low bioavailability reported by the Euro-Celtique study, it seems 
unlikely that sublingual naloxone will be clinically useful.  
 
6.4.4  Questions for future research 
Unanswered questions around non-injectable naloxone remain. 
All PK data reported in the referenced patent applications were from healthy volunteers. 
It remains unclear how these findings relate to the heroin/opioid users where non-
response rates (i.e. response judged by ambulance personnel to need supplementary 
injected dose) around 18–26% have been reported for IN naloxone (Kelly et al., 2005; 
Kerr et al., 2009). 
Secondly, naloxone plasma concentrations required to reverse opioid overdose remain 
unknown. The therapeutic naloxone dose may even differ according to route of 
administration, alongside dose, potency, and half-life of the opioid agonist as well as 
inter-individual variability. This requires further study. 
Thirdly, while the PK data from the patent applications indicated a negative relationship 
between volume and naloxone uptake, they did not allow us to determine a cut-off for IN 
spray volume (volumes above which naloxone is lost to pre or post-nasal drip). Definition 
of the maximum volume will affect repeat-administrations of IN naloxone spray. This too 
needs resolution. 
Fourthly, the poor IN bioavailability of non-concentrated naloxone using the MAD device 
also raises important questions (Dale, 2016; Strang & McDonald, 2016; Strang, 
McDonald, Tas, & Day, 2016). From a scientific perspective, how can such low absorbed 
doses be effective if they are indeed succeeding in reversing overdose? Also, the 
continued use of improvised (i.e. dilute) IN naloxone kits needs review.  
Finally, this chapter presents a new analytical method of synthesis of public patent data 
from the WIPO PatentScope database. The limitations discussed above illustrate that 
this method will require optimization and would benefit from enhanced functionality of 
the PatentScope interface, so that review of a greater volume of patent documents would 
become manageable. In future, such syntheses would also be more valuable if data were 
presented uniformly: this would require investigators of non-injectable naloxone 
formulations (including pharmaceutical companies) to publish their data even if findings 





Over the past fifteen years, IN naloxone sprays have been tested in humans, but no 
product was licensed and commercially available until late 2015 (FDA, 2015). With an 
ongoing epidemic of prescription-opioid overdose deaths alongside a more recent rapid 
rise in heroin deaths, an IN naloxone spray is finally available to prevent overdose deaths 
in opioid users - a target population vastly underserved for decades. This first licensed 
non-injectable naloxone marks a significant milestone towards wider naloxone access 
and more effective prevention of opioid overdose deaths. High-concentrate IN naloxone 
has good bioavailability although, thus far, formal product testing has only involved 
healthy volunteers. It remains possible that high-concentrate formulations may provoke 
naloxone over-antagonism in opioid-dependent patients. Options for dose-titration and 
alternative routes (e.g. buccal, see Chapter 9) also need exploration. PK data for 
naloxone products need to be routinely published in the peer-reviewed domain: only then 
can there be properly informed consideration of different naloxone products by the 
clinical, policy and scientific communities.  
I was able to obtain access to the original dataset of the 2012 Euro-Celtique patent 
application (WO/2012/156317), i.e. one of the three patent applications included in this 





Table 19 Pharmacokinetic properties of patent formulations 
          Observed values Dose-adjusted values (per mg) 
























IV AntiOp Trial 1 13 0.4  0.4/1.0   0.03±0.1 1.28±0.2 3.87±2.7 1.67±0.5   9.68a 4.18a  
 Euro-Celtique 11 1  1.0/1.0   0.85±1.6 0.89±0.1e 17.9±29.9 12.6±12.4e 10.5±7.2 17.9a 12.6a 10.5a 
IM AntiOp Trial 1 13 NA  1.0/NA 106a, d  0.33±0.5 1.41±0.3 2.54±1.0 4.43±1.2  2.54a 4.43a  
 AntiOp Trial 2 34 0.4  0.4/1.0   0.17 (0.1, 1.0) 1.38±0.3 1.05±0.4 1.67±0.4  2.63a 4.18a  
 Lightlake 1 14 0.4  0.4/1.0   0.34±0.1 1.21±0.2 0.77±0.2 1.42±0.3 1.38±0.3 1.91a 3.55a 3.45a 
 Lightlake 2 28 0.4  0.4/1.0   0.42 (0.1, 2.0) 1.19b 0.91±0.3 1.83±0.4 1.79±0.4 2.26±0.7 4.57±1.1 4.48a 
SQ AntiOp Trial 1 13 NA  1.0/NA 99a, d 94a, d 0.17±0.3 1.59±0.6 2.72±0.8 4.15±1.1  2.72a 4.15a  
IN AntiOp Trial 1 13 10 2 2.0/0.2 42a, d 39a, d 0.42±0.3 1.53±0.2 1.95±1.1 3.47±0.8  0.98a 1.74a  
 AntiOp Trial 1 13 10 1 1.0/0.1 36a, d 34a, d 0.50±0.2 1.41±0.3 0.84±0.5 1.52±0.5  0.84a 1.52a  
 AntiOp Trial 1 7 1 2 2.0/2.0 11a, d 10a, d 0.27±0.1 1.64±0.3 0.53±0.2 0.90±0.2  0.27a 0.45a  
 AntiOp Trial 2 33 10 2 2.0/0.2  31a, d 0.33 (0.3, 0.8) 1.37±0.3 1.78±1.0 2.63±1.3  0.89a 1.32a  
 AntiOp Trial 2 35 10 2+2c 4.0/0.4  26a, d 0.42 (0.2, 1.0) 1.41±0.3 3.06±1.6 4.42±2.2  0.77a 1.11a  
 Lightlake 1 14 10 2 2.0/0.2  57 0.33±0.1 1.19±0.1 2.32±1.0 3.44±1.0 3.41±1.0 1.16a 1.72a 1.71 
 Lightlake 1 14 10 2 4.0/0.4  48 0.31±0.1 1.22±0.1 4.55±2.9 5.68±1.6 5.63±1.6 1.14a 1.42a 1.41 
 Lightlake 2 28 20 1 2.0/0.1  54 0.33 (0.3, 1.0) 1.70b 3.11±1.1 4.86±1.5 4.81±1.5 1.56±0.6 2.43±0.7 2.41 
 Lightlake 2 28 20 2 4.0/0.2  55 0.33 (0.1, 0.5) 2.09b 6.63±2.3 9.91±2.7 9.82±2.7 1.66±0.6 2.48±0.7 2.46 
 Lightlake 2 28 40 1 4.0/0.1  49 0.50 (0.2, 1.0) 2.00b 5.34±2.4 8.87±3.3 8.78±3.3 1.34±0.6 2.22±0.8 2.20 
 Lightlake 2 28 40 2 8.0/0.2  45 0.33 (0.2, 1.0) 1.91b 10.3±4.0 16.1±3.8 15.9±3.8 1.29±0.5 2.01±0.5 1.99 
 Euro-Celtique 11 20 2 8.0/0.4  22)a, d  0.34±0.2 9.48±3.9f 12.8±4.5 22.0±4.2f 20.1±4.9 1.60a 2.76a 2.51a 
 Euro-Celtique 12 40 2 16.0/0.4 (21)a, d  0.39±0.2 9.09±2.7f 18.3±7.5 42.8±10.6f 32.8±10.2 1.14a 2.67a 2.05a 
SL Euro-Celtique 11 16  16.0/1.0 (1)a, d  3.91±10.6 1.13±0.2f 0.90±0.4 1.50±0.4f 2.67±1.8 0.06a 0.09a 0.17a 
Annotations: Values for tmax, Cmax, AUC, t1/2 denote mean ±SD, except for values in italics. Values in italics denote median ±SD or median (min, max). Inconsistent information between the patent 
and the PK data whether the formulation contained10mg/ml Naloxone HCl dihydrate or 10mg/ml Naloxone HCl. Dose-adjusted values (per mg) in table are based on Naloxone HCl.     
a calculated values; b harmonized mean; c re-administration after 5 minutes; d calculated F and FIM values based on AUC0-∞; e sample size = 3; f sample size = 4; NA = not available; IV = Intravenous; 




Table 20 Timeline of publication of patent applications 
Year Publication date Number Applicants Title Country Exclusion  
2016 14.01.2016 20160008349 Insys Pharma, Inc. Sublingual naloxone spray US No PK data 
 
14.01.2016 WO/2016/007245 Insys Pharma, Inc. Sublingual naloxone spray WO No PK data 
2015 27.12.2015 2572217 N/A  Pharmaceutical composition in form of naloxone-hydrochloride-based nasal 
spray and method of obtaining thereof  
RU No PK data 
 
17.09.2015 WO/2015/136373 Lightlake Therapeutics, Inc. Nasal drug products and methods of their use WO N/A 
 
17.09.2015 20150258019 Lightlake Therapeutics, Inc. Nasal drug products and methods of their use US Duplicate 
 
27.08.2015 20150238420 Hélène REY Naloxone mono-product and multi-layer tablet US No PK data 
 
25.06.2015 WO/2015/095644  AntiOp, Inc. Intranasal naloxone compositions and methods of making and using same WO N/A 
 
25.06.2015  20150174061 AntiOp, Inc. Intranasal naloxone compositions and methods of making and using same US Duplicate 
 
18.06.2015 WO/2015/086528 Develco Pharma Schweiz AG Naloxone mono-product and multi-layer tablet  WO No PK data 
 
07.05.2015 20150126540 Euro-Celtique S.A. Intranasal Pharmaceutical Dosage Forms Comprising Naloxone US Duplicate 
 
15.01.2015 20150018379 Euro-Celtique S.A. Intranasal Pharmaceutical Dosage Forms Comprising Naloxone US Duplicate 
2014 30.07.2014 2013/08280 Euro-Celtique S.A. Intranasal pharmaceutical dosage forms comprising naloxone ZA No PK data 
 
30.04.2014 103764119 Euro-Celtique S.A.* Intranasal pharmaceutical dosage forms comprising naloxone  CN Duplicate 
 
19.03.2014 2706982 Euro-Celtique S.A. Intranasal pharmaceutical dosage forms comprising naloxone  EP Duplicate 
2013 30.12.2013 194927 Euro-Celtique S.A. Intranasal pharmaceutical dosage forms comprising naloxone  SG No PK data 
2012 22.11.2012 WO/2012/156317 Euro-Celtique S.A. Intranasal pharmaceutical dosage forms comprising naloxone  WO N/A 
 
22.11.2012 2835940 Euro-Celtique S.A. Intranasal pharmaceutical dosage forms comprising naloxone  CA No PK data 
2011 31.08.2011 102166198 Chongqing Jewelland 
Pharmaceutical Development  
Stable naloxone hydrochloride freeze-dry preparation and preparation 
method  
CN No PK data 
 
06.04.2011 102000037 Beijing Shuanglu Lisheng 
Pharmaceutical Co. 
Sublingual naloxone hydrochloride dripping pill CN Animal PK 
data only 




Year Publication date Number Applicants Title Country Exclusion  
2007 24.10.2007 101057830 Beijing Tianchuan Junwei Medicine 
Technology Development Ltd. 
Naloxone hydrochloride sublingual spraying drug delivery system or 
composition and its preparation method 
CN Animal PK 
data only 
 
19.09.2007 101036650  Xue Jing Naloxone hydrochloride dropping pills CN No PK data 
 
19.09.2007 101036651 Xue Jing Naloxone hydrochloride spraying agent for mouth and nose CN No PK data 
2006 01.02.2006 1726915 PLA Academy of Military Science Nasal cavity taken drug system and combination of naloxone hydrochloride 
and preparation method 
CN Animal PK 
data only 
2005 09.02.2005 1575795 PLA Academy of Military Science Naloxone hydrochloride nasal spray CN No PK data 
 
19.01.2005 1565451 PLA Academy of Military Science Naloxone Hydrochloride nose powder preparation CN No PK data 
2004 08.02.2004 132646 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration IL No PK data 
2000 26.10.2000 WO/2000/062757 Britannia Pharmaceuticals Composition containing opioid antagonists and spray dispenser  WO No PK data 
 
07.06.2000 2349818 Britannia Pharmaceuticals Spray dispenser for opioid antagonists GB No PK data 
1997 20.08.1997 790058 Inresa Arzneimittel  Therapeutic use of transdermal naloxone (naloxone TTS) EP No PK data 
1996 01.05.1996 0709088  Labtec  Transdermal therapeutic system for application of naloxone EP No PK data 
 
11.01.1996 4423850 Labtec  Transdermal delivery device for naloxone hydrochloride DE No PK data 
1989 06.06.1989 1255229 ALZA Corporation Transdermal therapeutic systems for the administration of naloxone, 
naltrexone and nalbuphine 
CA No PK data 
1986 04.03.1986 4573995 ALZA Corporation Transdermal therapeutic systems for the administration of naloxone, 
naltrexone and nalbuphine 
US No PK data 
1985 12.03.1985 1183778 University of Kentucky Research 
Foundation 
Method of administering narcotic antagonists and analgesics and novel 
dosage forms containing same  
CA No PK data 
1984 07.08.1984 4464378 University of Kentucky Research 
Foundation 
Method of administering narcotic antagonists and analgesics and novel 
dosage forms containing same  
US Animal PK 
data only 
1984 11.11.1982 WO/1982/003768 University of Kentucky Research 
Foundation 
Novel method of administering narcotic antagonists and analgesics and 
novel dosage forms containing the same  
WO Animal PK 
data only 
Annotations: CA: Canada; CN: China; DE: Germany; EP: European Parliament; Exclusion: reason for exclusion; GB: Great Britain; IL: Israel; RU: Russia; SG: Singapore; US: United States; WO: 





Chapter 7  Early Study of Concentrated Nasal Naloxone 
 
Preface 
In this chapter I report on data from a Phase-I pharmacokinetic study in healthy 
volunteers originally conducted in 2004.  
In late 2014, the Cambridge-based pharmaceutical company Mundipharma Research 
Limited began consulting with my first supervisor regarding the potential development of 
a naloxone nasal spray for overdose reversal (see Chapter 8). Ten years prior, Purdue 
Pharma L.P., the U.S.-based partner company of Mundipharma, had developed and 
tested two concentrated nasal naloxone formulations as part of a study that aimed to 
explore the abuse liability of an opioid analgesic formulation. In 2012, Euro-Celtique S.A., 
an independent associated company of Mundipharma Research Limited, then patented 
these formulations (WO/2012/156317), as already described in Chapter 6. 
In discussion with my first supervisor, Mundipharma shared Excel graphs from the 2004 
Purdue study. These graphs appeared to depict only the mean naloxone absorption 
profiles for the nasal spray formulations tested, as already reported in the Euro-Celtique 
patent. However, a serendipitous discovery led to the realization that the original dataset 
from the 2004 trial was indeed embedded in the Excel graphs. I was subsequently 
granted permission from Mundipharma to conduct a new analysis of the original dataset 
from the 2004 trial, with focus on early naloxone absorption and potential of the nasal 
spray formulations for opioid overdose reversal. 
My analysis, as described in this chapter, has also been published as a first-authored 
short report entitled “Pharmacokinetics of concentrated naloxone nasal spray over first 
30 minutes post-dosing: analysis of suitability for opioid overdose reversal” in the journal 
Addiction (Mundin, McDonald, et al., 2017). 
The results show that concentrated naloxone nasal spray has a promising 
pharmacokinetic profile, with substantial bioavailability and early absorption. Moreover, 
the concentrated naloxone spray does not appear to cause nasal mucosa irritation or 
other adverse events related to the intranasal route of administration. Building on these 
results, Mundipharma conducted a larger Phase I trial of different nasal naloxone 
formulations in 2016, with the explicit aim of testing nasal naloxone formulations for 




7.1  Introduction 
Some opioid overdoses have insidious onset, while others occur rapidly. Darke and 
Duflou (2016) recently analyzed the time course of opiate metabolites post-mortem and 
concluded that heroin overdose death occurred within 20-30 minutes of injecting in 43% 
of cases, suggesting the time window for naloxone administration may be very narrow 
(Tas & McDonald, 2016). Hence, analysis of naloxone pharmacokinetics in the first 20-
30 minutes is vital.  
This chapter focuses on early naloxone exposure and presents a new analysis of 
previously unpublished data from a 2004 pharmacokinetic study of naloxone nasal spray. 
The 2004 study had originally been conducted by Purdue Pharma LP (US) for another 
reason, namely to investigate abuse liability of an oral oxycodone/naloxone formulation. 
This chapter re-examines the retrieved data in order to consider the potential of the 
tested high-concentration intranasal (IN) naloxone formulations from the different 
perspective of overdose reversal, with two aims: 
• Aim 1: to describe the pharmacokinetic properties of two high-concentration IN 
naloxone formulations 
• Aim 2: to assess naloxone absorption in the clinically-relevant period of the first 
30 minutes post-administration. 
• Aim 3: to assess dose proportionality of the two IN naloxone formulations. 
 
7.2  Methods 
This section describes the original study design and procedures, and the subject 
selection, and then also reports the new analyses conducted to investigate the study 
aims. 
 
7.2.1 Study design 
Participants had received naloxone in four dose/route combinations (one per session) in 
an open-label, randomized, 4-way crossover Latin-square design in the original study. A 
crossover design designates a type of longitudinal study in which subjects are randomly 
allocated to a series of different treatments on different occasions. Since crossover 
designs allow for within-subject comparisons, a washout period between all treatment 
sessions is needed to minimize the risk of carryover effects, i.e. treatment residue from 




human subjects, the minimum wash-out period is typically three days, and its duration is 
determined by the half-life of the active ingredient (including metabolites) to be tested. 
Relative to between-subject designs, crossover designs need a fewer number of 
subjects to produce meaningful results (Kar, 2011; p. 263). This makes the design 
particularly well-suited for the first-in-human study of new drug formulations, where 
smaller sample sizes are preferable to minimize human subject exposure to potentially 
unknown side effects of a drug. The Latin square is a special case of crossover designs 
that aims to reduce the experimental error by counterbalancing the distribution of the two 
potential error sources (variability in treatment sessions, subjects) so that the treatment 
effect of interest can be tested more sensitively (MacKenzie, 2013).  
 
 
Figure 23 Latin square design17 
 
The study had involved four dosing sessions which compared naloxone plasma 
concentrations from single-dose treatments, with a minimum 14-day washout between 
treatment sessions. The study duration was 45 days per subject, plus screening. Study 
subjects were healthy volunteers and received the following four treatments: 
• A: 1mg/mL intravenous (IV) reference (into the fossa ante cubital)   
• B: 16mg/mL sublingual (SL) administration (from 16mg/mL solution)  
• C: 8mg/0.4mL IN administration (from 20mg/mL solution) 
• D: 16mg/0.4mL IN administration (from 40mg/mL solution).  
The rows and columns of the square illustrated in Figure 23 represent the levels of the 
two extraneous factors (sessions, subjects). The Arabic numerals designate the four 
                                               




naloxone treatments, with each treatment occurring only once per position of the 
treatment sequence and only once per subject. 
 
7.2.2 Study procedures 
Data collection had originally been conducted between May 3 and June 27, 2004 at the 
Clinical Pharmacology Unit at Ohio State University (Columbus, OH, USA).  
Naloxone hydrochloride 10mg/10mL vials had been obtained from Bristol-Meyers 
Squibb (USA), and intravenous naloxone hydrochloride injection was administered as a 
1mg/mL bolus. 
Sublingual solution (16mg/mL) had been prepared by the site pharmacy by dissolving 
naloxone hydrochloride powder (Mallinckrodt Pharmaceuticals, USA) in 0.9% sodium-
chloride solution per study instructions. For sublingual dosing, subjects were 
administered 16mg/mL solution which subjects were instructed to retain under the 
tongue for 5 minutes.  
IN solution had been prepared by dissolving naloxone-hydrochloride powder 
(Mallinckrodt Pharmaceuticals, USA; 11.0g for 20mg/mL; 22.0g for 40mg/mL solution) in 
sodium-citrate stock solution (9.35g for 20mg/mL; 20.9g for 40mg/mL), and this solution 
brought up to 500mL volume using 0.9% sodium-chloride solution. IN solution was 
atomized using metered dose nasal spray devices (comprising a pump spray assembly 
threaded onto small amber glass bottle), with two 0.1mL aerosol actuations delivered 
per nostril, for a 0.2mL total volume per nostril. The droplet size of the nasal spray was 
not characterized.  
Subjects were required to remain upright (seated or standing) with the head tilted slightly 
forward from dosing until 4 hours post-dosing.  
 
7.2.3 Blood sampling and chemical analysis 
Pharmacokinetic blood samples were drawn into tubes containing the anticoagulant 
K2EDTA. Blood samples were collected pre-dosing, at minutes 1, 2, 4, 10, 30, 40, and 
at hours 1, 2, 4, 6, 8, 12, 16, and 24. 
The original bioanalysis was conducted by Purdue Pharma L.P. (Ardsley, NY, USA). 
Naloxone plasma concentration was determined by a validated liquid extraction method 
using liquid chromatography-tandem mass spectrometry (LC-MS/MS; as described in 




plasma samples were also assayed for the naloxone metabolite 6-alpha-naloxol, but 6-
alpha-naloxol concentrations are not covered in this chapter, as the metabolite is not 
considered clinically meaningful (Schulteis, 2009). Naloxone concentrations below the 
limit of quantification were set to zero for pharmacokinetic calculations. 
 
7.2.4 Pharmacokinetic analysis: Outcome measures for this new analysis 
The pharmacokinetic analysis program Phoenix WinNonlin 6.4 (Certara; Princeton, NJ, 
USA) was used to derive standard pharmacokinetic parameters from blood plasma 
naloxone concentrations at the above sampling time points using non-compartmental 
analysis. Non-compartmental analysis is a standard technique for the assessment of 
pharmacokinetic data and represents a simple alternative to model fitting by nonlinear 
regression analysis (Gabrielsson & Weiner, 2012). Non-compartmental pharmacokinetic 
analysis is not dependent on compartmental models, i.e. hypothetical structures used to 
describe how a drug is processed in a biological system following dosing. Instead, non-
compartmental analysis is based on the estimation of drug exposure, i.e. area under the 
curve (AUC). Since it involves fewer model assumptions, non-compartmental analysis is 
considered the method of choice for studies that aim to determine the degree of 
exposure from a drug (e.g. naloxone) and its associated pharmacokinetic parameters 
(Gabrielsson & Weiner, 2012). Non-compartmental analysis estimates AUC using the 
trapezoidal rule. The trapezoidal rule treats each segment of the plasma concentration-
time curve as a trapezoid, i.e. a four-sided figure where the adjacent sampling time points 
along the x-axis are the two parallel sides (Bourne, 2016). The trapezoidal rule is thus a 
numerical approximation method which allows us to calculate AUC directly from the 
concentration versus time data. The AUC of each individual segment can be determined 
by multiplying the segment width by the average plasma concentration (Cp; see Figure 
24). For the segment from time points (t) 2 to 3, the segment width is determined by the 
distance between the two sampling time points: 
 
Figure 24 Formula for AUC of an individual segment in trapezoidal method18 
 
                                               




Analogous to numerical integration, the total AUC can then be determined by addition of 
the individual segments (see Figure 25). 
 
 
Figure 25 Formula for AUC of multiple segments in trapezoidal method19 
 
Due to the dependence on the segment width, i.e. the duration of the blood sampling 
interval, the accuracy of the AUC is higher the more frequent blood sampling occurs, i.e. 
when the trapezoids are more likely to represent the actual shape of the plasma 
naloxone concentration-time curve.  
Non-compartmental analysis does not assume that the plasma naloxone concentration 
is identical to naloxone concentration at the target site (e.g. opioid receptors in the brain). 
Rather, any changes in the plasma naloxone concentration are assumed to quantitatively 
reflect changes in naloxone availability at the target site (see also Chapter 1) (Dhillon & 
Gill, 2006).  
The potential of IN naloxone for opioid overdose reversal was of main clinical interest for 
this new analysis, and consequently I focused on analysis of the pharmacokinetics within 
the first half-hour, examining plasma naloxone sample concentrations from dosing to 30 
minutes.  
Partial AUC values were determined from dosing to 1, 2, 4, 10, and 30 minutes. AUC 
values are expressed as h*ng/mL, i.e. hour(s) times nanograms per milliliter, 
representing naloxone exposure over time.  
The exploratory parameter T50%, defined as time from dosing to concentration equal to 
50% of maximum naloxone plasma concentration (Cmax) (Strang, McDonald, Tas, & 
Day, 2016) (see also Chapter 4), was introduced as additional measure of early 
absorption. 
 
                                               




7.2.5 Statistical analysis 
Inferential statistics were calculated using IBM SPSS Statistics 23 (Armonk, NY, USA). 
Analysis of variance (ANOVA) was conducted to determine if naloxone exposure from 
dosing up to 30 minutes (AUC30) was dose-proportional or if it differed by treatment arm. 
ANOVA is one of four standard approaches to test for dose proportionality (Deng, 2015). 
Following WHO guidance (Welink, 2009), dose-dependent AUC30 data were dose-
adjusted (per mg; i.e. AUC30 values were divided values by dose) and log-transformed 
to allow for normal distribution in the ANOVA. Tukey's HSD test was used for post-hoc 
comparisons, with significance level at p<.05. The null hypothesis (H0) assumes that 
dose-adjusted naloxone exposure up to 30 minutes (AUC30) post-dosing does not differ 
by IN formulation, i.e. AUC308mg/8mg = AUC3016mg/16mg. Dose proportionality exists if 
the null hypothesis is not rejected, i.e. when there is no evidence against dose 
proportionality (Deng, 2015).  
 
7.2.6 Protection of human subjects 
Ethics approval had been sought and was granted by the Western Institutional Review 
Board (Olympia, WA, USA). The sponsor of the study (Purdue Pharma L.P., USA) did 
not register the study on the public clinical trials registry ClinicalTrials.gov. Since the 
study was conducted in 2004, i.e. prior to enactment of the US FDA Administration 
Amendments Act of 2007, registration was not required. Therefore, the study does not 
have a National Clinical Trial (NCT) identifier number. The study was performed in full 
compliance with Good Clinical Practice (GCP) regulations. Written informed consent was 
provided by each subject prior to commencement of any study-specific procedures. The 
enrolled study population was defined as any subject who signed an informed consent 
form. 
 
7.2.7 Subject eligibility 
Subjects were screened for eligibility within 14 days prior to the first dosing session. 
Eligible subjects were males and/or females aged between 18 and 55 years who were 
in good health as determined by no clinically significant findings in medical history and 
at screening, which comprised physical examination (including nasopharyngeal and oral 
cavity), electrocardiograms (ECGs), and clinical laboratory determinations. Planned 
enrollment was 12 subjects (i.e. equivalent to three 4x4 Latin Squares), which is within 




7.2.8 Subject safety 
Subjects’ safety was assessed using adverse events, clinical laboratory results, vital 
signs, and ECGs. Subjects had an end-of-study medical evaluation after assessments 
for the fourth dosing were complete on day 45, or upon early study discontinuation. The 
safety population was defined as any subject who received any study treatment and had 
at least one subsequent safety assessment. 
 
Table 21 Sample sizes by treatment 
Subject ID 1mg IV 8mg IN 16mg IN 16mg SL 
Subject 1 x x x x 
Subject 2 x x x x 
Subject 3 excluded as outlier x x x 
Subject 4 x x x x 
Subject 5 x x x x 
Subject 6 x x x x 
Subject 7 missing x x missing 
Subject 8 x x x x 
Subject 9 x x x x 
Subject 10 x x x x 
Subject 11 x x x x 
Subject 12 x missing x x 
Total n = 10 n = 11 n = 12 n = 11 
 
 
7.3  Results 
7.3.1 Study participants and sensitivity analysis 
Twelve eligible healthy subjects were entered into the study, which is within the FDA 
recommendation of 6-36 subjects (FDA, 1997 ); 5 were males (age 20-41 years, height 
165-193cm, weight 74-106kg) and 7 females (19-48 years, 157-168cm, 51-83kg). 
Subject 12 did not attend the final 8mg IN session, and Subject 7 failed to attend the 
16mg sublingual and 1mg IV sessions. These three sessions were handled as missing 
data (see Table 21). The plasma naloxone concentration from Subject 3 was clearly 
anomalous at 20 minutes following IV administration, being 5-9 times greater than 




greater than the group median (6.64h*ng/mL). Since original plasma samples are no 
longer available for chemical re-analysis, all IV data for this individual were excluded. 
Consequently, values reported below refer to sample sizes of n=10 (1mg IV), n=11 (8mg 
IN, 16mg sublingual), and n=12 (16mg IN), unless otherwise specified.  
 
7.3.2 Pharmacokinetics 
Plasma naloxone concentrations over the first 6 hours are displayed in Figure 26 (left-
hand graph) and with expanded depiction of the first 30 minutes (right-hand graph). IV 
administration (1mg/mL) was characterized by rapid uptake and subsequent decline; 
whereas sublingual administration (16mg/mL) showed minimal absorption. Both IN 
administrations (8mg/0.4mL, 16mg/0.4mL) had similar time profiles, reaching peak 
concentrations in less than 30 minutes post-dosing. The 12 subjects’ individual plasma-
concentration curves are provided at the end of this chapter (see Figure 27, Figure 28, 
Figure 29).  
 
Figure 26 Mean naloxone plasma profiles within 6 hours (left) and expanded depiction of first 30 






Table 22 Pharmacokinetic parameters (mean, SD) 
Parameter n Unit 1mg IV 8mg IN  16mg IN 16mg SL 
AUC20 10-12 h*ng/mL 1.24 (0.62) 2.50 (1.35) 3.58 (2.25) 0.11 (0.09) 
AUC30 10-12 h*ng/mL 1.70 (0.62) 4.17 (1.68) 5.91 (0.30) 0.22 (0.11) 
AUCINF 2-8 h*ng/mL 5.44 (0.60) 22.19 (4.39) 36.71 (10.60) 1.50 (0.42) 
AUCt 10-12 h*ng/mL 8.83 (4.90) 20.07 (4.93) 32.81 (10.22) 2.67 (1.78) 
Cmax 10-12 ng/mL 9.64 (12.66) 12.83 (4.47) 18.25 (7.50) 0.90 (0.37) 
LambdaZ  2-8 1/h 0.75 (0.02) 0.07 (0.04) 0.06 (0.03) 0.64 (0.14) 
t1/2Z 2-8 h 0.93 (0.02) 14.84 (13.21) 16.60 (15.08) 1.12 (0.22) 
T50% 10-12 h 0.06 (0.05) 0.12 (0.06) 0.13 (0.07) 0.24 (0.10) 
Tmax^ 10-12 h    0.07              
(0.03, 4.00) 
0.33         
(0.07, 0.50) 
0.33        
(0.07, 0.67) 
0.67        
(0.50, 36.00) 
Annotations: AUC20 = partial area under the curve (AUC) from dosing to 20 minutes; AUC30 = partial AUC from dosing 
to 30 minutes; AUCINF = AUC from dosing up to infinity; AUCt = AUC from dosing to last measurable time point; Cmax 
= maximum observed plasma concentration; Tmax = time to Cmax; ^median (min, max). LambdaZ = terminal phase 
rate constant; t1/2Z = terminal phase half-life 
 
Pharmacokinetic parameters are shown in Table 22. The two IN administrations 
(8mg/0.4mL, 16mg/0.4mL) displayed similar uptake, with rapid median tmax of 20 
minutes (0.33 h) for both doses. Mean T50% was 7-8 minutes for both IN doses (8mg 
IN: x̄=0.12 h; 16mg IN: x̄=0.13 h), and hence slower than from IV administration (4 
minutes; x̄=.06 h). Cmax values following 8mg IN (x̄=12.83 ng/mL) and 16mg IN (x̄=18.25 
ng/mL) were greater than those following 1mg IV (x̄=9.64 ng/mL). Cmax values following 
16mg/mL sublingual naloxone were extremely low (x̄=0.90 ng/mL). 
 
Bioavailability 
Dose-adjusted AUC data (per mg) from IN and SL administrations were compared 
against the 1mg IV reference. Bioavailability was determined using AUCt (area under 
the curve from dosing to last measurable time point) data rather than AUCINF (area 
under the curve from dosing up to infinity) data. Due to missing data in the terminal 
curves and resulting small sample sizes (n= 2-8), the AUCINF data were not considered 
reliable (see Table 22). Mean bioavailability estimates were determined for subjects for 
whom paired data (i.e. for the test treatment and the IV reference) were available. Since 
comparisons were not possible for missing and excluded sessions (see Table 21), 
absolute bioavailability was determined from AUCt data for sample sizes of n=9 (8mg 
IN) and n=10 (16mg IN, SL). The rationale for the sample sizes for the bioavailability 




Table 23 Sample sizes for bioavailability comparisons 
Subject ID 8mg IN vs 1mg IV 16mg IN vs 1mg IV 16mg SL vs 1mg IV 
Subject 1 x x x 
Subject 2 x x x 
Subject 3 Not available Not available Not available 
Subject 4 x x x 
Subject 5 x x x 
Subject 6 x x x 
Subject 7 Not available Not available Not available 
Subject 8 x x x 
Subject 9 x x x 
Subject 10 x x x 
Subject 11 x x x 
Subject 12 Not available x x 
Total n = 9 n = 10 n = 10 
 
 
The mean absolute bioavailability (F%) from dosing to last measureable concentration 
(AUCt) was 2.0% for sublingual naloxone; hence it was not considered further. IN 
administration had F% of 27.7% (8mg) and 24.6% (16mg; see Table 24).  
Mean bioavailability values for partial AUC at 1, 2, 4, 10, 20, and 30 minutes post-dosing 
are also reported in Table 24, with similar increase over time for both IN doses (8mg, 
16mg): >5% at 4 minutes, ≥13% at 10 minutes, ≥20% at 20 minutes. 
 
 
Table 24 Absolute bioavailability (F%)  
 AUC1 AUC2 AUC4 AUC10 AUC20 AUC30 AUCt 
8mg IN 3.4% 2.4% 6.2% 17.5% 27.6% 33.1% 27.7%  
16mg IN 1.2% 1.7% 5.0% 13.0% 19.5% 23.2% 24.6% 






7.3.3  AUC30 and nasal dose equivalent to 1mg IV bolus 
Observed AUC30 values following 8mg IN (x̄=4.17 h*ng/mL) and 16mg IN (x̄=5.91 
h*ng/mL) were greater than following 1mg IV (x̄=1.70 h*ng/mL; see Table 22) 
administration.  
These AUC30 values were dose-adjusted, log-transformed and compared in a one-way, 
between-subjects ANOVA to test for dose-proportionality. AUC30 values differed 
significantly as a function of naloxone treatment [F(3,40)=255.11, p<0.001].  Post-hoc 
tests showed that dose-adjusted, log-transformed AUC30 was significantly higher with 
IV (x̄=3.21, SD=0.15) versus both IN concentrations (8mg IN: x̄=2.68, SD=0.19; 16mg 
IN: x̄=2.53, SD=0.18). However, there was no significant difference between both IN 
concentrations (p=0.230), and the null hypothesis (H0) was not rejected, confirming that 
naloxone absorption was proportional to IN dose administered.  
Hence, with dose-adjusted AUC30 values for 8mg (x̄=0.52 h*ng/mL per mg) and 16mg 
IN (x̄=0.37 h*ng/mL per mg) and 1mg IV (x̄=1.70 h*ng/mL) (from above observed 
values), one can calculate that, for AUC30, the IN-dose equivalent to 1mg IV would be 
3.3mg IN (20mg/mL formulation) and 4.6mg IN (40mg/mL).  
 
7.3.4  Safety 
No serious adverse events occurred. Side effects reported after naloxone administration 
included fainting (3 cases; one each after 8mg IN, 16mg IN, 1mg IV), headache (2 cases) 
and gastrointestinal symptoms (5 cases). These 10 cases were distributed by treatment 




Recent WHO guidelines (WHO, 2014) recommend that, similar to 
adrenaline/epinephrine for the treatment of allergic shock (Hogue, Goss, Kelly Hollis, & 
White, 2016), naloxone should be offered to anyone in the community likely to suffer or 
witness an opioid overdose (‘take-home naloxone’, see Chapters 2 & 3). However, the 
lack of licensed non-injectable naloxone formulations until late 2015 (which continues 
outside North America) has impeded widespread THN implementation (Coffin & Sullivan, 




Once non-injectable solutions exist, it is likely that naloxone can be provided more 
widely. 
 
7.4.1  Statement of principal findings 
The analysis reported in this chapter identifies a promising pharmacokinetic profile for 
concentrated naloxone nasal spray. In 2008, Dowling et al. reported only 4% absolute 
bioavailability with a nasal spray adaptation of a commercially-available concentration of 
naloxone (2mg/5mL), although the authors suggested the extremely low bioavailability 
may be a result of excessive volume at the nasal membrane. In sharp contrast, my 
analysis shows that, at much higher concentrations (8mg/0.4mL, 16mg/0.4mL), there is 
a mean absolute bioavailability between 25-28%. 
My analysis also shows that, crucially, half of the maximum observed concentration 
(T50%) was reached within 8 minutes and maximum concentration (tmax) within 20 
minutes of IN administration. This combination of bioavailability and time profile suggests 
that concentrated naloxone nasal spray may be suitable for the reversal of overdoses 
from heroin and other short-acting opioids (e.g. fentanyl), where rapid restoration of 
respiratory function within 30 minutes of opioid use may be essential (Darke & Duflou, 
2016).  
These results are broadly consistent with the recent paper by Krieter et al. (Krieter et al., 
2016) who reported a Cmax of 10.3 ng/mL for a 8mg/0.2mL IN dose as well as tmax 
values of 18-30 minutes and bioavailability of 44-54% (relative to intramuscular 
reference) for 0.1-0.2mL of 20mg/mL and 40mg/mL IN formulations. (Among these, the 
4mg/0.1mL formulation has been commercialized by Adapt Pharma under the 
trademarked name “NARCAN® Nasal Spray” 
and approved for the North American market by the FDA (FDA, 2015) and Health 
Canada (CBCnews, 2016), see Chapter 4). However, absence of an intramuscular 
reference in the 2004 study by Purdue Pharma means that a direct bioavailability 
comparison between the studies is not possible. 
 
7.4.2  Strengths and weaknesses of the chapter 
This chapter reports on the first human PK data for concentrated nasal naloxone 
reported in the patent literature. My data analysis is novel in that it focuses on the 




Several limitations need to be borne in mind. Some averages were based on low subject 
numbers (see Table 22). Particularly the terminal phase-dependent parameters 
AUCINF, LAMDAZ (terminal phase rate constant), and t1/2Z (terminal phase half-life) 
should be interpreted with great caution. Data were only available for 2-8 subjects 
(depending on naloxone treatment), and due to the long sampling period of up to 24 
hours compared to the short half-life of naloxone (1±0.5 hours; see Chapter 1), the 
reported values for these parameters are likely unreliable. The accuracy of 
pharmacokinetic data obtained using non-compartmental analysis is negatively 
associated with the duration of blood sampling intervals. After the first hour post-dosing, 
the duration of the sampling intervals in the 2004 Purdue study ranged from 1-8 hours. 
Since the longer intervals were considered prone to measurement inaccuracies, the 
focus of this analysis was on AUCt (instead of AUCINF) and particularly on the clinically 
relevant first half hour post-dosing.   
There was also variability in the tmax values for IV administration (median: 4 minutes), 
due to two outliers at 4 hours. The samples of these two outliers (Subjects 04 and 06) 
who had tmax values of 4 hours were not re-analyzed when the study was conducted in 
2004. A discussion of the potential reasons for these outliers would thus be purely 
speculative.  
It is also unclear if the low sublingual bioavailability resulted from subjects possibly 
swallowing (some of) the 1mL-volume of naloxone in saline, as the solution did not 
contain any additives to help keep it under the tongue.  
For the nasal route, only a 0.2mL-volume per nostril was tested in this study, meaning 
that a volume-absorption relationship cannot be determined.  
Finally, while it is generally assumed that atomization at a droplet size greater than 10µm 
increases nasal absorption (Kippax, Huck, Virden, Levoguer, & Suman, 2011), the 
droplet size distribution was not characterized in this study, and its potential impact on 
nasal deposition cannot be determined. 
 
7.4.3  Possible mechanisms and implications for clinicians 
The emergence of supportive pharmacokinetic data for concentrated IN naloxone, along 
with approval of a first nasal naloxone spray in North America (CBCnews, 2016; FDA, 
2015), constitutes a significant advancement for the field, after concerns over off-label 
use of injectable naloxone-hydrochloride solution as nasal spray sparked a lively debate 




absorption profile of concentrated nasal naloxone makes it suitable for emergency 
administration in the community, where rapid restoration of respiratory function is 
essential for opioid overdose reversal. 
My analysis found no significant difference between the two nasal formulations in their 
dose-adjusted naloxone absorption (AUC30). As follows, it was possible to estimate an 
IN dose-equivalent that would deliver the same naloxone exposure within 30 minutes as 
the reference (1mg/mL IV bolus injection): A nasal dose of 3.3mg (at 20mg/mL) and 
4.6mg (40mg/mL) would provide, over the clinically-critical initial 30-minute period, the 
same AUC30 as 1mg/mL IV. Based on these data, IN doses between 1.3mg and 3.7mg 
would equate to a 0.4–0.8mg parenteral dose range, as recommended by WHO (WHO, 
2014). 
As reported above, the concentrated intranasal naloxone formulations had a good safety 
profile in healthy volunteers. The incidence of all treatment-related adverse events was 
similar across all four treatment groups and thus neither specific to intranasal 
administration nor proportional to intranasal naloxone dose. No symptoms of nasal 
mucosa irritation were reported in the safety assessment. These observations are 
encouraging for the use of concentrated naloxone spray formulations in clinical practice. 
 
7.4.4  Possible mechanisms and implications for policymakers 
The time-lag between the original study conducted thirteen years ago (with its results 
subsequently archived) and this new analysis warrants concern. The new analysis 
presented in the chapter identifies the potential of concentrated naloxone nasal spray for 
overdose reversal. There has recently been considerable public investment to conduct 
healthy volunteer studies of nasal naloxone (Krieter et al., 2016). The field could have 
progressed faster if there had been awareness of the above data. In future, policymakers 
should put a mechanism in place to ensure awareness of relevant data by industry and 
academia. 
 
7.4.5  Questions for future research 
While the above findings support good bioavailability of 20mg/mL and 40mg/mL IN 
formulations in healthy subjects, the 8mg and 16mg IN doses were originally studied for 
different reasons. The pharmacokinetics of doses appropriate for OD reversal have yet 




Moreover, concentrated naloxone nasal spray has yet to be formally tested in the target 
population of opioid users. Algorithms exist for injectable naloxone to guide correct initial 
and repeat dosing (Clarke, Dargan, & Jones, 2005) but have yet to be developed for IN 
naloxone. The T50% data suggest that initial IN absorption is delayed compared to the 
IV bolus, with IN administration taking 7-8 minutes to attain half of the peak concentration 
(versus 4 minutes for IV), and IN absolute bioavailability only surpassing 10% between 
4-10 minutes (see Table 22). If this finding is robust, then lay responders may need to 
be advised to wait some minutes before administering a second IN dose to avoid risk of 
precipitating over-antagonism. Dose-titration protocols and repeat-dosing guidance for 
IN naloxone will need development, especially for take-home distribution to drug users, 
peers, and family members without medical training. 
 
7.5  Conclusion 
Concentrated naloxone nasal spray appears to be a feasible formulation with adequate 
speed of onset and acceptable bioavailability in the concentrated form. This appears 
directly relevant to prevention of opioid overdoses in medical settings and in the 
community (take-home naloxone). The above data find high doses of concentrated nasal 
spray solutions (8mg and 16mg from 20mg/mL and 40mg/mL, respectively) to have 
acceptable bioavailability and plasma levels over the clinically-critical first 30 minutes, 
with moderate uptake from 4-10 minutes onwards. Based on the naloxone plasma 
concentrations obtained from 8mg and 16mg IN naloxone administration, it was possible 
to estimate what IN doses would lead to similar naloxone exposure as a 0.4-0.8mg 
parenteral injection. Chapter 8 covers the study and identification of such lower IN doses 





Figure 27 Subjects 1-4: Individual naloxone plasma profiles within 6 hours post-dosing (excl. 
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Figure 28 Subjects 5-8: Individual naloxone plasma profiles within 6 hours post-dosing (N.B. 
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Figure 29 Subjects 9-12: Individual naloxone plasma profiles within 6 hours post-dosing 
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Chapter 8  New Study of Concentrated Nasal Naloxone 
 
Preface 
In this final chapter on nasal naloxone, I present my data analysis of a 2016 UK-based 
Phase-I pharmacokinetic study of two intranasal naloxone formulations developed 
specifically for opioid overdose reversal. Between October and December 2016, I had 
the opportunity to undertake an unpaid student industry placement with Mundipharma 
Research Limited in Cambridge. My role was to conduct the data analysis of the Phase-
I naloxone trial, both in collaboration with Mundipharma staff and also independently, 
and to interpret the data with regard to their clinical significance. I was also involved in 
the preparation of the regulatory submission to the European Medicines Agency. In late 
2015, my supervisor and I had advised Mundipharma on the research design for this 
Phase-I trial. Among others, this is reflected in the blood sampling time points, which 
were adapted from the clinical trial protocol that I had devised to test a novel buccal 
naloxone tablet, see Chapter 9. This sampling time series would allow for precise study 
of early naloxone blood concentrations as well as for future comparison with the 
concentrations obtained for the buccal tablet. Sponsored by Mundipharma, trial 
recruitment and data collection were outsourced to Richmond Pharmacology and took 
place between March and April 2016. I observed naloxone dosing and blood sampling 
during the last-patient-last-visit session on April 27, 2016. While Chapter 7 has already 
covered the pharmacokinetics of concentrated naloxone nasal spray (n=12) with focus 
on early absorption, this recent Phase-I trial is stronger in design. It includes an 
intramuscular reference (as per FDA guidelines, see Chapter 5) in addition to the 
intravenous reference, the sample size was considerably increased to n=38 (from n=12), 
and the intranasal doses were adjusted to reflect potential use in future clinical practice. 
I presented the results of this chapter at the SSA Annual Symposium 2016 and have 
been invited to give an oral presentation of these results at the CPDD (College on 
Problems of Drug Dependence) 79th Annual Meeting in Montreal, Canada in June 2017. 
I submitted a first-authored research report (“Pharmacokinetics of concentrated 
naloxone nasal spray for opioid overdose reversal: Phase-I healthy volunteer study”) to 
Addiction on April 30, and the manuscript is currently under review. 
The data in this chapter may in the near future form the basis of a new licensed naloxone 





8.1  Introduction 
For nasal naloxone spray to be effective, the dose must be adequate but not excessive, 
and early absorption must be comparable to intramuscular (IM) injection (see description 
of FDA criteria in Chapter 5). My re-analysis of a historical dataset in Chapter 7 provided 
proof-of-concept for substantial naloxone exposure from administration of concentrated 
nasal spray. However, the original study was conducted in 2004 for a clinical indication 
different from opioid overdose reversal, and the intranasal (IN) doses tested (8mg, 16mg) 
were far in excess of the FDA-recommended parenteral reference dose of 0.4mg 
naloxone.  
Since June 2016, two studies have been published which report on the pharmacokinetics 
of different IN naloxone formulations developed for opioid overdose reversal: a US 
analysis by Krieter et al. of the FDA and Health Canada-approved 4mg/0.1mL nasal 
spray (NARCAN®) (Adapt, 2015; FDA, 2015; Krieter et al., 2016) (CBCnews, 2016) (see 
Chapter 4) and, more recently, a Norwegian study by Tylleskar et al. (2017) of a 8mg/mL 
formulation. 
Results from these two recent studies and the 2004 PK study in Chapter 7 conflict with 
a 2008 report by Dowling et al. (2008): It seems likely that it is the highly-concentrated 
naloxone formulations which explain the better IN bioavailability of 46-54% (4mg/0.1mL 
relative to IM) (Krieter et al., 2016), 52-54% (0.8/0.1mL and 1.6mg/0.2mL dose relative 
to intravenous (IV)) (Tylleskar et al., 2017), and 25-28% (8mg/0.4mL and 16mg/0.4mL 
relative to IV) (Mundin, McDonald, Smith, Harris, & Strang, 2017) (see Chapter 7), in 
contrast to the extremely low bioavailability (4%, relative to IV) reported by Dowling et 
al. (2008) for a 2mg/5mL formulation.  
In the UK, through a recent collaboration between the Cambridge-based pharmaceutical 
company Mundipharma Research Limited and the Addictions Department at King’s 
College London, my supervisor and I have explored different concentrated IN 
formulations. The objective was to develop a nasal spray suitable for lay administration, 
which would produce rapid onset of action and adequate exposure during the overdose 
crisis, without risk of ‘over-antagonism’ (Hertz, 2012; Neale & Strang, 2015; UKMi, 2016). 
A PK study in healthy volunteers was conducted in early 2016 with the aim to identify an 
IN dose that would provide, during the crucial initial minutes following administration, a 
comparable naloxone plasma level and bioavailability to that provided by IM naloxone 
injection. In this chapter, I report on the PK characteristics of two purpose-made nasal 
naloxone formulations (10mg/mL, 20mg/mL) administered at three different doses, with 




The primary aims of this chapter are to twofold:  
• Aim 1: To assess the PK profile of IN naloxone 
• Aim 2: To compare its early partial systemic exposure to the IM reference.  
The secondary aim was as follows: 
• Aim 3: To determine IN bioavailability. 
 
8.2  Methods 
8.2.1  Study design 
A randomized, open-label, 5-way cross-over study (EudraCT number: 2015-004493-15) 
was conducted to determine naloxone pharmacokinetics from highly-concentrated nasal 
spray solution (10mg/mL, 20mg/mL; Summit Biosciences, US) at three doses.  
IN naloxone was administered as atomized spray with the Unit Dose System (Aptar 
Pharma, US). As determined by laser diffraction for ≥94% of droplets, the droplet size 
was greater than 10µm to ensure deposition of the spray in the nasal cavity. 
The reference routes were IM (primary reference) and IV administration of proprietary 
naloxone hydrochloride solution (Braun Melsungen, Germany). The IM route with its 
recommended dose of 0.4mg naloxone served as primary reference, as it constitutes the 
clinical standard in out-of-hospital settings. The IV route of administration was included 
for assessment of absolute bioavailability. 
Study subjects were healthy volunteers and received: 
A. 1mg naloxone IN (1mg/0.1mL in one nostril) 
B. 2mg naloxone IN (2mg/0.1mL in one nostril) 
C. 4mg naloxone IN (2mg/0.1mL in each nostril) 
D. 0.4mg naloxone IM (0.4mg/mL into the deltoid muscle of the shoulder) 
E. 0.4mg naloxone IV (0.4mg/mL into the ante cubital fossa via a cannula) 
The IN dose range was based on my analysis in Chapter 7 which identified 1-4mg IN as 
producing potentially similar early naloxone exposure as 0.4-0.8mg IV (Mundin, 
McDonald, et al., 2017), which is the injectable naloxone dose range recommended by 
WHO (2014). (The AUC data from dosing up until 30 minutes (AUC30) in Chapter 7 
suggested that an IN dose between 3.3mg and 4.6mg would produce plasma naloxone 




randomly assigned in a cross-over design, each subject received all five study 
treatments, with a single naloxone dose per session. Each session was separated by at 
least a 4-day washout period. In each study session, subjects were confined to the study 
unit from check-in on the day before dosing until post-dose safety assessments were 
completed 24 hours after dosing. Dosing occurred in the fasting state. Subjects were in 
a fully supine position, remaining supine for at least 1-hour post-dose and thereafter 
semi-supine until at least 4-hours post-dose. 
Vital signs (peripheral oxygen saturation (SpO2), blood pressure, pulse rate, respiration 
rate, and body temperature) were monitored pre-dose (i.e. within an hour before dosing) 
and up to 24 hours post-dose. Adverse events (AEs) were recorded throughout the 
study. Subjects returned to the study unit for a post-study medical evaluation 4 days after 
the last dosing. The total duration of the study per subject was up to 42 days. 
 
8.2.2  Blood sampling and chemical analysis 
Given the special interest in early absorption, blood collection included high-frequency 
sampling over the first 15 minutes to capture early systemic exposure, with a total of 19 
samples per session. Regular blood samples of 6mL each were taken pre-dose, at 1, 2, 
4, 6, 8, 10, 12.5, 15, 30, 45 minutes and 1, 1.5, 2, 4, 6, 8, 10 and 12 hours after dosing. 
In total, approximately 570mL of bloods (19 samples of 6mL on 5 occasions) were taken 
per subject. Blood samples were centrifuged (1500g, 4oC, 15 minutes) within 30 minutes 
of collection, with plasma stored (20oC) within one hour. Naloxone plasma 
concentrations were quantified by LC-MS/MS methodology using a previously validated 
assay. 
 
8.2.3  Pharmacokinetic analysis  
Individual subject PK parameters for naloxone were derived using non-compartmental 
analysis in Phoenix WinNonlin 6.4 (Certara LP, US), a validated PK analysis program. 
The area under the concentration-time curve (AUCt) was determined using the 
trapezoidal method (see Chapter 7) from the time of dosing (0 h) to the final observed 
plasma concentration (Clast) for AUCt. The ratio of Clast to LambdaZ was used to 
estimate the area between the last measured time-point and infinity and added to AUCt 
to yield AUCINF. The maximum observed plasma concentration (Cmax) and the time to 
Cmax (Tmax) were obtained directly from plasma concentration data. LambdaZ was 




(t1/2z) was determined from the ratio of the natural logarithm of 2 to LambdaZ. In addition 
to t1/2z, the half-value duration (HVD) was determined, which was defined as the time 
over which the plasma concentration for a given treatment remains above 50% of Cmax. 
 
8.2.4  Bioavailability 
Dose-adjusted AUC data (per mg) from IN administration were compared against the 
0.4mg IM and 0.4mg IV reference doses. Mean bioavailability estimates were 
determined for subjects for whom paired data were available (see Chapter 7 for 
rationale). 
 
8.2.5  Exploratory analyses 
In addition to standard PK parameters, exploratory analyses were conducted to consider 
early exposure relative to the IM reference and repeat administration of naloxone 
treatments. 
 
Early naloxone absorption 
Based on previous observations that reliance on Tmax may not fully describe the early 
absorption curve (Strang, McDonald, et al., 2016), three exploratory PK parameters were 
introduced to assess early exposure from IN naloxone relative to the 0.4mg IM reference: 
T50%, AUCp, and, for IN administrations only, T50%REF. T50% was defined as the time 
taken to achieve blood levels of 50% of Cmax (see Chapter 4). AUCp designated the 
partial AUC from time of dosing to median Tmax of the reference treatment, i.e. the 
0.4mg IM injection. The AUCp was thus equivalent to the AUC0-tmax interval, where 
tmax was the median tmax of the IM injection. T50%REF was defined as the time taken 
to reach 50% of the Cmax of the primary reference (0.4mg IM). 
 
Simulation of repeat administration:  
Exploratory analyses involved simulation of repeat administration. In emergency 
medicine, naloxone doses may be repeated to achieve the necessary individualized 
dose (see Chapter 1) (BMJ, 2016; McEvoy, 2012). Therefore, simulations of repeat 
administrations were performed using the superposition approach. Superposition relies 
on linear pharmacokinetics and employs a simple overlay technique, assuming that the 




concentrations after multiple dosing (Gilbaldi & Perrier, 1982). The principle of 
superposition assumes that each dose acts independently, i.e. that absorption of one 
dose does not interact with absorption of a previous dose. This is illustrated in Table 25, 
where the plasma concentrations for the second dose and consecutive doses can be 
predicted for any time point by adding the concentration values in one row. 
 
Table 25 Predicting plasma concentrations using superposition 
Dose # Time (h) Dose 1 Dose 2 Dose 3 Concentration (∑ by row) 
1 0 0 - - 0 
 1 59 - - 59 
 2 70 - - 70 
2 4 58 0 - 58 
 5 50 59 - 109 
 6 42 70 - 112 
3 8 30 58 0 88 
 9 25 50 59 134 
 10 21 42 70 133 
 12 15 30 58 103 
Source: Modified from Gilbaldi & Perrier (1982) 
 
Guidelines on the treatment of opioid overdose typically recommend initial administration 
of 0.4mg naloxone, repeated every 2-3 minutes if necessary (EMCDDA, 2016a; Hertz, 
2012; UKMi, 2016; WHO, 2011b). Consequently, repeat administration of five doses of 
the 0.4mg IM reference was simulated at 3-minute intervals (simulating the upper limit 
of the recommended dose range, 2mg IM), versus two doses of 2mg IN at 3-minute 
intervals (simulating similar naloxone exposure, assuming 50% IN bioavailability).  
 
Simulation of immediate administration of the full dose 
Mindful of the crisis situation, non-medical first-responders may forget or ignore 
instructions and administer the full available dose. Therefore, the observed PK curves 
were also scales to doses of 5 x 0.4mg IM and 2 x 2mg IN, i.e. the total doses that would 





8.2.6  Protection of human subjects 
The study was performed according to the Declaration of Helsinki (1964), International 
Conference on Harmonisation and Good Clinical Practice (CPMP/ICH/135/95) 
guidelines of the EMA and European Union Clinical Trials Directive 2001/20/EC. 
Approval was given by South Central – Berkshire B Research Ethics Committee 
(Reading, UK) in early March 2016. A copy of the ethics approval letter (REC reference: 
16/SC/0033) is provided in Appendix A of this thesis. Written informed consent was 
provided by each subject.   
 
8.2.7  Research site 
Data collection was performed under supervision of Principal Investigator Dr. Ulrike 
Lorch (Richmond Pharmacology Ltd.) at the clinical trials facility Richmond 
Pharmacology Ltd. at Croydon University Hospital (UK), a non-NHS research site. 
 
8.2.8  Subject eligibility 
Volunteers (female and male) were eligible for participation if they were healthy and free 
of significant abnormal findings as determined by medical history, physical examination, 
vital signs, laboratory tests and ECG. Eligible volunteers had to be aged 18-55 years, 
body weight 55-100kg and BMI ≥18.5 and ≤30.0. Volunteers were excluded if they had 
abnormal nasal anatomy, nasal symptoms (e.g. polyps, blocked/runny nose), current or 
recent (within 7 days prior to screening visit) respiratory tract infections, or history of hay 
fever/seasonal allergy/rhinitis. Nasal passage examination was conducted at screening, 
pre- and immediately post-dose for IN treatment sessions. Volunteers were also 
excluded if they were recent smokers (within 90 days of first dosing session), or if they 
had positive results in the urine drug screen or alcohol test. Female volunteers were 
excluded if pregnant or lactating. Subjects attended a screening visit ≤ 21 days prior to 






Table 26 Adverse events 
System Organ Class 



















    
Subjects with at least one AE 3 (9.1)  7 (19.4)  3 (8.8)  2 ( 6.3)  7 ( 20.6)  17 (44.7)  
       
GASTROINTESTINAL DISORDERS  1 (3.0)  1 (2.8)  –  –  –  2 (5.3)  
     Enamel Anomaly  –  1 (2.8)  –  –  –  1 (2.6)  
     Nausea  1 (3.0)  –  –  –  –  1 ( 2.6)  
       
INFECTIONS AND INFESTATIONS  1 (3.0)  2 (5.6)  1 (2.9)  –  3 (8.8)  7 (18.4)  
     Gastroenteritis  –  –  –  –  1 (2.9)  1 (2.6)  
     Gingivitis  –  –  1 (2.9)  –  –  1 (2.6)  
     Nasopharyngitis  –  –  –  –  1 (2.9)  1 (2.6)  
     Oral Herpes  –  1 (2.8)  –  –  –  1 (2.6)  
     Rhinitis  –  –  –  –  1 (2.9)  1 (2.6)  
     Upper Respiratory Tract Infection  1 (3.0)  1 (2.8)  –  –  –  2 (5.3)  
       
INVESTIGATIONS – 1 (2.8) 1 (2.9) 1 (3.1) – 3 (7.9) 
     Blood pressure decreased – 1 (2.8) – 1 (3.1) – 2 (5.3) 
     Respiratory rate decreased – – 1 (2.9) – – 1 (2.6) 
       
MUSCOLOSKELETAL AND CONNECTIVE TISSUE DISORDERS – – – 1 (3.1) – 1 (2.6) 
     Back pain – – – 1 (3.1) – 1 (2.6) 
       
NERVOUS SYSTEM DISORDERS 2 (6.1)  2 (5.6)  1 (2.9)  –  3 (8.8)  6 (15.8)  
     Headache 2 (6.1)  2 (5.6)  1 (2.9)  –  3 (8.8)  6 (15.8)  
       
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS  –  1 (2.8)  –  –  –  1 (2.6)  
     Rhinitis Allergic  –  1 (2.8)  –  –  –  1 (2.6)  
       
SKIN AND SUBCUTANEOUS TISSUE DISORDERS  –  1 (2.8)  –  –  1 (2.9)  2 (5.3)  
     Dermal Cyst  –  –  –  –  1 (2.9)  1 (2.6)  
     Nail Discolouration  –  1 (2.8)  –  –  –  1 (2.6)  
    




8.3  Results 
8.3.1  Study participants  
Thirty-eight eligible healthy subjects (age 20-54) were randomized, of whom 27 were 
males and 11 females. This sample size of n=38 is slightly above the recommended 6-
36 subjects set out by  FDA guidelines (FDA, 1997 ), as it was assumed that up to 20% 
of subjects might not provide valid PK data for the comparison of interest. In total, six 
subjects did not complete the study: six missed the 0.4mg IM session; five missed the 
1mg IN session, four missed the 4mg IN and 0.4mg IV sessions, and two missed 2mg 
IN session. These 21 sessions were handled as missing data. Consequently, values 
reported below refer to sample sizes of n=32 (0.4mg IM), n=33 (1mg IN), n=34 (4mg IN, 
0.4mg IV), and n=36 (2mg IN), unless otherwise specified.  
  
8.3.2 Safety 
No severe AEs occurred. In total, 17 (of n=38) subjects experienced 22 AEs (see Table 
26), of which 11 AEs in 9 subjects were assessed as naloxone-related. AE-occurrence 
did not seem dose-related: 7 subjects experienced AEs after 2mg IN dose while only 3 
subjects experienced AEs after 4mg IN dose. 
 
8.3.3  Pharmacokinetic profiles 
PK parameters are shown in Table 27. Mean plasma naloxone concentrations over the 
first two hours post-dosing are displayed in Figure 30 (left-hand graph), including 
expanded depiction of the first 20 minutes (right-hand graph). 
IV administration (0.4mg) was characterized by an extremely rapid spike in plasma 
concentration, reaching early peak (mean Cmax 5.94ng/mL, median Tmax 2 minutes), 
followed by rapid decline over the next 10 minutes and gradual decline thereafter.  
IM administration (0.4mg) was characterized by more gradual early uptake, leading to 
lower and later peak concentration (mean Cmax 1.27ng/mL, median Tmax 10 minutes), 
with flatter and slower decline thereafter. Overall exposure based on AUCt was 
comparable for IM and IV. The three IN doses tested (1mg, 2mg, 4mg) all achieved 
maximum plasma levels within 15-30 minutes (median Tmax). Mean Cmax values for 
1mg IN (1.51ng/mL), 2mg IN (2.87ng/mL), and 4mg IN (6.02ng/mL) were greater than 




Table 27: Pharmacokinetic parameters (mean, SD) 
Parameter Unit 1mg IN 2mg IN 4mg IN  0.4mg IM 0.4mg IV 
AUCt * h*ng/mL 2.56 (43.2) 4.86 (39.4) 10.01 (35.8) 2.01 (17.7) 2.01 (22.5) 
AUCINF * h*ng/mL 2.69 (40.5) 4.97 (38.5) 10.07 (35.8) 2.12 (16.6) 2.10 (21.1) 
Cmax * ng/mL 1.51 (50.2)  2.87 (49.6) 6.02 (54.5) 1.27 (55.8) 5.94 (92.9) 
LambdaZ  1/h  0.55 (0.12)  0.53 (0.12)  0.44 (0.12)  0.53 (0.11)   0.57 (0.09)  
t1/2Z min 80 (23)  84 (30)  102 (28)  81 (16)  75 (13)  
HVD min 79 (40) 76 (33) 75 (38) 65 (67) 8 (12) 
Tmax ^ min 15 (10, 60) 30 (8, 60) 15 (10, 60) 10 (4, 90) 2 (1, 15) 
Annotations: AUCt = area under the curve (AUC) up to last measurable time point; AUCINF = AUC up to infinity; Cmax 
= maximum observed plasma concentration; LambdaZ = terminal phase rate constant; t1/2Z = terminal phase half-life; 
HVD = half-value duration; Tmax = time to Cmax; *geometric mean (CV%); ^median (min, max). 
 
For all three IN doses, mean AUCt values (2.56-10.01 h*ng/mL) exceeded those of 
0.4mg IM and IV (both: 2.01 h*ng/mL). Of the three IN doses, the 2mg dose most closely 
followed the 0.4mg IM curve during the first 10 minutes post-dose, reached blood levels 
at twice the 0.4mg IM dose by 15 minutes and maintained blood levels at more than 
twice the 0.4mg IM dose for the next two hours. 
 
 
Figure 30 Mean plasma naloxone concentrations (observed values): dosing to 120 minutes (left) 
and dosing to 20 minutes (right) 
 
8.3.4  Intranasal bioavailability 
The mean absolute bioavailability (F%) estimates for IN naloxone (i.e. relative to IV) from 
dosing to last measureable concentration (AUCt) were 50.2% (1mg IN; n=32), 46.8% 




bioavailability relative to IM (FIM%) of 50.8% (from 1mg IN), 47.1% (2mg IN), and 48.3% 
(4mg IN), also determined from AUCt data (all n=32).  
 
Table 28: Absolute (F%) and relative (FIM%) mean bioavailability (90% CI)  
 Reference n 1mg IN 2mg IN 4mg IN 
FIM% 0.4mg IM 32 50.8 (45.2, 57.1) 47.1 (41.5, 53.5) 48.3 (43.2, 54.1) 
F% 0.4mg IV 32-33 50.2 (44.6, 56.6) 46.8 (41.7, 52.6) 48.1 (43.3, 53.5) 
Annotation: Bioavailability estimates are based on AUCt 
 
8.3.5  Elimination 
Following a single intranasal administration of the 1mg and the 2mg IN doses, the mean 
plasma half-life of naloxone was 80 minutes and 84 minutes, respectively. This differed 
only slightly from the 81-minute mean half-life observed for the 0.4mg IM reference. 
However, the 4mg IN dose (administered as two 2mg doses) exceeded the half-life of 
the IM reference by 21 minutes, with a mean value of 102 minutes. The half-value 
duration across all three IN doses (75-79 minutes) was substantially longer than for IM 
(65 minutes) and IV (8 minutes) administration, respectively. 
 
8.3.6  Exploratory analyses: 
Since the 2mg IN dose followed the 0.4mg IM reference most closely (see above), the 
2mg IN dose was chosen as comparator against the IM reference in exploratory 
analyses.  
 
Early naloxone absorption  
Given the special interest in early uptake, I examined AUCp, T50%, and T50%REF for the 
early part of the plasma concentration-time profiles for IN naloxone relative to the IM 
reference (see Table 29).  
AUCp: The rounded partial AUC values, measured from dosing to Tmax of the IM 
reference, were equal for both 0.4mg IM and 2mg IN (mean: 0.11 h*ng/mL).  
T50%: IM achieved plasma levels >50% of Cmax (C50%) at 4 minutes. The 2mg IN dose 




T50%REF: The 2mg IN dose achieved concentrations equivalent to C50% of the IM 
reference at 6 minutes, i.e. within two minutes of the IM reference, suggesting IN and IM 
naloxone administration did not differ greatly in their early plasma concentrations. 
 
Table 29: Exploratory pharmacokinetic parameters (mean, SD) 
Parameter Unit 1mg IN 2mg IN 4mg IN  0.4mg IM 0.4mg IV 
AUCp * h*ng/mL 0.05 (112.2) 0.11 (105.1) 0.27 (98.6) 0.11 (67.9) 0.44 (56.2) 
T50% min 10 (5) 9 (4) 9 (5) 4 (1) 1 (1) 
T50%REF min 10 (8) 6 (4) 4 (2) (4 (1)) 1 (2) 
Annotations: AUCp = partial AUC with cut-off at Tmax of reference; T50% = time to 50% of Cmax; T50%REF = 
time to C50% of 0.4mg IM (primary reference); *geometric mean (CV%). 
 
Simulation of repeat administration 
In the first simulation, the pharmacokinetics of repeated administration were explored. 
The bioavailability of IN naloxone (relative to IM, as reported above) was in the range of 
47-51%, hence a 2:1 dose ratio (IN:IM) was assumed for the simulations, comparing 
cumulative 2 x 2mg IN doses at 3-minute intervals with five cumulative 0.4mg IM doses 
at 3-minute intervals (total 2mg IM). Figure 31 shows the peak plasma level from the 
observed 2mg IN dose occurring between those from the observed IM 0.4mg dose and 
the simulated 2mg IM dose (5 x 0.4mg administered 3 minutes apart). From this 
simulation it is evident that, in a hypothetical overdose scenario, a second dose of 2mg 
IN administered after 3 minutes (as broadly recommended for IM administration by the 
British National Formulary (BNF, 2017) would expose the patient to approximately the 
same naloxone levels, in terms of both initial rise in plasma concentrations and peak 
concentrations, as five consecutive IM 0.4mg doses (also 3 minutes apart), i.e. 2mg in 
total. In addition, the plasma naloxone levels from the simulated 2 x 2mg IN dose 
declined more slowly than the simulated 5 x 0.4mg IM administrations, indicating that 
plasma concentrations would be sustained for longer than those from IM dosing.  
 
Simulation of immediate multiple dose administration of the full dose 
In the second simulation (see Figure 32), the observed PK profiles, scaled in dose, were 
used to explore the pharmacokinetics of possible unintended immediate administration 
of the full 2mg IM injection (i.e. all five 0.4mg doses up to the top of approved therapeutic 
dose range) versus two simultaneous doses of 2mg IN. The scaled concentration data 




4mg profile (two 2mg IN doses) was compared with the observed data from the 4mg IN 
dose (administered as 2mg per nostril): the scaled 4mg IN profile lagged only slightly 
behind the observed 4mg IN profile. However, in terms of dose-adjusted AUC, the three 
administrations (2mg IM, 2x2mg IN, 4mg IN) were roughly equivalent. 
 
Figure 31 Scaled mean plasma naloxone concentrations after repeat administration at 3-minute 
intervals (vs mean observed profiles of 0.4mg IM and 2mg IN doses) 
 
Figure 32 Scaled mean plasma naloxone concentrations after immediate administration of 
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8.4  Discussion 
8.4.1  Statement of principal findings 
My analysis of the previously unpublished PK data in Chapter 7 established proof-of-
concept for IN administration of concentrated naloxone formulations (Mundin, McDonald, 
et al., 2017). The results of this chapter suggest feasibility of concentrated naloxone 
spray at three doses (1mg/0.1mL; 2mg/0.1mL; 4mg as 2x2mg/0.1mL) for use by medical 
and non-medical first-responders. 
 
Bioavailability 
The results of this chapter confirm IN naloxone bioavailability of approximately 50% (both 
relative to IM and to IV), thus markedly different from the 4% absolute bioavailability 
reported for dilute IN naloxone formulation (2mg/5mL) by Dowling et al. (2008), yet very 
similar to the 52-54% absolute bioavailability reported by Tylleskar et al. (2017) and the 
44-54% relative bioavailability reported by Krieter et al. (2016) for concentrated naloxone 
nasal spray formulations.  
The importance of low volume for IN formulations, as already highlighted in Chapter 6, 
is also evident from comparison of the results from this chapter and those from the 2004 
PK study covered in Chapter 7. In Chapter 7, I identified mean absolute bioavailability 
between 25-28% for two IN formulations (8mg/0.4mL, 16mg/0.4mL), i.e. only about half 
the absolute bioavailability (47-50%) of the data reported in this chapter. The 2004 PK 
study used a larger spray volume (0.4mL), which may have impacted absorption of 
naloxone from the nasal mucosa. From the results of the present chapter as well as 
Krieter et al. (2016) and Tylleskar et al. (2017), it appears that the administration of only 
0.1mL volume of concentrated nasal spray likely reduces runoff and improves coating of 
the nasal mucosa and subsequent naloxone absorption.  
 
Rapid absorption and slow elimination  
With all three IN doses (1mg/0.1mL; 2mg/0.1mL; 4mg as 2x2mg/0.1mL) studied in this 
chapter, naloxone plasma concentrations increased rapidly, with median peak 
concentrations achieved between 15 and 30 minutes. These results are consistent with 
Tmax values of 18-90 minutes and 20-30 minutes reported for concentrated IN naloxone 
(also 0.1mL volume) by Tylleskar et al. (2017) and Krieter et al. (2016), respectively, and 
confirm that IN naloxone is rapidly absorbed into the systemic circulation via the nasal 




uptake and exposure comparable to the 0.4mg IM reference, suggesting it may be a 
suitable alternative to an IM injection for community-based naloxone use. 
It is interesting to consider the shape of the PK curves following IN naloxone 
administration. For all three IN doses, there is reasonably rapid early absorption, 
followed by good maintenance of plasma levels throughout the time period reported. This 
is in sharp contrast to the shape of the PK curves following IV (where the sudden rise in 
plasma level is followed by rapid decline) and IM administration (which mainly differs 
from the IV curve by lacking the initial spike). If IM is the reference route of administration, 
then, after dose-adjustment, concentrated nasal naloxone appears to offer comparable 
early onset followed by better maintenance of plasma levels over the intermediate 
period. The prolonged maintenance of naloxone plasma levels is reflected in the superior 
half-value duration of all three IN treatments (75-79 minutes) compared to the IM (67 
minutes) and IV (12 minutes) reference treatments (see Table 27). With regard to the 
elimination pattern of nasally administered naloxone, it is also worth noting that the mean 
terminal half-life range reported by Krieter et al. (2016) (114-144 minutes) exceeded the 
values reported by Tylleskar et al. (2017) (70-90 minutes) as well as those observed for 
the three IN doses (80-102 minutes; see Table 27) in this chapter. It is unclear whether 
the variations in terminal half-life between the three studies may be due to differences in 
the excipients used in the IN naloxone formulations. 
 
Inter-subject variability 
It is also interesting to note that the inter-subject variability of IN naloxone exposure from 
dosing to AUCt was in the range of 36-43%, as demonstrated by the coefficient of 
variation (CV%). A lower degree of variation was seen with the IM (18%) and IV (23%) 
reference treatments. Variability was pronounced for early naloxone exposure from 
dosing to the Tmax of the IM reference (10 minutes; i.e. AUCp), with 99-112% for the 
three IN doses. Variability in AUCp values, though to a lesser extent, was also apparent 
for the IM (68%) and IV (56%) references. While a certain degree of variation is to be 
expected for non-injectable routes of administration, the inter-subject variability in AUCp 
data highlights that early naloxone exposure from the same naloxone dose may differ 
substantially among two subjects. The CV% values for the IN and injectable treatments 
indicate that there is unlikely a “one-size-fits-all” naloxone dose and that dose-titration 




8.4.2  Strengths and weaknesses of the chapter 
The central focus of my PhD project has been the study of non-injectable naloxone 
formulations to identify a dose and formulation comparable to IM administration (e.g. 
0.4mg) that is also similarly appropriate for dose-titration, as currently recommended for 
the IM route (BNF, 2017). The exploratory dose simulations indicate that a 2mg IN dose 
provides opportunity for titration, with administration of a second 2mg IN dose resulting 
in similar naloxone exposure as a series of five IM 0.4mg doses (i.e. 2mg IM in total). 
Such an IN schedule would straddle the overall dose range of an “initial [injectable] dose 
between 0.4mg–2mg”, as recommended by WHO (2014). The validity of the analyses 
presented in this chapter are strengthened by the intense sampling schedule during the 
clinically relevant first half-hour post-dosing (Darke & Duflou, 2016; McDonald & Tas, 
2016): 9 samples were taken within this half hour, of which 6 samples in the first 10 
minutes post-dosing alone. For comparison, the studies by Krieter et al. (2016) and 
Tylleskar et al. (2017) only comprised 6 to 7 post-dosing samples up to 30 minutes, with 
only 3 samples in the first 10 minutes post-dosing. This indicates that the AUCp data 
from dosing up to 10 minutes (i.e. tmax of the IM reference) was generated with greater 
accuracy in this study. 
In addition, the study included both an IM and an IV reference (unlike Krieter et al. (2016) 
and Tylleskar et al. (2017) who only tested one injectable reference), allowing for better 
comparability of the bioavailability results across studies.  
A weakness of the study concerns the fact that the Aptar devices were not weighed 
before and after dosing. Tylleskar et al. (2017) used 0.2mL Aptar devices in their study 
and weighed the devices before and after filling with the IN formulation as well as before 
and after actuation. Surprisingly, Tylleskar et al. (2017) found that the actual filling 
volume was 6% less than advertised by Aptar and the spray volume reduced by about 
7%. If we assume that these Aptar device inaccuracies occur across studies, then we 
need to consider that IN bioavailability may be slightly underestimated across studies, 
given that AUC comparisons were possibly conducted for only 93% (i.e. 100% minus 
7%) of the IN dose versus 100% of the parenteral dose. This potential issue needs to be 
quantified and taken into account. 
Moreover, while the findings in the chapter support good early absorption and overall 
bioavailability in healthy subjects, concentrated naloxone nasal spray has yet to be 





8.4.3  Possible mechanisms and implications for clinicians 
In recent years, international clinical practice has seen a shift from IV to IM naloxone for 
greater ease of administration, given that venous access can be difficult to establish in 
long-term injecting drug users (EMCDDA, 2016a). IV administration leads to an 
immediate increase of plasma naloxone levels with early Tax, high Cmax, and rapid 
decline in plasma concentrations thereafter. By comparison, IM administration produces 
slower absorption (i.e. later Tmax) and lower Cmax. However, the plasma profile 
following IM administration is now increasingly considered therapeutically beneficial: it 
avoids the extreme spike of IV naloxone but still attains efficacious plasma levels within 
the first minutes post-dosing; I have additionally studied the T50% parameter for this 
very reason. Furthermore, the longer duration of effect of IM naloxone is may protect 
against re-narcotization (Vilke, Sloane, Smith, & Chan, 2003).  
Overall, the results of this chapter point to the worth of concentrated IN spray for opioid 
overdose reversal. The 2mg IN dose matched the early exposure (AUCp) from the 0.4mg 
IM reference, but maintained plasma levels at the approximate level of two 0.4mg IM 
doses for over two hours post-dosing. Plasma concentrations from the 2mg IN dose 
exceeded those from 0.4mg IM injection within 6 minutes post-dosing on average (see 
Figure 30).  
The repeat dose simulations in this chapter highlight the potential for dose-titration using 
the 2mg IN dose. The focus on this 2mg IN dose may be particularly applicable to 
emergency administration using a dose-escalation schedule such as recommended with 
IM doses (EMCDDA, 2016a; UKMi, 2016; WHO, 2011b), starting at 0.4mg and increased 
at intervals (e.g. 3-minute intervals) to a total of 2mg. A comparable IN dose-escalation 
schedule would involve an initial 2mg dose to achieve onset comparable to IM 0.4mg, 
followed by a second 2mg IN dose three minutes later; this is the hypothetical schedule 
examined in the repeat-dosing simulation. Since the second IN dose is given to the 
unused nostril, absorption from both administrations should be equal, and the similarity 
between the simulation and the 4mg tested dose supports this assumption. Furthermore, 
the sustained plasma concentrations for the 2mg IN dose compared with the IM 
reference may benefit post-resuscitation care. Given that the half-life of some opioids 
substantially exceeds that of naloxone (1-1.5h) (WHO, 2014) (see also Chapter 1), 
sustained plasma naloxone concentrations from IN administration would likely reduce 
the risk of rebound toxicity when naloxone concentrations drop following IV or IM 
administration. The longer duration of action of IN naloxone and its potential for dose 
titration may therefore be of clinical value especially for the reversal of overdoses from 




The possibility of dose titration also presents distinct advantages in the community 
setting. Incremental dose titration could significantly reduce the risk of adverse reactions. 
High initial naloxone doses may trigger severe sudden-onset opioid withdrawal 
(Buajordet et al., 2004; WHO, 2014). A recent qualitative analysis of cases of 
heroin/opioid overdose reversals identified apparent excessive naloxone dosing (‘over-
antagonism’), sometimes triggering patient self-discharge and active further drug-
seeking (Neale & Strang, 2015). In addition to pharmacological toxicity, such ‘behavioral 
toxicity’ needs to be considered. Withdrawal symptoms can be particularly challenging 
for overdose witnesses to manage in the community setting. Simulation of repeat 
administration of the 2mg IN dose produced roughly equivalent plasma naloxone levels 
as a single 4mg IN dose. Giving a single 2mg IN dose at first and following up with a 
second 2mg IN dose only if needed could lower the risk of naloxone ‘over-antagonism’ 
and improve the safety of the overdose victim and those attending the overdose scene. 
In addition, if naloxone doses trigger frequent severe withdrawal symptoms, then there 
is a real danger that, despite its life-saving value, naloxone may be viewed as a punitive 
medication that is to be avoided, as was the perspective of many overdose patients 
interviewed (Neale & Strang, 2015). This might be regarded as ‘reputational toxicity’. 
 
8.4.4  Possible mechanisms and implications for policymakers 
In terms of policy implications, a naloxone nasal spray licensed by the European 
Medicines Agency may in future have potential for classification as over-the-counter 
medication, as it would not be subject to Article 71 of the EU Medicinal Products Directive 
(2001/83), according to which injectable medicinal products are by definition 
prescription-only medications (EMCDDA, 2016a). 
 
8.4.5  Questions for future research 
Regulatory authorities – when deciding about the potential approval of novel formulations 
of already licensed drugs – require evidence of overall drug exposure (AUC), 
bioavailability, the maximum dose achieved (Cmax) and time between dosing and Cmax 
(tmax). While the above PK data for the Mundipharma nasal spray formulations, 
particularly the 2mg/0.1mL dose, look promising, at least four unanswered questions 
remain that will likely be relevant to regulatory review and future research.    
The first two address naloxone use in clinical practice in general, whereas the final two 




Impact of Cmax 
In relation to the 0.4mg IM reference, the Cmax of the 2mg IN dose was substantially 
higher and roughly equivalent to a 1mg IM dose. Even though the early partial AUC 
values were similar for 0.4mg IM and 2mg IN, the elevated IN Cmax may pose a potential 
reason for concern, as dose-related adverse effects often occur around the Cmax (Rang 
et al., 2012). As described in Chapter 1, the British National Formulary (BNF) 
recommends repeat administration (if necessary) of 0.4mg IM doses at 2-3 minute 
intervals for non-medical settings (BNF, 2017). In the exploratory repeat dosing 
simulations, administration of two 2mg IN doses was scheduled at a 3-minute interval, 
displaying similar peak plasma concentration (approximately 5.5 ng/mL) as five 0.4mg 
IM doses also administered at 3-minute intervals. It is unclear if these simulated peak 
plasma concentrations would induce adverse effects in opioid overdose victims.  
In an Australian ambulance-based randomized trial (Kelly et al., 2005), which assigned 
155 opioid overdose victims to receive either 2mg IM or 2mg/5mL IN naloxone, minor 
adverse reactions (agitation/irritation, nausea/vomiting, headache, tremor, sweating) 
were more common in the IM group (21%) than the IN group (12%), but this difference 
may have been due to the dilute nasal formulation used. For concentrated naloxone 
nasal spray, the pharmacodynamic effects of the Cmax and the optimal timing for repeat 
dosing have yet to be empirically tested. 
 
Time-to-naloxone administration 
My exploratory analysis of early naloxone absorption showed that the 2mg IN dose took, 
on average, two minutes longer than the IM reference (6 versus 4 minutes) to reach 50% 
Cmax of the IM reference (T50REF%). It is unclear what implications this 2-minute delay 
may have in out-of-hospital settings.  
The administration of injectable naloxone presents multiple logistical challenges, such 
as the fear of needle/syringe preparation and injecting procedures, the potential absence 
of a sterile syringe, or insufficient training in needle-and-syringe assembly, which can all 
delay the time to drug administration for the intramuscular naloxone injection (Beletsky 
et al., 2012; EMCDDA, 2016a). In their review of naloxone products licensed in the UK, 
the UKMi (2016) noted that for layperson use of pre-filled syringes for IM administration 
“some manipulation will be required to attach the needle to the product”. 
Consideration needs to be given to how quickly the nasal spray versus injectable 




pharmacokinetics-derived speed of onset. It is possible that the speed of administration 
of the nasal spray may be quicker than administration of an IM injection, so that the 2-
minute delay may be partially or fully offset. Measurement of the time involved in 
preparing and administering the device is largely absent from current considerations of 
different naloxone formulations. An early exception is Wanger and colleagues’ 
ambulance study (1998) of subcutaneous naloxone: the time from arrival at the patient’s 
side to dose administration was 4 minutes (subcutaneous) versus 6 minutes (IV). 
Inclusion of these time intervals is essential for consideration of the merits of different 
routes of administration, especially in case of layperson administration. Future studies 
should examine the time to naloxone administration for different devices when used by 
laypersons without medical training. Such studies could assess whether the slightly 
earlier onset of IM administration seen in the results of this chapter may be offset by 
potentially better usability of the nasal spray device.  
 
Impact of nasal damage 
In the study reported in this chapter, healthy volunteers underwent nasal passage 
examination at screening, pre- and immediately post-dose, and any nasal irregularity 
was considered a reason for exclusion. The pharmacokinetics of the naloxone nasal 
spray formulations were thus tested under optimal conditions. However, nasal naloxone 
might be absorbed differently by opioid users in whom the nasal mucosa may be 
compromised (e.g. due to chronic ulceration from drug snorting (Peyrière et al., 2013)) 
or obstructed from mucus or from vomit during overdose (Strang, McDonald, et al., 
2016). At a practical level, it is challenging to quantify the impact of nasal congestion or 
mucosa damage, both in terms of possible reduction in, or alternatively enhancement, 
of absorption (Arora, Sharma, & Garg, 2002).  
Only one study has been conducted which investigated the pharmacokinetics of nasal 
naloxone in a special patient group. Using a randomized crossover design, Edwards et 
al. (2016) compared an IM injection (2mg/2mL) to two nasal spray conditions in patients 
with chronic rhinitis (n=36): one nasal treatment involved dilute IN naloxone on its own 
(2mg/2mL, with 1mg/mL per nostril), whereas the other treatment comprised the same 
IN naloxone dose but preceded (30 minutes prior) by pretreatment with a nasal 
decongestant spray (oxymetazoline, dose not reported). Pretreatment with 
oxymetazoline led to a delayed IN tmax (20 minutes versus 15 minutes) and reduced 
relative bioavailability of IN naloxone from 15% to 12% (based on AUCt). While these 




enhanced IN naloxone absorption, they need to be interpreted with great caution. The 
study did not include a healthy control group, and it is thus impossible to draw causal 
conclusions on the effect of rhinitis on naloxone absorption. 
Regarding compromised mucosa from drug snorting, it is unclear how prevalent nasal 
mucosa damage from heroin snorting may be, as only limited data are available. A single 
case series of 24 chronic intranasal heroin users has been published, whose 
complications comprised nasal perforation (11 cases), nasal ulceration or erythema (5 
cases), nasal septum necrosis (5 cases), pharyngeal ulceration (3 cases), and palate 
damages (5 cases) (Peyrière et al., 2013). It should be noted that heroin snorting is 
relatively uncommon (EMCDDA, 2016), with injecting and smoking constituting the most 
prevalent routes of heroin use (Barrio et al., 2001; Novak & Kral, 2011). There is thus 
greater likelihood of nasal damage in opioid overdose victims resulting from the snorting 
of other drugs, such as cocaine. The link between cocaine snorting and nasal damage 
is well documented. For instance, in an Italian sample of more-than-weekly cocaine 
users, about 10% had nasal septal perforation (Businco et al., 2008). 
Clinical evidence suggests that the risk of modified absorption of IN naloxone may be 
small: In an Australian ambulance-based randomized trial (Kelly et al., 2005) which 
assigned patients with suspected opioid overdose (n=155) to naloxone treatment of 
either dilute nasal spray (2mg/5mL) or 2mg/2mL IM injection, there was no significant 
group difference regarding the need for a rescue injection of naloxone. Nonetheless, 
future research should systematically study the impact of temporary or chronic nasal 
abnormalities on the absorption of concentrated nasal naloxone. 
 
Impact of liver damage 
In the UK, injecting drug use constitutes the main risk factor for hepatitis C virus (HCV) 
transmission, as approximately half of current or recent injecting drug users are infected 
with HCV (Budd & Robertson, 2005; Martin et al., 2012; Nelson et al., 2011). Hepatitis 
and other forms of liver disease affect the pharmacokinetic behavior of many drugs, with 
the largest impact seen for drugs that are normally characterized by high first-pass 
metabolism, such as naloxone (Weeks & Tomlin, 2006). In patients with liver disease 
and hepatic impairment, first-pass metabolism is reduced, which leads to increased drug 
bioavailability. 
In healthy individuals, naloxone is rapidly metabolized when it reaches the liver. As 
discussed in Chapter 1, orally administered naloxone has a very low bioavailability of 




2% bioavailability, presumably because the naloxone solution was swallowed (Mundin, 
McDonald, et al., 2017).  
In patients with moderate and severe hepatic impairment, significantly elevated plasma 
naloxone levels have been observed following sublingual naloxone administration 
(Nasser et al., 2015). Nasally administered naloxone largely avoids the first-pass 
metabolism. However, once nasally administered naloxone is available systemically, it 
is possible that hepatic impairment may influence its metabolic clearance. It is unclear 
to what extent naloxone bioavailability from nasal administration may be increased in 
patients with hepatic impairment and whether this may be associated with an elevated 
risk of adverse events. 
In the US, where about three quarters of injecting drug users are infected with HCV 
(Nelson et al., 2011), 245 cases of administration of the FDA-approved 4mg nasal spray 
(NARCAN® by Adapt; see Chapter 4) reportedly led to withdrawal syndrome in 14% of 
overdose victims (Fiore, 2017). It is reasonable to assume that the incidence rate of 
withdrawal associated with a 2mg IN dose would be lower. However, it is unknown how 
many (if any) of these 245 cases of suspected opioid overdose suffered from hepatic 
impairment.  
In future, a pharmacokinetic study of nasal naloxone administration in (non-opioid using) 
patients with degrees of hepatic impairment could provide more accurate data. 
 
8.5  Conclusions 
Taken together with other recently published data (Krieter et al., 2016; Mundin, 
McDonald, et al., 2017; Tylleskar et al., 2017), the results of this chapter lend strong 
support to the potential value of concentrated IN naloxone spray for opioid overdose 
reversal. Across all three IN doses, naloxone exposure was dose-proportional, with 
approximately 50% absolute bioavailability. The 2mg/0.1mL IN dose was most similar to 
the 0.4mg IM reference, producing comparable early partial naloxone exposure, 
indicating they would also deliver comparable therapeutic concentrations in the event of 
an opioid overdose. The 2mg IN dose had the added feature of potential benefit of 
stronger maintenance of plasma levels for the next two hours. During my industry 
placement at Mundipharma, the company submitted a product portfolio for the 2mg IN 
dose to the European Medicines Agency for regulatory approval, framing the spray as a 
product “developed to combine the advantages of an effective dose of naloxone with 




or otherwise) needing to help [an opioid overdose victim] […] before emergency 
healthcare can be provided” (Mundipharma, 2016). 
At the time of writing, it is anticipated that the European Medicines Agency may approve 
a first nasal naloxone spray by late 2017 or early 2018. If a naloxone nasal spray (i.e. 
the Mundipharma 2mg/0.1mL formulation or a similar product by other manufacturers) 
receives regulatory approval in Europe, clinicians and policymakers will need to consider 
the potentially different merits of the various time-course profiles (including speed of 
onset and duration of effect) of IN versus injectable naloxone and may also see 
implementation advantages with IN naloxone for broad-based take-home naloxone 
provision.  
Following the pharmacokinetic analysis of intranasal naloxone formulations in this 
chapter and in preceding Chapters 6 and 7, the next chapter will describe the 





Chapter 9  Beyond Nasal: The Exploration of Buccal Naloxone 
 
Preface 
In Chapter 5, I explored the buccal, sublingual, and nasal routes of administration as 
candidates for non-injectable naloxone delivery for opioid overdose reversal. While 
Chapters 6 to 8 focused primarily on concentrated nasal formulations, this chapter 
explores the potential of buccal naloxone delivery. 
As part of my PhD project, my supervisors and I were involved in the development of a 
novel buccal naloxone tablet, in collaboration with Professor Ben Forbes, Dr. Paul 
Royall, and Dr. Abdulmalik Alqurshi from the Institute of Pharmaceutical Science at 
King’s. In 2015, the university applied to register intellectual property on the buccal 
naloxone tablet formulation. A copy of the international patent application 
(WO2016/146981 A1) is included in Appendix C and lists me as co-inventor. 
This chapter comprises content from my November 2015 presentation (“Buccal naloxone 
for opioid overdose reversal: rationale for and development of a novel instant-dissolving 
tablet formulation”) at the Neuroimaging and Experimental Medicine conference at 
IoPPN, for which I received a poster award, as well as from my co-authored paper 
(“Amorphous formulation and in vitro performance testing of instantly disintegrating 
buccal tablets for the emergency delivery of naloxone”) that was published in Molecular 
Pharmaceutics (Alqurshi et al., 2016). 
I have divided the chapter into five sections. The first part describes the rationale behind 
the design of a buccal naloxone tablet. The development and composition of the buccal 
tablet are summarized in the second part of the chapter, and the third part reviews its in 
vitro properties. The fourth part of the chapter addresses plans for in vivo testing. Two 
clinical trials of the pharmacokinetics of buccal naloxone administration were originally 
planned as empirical basis of my PhD project. Unfortunately, these clinical trials faced 
several internal regulatory obstacles and never reached the data collection stage. The 
reasons for the failure to complete the trials are provided in the fifth and final section of 





9.1  Rationale 
Oral tablets can constitute low-cost and highly portable medical technologies. However, 
orally ingested naloxone dosage forms are unsuitable as they are not easily administered 
to an unconscious patient. Moreover, orally ingested naloxone has low bioavailability (< 
1%) as a result of high first-pass metabolism (Fishman et al., 1973; Hussain et al., 1987) 
(see Chapters 1 & 5). 
By contrast, with its lack of hepatic and gastrointestinal first-pass effect, buccal delivery 
provides an attractive alternative route of administration for the emergency delivery of 
drugs (Lam et al., 2014; Sankar et al., 2011; Sudhakar et al., 2006). The buccal route is 
particularly useful for drug delivery in unconscious patients. Even in the case of jaw lock 
in the patient, the buccal cavity is easy for bystanders to access, and application of a 
dosage form (e.g. tablet) to the inner cheeks of the oral cavity is simple and can be 
precisely located (Sudhakar et al., 2006). In case of drug toxicity or adverse reactions, 
buccal dosage forms can also easily be removed. Dosage forms for buccal delivery 
include (i) tablets and lozenges, (ii) films, wafers and patches, (iii) liquids, creams, gels, 
ointments, (iv) sprays, lozenges, chewing gum and mucoadhesive film (Patel et al., 
2011).  
Buccal delivery has been proven effective in other pharmacotherapies, e.g., buccal 
midazolam (“Buccolam”) for the treatment of epileptic seizures and agitation (McIntyre 
et al., 2005; Schwagmeier et al., 1998; Taylor et al., 2008). Buccolam produces rapid 
onset of action and has a mean bioavailability of 75% (Schwagmeier et al., 1998). It is 
now a licensed treatment that bystanders can administer while awaiting professional 
medical care (MHRA, 2011). 
In rats, naloxone bioavailability from buccal administration has been reported to be 70%, 
compared to 0.3% via the oral route, with maximum plasma levels obtained within 15 
min (Hussain et al., 1987). However, the absorption of naloxone from the human buccal 
cavity is unknown. 
For buccal naloxone administration in humans, tablets may provide a suitable dosage 
form. Among the above described options for buccal dosage forms, tablets provide the 
simplest, most portable and easily applied formulation as an emergency medicine. 
However, immediate dissolution of the tablet upon application will be crucial for clinical 
efficacy in the opioid overdose emergency. Speed of onset is critical to reverse the life-






The aims of this chapter are threefold: 
• Aim 1: To develop a buccal tablet that contains a clinically relevant naloxone dose 
and dissolves instantly (e.g. ≤ 30 s); 
• Aim 2: To test the stability and dissolution of the tablet in vitro; 
• Aim 3: To prepare for PK study of buccal naloxone administration in humans. 
 
9.2  Tablet specifications and development 
At the start of my PhD, I was involved in discussions with my supervisors and project 
partners Professor Ben Forbes, Dr. Paul Royall, and Dr. Abdulmalik Alqurshi (himself a 
PhD student at the time) around the desired properties of a buccal naloxone tablet. We 
had agreed on the aim to develop a safe, easily administered, buccal tablet which would 
be suitable for the rapid delivery of naloxone in opioid overdose. The following product 
design specifications were drawn up:  
The size and shape of the buccal tablet would need to ensure a high surface area contact 
with the buccal epithelium to maximize naloxone absorption, and the physical structure 
of the tablet would need to allow for ‘instant’ naloxone liberation and dissolution rates 
(e.g. ≤ 30 s) to be suitable as emergency medicine. Determination of the target dose was 
challenging. There was no data on buccal naloxone administration in humans, and 
existing published pharmacokinetic or pharmacodynamic studies of parenteral or 
intranasal naloxone did not enable simple determination of the appropriate dose required 
to achieve a target concentration or concentration–time profile to maximize its antidote 
efficacy (Dowling et al., 2008; Preston et al., Loimer et al., 1994). The naloxone dosing 
algorithm by Clarke et al. (2005) recommended an initial intramuscular or subcutaneous 
dose of 0.4-0.8mg. Similarly, the WHO guidelines (2014) noted that [parenteral 
administration] of 0.4-0.8mg naloxone was an effective dose in most cases (see also 
Chapter 1). Similarly,  
Preclinical research had found buccal naloxone bioavailability of up to 71% in non-
human animals (Hussain et al., 1987; Hussain et al., 1988) (see also Chapter 5). 
Therefore, 0.8mg, i.e. the upper limit of the dose range recommended by WHO (2014), 
was chosen as target dose for the buccal naloxone tablet: if buccal naloxone 
bioavailability in humans was anywhere between 50-100%, then naloxone exposure 
from a 0.8mg buccal tablet should equate to naloxone exposure from a 0.4-0.8mg 





9.2.1 Tablet manufacture 
Instant-dissolving tablets buccal naloxone tablets were successfully developed using 
freeze-drying technology (lyophilization). The tablets were produced at the Institute of 
Pharmaceutical Science and later also, in accordance with ICH (International Council for 
Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) 
guidelines, in the Pharmacy Manufacturing Unit of Guy’s Hospital of the Guy’s and St 
Thomas’ NHS Foundation Trust. The development and optimization of the tablets has 
been described in depth by Alqurshi et al. (2016). To review briefly, the manufacture of 
the tablets (with a yield of 20 tablets per batch) involved five key steps: 
1. Feed solution for tablet preparation was prepared by dissolving gelatin powder 
(Fagron Ltd), sodium bicarbonate powder (Fagron Ltd; Newcastle upon Tyne, 
UK) and mannitol (Fresenius Kabi; Runcorn, UK) in water for injection (WFI) held 
at 70oC.  
2. Once the feed solution had cooled down to room temperature, naloxone 
hydrochloride dihydrate (Fagron Ltd) was dissolved in it.  
3. The naloxone hydrochloride feed solution (1.500 g each) was filled into empty 
aluminium blister wells (Zhejang Xinfei Machinery Ltd; Zhejiang,China) and 
cooled down to -80oC.  
4. Frozen tablets where transferred from the blister wells into pre-cooled freeze-
drying vials (1 oz. Clear Glass Universal Type 1), and a 5-day freeze drying cycle 
inside a temperature controlled freeze-drying chamber (Lyotrap freeze dryer; 
LTE Scientific Ltd; Oldham, UK) at -40oC was initiated.  
5. At the end of the freeze-drying cycle, the freeze-drying vials containing the tablets 
were sealed under nitrogen for protection. 
 
9.2.2 Tablet composition and dimensions 
Tablet composition was optimized as follows: Ratios of mannitol, gelatin and sodium 
bicarbonate were varied with the aim of identifying a tablet composition that would form 
a non-crystalline solid freeze-dried product. Mannitol was utilized because of its 
hydrophilic nature, bulking properties, and protective function for freeze-dried material 
(Jawad et al., 2012). Gelatin was selected to provide structural strength, and it has 
mucoadhesive properties. Sodium bicarbonate was added to reduce crystallization within 
the tablets. Thus, an optimized formulation with a composition of 24% w/w mannitol, 65% 
w/w gelatin and 11% w/w sodium bicarbonate and target drug content of 0.8mg of 




length, 16.1 ± 0.5mm in width with a depth of 3.0 ± 0.2mm and weighed 17.7 ± 0.4mg 




Figure 33 The instant dissolving tablet with display of its length in mm (left) and intended 
application method (right) 
 
Table 30 Instant dissolving tablet specification and stability data (mean, SD)  
   Stability  
  0 months 9 months 9 months 
Parameter Specification  4oC 25oC 
Tablet weight (mg)  16.9 - 20.7 17.8 ± 0.5 17.8 ± 0.5 17.6 ± 0.5 
Dimension - length (mm) 20.0 - 30.0 29.4 ± 0.2 29.1 ± 0.3 29.1 ± 0.7 
Dimension - width (mm) 14.0 - 18.0 16.1 ± 0.5 16.1 ± 0.3 16.0 ± 0.3 
Disintegration test (s) ≤180 14.0 ± 5.9   9.0 ± 5.0 10.0 ± 5.0 
Naloxone HCL assay (mg) 0.76 - 0.84 0.80 ± 0.01 0.81 ± 0.02 0.80 ± 0.03 




9.3  In vitro testing  
The following in vitro tests were performed by Dr. Abdulmalik Alqurshi as part of his PhD 
project at the Institute of Pharmaceutical Science, and the methodology is described in 





To ensure standard delivery of a dose of 0.8mg ±5% of naloxone, the buccal tablet was 
tested for chemical and physical stability.  
As part of quality control, a tablet specification was developed for weight, dimensions, 
rate of disintegration and drug content and used to verify batch-to batch reproducibility 
and stability (see Table 30). The instant dissolving buccal tablets matched the quality 
specifications for weight, size, speed of dissolution and drug content at baseline and 
were physically stable over 9 months when stored under nitrogen at 4oC or 25oC. 
A validated reverse phase HPLC assay for naloxone hydrochloride was used to assess 
chemical stability at 9 months, and the target drug content, 0.8mg of naloxone 
hydrochloride per tablet was confirmed (range: 0.80 ± 0.03mg; see Table 30).30 
 
9.3.2  Dissolution  
Tablet dissolution testing was conducted to provide information on drug release for 
quality control purposes and to potentially predict in vivo performance. Since speed of 
naloxone liberation is critical for a buccal tablet designed for emergency use in opioid 
overdose, a novel digital imaging-based dissolution assay (see Figure 34) was 
developed to represent the temperature and saliva volume conditions in the buccal 
cavity: i.e. a temperature range of 33-37oC was tested in combination with dissolution 
volumes in the range of 0.1-0.7mL (see Figure 35) (DiSabato et al., 1996; Moore, 1999). 
This volume range was chosen because a volume of 0.7mL of oral fluid is typically 
available in the buccal cavity of adults, but the volume may be reduced in opioid users 
and in opioid overdose (Patel, Liu, & Brown, 2012). Two types of dissolution medium 
were tested: phosphate buffer and a synthetic saliva (consisting of mucin 2.16 g/L from 
porcine stomach, distilled water, and salts) (Quilaqueo et al., 2015). Dissolution was 
measured using a camera located above a test blister well (with its background painted 
black to provide contrast for the white tablet) which would take a reference image (blister 
filled with dissolution medium) before testing and then, a baseline image (t = 0 seconds) 
once the table was placed in the dry blister, and a series of 100 test images at 0.4 second 
intervals once the dissolution medium was added (e.g., 0.7mL distilled water at 35oC). 
Assay temperature was adjusted by use of a temperature-controlled water bath. The 
effects of temperature, solvent volume and composition on the dissolution of the tablets 
were as follows: The tablets dissolved fully (>90%) within 30 seconds under all 
conditions. Tablets dissolved in <10 seconds in 0.7mL of phosphate buffer at 35oC (see 




buccal cavity) did not alter the dissolution rate, but the rate was 4-5 times slower at 25oC. 
Reducing the dissolution volume progressively reduced the rate at which the tablet 
dissolved, with dissolution in 0.1mL being 4.5 times slower than in 0.7mL (see Figure 35, 
B). Interestingly, when phosphate buffer was replaced with synthetic saliva, a slightly 
quicker dissolution rate was observed (see Figure 35, C), suggesting that human in vivo 
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9.4  Plans for in vivo testing 
As part of my PhD project, I planned two first-in-human clinical trials of buccal naloxone 
administration. Both trials were devised as Phase-I healthy volunteer studies that would 
generate buccal naloxone pharmacokinetics data. Since buccal administration of neither 
licensed naloxone-hydrochloride solution nor the novel naloxone tablet had been tested in 
humans before, both studies were classified as CTIMP (Clinical Trial of an Investigational 
Medicinal Product). My role involved the following responsibilities: overall study 
coordination; application for risk assessment and EudraCT registration; application for 
ethical, MHRA, and R&D approvals; (participant recruitment; data collection; data 
management and analysis). Due to regulatory obstacles, the trials did not reach the 
recruitment stage (see Table 31). 
 
9.4.1  Rationale 
The first clinical trial (EudraCT number 2014-001802-16) was designed to provide proof-of-
concept for buccal administration by examining absorption of licensed naloxone 
hydrochloride solution from the buccal cavity. The second clinical trial (EudraCT number 
2016-000582-23) would assess naloxone exposure from the buccal tablet (see above). Both 
trials would compare the pharmacokinetics of a single and multiple 0.8mg doses of buccal 
naloxone relative to a 0.8mg dose of licensed naloxone-hydrochloride solution by 
intravenous and intramuscular injection. As such, the trials would assess whether naloxone 
absorption from the buccal naloxone tablet is sufficiently rapid and dose-related and would 
contrast naloxone exposure from the buccal solution versus tablet formulation. 
 
9.4.2  Aims 
The aims of the two clinical trials were as follows: 
• Aim 1: To determine and compare overall naloxone exposure and bioavailability from 
buccal administration compared to the licensed IM and IV routes of administration.  
• Aim 2: To identify an optimal dosage range (based on onset of action and maximum 
concentration) for the buccal naloxone administration.  
• Aim 3: To assess whether naloxone absorption from the buccal tablet is sufficiently 






9.4.3  Study design 
Both trials were devised an open-labelled, 4-period, randomized crossover design in healthy 
volunteers. The distribution of the 4 treatments would follow a Latin square design, where 
each treatment occurs only once at each position of the treatment sequence and only once 
for each subject (see also Chapter 7). The crossover design was considered appropriate as 
the half-life of naloxone is known (1±0.5 hours, see Chapter 1) and the washout period of at 
least 3 days was deemed sufficient to mitigate against any carryover effects. The similarities 
and differences in the study design of the two trials are outlined in Table 31. 
 
9.4.4  Dose justification 
The proposed buccal naloxone doses (0.8-3.2mg) were below the dose approved by the 
FDA for Adapt naloxone nasal spray (4mg) (FDA, 2015). Buccal naloxone availability was 
estimated to fall into the range of 16-75% based on prior research which had found 16-71% 
buccal bioavailability of naloxone in non-human animals (Hussain et al., 1987; Hussain et 
al., 1988) and 65-75% buccal availability of other active ingredients (fentanyl, midazolam) 
in humans (Loetsch et al., 2013; Schwagmeier et al., 1998). The referenced studies had 
found buccal availability to be lower than nasal bioavailability (i.e. for naloxone, fentanyl, 
midazolam) across species. The upper buccal naloxone dose of 3.2mg in Trial 2 
(administered bilaterally as four 0.8mg tablets) was also chosen for tablet development 
reasons: if the trial were to indicate that buccal naloxone availability was low, then the 
naloxone content of the buccal tablet would in future likely need to be increased to a dose 
higher than 0.8mg. In terms of tablet formulation, it was expected that the lyophilized tablet 
could potentially be loaded with a naloxone content of up to 3.2mg, and it was therefore 
considered useful to study the pharmacokinetics of this upper dose. Naloxone-related 
adverse events were not expected at the proposed doses (0.8-3.2mg), as naloxone does 
not have any pharmacological effects in non-opioid using healthy volunteers (see Chapter 
1). There is limited clinical experience with naloxone overdose in humans, and adverse 
events in non-opioid users have only been reported for doses ≥2mg/kg of bodyweight. The 
buccal doses for administration in the two trials were therefore considered safe and 




Table 31 Comparison of the buccal naloxone clinical trials 
 TRIAL 1: 
Buccal solution (pilot) 
TRIAL 2: 
Buccal naloxone tablet 
Title A Pilot, Phase 1, Open-Labelled, 4 
Period, Randomised, Crossover Study 
to Evaluate the Pharmacokinetics of 
Naloxone when Given by the IV, IM and 
Buccal Routes of Administration in 
Healthy Male Subjects  
A Pilot, Phase 1, Open-Labelled, 
Randomised, Crossover Study to 
Evaluate the Pharmacokinetics of 
Naloxone in Healthy Male Subjects 
when Given by a Novel Buccal Tablet 
Compared to IV and IM Administration  
EudraCT 2014-0001802-16 2016-000582-23 
Clinical phase Phase I idem 
Investigational site Clinical Research Facility 
King's College Hospital 
London SE5 9RS 
idem 
Study design open-labelled, 4-session, randomized 
crossover (Latin square) 
idem 
Duration of treatment 4 doses over a maximum of 4 weeks idem 
Treatments • 0.8mg buccal solution1 
• 1.6mg buccal solution1 
• 0.8mg IM injection2 
• 0.8mg IV injection2 
• 0.8mg buccal tablet1 
• 3.2mg buccal tablet1 
• 0.8mg IM injection2 
• 0.8mg IV injection2 
1Test product Prenoxad® 1mg/ml naloxone 
hydrochloride injection (manufactured 
by Martindale Pharmaceuticals Ltd.), 
squirted into the buccal pouch  
0.8mg buccal naloxone tablet 
(manufactured by the Pharmacy 
Manufacturing Unit, Guy’s Hospital); 
3.2mg dose = 4 x 0.8mg tablets 
2Reference product Prenoxad® 1mg/ml naloxone 
hydrochloride injection (manufactured 
by Martindale Pharmaceuticals Ltd.) 
idem 
Number of subjects n = 4 n = 8 
Eligibility  Healthy male volunteers: 
- Age 18–64 years 
- BMI of 19–29.9 kg/m2.  
Without previous or current opioid 
dependence or abuse, current use of 
opioid analgesics for pain relief, or any 
current or recent oral tract infection or 
lesion. 
idem 
Blood collection schedule -5, +1, 2, 3, 4, 6, 8, 10, 12.5, 15, 30, 45, 
60, 75, 90, 120, 150, 180, 240, 300, 360, 
420, 480 minutes 
idem 
Outcomes Pharmacokinetics: 
F%, AUC, Tmax, Cmax, T1/2 
 
Safety: 
Adverse events, vital signs 
idem 
Regulatory approvals   
IoPPN risk assessment Yes (July 2014) Yes (April 2015) 
MHRA Yes (November 2014) X 
Ethical approval Yes (March 2015) X 





9.4.5 Study population 
Target enrollment involved healthy male subjects aged 18 to 64 years, with n=4 (maximum 
enrollment of 6 subjects, in case of withdrawals from the study) for the pilot and n=8 
(maximum 12 subjects) for the tablet study. Females were excluded, as the safety of buccal 
naloxone during pregnancy has not been established. 
 
9.4.6  Study procedures 
Since both trials were considered first-in-human studies, the NIHR and Wellcome Trust 
King’s Clinical Research Facility, which provides direct access to King’s College Hospital, 
was proposed as investigational site. Subjects would be screened at least 14 days prior to 
the first treatment period. Subjects would be admitted to the Clinical Research Facility on 
the morning of each treatment Period and would remain under medical supervision until the 
8-hour post dose assessment has been completed. Naloxone, in accordance with a pre-
determined randomization sequence, would be administered on the morning of each 
treatment period. Serial blood samples for the assay of naloxone would be taken pre-dose 
and at specified time intervals up to 8 hours post-dosing (see Table 31). Subjects would be 
monitored for adverse events and remain under medical supervision at the Clinical 
Research Facility for a period of 8 hours post-dosing.  
 
9.5  Challenges of conducting this work 
The project faced many regulatory obstacles, which ultimately led to the early termination of 
the buccal naloxone pilot (EudraCT: 2014-001802-16) in July 2016. While the second trial 
which would assess the pharmacokinetics of the buccal tablet (EudraCT: 2016-000582-23) 
obtained clearance from the IoPPN risk assessment committee in April 2015, the study was 
never submitted for HRA or MHRA approval. 
At the start my PhD in October 2013, the development of the buccal naloxone tablet was 
still ongoing, as the tablet composition was being optimized and tested in vitro (see above). 
To make use of the time needed for tablet development, I devised the protocol for a pilot 
study that would assess the pharmacokinetics of buccal administration of licensed naloxone-
hydrochloride solution. The purpose of this pilot was to establish feasibility of naloxone 
delivery by the buccal route (see above), but also to serve as a dry run for the “main” trial 
involving the buccal naloxone tablet. The pilot would provide the opportunity to establish the 




that was being developed by colleagues at the Toxicology Unit with the Department of 
Clinical Biochemistry at King's College Hospital. 
Unfortunately, the delay associated with the regulatory obstacles of the buccal naloxone 
pilot developed a dynamic of its own, and neither of the two buccal naloxone studies 
managed to reach the data collection stage. The reasons for this failure are described in the 
following sections. 
 
9.5.1  A clinical trial is a clinical trial is a clinical trial  
The pilot study (buccal administration of licensed naloxone-hydrochloride solution vs. 
parenteral administration) required a full application to the Medicines and Healthcare 
Products Regulatory Agency (MHRA). Even though naloxone had been used in clinical 
practice for more than 40 years, and even though the pilot study was only going to recruit 
healthy volunteers in whom naloxone would not produce any pharmacodynamic effects (see 
Chapter 1), the MHRA classified the study as a Clinical Trial of an Investigational Medicinal 
Product (CTIMP), because naloxone was not licensed for use by the buccal route. 
While I managed to secure MHRA approval in late November 2014, i.e. within just 14 months 
of the start of my PhD, the classification of the pilot trial as CTIMP triggered internal 
regulatory obstacles within King’s Health Partners, i.e. the academic health science center 
comprising King’s College London, Guy’s and St Thomas’, King’s College Hospital, and 
South London and Maudsley (SLaM) NHS Foundation Trusts. As CTIMP, the pilot trial fell 
under the authority of the King’s Health Partners Clinical Trials Office, which – unbeknownst 
to my supervisors and me –  would have indirect and direct financial implications for the 
proposed buccal naloxone studies: The Clinical Trials Office uses performance targets for 
externally funded trials, which meant that externally funded trials were automatically 
prioritized over internally funded ones, and the processing times of internally funded studies 
(such as my pilot trial) were accordingly disadvantaged. 
Moreover, the quality standards of the Clinical Trials Office apply to any CTIMP regardless 
its size. My planned naloxone studies with their sample sizes of only n=4-8 healthy 
volunteers had to meet the exact same criteria as a multi-site trial of a new active ingredient 
in hundreds of patients. While this principle may be logical and necessary from a research 
ethics perspective, it caused at least two specific practical issues.  
Firstly, under King’s Health Partners Clinical Trials Office guidelines, any clinical trial 




King’s Clinical Trials Unit, which is part of the Department of Biostatistics. However, the 
randomization service of the Clinical Trials Unit charges a fee of £6.50 per subject, with a 
minimal charge of £650 (equivalent to 100 subjects) (CTU, 2017). For sample sizes of n=4-
8 subjects, the charge for randomization would thus have equated to up to £162.50 per 
subject, for an open-label randomized crossover design in which each subject receives each 
treatment anyway. 
Secondly, the King’s Health Partners Clinical Trials Office requires any (de-identified) 
human subjects’ data from a clinical trial to be stored on a validated eCRF (electronic Case 
Report Form) database. Data storage in Microsoft Access or Excel is not permitted since 
neither software produces an audit trail. Use of the King’s Clinical Trials Unit’s eCRF 
database service is recommended, but their minimum service charge for a UK-based single-
site study is £7,340 (CTU, 2017). At 23 blood samples per participant and a sample size of 
n=4, this would have translated into a charge of £80 per data point in my buccal naloxone 
pilot trial.  
At a combined minimum charge of £7,990 for data storage and participant randomization 
alone (in addition to the standard £3,400 MHRA application fee), these expenses would 
easily have exceeded the research funds of my PhD studentship. While my first supervisor 
and I eventually managed to negotiate exemptions from both regulations, nearly six months 
were lost in the process of these negotiations. Taken together, these issues raise the 
question whether CTIMPs are feasible as 3-year PhD projects. 
 
9.5.2  Is a healthy volunteer a patient? 
A separate issue – which ultimately caused the early termination of the pilot study – arose 
from the regulatory status of the proposed investigational site for both studies, i.e. the NIHR 
and Wellcome Trust King’s Clinical Research Facility within King’s Health Partners. The 
Clinical Research Facility is a shared facility of King’s College London, Guy’s and St 
Thomas’, King’s College Hospital, and SLaM NHS Foundation Trusts. 
Geographically, the Clinical Research Facility is housed within King’s College Hospital for a 
simple reason: in the event of adverse events, study participants can receive immediate 
medical care at the hospital. However, all study participants must pre-register as King’s 
College Hospital patients so that, in case of an adverse event requiring treatment, 
participants can circumvent the waiting room of the emergency department and be directly 




The crucial question for the buccal naloxone pilot became: did healthy volunteers attending 
the Clinical Research Facility for data collection become NHS patients solely by pre-
registering as King’s College Hospital patients to allow for immediate treatment in the 
improbable event of an emergency? And if so, did healthy volunteer studies at the Clinical 
Research Facility require NHS co-sponsorship?    
After submitting the protocol for the buccal naloxone pilot to the IoPPN Research & 
Development (R&D) office for initial risk assessment, the study was first assigned shared 
King’s College London and SLaM NHS Foundation Trust co-sponsorship in August 2014, 
suggesting that healthy volunteers at the Clinical Research Facility were indeed considered 
NHS patients. However, just one month later, in September 2014, the IoPPN R&D office 
revoked its decision, stating that King’s College London would be the sole sponsor as there 
was no NHS involvement. I subsequently submitted the protocol and related study 
documents to the MHRA and the National Research Ethics Service (NRES) for regulatory 
approval, with King’s College London listed as sole sponsor of the proposed pilot study. 
Regulatory approvals from the MHRA and the National Research Ethics Service (REC 
15/LO/0103, see Appendix A) were received in November 2014 and March 2015, 
respectively.  
In May 2015, the King’s Health Partners Clinical Trials Office convened a meeting with the 
King’s College Hospital R&D office to clarify the regulatory status of studies using the Clinical 
Research Facility as investigational site. Following the meeting, I received notification from 
the King’s Health Partners Clinical Trials Office that I would not need to apply to the King’s 
College Hospital R&D office (as authority responsible for studies at the Clinical Research 
Facility) for full research governance approval; a confirmation letter from the Clinical 
Research Facility as investigational site and simple registration of the buccal naloxone pilot 
with the King’s College Hospital R&D office would be sufficient. As advised, I applied to the 
King’s College Hospital R&D for registration of the study, but my follow-up attempts over the 
course of the multiple months failed to elicit a response. My supervisors intervened in early 
2016, and in March 2016, the King’s College Hospital R&D office eventually responded to 
our inquiries with the following decision: “We have reached the following outcome - your 
study comes under the remit of the Research Governance Framework for Health and Social 
Care and as such it requires NHS permission before the study can start recruiting 
participants in the NHS. The [Clinical Research Facility] is hosted by KCH and provides 
services to KCH and SLaM - the responsibility for the study review is therefore shared 
between these two organizations for studies undertaken by their staff recruiting their patients 




This decision not only meant that co-sponsorship between King’s College London and either 
the SLaM or King’s College Hospital NHS Trusts was now required, but also that the existing 
MHRA and NRES approvals of the buccal naloxone pilot were no longer valid and had to 
undergo major amendments to allow for the required change in study sponsor. Complicating 
the issue further, the decision coincided with a procedural change: In March 2016, Health 
Research Authority (HRA) approval became the centralized process for all research studies 
involving NHS sites (HRA, 2016), and a backlog of approximately three months was 
anticipated at HRA-level for the processing of new applications.  
Following receipt of the King’s College Hospital R&D response, my first supervisor and I 
decided not to pursue the buccal naloxone pilot further, as the application to the HRA and 
MHRA for renewed regulatory approval would have delayed the study beyond my PhD 
submission deadline. The end-of-trial forms were submitted to the MHRA and research 
ethics committee in July 2016. 
While this experience was very frustrating, the buccal naloxone pilot became the case that 
settled the debate between the IoPPN and KCH R&D offices over the status healthy 
volunteer studies at the Clinical Research Facility, and the sponsorship issues that caused 
the delays and failure of the pilot will hopefully not affect future trials.  
 
9.5.3  Can academia-led innovation compete with industry?   
As discussed in Chapter 8, I had the opportunity to undertake a student industry placement 
with the Cambridge-based pharmaceutical company Mundipharma Research Limited from 
October to December 2016. The central task of my placement was to conduct the data 
analysis of their recent Phase-I pharmacokinetics trial of concentrated nasal naloxone 
formulations (1mg, 2mg, 4mg), but I was involved in various other aspects of the naloxone 
project, including the regulatory submission to the European Medicines Agency (EMA) and 
marketing considerations.  
The placement allowed me to gain a basic understanding of the different steps involved in 
getting a new pharmaceutical drug from the drawing board to the market. Moreover, it 
introduced me to the industrial workflow within a pharmaceutical company where every staff 
member has a clearly defined role with specific competencies. Staff members would apply 
their specific expertise to any new project for any clinical indication. Tasks that require 
additional competencies are outsourced. This high-powered staffing model is different from 




comparatively small number of people to work on a wide range of tasks related to one 
specific clinical indication.  
The contrast between the timelines for the Mundipharma nasal naloxone trial and the buccal 
naloxone pilot at King’s was striking: In August 2015, Mundipharma created the study 
protocol for its nasal naloxone trial with input from my first supervisor and me. Data collection 
began in early 2016, and the last patient last visit occurred in late April 2016. Mundipharma 
thus easily overtook the buccal naloxone pilot. By April 2016, my supervisors and I had been 
trying for 13 months, in vain, to obtain internal approval within King’s Health Partners to start 
recruitment, after NRES approval had already been secured in March 2015.   
This begs the question as to how academia-led innovation can possibly compete with 
pharmaceutical industry, where, as the Mundipharma nasal naloxone trial illustrates, a 
CTIMP can be designed, rolled out, and completed in less than a year. 
The two planned buccal naloxone studies certainly would have benefitted from dedicated 
project funding. From my experience, King’s Health Partners appears to be moving 
increasingly towards a commercial business model, but without the benefit of large-scale 
pharmaceutical industry funding. For instance, the privatization of certain NHS services 
means that previously existing research capacity is now operating on a fee-for-service basis. 
Such was the case with the laboratory within the Department of Clinical Biochemistry at 
King’s College Hospital. While research staff at the laboratory were project partners and 
willing to contribute blood analyses in kind, the laboratory had been privatized, which meant 
that it was now a separate legal entity, and quotes and service-level agreements had to be 
arranged for the buccal naloxone trials.  
Stronger funding mechanisms may be needed for early-stage translational research. As part 
of my PhD, I sought additional project support via two funding schemes, the BRC 
(Biomedical Research Centre) Experimental Medicine and Early Phase Clinical Trials Pilot 
funding in December 2014 and the BRC STEM (Science, Technology, Engineering and 
Mathematics) Early Career Award in January 2016. However, the buccal naloxone project 
was not considered competitive due to the lack of proof-of-concept pilot data. This put the 
project in a catch-22: without pilot data from human bloods, the project could not attract 
funding, and without funding, the project could not collect human bloods. 
Following the early termination of the buccal naloxone pilot in July 2016 (see above), my 
first supervisor approached pharmaceutical industry about taking on the buccal naloxone 
tablet and conducting the Phase-I trials on behalf of King’s College London. However, the 




it offered no financial benefit over the intranasal naloxone formulations which were already 
being explored. 
Additional funding schemes may be needed to support the development of therapeutic 
agents which are not necessarily financially profitable but have potential to address public 
health issues. This would be particularly relevant for public health in low and middle-income 




It is disappointing that I was not able to advance the novel instant-dissolving buccal naloxone 
tablet to in vivo testing during the three years of my PhD studies. The rapidly dissolving 
tablet was successfully produced to good manufacturing practice standards. The 
composition, based on three excipients, mannitol, gelatin and sodium bicarbonate, fulfills 
the design aims for a buccal naloxone tablet for opioid overdose reversal. The buccal 
naloxone tablets are chemically and physically stable for at least nine months and are 
suitable for first-in-human proof-of-concept testing to determine the pharmacokinetics of 
naloxone administration via the buccal route. For the reasons outlined above, naloxone 
exposure from the buccal tablet has yet to be assessed in humans. If buccal naloxone 
administration produces acceptable bioavailability, then future work may also investigate 
ways to optimize the buccal tablet and change its speed of absorption and duration of action, 
for instance through addition of absorption enhancers and surfactants or modification of pH 
(.power of Hydrogen). 
The concept of buccal naloxone is promising: Tablets generally have greater stability than 
solutions, and the buccal naloxone tablet is easy to transport, which may provide distinct 
advantages over injectable and intranasal naloxone formulations. If successful, the buccal 
naloxone tablet could become a viable, cost-effective alternative to existing products. 
In the following and final Chapter 10, I discuss the implications of the integrated findings 








Chapter 10 Discussion 
 
Preface 
This final chapter follows the structure of the Discussion sections of the preceding 
chapters. I first highlight the key findings of the thesis and then discuss its strengths and 
limitations as well as its implications for clinical practice, policy, and future research. 
 
10.1  What this research adds: Statement of principal findings 
Naloxone is a life-saving medication. As described in Chapter 1, the antidote is more 
powerful than its predecessors, while posing fewer side effects and no risk for abuse. In 
1996, following nearly three decades of naloxone use in hospital and ambulance 
settings, a BMJ editorial proposed that pre-provision of naloxone should be made directly 
available to opioid users for emergency use (Strang et al., 1996).  
In Chapter 2, I reviewed the evolution of take-home naloxone (McDonald, Campbell, & 
Strang, in press), finding that – despite positive reception among users, their family 
members, and the wider harm reduction community – lack of provider familiarity with the 
intervention challenged early implementation up until the mid-2000s. However, in the 
past decade, exploration of obstacles and response to social and legal concerns has led 
to the growth of take-home naloxone programs in number and size. Today take-home 
naloxone is increasingly accepted as an effective public health strategy.  
My Bradford Hill analysis in Chapter 3 (McDonald & Strang, 2016) was the first 
systematic review to assess the effectiveness of take-home naloxone in terms of impact 
on opioid overdose mortality, concluding that – at a low rate of adverse events – take-
home naloxone programs reduce overdose mortality among program participants 
themselves and in the community. In studies with systematic follow-up, 122 out of 123 
overdose victims who were administered take-home naloxone survived overdose, while 
one person died. Taking into consideration that approximately one in every 20-30 heroin 
overdose events naturally result in death (i.e. equivalent to an expected 4-6 fatalities per 
123 overdose events) (Darke et al., 2003), this approximates 3-5 lives saved among the 






systematic review as key evidence for the effectiveness of take-home naloxone (FDA, 
2016a). 
However, the lack of non-injectable naloxone formulations has impeded widespread 
take-home provision. In the absence of licensed non-injectable devices, the 
Massachusetts take-home naloxone program was the first to distribute improvised nasal 
naloxone kits consisting of a 2mg/ 2mL pre-filled syringe with a nasal mucosal atomizer 
device in 2005 (Doe-Simkins et al., 2009). These were later introduced elsewhere in the 
US, Denmark, Norway, and Scotland’s Highland region. My review of the evidence base 
for the off-label nasal spray kits in Chapter 4 (Strang, McDonald, et al., 2016) outlined 
how the administration of 2mL of naloxone solution as 1mL per nostril greatly exceeded 
the volumes that could be absorbed intranasally (i.e. up to 0.2mL per nostril). Moreover, 
I determined that the existing safety and pharmacokinetic data (i.e. ≤10% bioavailability 
relative to intramuscular administration, see also Chapter 6) were insufficient to justify 
the continued off-label use of improvised nasal kits, arguing that medications used in 
opioid users should be subject to the same testing standards as medications used in any 
other patient population. Where improvised nasal naloxone kits remain in use, they 
should thus be replaced with licensed products or, at a minimum, supplemented with a 
needle for back-up injection in case of non-response to the dilute naloxone nasal spray. 
In April 2012, the FDA presented regulatory criteria for non-injectable naloxone products 
(Hertz, 2012), describing sufficient bioavailability and rapid onset of action relative to the 
reference treatment of a 0.4mg intramuscular injection as the benchmark. To address 
the need for formally tested non-injectable naloxone formulations, I conducted a 
systematic review in Chapter 5 (Strang, McDonald, Alqurshi, et al., 2016) which applied 
these regulatory criteria to all 112 FDA-recognized routes of drug administration, 
concluding that the nasal, sublingual, and buccal routes were potentially suitable for 
naloxone delivery in an overdose emergency and warranted serious consideration.   
Study of the nasal route has been most advanced, and my subsequent review of 
pharmacokinetic data contained within international patent applications for non-
injectable naloxone formulations in Chapter 6 (McDonald, Glende, Dale, & Strang, in 
press) identified good bioavailability (i.e. 21-42% relative to intravenous; 26-57% relative 
to intramuscular administration) for concentrated nasal naloxone spray, with negative 






In Chapter 7, my analysis of previously unpublished data from a 2004 clinical trial 
established proof-of-concept for IN administration of concentrated naloxone 
formulations, demonstrating substantial naloxone exposure in the clinically relevant 30 
minutes post-dosing (Darke & Duflou, 2016; Tas & McDonald, 2016).    
Chapter 8 reports my analysis of the results of a recent Phase-I pharmacokinetic trial of 
a concentrated nasal naloxone spray that was developed specifically for the indication 
of opioid overdose reversal and is currently under regulatory review by the European 
Medicines Agency. My data analysis (McDonald et al., under review) finds equal early 
naloxone exposure (i.e. within the first 10 minutes post-dosing) from a 2mg/0.1mL 
intranasal dose and a 0.4mg intramuscular dose – thus meeting the central aim of my 
PhD project, namely to identify a non-injectable formulation comparable to the 
intramuscular reference. 
Chapter 9 describes my involvement in the development and testing of a novel buccal 
naloxone tablet (Alqurshi et al., 2016) on which King’s College London has applied to 
register intellectual property, naming me as co-inventor (see Appendix C). Relative to 
concentrated nasal naloxone sprays, the buccal tablet may have a different 
pharmacokinetic profile and may be easier to carry due to its smaller size. While the 
buccal naloxone tablet shows promising in-vitro properties regarding stability and 
dissolution, pharmacokinetic testing of the tablet in healthy volunteers, which was 
originally a component of my PhD project, could not be completed within the period of 
my PhD studies due to regulatory challenges. 
Taken together, the findings of my six first-authored papers (plus one first-authored 
manuscript currently under review) which are incorporated into this thesis strengthen the 
evidence base for take-home naloxone in general (McDonald, Campbell, et al., in press; 
McDonald & Strang, 2016) and, more specifically, for the distribution of licensed 
concentrated nasal naloxone spray for the community-based prevention of opioid 
overdose deaths (McDonald, Glende, et al., in press; Mundin, McDonald, et al., 2017; 
Strang, McDonald, Alqurshi, et al., 2016; Strang, McDonald, et al., 2016). The findings 
of my thesis have several implications for clinical practice and policy, which I discuss in 
the following sections. 
From a methods perspective, this thesis introduces a new exploratory pharmacokinetic 
parameter to the literature: T50%, defined as the time taken to reach 50% of the peak 






applied it to the pharmacokinetic data analysis in Chapters 7 and 8) to correct the missing 
capture of the early curve shape by simple measure of bioavailability (F%), Cmax, and 
Tmax. Whereas Cmax and Tmax denote the time and extent of the peak concentration, 
bioavailability relates only to the naloxone proportion that reaches the systematic 
circulation, neglecting the pace of absorption (Rang et al., 2012). T50% can thus give an 
indication of meaningful early naloxone exposure between different formulations and 
routes of administrations. The new parameter has already been adopted by Norwegian 
colleagues in their recent naloxone paper (Tylleskar et al., 2017) and may also be of 
value for the pharmacokinetic analysis of other life-saving emergency medications where 
early absorption is essential. 
 
 
10.2  Strengths and weaknesses of the thesis 
The main strength of the thesis lies in its integration of novel and archived data from 
academia and industry to create what is likely the most comprehensive work to date on 
non-injectable naloxone formulations for the prevention for opioid overdose deaths. 
However, there are at least three major limitations which will need to be addressed in 
the future.  
 
Limitation 1: Weak evidence base for take-home naloxone distribution 
The evidence base from observational studies of take-home naloxone distribution is of 
moderate to low quality, and the strength of the conclusions of the Bradford Hill 
systematic review in Chapter 3 is limited accordingly. Of the 22 studies included in the 
systematic review, none involved randomization. Most studies were uncontrolled and 
relied on self-report of naloxone usage and overdose outcomes. The number of (self-
reported) overdose reversals was used as proxy for the impact of take-home naloxone 
provision on opioid overdose mortality. However, given that 21 of the 22 studies did not 
validate self-reported overdose events (e.g. using ambulance records) and follow-up 
rates differed greatly across studies, this outcome measure must be considered subject 






The utility of application of the Bradford Hill criteria (or “considerations”) to assess 
causality has been questioned in the literature. This criticism has been considered in the 
wider scientific field but appears not to have been considered in the addictions field. For 
instance, it has been argued, elsewhere, that Hill did not provide a clear definition of 
what he meant by “causal effect” (Hoefler, 2005). Rothman and Greenland (2005) point 
out that only the temporality criterion is inarguable and state that use of the criteria as 
checklist for causation should be avoided as its interpretation is prone to researcher bias. 
The authors conclude that objective causal criteria do not exist in epidemiology: “Causal 
inference in epidemiology is better viewed as an exercise in measurement of an effect 
rather than as criterion-guided process for deciding whether an effect is present or not”. 
Further research is thus likely needed to assess the effect of take-home naloxone 
distribution on population-wide opioid overdose mortality and to determine what 
naloxone coverage rates are required. Such future findings may impact confidence in 
the conclusions of the Bradford Hill systematic review presented in Chapter 3. The need 
for evaluation of population-wide impact is illustrated by the example of the Scottish 
National Naloxone Program, where take-home naloxone distribution has been 
associated with a reduction in the proportion of opioid-related deaths in the first four 
weeks following prison release (Bird et al., 2015, 2016), but this reduction in deaths in 
the high-risk population of prisoners on release has not translated to the wider population 
of opioid users. Despite widespread take-home naloxone provision, the largest number 
of drug-related deaths on record was registered for 2016 (i.e. 867 deaths, of which 88% 
opioid-related), representing a greater than hundred percent increase since 2006 (NRS, 
2017). There are clearly still aspects of the observed data which need more probing 
study. 
In 2014, the World Health Organization Guideline Development Group issued the 
recommendation that “people likely to witness an opioid overdose should have access 
to naloxone”. Interestingly, the Guideline Development Group determined that – despite 
the low-quality evidence from existing observational studies – this recommendation 
should be strong due to the risk-benefit ratio of naloxone distribution, i.e. the potentially 
life-saving nature of the intervention and the apparent absence of significant harm. In 
light of this recommendation, it seems unlikely (for most settings) that parallel trial 
designs, where a control group is not provided access to take-home naloxone, would be 






Cohort studies and database linkage studies (e.g. tracking individuals who have or have 
not been prescribed naloxone in mortality databases) are feasible but would require large 
sample sizes. It also needs to be borne in mind, in the analyses and interpretations, that 
the emerging evidence can be confounded by the possibility that take-home naloxone 
recipients may use their naloxone supply to reverse overdose in a third person.  
A more sophisticated approach which would allow for evaluation of impact on opioid 
mortality rates involves the stepped wedge randomized design (Brown & Lilford, 2006), 
where take-home naloxone distribution is rolled out sequentially across all participating 
clusters (e.g. cities or regions) over multiple time-points, and the order of intervention 
delivery across sites is randomized. A key feature is that once a cluster begins to receive 
the intervention, it does not switch back to the control. A stepped wedge design requires 
that the intervention is not available in any of the participating clusters at baseline to 
allow for comparison of outcomes (i.e. mortality rates) before (i.e. control) and during 
exposure to the intervention. There may be special opportunities, available for only a 
short period of time, as the provision of take-home naloxone is gradually being accepted 
as an expected or required practice. For example, countries such as Sweden, which 
have robust data collection on drug-related deaths and are only now considering the 
introduction of take-home naloxone thus have the opportunity to strengthen the evidence 
base by using a stepped wedge randomized design for evaluation.   
 
Limitation 2: Lack of human in vivo data for buccal naloxone 
For the reasons discussed in Chapter 9, I was unable to conduct two planned clinical 
trials (EudraCT numbers: 2014-001802-16, 2016-000582-23) of the pharmacokinetics of 
buccal naloxone in healthy volunteers. Even though the buccal naloxone tablet has been 
manufactured and is fit for first-in-human testing, its bioavailability can at present only be 
estimated based on preclinical data (see Chapter 5). It is hoped that future completion 
of the Phase-I trial of the buccal tablet will fill this knowledge gap and allow the tablet to 
advance to the next stages of drug development – and potentially to regulatory approval. 
The time series for blood sampling in the trial protocols in Chapters 8 and 9 is identical, 
meaning that the results of the buccal naloxone tablet trial, once completed, will allow 
for direct comparison of its pharmacokinetics to those of the 1mg/0.1mlL, 2mg/0.1mL, 






Limitation 3: Lack of pharmacokinetic data from clinical samples 
The third limitation concerns the fact that all pharmacokinetic data reported in this thesis, 
and indeed all pharmacokinetic studies of nasal naloxone conducted internationally, 
have thus far only been collected in healthy volunteers, and the degree of potential 
variation in clinical samples has yet to be determined. Pharmacokinetic data are sample-
dependent and describe aggregate blood plasma concentrations of a specific 
formulation administered to an individual on a given occasion (Rang et al., 2012). The 
bioavailability of a naloxone formulation is thus not solely a function of the formulation 
itself but is also affected by intra-subject and inter-subject variability. Cross-over designs, 
as used in the studies in Chapters 7 and 8, seek to reduce these sources of variability 
(MacKenzie, 2013), and the similarity of the bioavailability and Tmax values in Chapter 
8 and the studies by Krieter et al. (2016) and Tylleskar et al. (2017) support the validity 
of these findings. Nonetheless, it needs to be borne in mind that the registration trials 
reported in Chapter 8 and by Krieter et al. (2016) tested the pharmacokinetics of 
intranasal naloxone under optimal laboratory conditions in healthy volunteers who 
underwent extensive screening and frequent nasal passageway examinations. The 
bioavailability of intranasal naloxone in patients with nasal or hepatic irregularities may 
thus differ substantially (see Chapter 8). Similarly, while the healthy volunteer studies in 
Chapters 7 and 8 and those by Krieter et al. (2016) and Tylleskar et al. (2017) support 
good tolerability of the concentrated intranasal formulations, no definite conclusions can 
be drawn as to their clinical safety in the target population of opioid overdose victims. 
 
What kind of studies could strengthen the pharmacokinetic evidence and prepare 
for clinical trials? 
At least three kinds of studies could be conducted to strengthen the pharmacokinetic 
evidence for concentrated nasal naloxone spray and prepare for clinical trials in the 
target population.  
Firstly, the generalizability of the pharmacokinetic evidence could be increased by 
conducting a richly sampled Phase I pharmacokinetic study with the aim to study the 
sources and correlates of variability in naloxone concentrations between individuals. 
While pharmacokinetic study of naloxone in opioid users would undoubtedly be ethically 






be recruited instead. Dose-concentration relationships can be affected by subjects’ 
demographical and clinical features, such as body weight, metabolic and excretory 
functions, and the presence of other substances (FDA, 1999). There may thus be merit 
in studying the variability of naloxone concentrations in non-opioid using individuals with 
nasal abnormalities or nasal mucosal damage, varying degrees of hepatic impairment, 
very low or high body weight (or Body Mass Index, BMI), and in smokers – all of which 
were exclusion criteria for the studies in Chapters 7 and 8. For instance, it is currently 
unknown whether nasal damage from drug snorting would decrease (due to scarring) or 
increase (due to greater mucosal permeability) the absorption of nasal naloxone.  This 
could potentially be tested in (former) cocaine users with nasal damage.  
Secondly, in order to empirically test the simulations of repeat administrations presented 
in Chapter 8, the effects of repeat dosing (administering a naloxone nasal dose every 3 
minutes, for instance) on naloxone plasma concentrations could be assessed in healthy 
volunteers and compared to parenteral routes. This could also involve comparison of 
repeat administration of the nasal spray in the same nostril versus the alternate nostril. 
Such study of repeat administration could inform the development of treatment 
algorithms for naloxone nasal spray, which currently do not exist. 
A third option involves existing clinical situations which provide the opportunity to safely 
study the efficacy of naloxone nasal spray and required dosage in controlled medical 
settings. These clinical situations include naloxone reversal of opioid anesthesia 
following surgery as well as opioid overdose reversal in ambulance settings or in 
supervised injecting facilities. The post-operative recovery setting may provide the added 
benefit that patient consent can be obtained prior to surgery. Where consent is given, 
blood samples for pharmacokinetic analysis could thus be drawn during opioid 
anesthesia and naloxone reversal and provide valuable information on how naloxone 
blood levels correlate with recovery. Existing research plans for an ambulance-based 
trial comparing intranasal and intramuscular naloxone are described in more detail in 








What statistical tests could be used to test a hypothesis of “equivalence” between 
naloxone preparations compared to “gold standard”/ treatment as usual?  
With regard to statistical tests, the standard approach to test for pharmacokinetic 
equivalence (i.e. equivalence of the plasma concentration profiles) is to perform a 
bioequivalence evaluation. (Bioequivalence testing involves calculating comparison 
ratios for a test treatment and a reference treatment for AUC and Cmax, plus associated 
confidence intervals. If the 90% confidence intervals for the comparison ratio 
(test/reference treatment) fall within the range of 80 to 125%, bioequivalence can be 
concluded). 
However, pharmacokinetic bioequivalence is only relevant if two treatments are given by 
the same route of administration (e.g. two treatments for oral administration).  For the 
comparison of one or multiple naloxone nasal spray formulations to the clinical standard 
of an intramuscular injection, bioequivalence evaluation thus does not apply. 
Repeated measures ANOVA can be applied to compare PK parameters (e.g. Cmax, 
AUC) from different routes of administration. For 2×2 crossover designs (e.g. one 
intranasal dose vs. one intramuscular reference dose), a standard repeated measures 
ANOVA can be conducted with sequence as between factor and treatment as within 
factor.  
For crossover designs that are more complex than the 2×2 crossover (such as the trials 
in Chapters 7 and 8 which compared multiple nasal spray doses), extensive modeling is 
often required, and mixed-effects linear models may be considered preferable, as they 
can deal with missing values and account for potential sequence, period, and carryover 
effects (Li, 2014; see also Senn, 2002).  
 
 
10.3  Possible mechanisms and implications for clinicians 
Multiple products are currently under review by the European Medicines Agency, and a 
first concentrated naloxone nasal spray will likely receive regulatory approval from the 







10.3.1  Implications for take-home naloxone provision 
Injectable naloxone formulations have been considered a barrier to community-based 
naloxone use (Beletsky et al., 2012; Wermeling, 2013) on the basis that bystanders may 
be less willing to administer an injection for lack of familiarity with needle-and-syringe 
assembly or for fear of needle-stick injury and potential contraction of blood-borne 
diseases (e.g. hepatitis C, HIV) which are highly prevalent among injecting drug users 
(Degenhardt et al., 2016). A licensed naloxone nasal spray would remove these barriers 
and may have several implementation advantages. 
Since a nasal spray does not require training in needle-and-syringe assembly, it could 
be pre-provided to a wider intervention workforce, including hostel staff, outreach 
workers, and police. In fact, the London Metropolitan Police has already expressed 
interest in carrying naloxone once a licensed nasal spray becomes available in the UK 
(Broughton, 2017).  
Moreover, by removing the needle from the antidote, non-injectable naloxone could also 
be made available in communities (e.g. Liverpool) and countries (e.g. Sweden) which 
thus far have blocked take-home naloxone implementation on the basis that the 
administration of injections is restricted to medical professionals (EMCDDA, 2016a).  
Clinicians may also feel more comfortable about providing a naloxone nasal spray to 
opioid users and their family members. Injecting drug users have expressed strong 
preference of intranasal naloxone over injection-based administration, among others 
because a nasal spray would eliminate the need to carry a spare clean needle and would 
be less alarming to use in public (Kerr, Dietze, Kelly, & Jolley, 2008). Family members 
and other potential overdose witnesses without medical training may prefer the 
functionality of the ready-to-use Aptar device compared to existing pre-filled syringes 
which require manipulation (UKMi, 2016) and to improvised nasal kits (see Chapter 4) 
for which cases of assembly failure have been reported (Doe-Simkins et al., 2009). 
Family members already carry out 20% of overdose reversals (Bagley, Forman, Ruiz, 
Cranston, & Walley, 2017), and this proportion could increase in future with ready-to-use 
non-injectable devices. 
The ease of administration of the Aptar device may also be advantageous when those 
witnessing an overdose are heavily intoxicated themselves. Such was the case in a 






2003 (Hickman et al., 2007). The coronial files suggested that even though 60% of 
overdoses were witnessed, the witnesses’ capacity was compromised in most cases. 
The authors estimate that one quarter of witnessed deaths could have been prevented 
had the witnesses intervened sooner. (Nota bene: It is unclear if any of the witnesses 
had access to take-home naloxone, which had only been introduced by very few services 
in South London in the year 2001, see Chapter 2). 
This points to an issue that availability of non-injectable naloxone products alone is 
unlikely to solve. Take-home naloxone administration is only possible where death is not 
immediate and a witness is present who recognizes the opioid overdose. Using alone is 
a known risk factor for fatal overdose and may particularly affect older opioid users (age 
≥40 years) (EMCDDA, 2016a, 2016b; Hickman et al., 2007); whose overdose risk is 
already pronounced due to physical comorbidities and who may be more likely than 
younger cohorts to live alone. 
Particularly for those who inject alone, mechanisms for detection of opioid overdose are 
urgently needed. Survival rates of overdose could potentially be improved through novel 
technology that would detect when a user is unresponsive, trigger an ambulance call, 
and submit the GPS location of the overdose victim (Tas & McDonald, 2016). However, 
despite commendable efforts by the US Substance Abuse and Mental Health Services 
Administration (SAMHSA) to promote the development of technology-based tools for 
opioid overdose prevention (3), these remain largely non-existent. 
In their audit of drug overdose fatalities, Hickman and colleagues (2007) found that over 
a third of cases (36%) had been in contact with specialist drug treatment services, 
emergency care (ED visits) or primary care in the month prior to their death. While drug 
treatment services may be the obvious access point for take-home naloxone provision 
due to the high concentration of opioid users, this finding suggests that primary care and 
emergency care are also potentially useful venues for engaging the high-risk 
subpopulation of users not enrolled in opioid substitution treatment (Degenhardt et al., 
2011; Pierce et al., 2016). The implications of my thesis for take-home naloxone 







10.3.2  Drug treatment services 
A recent cost-effectiveness modelling study (Uyei, Fiellin, Buchelli, Rodriguez-Santana, 
& Braithwaite, 2017) suggests that the provision of take-home naloxone in combination 
with methadone treatment is cost-saving. This extends the findings of two earlier cost-
effectiveness modelling studies (Coffin & Sullivan, 2013a, 2013b) who concluded that 
take-home naloxone was cost-effective even under conservative model assumptions 
and lends further support to the large evidence-base for opioid substitution treatment. 
Multiple systematic reviews and meta-analyses show that retention in opioid substitution 
treatment reduces heroin use and protects against overdose mortality (Degenhardt et 
al., 2011; Mattick, Breen, Kimber, & Davoli, 2009; Sordo et al., 2017). 
Studies in Italy (Davoli, Bargagli, Perucci, Schifano, Belleudi, Hickman, Salamina, 
Diecidue, Vigna‐Taglianti, et al., 2007), England (Cornish et al., 2010), Norway (Ravndal 
& Amundsen, 2010) and Scotland (Merrall, Bird, & Hutchinson, 2013) have found that 
the first month following the end of treatment generally bears an elevated risk of 
overdose (see also Chapter 2). Take-home naloxone should thus be a standard of care 
for patients in opioid substitution treatment as well as those in abstinence-based 
treatment. Strang and colleagues (2003) found that patients who had successfully 
completed inpatient abstinence-based treatment for opioid use disorder were more likely 
to die of overdose than those who had failed to complete the program. Abstinence-based 
treatment providers have traditionally been reluctant to distribute take-home naloxone 
(McDonald et al., 2016), presumably for fear of a safety net effect – for which no empirical 
evidence exists (Kerensky & Walley, 2017; McDonald & Strang, 2016). However, 
availability of a licensed naloxone nasal spray (or other non-injectable formulations) may 
facilitate organizational buy-in from clinical leadership, as the nasal route of 
administration bears no resemblance to injecting drug use and would unlikely be 
considered to trigger relapse. 
 
10.3.3  Primary care 
Despite evidence of reduced mortality risk following primary care-based initiation of 
opioid substitution treatment (Kimber et al., 2010) and despite extensive contact with 
users seeking treatment for often complex health issues, many primary care providers 






While some primary care providers have expressed favorable attitudes towards wider 
naloxone availability in survey studies, many have remained wary of providing take-
home naloxone (Barry, Klimas, Tobin, Egan, & Bury, 2017; NPHL, 2014). US primary 
care providers described insufficient time during patient appointments and inability to 
follow up with patients as main organizational barriers to take-home naloxone 
(Binswanger et al., 2015). Canadian primary care providers considered existing 
naloxone guidelines inadequate and identified the lack of user-friendly naloxone devices, 
sufficient funding and training as central barriers to take-home naloxone provision 
(Leece, Orkin, Shahin, & Steele, 2015). In Scotland, many primary care providers 
reported low awareness of the national take-home naloxone program, which points to 
the need for provider training (Matheson et al., 2014). These implementation barriers 
also highlight the need to change policy and allocate appropriate funding to prioritize the 
management of opioid users in primary care, including take-home naloxone provision 
(Robertson, 2016). 
Take-home naloxone research has been largely confined to injecting drug users, and the 
question of co-prescription of naloxone as a universal precaution for chronic pain 
patients being treated with opioids in primary care is just now being raised (Kerensky & 
Walley, 2017). A San Francisco-based project of naloxone co-prescribing for primary 
care patients receiving long-term opioid pain therapy established that the intervention 
was feasible, acceptable to patients (Behar, Rowe, Santos, Murphy, & Coffin, 2016) and 
associated with significantly reduced opioid-related emergency department (ED) visits 
at 1-year follow-up (Coffin et al., 2016). Naloxone nasal spray may be more acceptable 
to chronic pain patients than an injectable kit, since these patients may not consider 
themselves at risk of overdose and may not want to be associated with injecting drug 
use in the broadest sense. 
 
10.3.4  Emergency care 
Emergency care settings present the unique opportunity to reach high-risk patients 
seeking treatment for opioid-related injuries and overdose. The Massachusetts take-
home naloxone program already provides take-home naloxone at EDs, and feasibility 
has recently also been studied elsewhere. A British Columbia survey of ED patients at 
risk of opioid overdose (Kestler et al., 2017) found that two-thirds accepted take-home 






overdose prevention. Ambulance-based take-home naloxone provision following 
overdose reversal is currently being piloted in San Francisco, and the feasibility of using 
the post-resuscitation period as a “teachable moment” for brief intervention – similar to 
the Screening, Brief Intervention, and Referral to Treatment (SBIRT) model (Babor et 
al., 2007; Barbosa, Cowell, Bray, & Aldridge, 2015; Madras et al., 2009) – is now being 
explored. 
 
10.3.5  Dosing 
The approval of one or multiple concentrated naloxone nasal spray products by the 
European Medicines Agency would significantly diversify the range of naloxone 
formulations available to clinicians. If either product receives regulatory approval, the 
pharmacokinetic data reported in this thesis for the 2mg/0.1mL nasal spray as well as 
the data previously published by Krieter et al. (2016) on the Adapt 4mg/0.1mL spray 
should be made available to clinicians so that they can make correct clinical decisions 
on dose adjustment for the new nasal spray (relative to the established injectable 
formulations for which dose guidance has been developed). 
The 2mg/0.1mL intranasal dose tested in Chapter 8 was characterized by maintenance 
of substantial plasma levels for two hours post-dosing. The concentrated nasal spray 
formulations tested by Krieter et al. (2016) and Tylleskar et al. (2017) had similar profiles. 
Concentrated nasal naloxone spray could thus prevent re-narcotization following heroin 
overdose and be beneficial for the treatment of overdose from long-acting opioids (see 
Chapter 1) 
The dosage of any new intranasal formulation will need to strike a balance between 
reversing opioid action without causing severe adverse reactions (Hertz, 2012). Reports 
of the harm caused by naloxone over-antagonism have been described, and high-dose 
naloxone formulations with increased risk of over-antagonism may also result in negative 
attitudes from drug users, as previously reported (Neale & Strang, 2015). 
It is worth noting that the FDA and the European Medicines Agency appear to differ in 
their assessment of the safety implications of concentrated naloxone nasal spray 
formulations. Whereas the FDA has highlighted that the potential benefits of the Adapt 
NARCAN 4mg/0.1mL product (i.e. overdose reversal) outweigh the risks of withdrawal 






the 2mg/0.1mL formulation studied in Chapter 8, has raised several questions regarding 
the potential risks of withdrawal. It is interesting to note that a bold regulatory approach 
is not uncommon for the FDA: A recent analysis by Downing et al. (2017) found that one 
in every three new drugs approved by the FDA between 2001 and 2010 has had post-
market safety issues.  
At a minimum, clinicians will thus need to carefully monitor any licensed new naloxone 
product for its potential side effects and non-response rate, and take-home naloxone 
recipients should be actively encouraged to report any adverse reactions or safety issues 
that may occur. 
 
10.3.6  Potential use for other clinical indications 
By removing the needle from naloxone, non-injectable formulations of the opioid 
antagonist may potentially also be of value for the treatment of other clinical indications, 
where daily dosing is required. Binge eating disorder, for instance, is associated with 
mu-opioid receptor dysregulation (Heal et al., 2017; Majuri et al., 2017). According to a 
recent literature review (McElroy, Guerdjikova, Mori, & Keck, 2015), a conference 
abstract on a double-blind Phase-II randomized controlled trial sponsored by Lightlake 
reported a reduction of binge eating episodes and body mass index (BMI) following daily 
intranasal naloxone treatment (2-4mg; volume not reported) over the course of six 
months. An upcoming 12-week multi-site clinical trial sponsored by Opiant will assess 
the impact of daily treatment of up to two doses of the Adapt naloxone nasal spray 
(4mg/0.1mL) on binge eating episodes in patients with bulimia nervosa. One of the 
participating study centers is the Eating Disorders Research Group at King’s College 
London, where data collection is scheduled to commence in June 2017 under 
supervision of Professor Janet Treasure. 
 
10.4 Possible mechanisms and implications for policymakers 
10.4.1  Calls for universal take-home naloxone provision  
My Bradford Hill analysis in Chapter 3 concluded that take-home naloxone distribution 
to opioid users should be introduced as standard of care for the community-based 






volumes of take-home naloxone kits have been distributed relative to the growing 
international clinical need, as evident in 106,000 annual deaths from opioid overdose 
worldwide (UNODC, 2016b). 
Beyond lack of funding or political support, low prescriber awareness and commitment 
persist as central barriers to wider take-home naloxone provision. Despite evidence of 
effectiveness and endorsements from professional organizations (ACMD, 2000, 2012, 
2016; AMA, 2012), many providers fail to integrate take-home naloxone into standard 
care for at-risk patients. Dissemination was found to be difficult even among addiction 
treatment staff (Mayet, Manning, Williams, Loaring, & Strang, 2011) with the anticipated 
cascade of the ‘train-the-trainer-model’ occurring at the disappointing pace of one drug 
user trained per clinician trainee in an average of 11 months. 
The introduction of non-injectable naloxone alone may not change provider behavior. 
Providers struggle with competing clinical demands, making opt-in medical services low 
priority. A more proactive approach whereby take-home naloxone was routinely 
prescribed to all at-risk patients unless patients declined (‘opt-out’ system) would likely 
increase coverage. In theory at least, an ‘opt-out’ system of required naloxone pre-
provision could even open the doors to the possibility of medical malpractice lawsuits in 
cases where providers issue high-dose opioid scripts without co-prescribing take-home 
naloxone, and the patient then suffers opioid-related injury or death. 
In a recent US study, Barnett and colleagues (2017) conducted a retrospective analysis 
of prescription claims for Medicare patients (n=377,629; mean age: 69 years) who had 
an ED visit during the study period (2008-11) and had not been prescribed opioids in the 
6 months leading up to the ED visit. The authors found that patients’ opioid use in the 12 
months following the ED visit was associated with the prescribing behavior of the treating 
ED physician. The ED physician’s opioid prescribing intensity (both in terms of dose and 
frequency) predicted patients’ opioid use at 12 months, with long-term opioid use (≥180 
days’ opioid supply) significantly higher among patients treated by a high-intensity than 
a low-intensity prescriber (odds ratio: 1.31; 95% confidence interval = 1.24, 1.39) during 
their initial ED visit. 
Opt-out guidelines for required take-home naloxone provision, together with mandatory 
provider participation in prescription drug monitoring programs (PDMPs) (Moyo et al., 
2017; Wen, Schackman, Aden, & Bao, 2017) could thus lead to substantial 






With a view to global naloxone access, the United Nations Office on Drugs and Crime 
(UNODC) proposed an international coverage target at the 60th session of the 
Commission on Narcotic Drugs in March 2017 (UNODC, 2017), analogous to the existing 
UNAIDS (Joint United Nations Program on HIV/AIDS) 90-90-90 ‘test and treat’ strategy 
that had been introduced to help end the AIDS epidemic (UNAIDS, 2014), The UNODC 
target specifies that '90% of those likely to witness an opioid overdose (users, peers and 
family) will have received training in overdose risk and emergency management, of 
whom 90% will have received take-home naloxone, of whom 90% will be carrying 
naloxone or have it close at hand.’ While this target is extremely ambitious in nature and 
does not define a target date for attainment, the former two aims may represent useful 
indicators to quantify and monitor overdose prevention efforts and naloxone coverage 
relative to the target population in countries affected by opioid-related mortality. 
Future studies will need to look at the extent to which widespread take-home naloxone 
coverage, as perhaps achieved in Scotland (Bird, McAuley, Munro, Hutchinson, & 
Taylor, 2017; McAuley et al., 2017), Norway (Madah-Amiri et al., 2017) and several 
states in the US (Walley, Xuan, et al., 2013), results in a reduction in opioid overdose 
mortaliy at the state or national level. Researchers estimate that target naloxone 
coverage should exceed 100 kits per 100,000 population (Walley, Xuan, et al., 2013) or 
at least nine times as many naloxone kits as there are annual opioid-related deaths to 
impact opioid mortality (Bird et al., 2015; Madah-Amiri et al., 2017). However, optimum 
coverage levels of take-home naloxone will likely be context-dependent. Vickerman and 
colleagues (2006), using mathematical model projections, sought to determine a 
coverage threshold for syringe distribution that would lead to reductions in HIV 
prevalence among injecting drug users, have highlighted the challenges of establishing 
a single universal coverage target, and they consider that multiple environmental factors 
would come into play. A recent spatial analysis of San Francisco census tracts indicates 
that greater geographical distance to take-home naloxone distribution sites was 
associated with a lower number of naloxone reversals (Rowe et al., 2016). This suggests 
that required coverage levels may also differ by population density, e.g. for urban versus 
rural communities. In terms of global health, target naloxone coverage will likely depend 
on the existing healthcare infrastrure, with increased naloxone coverage needed in 
countries where access to opioid subsitution treatment and availiability of emergency 
medical care are low or associated with risk of financial burden or legal consequences 






10.4.2  Over-the-counter naloxone 
Injectable medicinal products are subject to prescription according to Article 71 of the 
European Union Medicinal Products Directive (2001/83) (EMCDDA, 2016a): “Medicinal 
products shall be subject to medical prescription where they […] are normally prescribed 
by a doctor to be administered parenterally.” Since naloxone is currently licensed only 
for injection by the European Medicines Agency, it follows that naloxone should normally 
be available by prescription. Given that naloxone self-administration is unlikely during 
overdose, prescription-only status implies that naloxone can be administered to the 
patient to whom the prescription was issued by only a medical practitioner (e.g. doctor 
or nurse) or those acting under the medical practitioner’s instructions (e.g. family 
members) (EMCDDA, 2016a). 
By definition, non-injectable naloxone products, including nasal sprays, would not 
involve parenteral administration and may therefore enable future re-classification to 
over-the-counter medication (EMCDDA, 2016a). Over-the-counter status already exists 
in Italy and Australia (notably for injectable naloxone), and Canada, the UK, and several 
states in the US have put special guidelines in place to make naloxone available without 
prescription. 
Until recently, Italy was the only country where naloxone was available without a 
prescription. In 1996, the Italian Ministry of Health classified naloxone as an over-the-
counter medication, allowing pharmacists to issue naloxone without a prescription 
(Senza Obbligo di Prescrizione) (ForumDroghe, 2016, 2017; Lenton & Hargreaves, 
2000; WHO, 2014). However, naloxone cannot be publicly displayed on shelves to which 
customers have direct access. Customers must request naloxone directly from the 
pharmacist. While no causal conclusions may be drawn, the 1996 introduction of over-
the-counter status in Italy was succeeded by a gradual decline in opioid overdose 
mortality rates, with 470 deaths in 1999, 280 in 2005, and 101 in 2015 (ForumDroghe, 
2016, 2017). As of 2016, 57 Italian harm reduction services distribute take-home 
naloxone, but there are stark regional disparities, with services predominantly clustered 
in the major metropolitan areas (i.e. Rome, Milan, Bologna, Turin, Naples) 
(ForumDroghe, 2016).  
Although take-home naloxone was only introduced in Australia in 2011, Australia 
became the second country to have naloxone formally available over-the-counter, 






used for the treatment of opioid overdose” on Schedule 3, thereby approving over-the-
counter status (Lenton et al., 2016). Since early 2016, Australian community pharmacists 
have been able to supply naloxone without a prescription. 
In Canada, take-home naloxone programs exist in seven of the 13 provinces and 
territories, with large programs in British Columbia (120 sites, 6,389 kits distributed) and 
Ontario (22 sites, 2,734 kits distributed) (CCSA, 2016). In 2016, Health Canada 
approved the previously FDA-licensed nasal naloxone product (NARCAN®; 4mg/0.1mL) 
and issued an interim order to make the spray available without a prescription 
(CBCnews, 2016). 
Select US pharmacies in at least 15 states have special practice agreements allowing 
pharmacists to sell naloxone (incl. the FDA-approved nasal spray) without a prescription 
(EMCDDA, 2016a). However, it is unclear if or how soon formal re-classification of 
naloxone from prescription-only medicine to over-the-counter status may occur. An 
earlier legal analysis suggested this regulatory process might be lengthy and cost-
intensive (Burris et al., 2001), as the FDA would require additional data demonstrating 
the ability of laypersons without medical training to correctly diagnose an overdose and 
administer the formulation (Compton, Volkow, Throckmorton, & Lurie, 2013; FDA, 2012). 
In the UK, new UK legislation, as summarized in the 2015 PHE guidelines, allow people 
engaged or employed in NHS drug treatment services to make take-home naloxone 
available to opioid users, family members, and hostel staff without prescription, provided 
the naloxone supply is documented accurately (PHE, 2016). Even though naloxone 
technically remains a prescription-only medication, the guidelines reduce the staffing 
burden for take-home naloxone as staff without prescribing authority can issue take-
home naloxone for emergency use. Community pharmacists are now being allowed, 
according to the new UK legislation, to provide naloxone directly to opioid users. 
While over-the-counter status would likely reduce bureaucratic hurdles, naloxone access 
solely over-the-counter, i.e. without additional free distribution, may only yield limited 
community-based coverage (Pricolo & Nielsen, 2017). Such is the case in Italy, where 
some regions remain without community-based naloxone coverage despite over-the-
counter status, presumably because of lack of a national harm reduction policy and 
insufficient public investment (ForumDroghe, 2016). As follows, the Italian experience 
highlights that over-the-counter status per se does not imply necessarily that pharmacies 






10.4.3  Cost of non-injectable naloxone formulations 
The issue of take-home naloxone cost also needs to be considered. In countries where 
individuals can purchase naloxone, it remains unknown how likely potential overdose 
witnesses are to access and obtain naloxone via take-home naloxone programs at no 
cost versus over-the-counter medication for sale. By analogy, in the prevention of 
sexually transmitted infections (STIs), a systematic review identified cost as barrier to 
condom use (Ubrihien, Davies, & Driscoll, 2016). Consequently, recent National Institute 
for Health and Care Excellence (NICE) guidelines recommend free-of-charge condom 
distribution schemes to target populations at highest risk of STIs (Iacobucci, 2017; NICE, 
2017). A dual implementation model is therefore recommended: potential over-the-
counter sales of non-injectable naloxone must not replace free-of-charge distribution 
schemes in future.  
When comparing the different existing naloxone devices, with ampoules being the most 
basic, there is a clear trade-off between usability and cost. This point is perhaps best 
illustrated with the example of the Kaléo Pharma’s naloxone auto-injector (Evzio®; 
0.4mg/0.4mL), which was FDA-approved in April 2014 (Kaleo, 2014). The product, which 
is packaged with two single-use auto-injectors and a trainer (FDA, 2016), does not 
require any assembly and provides audio-instructions. However, its usability comes with 
a hefty price-tag: At US $4,500 (Lazarus, 2017), the auto-injector becomes almost 
irrelevant for community-wide provision. 
The affordability of non-injectable naloxone products will define their availability in a 
healthcare system, and ultimately, their accessibility for the target population. The 
different manufacturers of the naloxone nasal sprays currently under review by the 
European Medicines Agency have indicated that they would aim to introduce their 
respective products (packaged with two single-use devices) at a market price that would 
match that of the Prenoxad® pre-filled syringe, which is currently listed in the BNF at 
£15.30 (NHS indicative price) (BNF, 2017). 
Bearing in mind that affordability will likely differ by country and depend on the 
purchasing power of its healthcare system, the question of cost of non-injectable 
naloxone becomes particularly relevant for global health. Following my involvement in 
the development of the 2014 WHO Guidelines (WHO, 2014), I have recently had the 
opportunity to support UNODC as a consultant working on a feasibility study of take-






middle-income countries (LMIC) in Eastern Europe and Central Asia. With support from 
the Global Fund, the four project countries currently procure naloxone ampoules from 
two manufacturers in Ukraine and Poland at the low cost of approximately US $0.50 per 
ampoule (0.4mg/ml), subject to exchange rate. Local non-governmental organizations 
typically hand out two take-home ampoules per client, i.e. equivalent to a total medicine 
cost of US $1.00 per person. Given the current cost disparity between the nasal spray 
and local ampoule supply, the purchase of naloxone nasal spray is not sustainable for 
the project countries at present. Whether non-injectable products can improve 
community-based naloxone availability in LMIC in the future remains to be seen. Bulk-
buying and the production of generics could lower costs in the long term, as has been 
achieved for second-line antiretroviral therapy for HIV/AIDS in LMIC, where the 
medication cost per patient per year was reduced by 60% from US $1,500 in 2006 to US 
$527 in 2011 (Unitaid, 2016). 
 
 
10.5  Questions for future research 
Many questions are still unanswered about take-home naloxone in general and non-
injectable naloxone in particular, including questions about efficacy and optimal dose 
range (especially for overdose from synthetic opioids) (FDA, 2016a), and questions on 
implementation strategies, user engagement, and device preference. I have sought to 
address these questions in the following sections.  
 
10.5.1  Clinical experimental studies: Ambulance-based 
While the pharmacokinetic studies in healthy volunteers in Chapters 6 to 8 have allowed 
me to compare naloxone exposure from different routes of administrations and 
formulations, pharmacokinetic data only provide estimates of expected performance in 
clinical samples (see Chapter 8). It is thus crucial to examine the efficacy of concentrated 
naloxone nasal spray versus intramuscular naloxone in the target population of opioid 
overdose victims. Given the life-threatening nature of opioid overdose, this cannot safely 
and ethically be tested in a non-medical setting. The ambulance setting is crucial for 
patient safety and has full supplementary interventions available, if required. Two 






previously successfully tested intranasal (2mg) versus intramuscular (2mg) naloxone for 
treatment of opioid overdose. However, the findings of these trials are outdated because 
dilute naloxone nasal spray formulations (2mg/mL; 2mg/5mL) were used. Ambulance-
based study of the efficacy of concentrated naloxone nasal spray (e.g. 2mg/0.1mL) for 
take-home naloxone use is thus urgently needed and would allow for robust testing of 
its non-response rate, dose adequacy and inter-subject dose variability, and the speed 
with which concentrated naloxone nasal spray reverses central opioid action. 
Together with my PhD supervisor Professor Sir John Strang, I am currently developing 
a feasibility trial that will assess the acceptability and logistics of conducting a 
randomized controlled trial of intranasal versus intramuscular naloxone in the London 
Ambulance Service. London Ambulance Service staff has already expressed preliminary 
interest in trialing concentrated naloxone nasal spray, as it could remove the risk of 
needle-stick injury and thus improve occupational health for paramedics (Barton et al., 
2005; Barton et al., 2002; Merlin et al., 2010; Robertson et al., 2009). The feasibility study 
will explore paramedics’ attitudes towards the use of naloxone nasal spray in clinical 
practice and towards participation in a randomized trial and will also assess the case 
notes of a small number of opioid overdose victims (n=50) for completeness regarding 
key clinical outcomes. A key limitation of the Australian trials was that their open-label 
design confounded a key outcome (use of rescue naloxone by intramuscular injection) 
in that it was not clear whether the use of a rescue injection was a true reflection of the 
lack of efficacy of the dilute naloxone nasal spray or the paramedics’ expectation thereof. 
A double-blind, double-dummy design will therefore be considered as part of the 
feasibility study. 
 
10.5.2  Clinical experimental studies: Laboratory setting 
While an ambulance-based randomized controlled trial would provide valuable evidence 
on intranasal naloxone efficacy and dose comparability in clinical samples, its central 
limitation concerns the fact that, apart from perhaps the duration of action of the opioid 
agonist and the presence of absence of alcohol intoxication, it is difficult to determine 
what opioids were consumed in what quantities and what other concomitant drugs may 






Studies of fatal (Hickman et al., 2007) and non-fatal (Darke, Ross, & Hall, 1996) opioid 
overdoses have reported that approximately two thirds of heroin overdoses occur in the 
presence of other central nervous system depressants, i.e. most frequently alcohol, but 
also cocaine, benzodiazepines, and other opioids. The issue of polysubstance use has 
recently received considerable attention in the context of rising rates of overdoses 
involving fentanyl and fentanyl derivatives in North America (FDA, 2016; Kerensky & 
Walley, 2017; Paone & Kunins, 2016; Rudd, Seth, David, & Scholl, 2016). However, it is 
largely unknown how the presence of multiple central nervous system depressants may 
impact the chances of overdose survival, both in terms of how their pharmacological 
interaction may affect tolerance levels and in terms of the naloxone dosage levels 
required to reverse such overdoses. Two methodological approaches involving 
laboratory-based testing may shed light onto this issue and are not mutually exclusive. 
In a “For Debate” piece in Addiction, Hickman et al. (2008) have proposed the integration 
of epidemiological data and findings from preclinical experiments. This translational 
approach would offer the opportunity to use animal models to experimentally test the 
interaction between commonly used opioid agonists and other central nervous system 
depressants at different dose levels and in the presence or absence of naloxone. A 
recent multidisciplinary study by Lyndon et al. (2017) has integrated evidence from 1) a 
preclinical experiment in mice which measured the effects of [pregabalin] versus 
[pregabalin + morphine] treatment on respiratory depression with 2) Office for National 
Statistics (ONS) data, 3) community prescriptions data, and 4) qualitative interview data, 
finding that co-use of gabapentin or pregabalin can increase the risk of fatal opioid 
overdose in heroin users through interaction or additive effects on respiratory 
depression. 
While this innovative approach is extremely promising, a limitation may be that it is 
unclear to what extent pharmacokinetic and pharmacodynamics data truly “translate” 
across species. Differences in protein binding are common between human plasma and 
rodent plasma and can have large impact on free drug metabolite concentrations and 
drug effect (Rang et al., 2012). 
The second methodological approach thus involves the possibility of studying the 
pharmacodynamics of naloxone directly in opioid users. In theory at least, two study 
designs come to mind which could be used to test the potency of naloxone relative to 






standard naloxone pre-treatment (e.g. 0.4mg intramuscular) on an opioid agonist dose 
in non-dependent opioid users, with variation of the opioid agonist across sessions. The 
second design could test the subjective onset of action of naloxone using a naloxone 
dose-escalation series across multiple sessions in dependent opioid users. Analogous 
to signal detection studies, the naloxone dose-escalation series could be interspersed 
with random placebo sessions to capture accuracy of the self-report data. Experimental 
study of low-dose naloxone in an opioid-using population would provide the distinct 
advantage that the onset of brain effect could be detected very sensitively, alongside 
blood plasma concentrations. 
At least two studies have previously been conducted in opioid-dependent volunteers to 
assess the pharmacodynamics of intranasal naloxone (Loimer et al., 1992; Loimer et al., 
1994). However, this research almost certainly violated ethical standards for studies in 
vulnerable populations: intravenous (1mg) and intranasal (1mg/0.4mL) naloxone was 
administered to prisoners in Pakistan as opioid challenge test, i.e. with the aim to induce 
opioid withdrawal symptoms. 
I have been awarded a Society for the Study of Addiction Travelling Scholarship to 
undertake a research visit with Professor Sandra Comer at the Substance Use Research 
Center at Columbia University (New York, USA) in July 2017. A primary focus of 
Professor Comer’s lab is the study of opioid agonists and antagonists using a preclinical 
human laboratory model. The basic tenet of this model is that – in order to determine the 
potential utility of a medication for opioid dependence – the effects of the medication on 
opioid use must be studied directly in the user population. This line of research is 
intrinsically challenging.  
During the research visit, I will develop a discussion paper (in collaboration with 
Professor Comer, my PhD supervisor Professor Sir John Strang, and Drs. Joanne Neale 
and Charlotte Tompkins) which will explore the challenges of conducting experimental 
medicine trials, including naloxone studies, in opioid user populations. This discussion 
paper will draw on experiences at Professor Comer’s lab as well as on a qualitative study 
for which we have recently concluded the interviews (“Patient perceptions and 
experiences of different types of medication formulation”; REC reference: 17/SC/0037) 
involving focus groups with opioid users that Dr. Charlotte Tompkins and I jointly 
conducted in South London between March and May 2017. A central part of the focus 






could be feasible and ethically sound for potentially testing the pharmacodynamics of 
naloxone to inform dosing in clinical practice.  
 
10.5.3  Take-home naloxone: Models for implementation 
Implementation research will be necessary as take-home naloxone programs 
progressively move into new settings. One such feasibility study is currently being 
undertaken in correctional and reentry settings in California, where stakeholder 
interviews and focus groups are being conducted to address take-home naloxone 
implementation barriers (NIH project number: 5R34DA039101-02).  
Research is also needed to compare systematically different settings and distribution 
models for take-home naloxone to identify those with biggest reach among target 
populations. Take-home naloxone implementation studies have mostly recruited heroin 
users via urban harm reduction infrastructures, including needle exchange schemes. 
Implementation studies are needed for emerging target groups such as rural user 
populations and prescription opioid users (including chronic pain patients) whose 
overdose risk awareness may be low (Albert et al., 2011; Coffin et al., 2016; Compton & 
Volkow, 2006; Paulozzi & Ryan, 2006). Community pharmacy-based naloxone has been 
piloted as a means by which to promote naloxone access in rural areas (T.C. Green, 
Dauria, Bratberg, Davis, & Walley, 2015). It will be important to examine the 
demographics of prescription opioid users (including chronic pain patients) in greater 
detail (Coffin et al., 2016; Ling, 2017; Volkow & McLellan, 2016) to identify high-yield 
implementation strategies. 
 
10.5.4  Take-home naloxone: Opioid user engagement 
Despite increasing take-home naloxone provision among (recent) injecting drug users 
from 8% (2006-10 baseline) to 51% (2014-2015) (Bird et al., 2017), the Scottish National 
Naloxone Programme reported naloxone carriage rates of only 5-16% (A. McAuley et 
al., 2016), highlighting the need to improve user engagement in take-home naloxone 
programs and to ensure their understanding of, and adherence to, the importance of 






Qualitative research may help shed light onto barriers to take-home naloxone 
intervention uptake. While opioid users in Baltimore and Chicago reported predominantly 
positive interactions with police and paramedics (Sherman et al., 2008) and expressed 
interest in take-home naloxone provision as well as willingness to share information on 
overdose emergency management with peers and family members (Sherman et al., 
2009), naloxone experiences likely differ. Qualitative interviews conducted in Scottish 
cities in 1997-99 (Neale & Strang, 2015) revealed opiate users’ negative views of 
naloxone and accounts of harm caused by its administration (e.g. acute withdrawal, 
aggression, self-discharge and further drug-seeking), even though this was not apparent 
in observational data. Similarly, opioid users in New York and Los Angeles reported fear 
of withdrawal and police involvement as key concerns associated with take-home 
naloxone distribution (Lankenau et al., 2013; Worthington et al., 2006), and continued 
use of folk remedies posed a barrier to take-home naloxone use (Lankenau et al., 2013). 
Reasons for poor naloxone implementation need to be understood (Black et al., 2017), 
and systematic study of lived naloxone experiences is needed to identify strategies to 
increase user engagement in take-home naloxone programs. 
 
10.5.5  Take-home naloxone: Carriage rates 
As mentioned in the previous section, naloxone carriage rates of only 5-16% were 
reported for the Scottish National Naloxone Programme among a sample of injecting 
drug users (McAuley et al., 2016). Low naloxone carriage rates pose a major concern 
as they suggest low probability of naloxone availability at the time of an overdose. There 
are at least three possible explanations for the observed low carriage rates in the 
McAuley et al. study (2016) that warrant further study.  
Firstly, carriage rates were lowest among those not recently injecting. Is it possible that 
naloxone carriage is associated with current injecting behavior and perceived personal 
risk of experiencing an overdose? Such potential optimism bias in opioid users (Sharot, 
Guitart-Masip, Korn, Chowdhury, & Dolan, 2012) would be very risky considering that 
risk of overdose is pronounced following periods of abstinence (see Chapter 2). 
Secondly, the data showed a negative association between volume of community-wide 
take-home naloxone distribution (observed increase) and individual naloxone carriage 






their individual naloxone kit when the perceived overall availability of naloxone kits in 
their community has gone up? If so, the risks of such diffusion of responsibility need to 
be addressed as part of the curriculum of overdose prevention training. 
Finally, the authors cite the physical properties (e.g. size, weight) of the Prenoxad 
injectable naloxone kits distributed in Scotland as possible reason for low carriage 
(McAuley et al., 2016). While it is generally assumed that the introduction of non-
injectable naloxone products would lead to higher carriage and usage rates, this has yet 
to be empirically studied. 
Starting in June 2017, I will conduct an electronic survey of potential opioid overdose 
witnesses in the UK and at least four European countries (n=500) with the aim to assess 
naloxone device preference and likelihood of carriage and use among relevant sub-
populations (opioid users, family members, peers, service staff). Naloxone devices 
presented as stimulus material in the survey will comprise ampoules, pre-filled syringes, 
improvised nasal kits, purpose-developed nasal spray (Aptar device, see Chapter 4), 
and the buccal tablet (see Chapter 9). It is anticipated that the results of this survey-
based exploratory study of the naloxone device-user interaction will inform policymakers, 
clinicians, as well as those developing new naloxone medications, regarding which 
naloxone devices will have suitability and acceptability among the sub-populations of 




Despite demonstrable benefits, take-home naloxone remains underused as a public 
health strategy. To date, its distribution has mostly been made possible by community-
based harm reduction organizations with limited central funding. To tackle the rising 
numbers of opioid-related deaths internationally, governments and non-governmental 
organizations will need to provide political leadership and perhaps specific financial 
support to improve the necessary extent of coverage of this potentially life-saving 
intervention. 
Take-home naloxone needs to be embedded into an evidence-based harm reduction 
strategy that promotes access to opioid substitution treatment and clean needles to 






low-threshold intervention, take-home naloxone becomes particularly important where 
opioid substitution treatment is not available or not accessed. Accordingly, its impact on 
opioid overdose mortality is likely greatest among those not enrolled in treatment. 
At the time of submission of this thesis, the prevalence rates of opioid overdose mortality 
in the UK and the US (see Preface) show no signs of slowing down. Politically, both 
countries are at a crossroads. 
The impact of the upcoming UK general election on June 8, 2017 and of Brexit 
negotiations on public health is unknown. It remains to be seen whether a weakening 
currency and changes to existing trade agreements will impact the cost of imported drugs 
and medical equipment, and whether restrictive immigration policies will lead to NHS 
staff shortages (Gulland, 2017; Majeed, 2017; Modi, 2017; Simpkin & Mossialos, 2017). 
If so, such challenges may add to the pressures of ongoing austerity policy that have 
already affected the commissioning of drug treatment services and the lives of patients 
(PHE, 2014). 
In the US, the House of Representatives voted to repeal the [Patient Protection and] 
Affordable Care Act (ACA) on May 4, 2017. The ACA had been signed into law by 
President Obama in March 2010 and included two central provisions that facilitated 
access to opioid substitution treatment (Friedmann, Andrews, & Humphreys, 2017). 
Health insurance coverage was significantly increased through Medicaid expansion as 
well as private insurance, and insurance plans were required to cover treatment for 
opioid use disorder at parity with treatment for medical or surgical procedures. It is 
estimated that by 2016 the ACA had expanded health insurance to close to 700,000 
patients with opioid use disorder (Friedmann et al., 2017). On May 9, 2017, US Secretary 
of Health and Human Services Dr. Tom Price reportedly lauded faith-based programs 
during his visit to West Virginia (Eyre, 2017), i.e. the state with the highest per capita rate 
of opioid overdose mortality (CDC, 2016a), announcing: "If we’re just substituting one 
opioid for another, we’re not moving the dial much. […] Folks need to be cured." On May 
23, 2017, the Trump administration released its 2018 budget request. The budget plan 
seeks to cut funding for the US Centers for Disease Control and Prevention by 17 percent 
(Achenbach & Sun, 2017) and additionally proposes to cut Medicaid funding by US $800 
billion over the next decade (Paletta, 2017). According to the Congressional Budget 







It is uncertain how the UK and US drug treatment landscapes may change in the coming 
years. However, in consideration of the above scenarios, it appears unlikely that the 
need for take-home naloxone will diminish. 
Naloxone was, until recently, only licensed as injection, but its reformulation and the 
arrival of non-injectable naloxone may bring about change and possibly greatly improved 
impact. Concentrated nasal spray offers multiple implementation advantages and has 
the potential to significantly increase community-based naloxone availability, carriage 
rates, and use.  
I hope that the evidence presented in this thesis will reduce barriers to naloxone access 
among those in need and, ultimately, contribute to reducing the number of preventable 
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Sponsors are not required to notify the Committee of approvals from host organisations 
 
Registration of Clinical Trials 
 
All clinical trials (defined as the first four categories on the IRAS filter page) must be registered 
on a publically accessible database. This should be before the first participant is recruited but no 
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opportunity e.g. when submitting an amendment.  We will audit the registration details as part of 
the annual progress reporting process. 
  
To ensure transparency in research, we strongly recommend that all research is registered but 
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A B S T R A C T
Background: Opioid overdose is a major cause of mortality, but injury and fatal outcomes can be prevented by
timely administration of the opioid antagonist naloxone. Pre-provision of naloxone to opioid users and family
members (take-home naloxone, THN) was Trst proposed in 1996, and WHO Guidelines were issued in 2014.
While widespread in some countries, THN is minimally available or absent elsewhere. This review traces the
development of THN over twenty years, from speculative harm reduction proposal to public health strategy.
Method: Medline and PsycINFO were searched for peer-reviewed literature (1990 2016) using Boolean queries:
1) naloxone OR Narcan ; 2) (opioid OR opiate) AND overdose AND prevention . Grey literature and specialist
websites were also searched. Data were extracted and synthesized as narrative review, with key events presented
as chronological timeline.
Results: Results are presented in 5-year intervals, starting with the original proposal and THN pilots from 1996 to
2001. Lack of familiarity with THN challenged early distribution schemes (2001 2006), leading to further test-
ing, evaluation, and assessment of challenges and perceived medicolegal barriers. From 2006 2011, response to
social and legal concerns led to the expansion of THN programs; followed by high-impact research and efforts to
widen THN availability from 2011 to 2016.
Conclusions: Framed as a public health tool for harm reduction, THN has overcome social, clinical, and legal bar-
riers in many jurisdictions. Nonetheless, the rising death toll of opioid overdose illustrates that current THN cov-
erage is insufTcient, and greater public investment in overdose prevention will be required if THN is to achieve
its full potential impact.
1. Introduction
Over the past two decades, take-home naloxone (THN) has moved
from its initial conceptualization as harm reduction measure for pre-
venting opioid overdose deaths to becoming an evidence-based public
health strategy with organized implementation (UNODC/WHO, 2013).
Strong advocacy by local early adopters has enabled emergence of THN
initiatives around the world. In Italy, a harm reduction service on the
outskirts of Turin reportedly provided naloxone access to clients as
early as 1991 (ForumDroghe, 2016). Today, formal THN programs ex-
ist in Australia, Canada, at least nine European countries (EMCDDA,
2016), and the US; as well as pilots in low- and middle-
income countries, including Afghanistan, China, India, Kazakhstan, Kyr-
gyzstan, Russia, Tajikistan, Thailand, Ukraine, and Vietnam (UNODC/
WHO, 2013). The World Health Organization issued new guidelines
for community-based overdose management, suggesting that [p]eople
likely to witness an opioid overdose should have access to naloxone and
be instructed in its administration (WHO, 2014).
Despite these recent advances, dissemination of THN remains re-
markably slow. THN was Trst proposed in 1996, and it was not until the
late 2000 s that serious consideration of THN implementation at state or
national level began.
Opioid overdose continues to account for approximately
68,000 104,000 annual deaths worldwide (UNODC, 2016b), with
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sharp increases reported for the UK (ISD, 2016; ONS, 2016) and US
(CDC, 2016). Many of these deaths could be prevented if THN was
available: A recent analysis of the time course of opiate metabolites
post-mortem found that survival times post-injecting exceeded
20 30 min in the majority of heroin overdose deaths (Darke and DuUou,
2016), suggesting that there is indeed sufTcient time to intervene
(Darke and DuUou, 2016; Tas and McDonald, 2016). However, adequate
intervention is only possible where witnesses recognize the opioid over-
dose. In addition to naloxone supply, it is thus essential for THN pro-
grams to teach awareness of overdose risk factors (e.g., using alone,
street injection), crisis detection (e.g., snoring following opioid use may
signal overdose), interim emergency care aid, and need for continued
care (McAuley et al., 2010; Seal et al., 2005; Strang et al., 2008a).
This brief history chronicles major milestones and events in the
emergence and evolution of THN.
2. Method
2.1. Literature search
The Trst author (RM) searched Medline and PsycINFO for THN-re-
lated peer-reviewed literature published between January 1990 and De-
cember 2016 using the Boolean queries: 1) naloxone OR Narcan ; 2)
(opioid OR opiate) AND overdose AND prevention . Specialist websites
and databases of Public Health England, the European Monitoring Cen-
tre for Drugs and Drug Addiction, US National Institute on Drug Abuse,
and United Nations agencies were also searched for THN-related entries.
Additional materials from the non-peer-reviewed literature were con-
sulted to reconstruct the historical timeline.
2.2. Data extraction and evidence synthesis
THN-related evidence was extracted and synthesized as narrative re-
view by all three authors (RM, NC, JS). Relevant events were considered
according to occurrence in one of four developmental phases of con-
structed quinquennia (with some overlap naturally occurring), which
cover the 20-year period from 1996 to 2016.
3. Results
We present results in four sections which discuss the following
themes. Firstly, we examine formal articulation of the need for THN,
along with preliminary testing and implementation (1996 2001; Sec-
tion 3.1). We then document early THN schemes and challenges
(2001 06; Section 3.2). We then explore new national or state-level
naloxone programs made possible through the identiTcation and re-
sponse to legal concerns (2006 11; Section 3.3). Finally, we review the
emergence of research studies meeting higher evidentiary standards and
examine efforts to widen THN availability (2011 16; Section 3.4). Key
events are also summarized as a chronological timeline (see Table 1).
3.1. 1996-2001 circa: conception, testing the notion, and early
implementation
3.1.1. Original articulation
Naloxone was Trst synthesized and patented in the early 1960s
(Blumberg et al., 1961; Lewenstein and Fishman, 1966) and FDA-ap-
proved in 1971 for intravenous, intramuscular, and subcutaneous ad-
ministration for partial or complete reversal of opioid overdose
(GarTeld, 1983) (see Table 1). Although not the Trst opiate antago
Table 1
Key events in the emergence and evolution of take-home naloxone.
Year Month Country Event
1961 March USA Drs. Jack Fishman and
Mozes J. Lewenstein apply
for Trst US patent for
synthesis of naloxone (issued
in May 1966)
USA Dr. Harold Blumberg and
colleagues publish abstract
in Federation Proceedings in
which he introduces
naloxone as potent, rapid-
acting, and relatively pure
narcotic antagonist.
1962 March UK Sankyo applies for British
patent for naloxone (issued
in October 1963)
Japan Minakami et al. of Sankyo
Company Ltd. Publish Trst
full-length journal article on
naloxone in Life Sciences
1971 USA FDA licenses naloxone as
prescription-only
medication; naloxone enters
clinical practice in Europe in
subsequent years
1983 Int l Naloxone is included in the
1983 WHO List of Essential
Medicines (and subsequent
editions)
1991 Italy Report of community-based
naloxone access in Turin
suburb
1992 March Australia Notion of THN provision to
at-risk populations is mooted
at 3rd International Harm
Reduction Conference in
Melbourne
1996 June UK BMJ editorial by Strang et al.
states home-based supplies
of naloxone would save
lives
ca. June USA Chicago Recovery Alliance
(CRA) distributes Trst THN
kits
Italy Ministry of Health classiTes
naloxone as over-the-counter
medication
Italy Reports of THN distribution
in Padua
1998 September Italy Simini announces plans to
distribute THN in Bologna
and surrounding Emilia
Romagna region in The
Lancet
October UK Island of Jersey starts THN
distribution
1999 January Germany Fixpunkt Berlin starts THN
distribution
March USA San Francisco Needle
Exchange starts THN
distribution
2001 April Germany/UK First published report of
THN distribution by Dettmer
et al. in BMJ
Spain Reports of underground THN
distribution in Barcelona
USA New Mexico launches THN
program
UK Introduction of Trst
mainland THN scheme
(south London)
2002 March USA Dan Bigg of CRA reports Trst
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Table 1 (Continued)
Year Month Country Event
2003 USA San Francisco Public Health
Dept. starts THN program
2004 June USA Lower East Side Harm
Reduction Coalition in New
York starts THN distribution
USA Baltimore launches Staying
Alive Drug Overdose
Prevention Program
2005 November UK Legal status of naloxone
changed to permit
emergency administration of
naloxone by any member of
the general public (Schedule
7 of the Medicines Act)
2006 August USA Boston Public Health
Commission authorizes start
of THN program, including
provision of intranasal
naloxone kits
2006 UK National Treatment Agency
for Substance Misuse (NTA)
funds THN training pilot in
16 sites in England
2007 UK Scotland and Wales establish
THN pilots
2008 UK Medical Research Council
funds N-ALIVE trial
Spain Formal THN program
launched in Barcelona
2010 USA ONDCP National Drug
Control Strategy endorses
community use of naloxone
November UK Scotland launches national
THN program
2011 UK Scottish Lord Advocate
issues new guidelines
UK Wales launches national
THN program
Australia First Australian THN
program starts in Canberra
2012 March Int l UNODC Resolution 55/7
states opioid overdose
treatment, including the
provision of opioid receptor
antagonists such as
naloxone, is part of a
comprehensive approach to
services for drug users
April USA FDA, CDC, NIDA, and HHS
convene naloxone meeting
May UK Advisory Council on the
Misuse of Drugs urges
Department of Health to
review naloxone
prescription-only status
December Australia Naloxone is added to the
Pharmaceutical BeneTt
Scheme
2013 March Denmark THN program starts (dual
kits: intranasal and
injectable)
Estonia Harju and East-Viru counties
start THN distribution
2014 July Norway THN program starts
(intranasal)




Year Month Country Event




October UK Public Health England
release guidelines allowing
drug services to issue THN
without prescription
November USA FDA approves a Trst
naloxone nasal spray product
2016 February Australia Injectable naloxone becomes
available over-the-counter
April Int l UNGASS 2016 includes
naloxone in its scientiTc
summary
October Canada Health Canada approves
naloxone nasal spray product
without prescription
requirement
October USA FDA convenes meeting to
discuss naloxone dosing
standards
nist, naloxone was the Trst largely free of agonist effects. Naloxone be-
came standard rescue medication in emergency management of heroin
overdose in hospital and ambulance settings and has been included in
the WHO List of Essential Medicines since 1983 (WHO, 2011, 2014).
The idea to enable opioid users and/or family and friends to take
naloxone home did not arise until more than two decades after initial
FDA-approval. It was Trst mooted at the 3rd International Harm Reduc-
tion Conference in March 1992 (Strang, 1992, 1993; Strang and Farrell,
1992) as a mere throwaway example of harm reduction alternatives that
were being overlooked. However, the Trst serious consideration of THN
was in the 1996 BMJ editorial (Strang et al., 1996) which identiTed key
elements of the intervention, including provision to: (1) individuals at
high risk of overdose, e.g., those leaving emergency care following over-
dose and those who lost tolerance due to detoxiTcation, incarceration,
or abstinence-based treatment; (2) patients enrolled in treatment pro-
grams (despite treatments protective beneTts, they remain at risk); and
(3) active users.
The editorial also described the poor suitability of existing naloxone
products (ampoules, vials) compared to pre-Tlled syringes and identi-
Ted medico-legal challenges raised by the prospect of third parties, such
as family members, requesting or administering naloxone. Finally, the
editorial urged reconsideration of naloxone s prescription-only medica-
tion status. These central points of the editorial shaped implementation
and research in the subsequent years.
3.1.2. Early implementation
The introduction of THN was made possible through user advocates
working with physicians willing to prescribe naloxone despite medicole-
gal barriers. First THN provision occurred in the late 1990s, in the
United States (Chicago, San Francisco), Germany (Berlin), the UK (Jer-
sey), and Italy (Turin, Bologna, Padua).
3.1.2.1. United States The Chicago Recovery Alliance (CRA) began ob-
taining and distributing naloxone in 1996. Due to high user demand
during a fourfold increase in drug-related deaths from 1996 to 2000,
distribution by mobile van was introduced in 1998 and converted into
a formal training curriculum in 2001 (Bigg, 2002).
During the late 1990s, CRA began discussions with harm reduction
advocates in other places around starting THN-programs and served as
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San Francisco Needle Exchange introduced a small-scale THN pilot
for youth in the Haight-Ashbury district in 1999 (Bigg, 2000; Giuliano,
2000; Seal et al., 2001). The pilot was later scaled up in conjunc-
tion with the DOPE (Drug Overdose Prevention and Education) project
(Giuliano, 2000; Seal et al., 2001) and moved to the San Francisco Pub-
lic Health Department in 2003.
In 2000, the Drug Policy Alliance (formerly Lindesmith Center) part-
nered with the University of Washington Alcohol and Drug Abuse Insti-
tute to explore pragmatic approaches to Preventing Heroin Overdose,
which included sessions on naloxone distribution.
3.1.2.2. Continental Europe Multiple sources point to largely undocu-
mented early community-based naloxone availability in parts of Italy,
notably Turin (1991) and the Emilia Romagna region (incl. Bologna,
1998) (ForumDroghe, 2016; Simini, 1998).
There were reports of THN distribution in Padua in 1996, where
a methadone clinic distributed 150 naloxone vials within 18 months.
While overdose deaths decreased citywide, there was no formal evalua-
tion of THN usage (Schifano, 2001).
Two pilot schemes in Berlin and the British island of Jersey (Dettmer
et al., 2001) constitute the Trst published outcomes report on THN pro-
vision. Between 1998 and 2000, 101 clients of a community-based drug
clinic in Jersey were trained in overdose management and received THN
kits, with Tve reported overdose reversals (Dettmer et al., 2001). In
Berlin, THN was introduced at a mobile needle and syringe exchange
scheme ( Fixpunkt ) in 1999. Within 16 months, 124 THN kits had
been issued; 22 users reported administering naloxone for a total of 29
overdose reversals (Dettmer et al., 2001). The article attracted support
but also sharp criticism (Ashworth, 2001; Blackwood, 2001; Mountain,
2001), noting low response rate and the lack of systematic follow-up,
objective mortality data, and risk assessment concerns echoed in the
THN debate throughout the 2000s. The Berlin pilot was discontinued af-
ter 2002 due to lack of funding (AIDS-Hilfe, 2013; Dettmer, 2014).
3.1.3. Testing the notion: is the intervention necessary?
Several studies in the late 1990s and early 2000s identiTed situa-
tions in which naloxone should be made available:
3.1.3.1. Injecting use In a London-based community sample of heroin
users, the vast majority of reported overdoses occurred among injec-
tion users (Gossop et al., 1996). Injecting bears a much higher risk of
fatal overdose than chasing the dragon (i.e., inhalation following sub-
limation with heat) (Strang et al., 1997), snorting or oral use. (It was
later estimated that one in four injecting drug users would experience
an overdose each year (Darke et al., 2003)).
3.1.3.2. Return into the community An inUuential early study by
Seaman et al. (1998) identiTed the period following release from
prison as the most striking high-risk situation, with within two weeks
of release (Bird and Hutchinson, 2003). (The Tnding of increased risk
up to four weeks post prison release was subsequently quantiTed as 1
in 200 prisoners with history of heroin use dying from opioid overdose
in the Trst two weeks post-release and was replicated internationally
(Merrall et al., 2010). Similar but less intense concentrations of over-
dose deaths were subsequently also observed among patients complet-
ing in-patient detoxiTcation (Strang et al., 2003), residential rehabilita-
tion (Davoli et al., 2007), and hospital/residential treatment (Merrall et
al., 2013; Ravndal and Amundsen, 2010)).
3.1.3.3. Opioid agonist treatment The Trst weeks on oral methadone
treatment were found to be associated with a transient increase in risk
of overdose death (Caplehorn, 1998; Caplehorn and Drummer, 1999).
3.1.4. Testing the notion: is the intervention acceptable for those involved?
Parallel to early THN implementation, research assessed the feasibil-
ity and acceptability among users, carers and providers.
3.1.4.1. Opioid users The 1996 BMJ editorial identiTed opiate users as
the primary target group for THN because they are at risk of future
overdose themselves and highly likely to witness and intervene in
someone else s overdose. Users have expressed strong support of THN.
A London-based survey of injecting drug users (Strang et al., 1999) es-
timated that two-thirds of witnessed overdose deaths could have been
avoided with THN. Most respondents had already witnessed at least
one overdose; 89% expressed willingness to administer naloxone in the
event of an overdose; 70% agreed with the proposal that naloxone
should be provided; and nearly 90% of those who had witnessed an
overdose stated that they would have used the medication had it been
available. Subsequent interview studies identiTed opioid users willing-
ness to be trained in overdose management and naloxone administra-
tion (Bennett and Higgins, 1999; Strang et al., 2000).
3.1.4.2. Carers Most opiate overdoses occur at private homes and/or
in presence of peers, family members, and partners (Best et al., 2002;
McGregor et al., 1998). Constituting a potential intervention resource,
close contacts of users are thus the second target group for THN and
training.
3.1.4.3. Health care providers An early US legal analysis (Burris et al.,
2001) found that providers risk of malpractice liability associated with
prescribing THN was no greater than for general health care provision.
Prescribing THN to an at-risk patient for administration by a trained
partner/family member is analogous to the pre-provision of anti-epilep-
tic medication or injectable adrenaline/epinephrine (EpiPen). How-
ever, in situations where naloxone is being prescribed without speciTc
knowledge of who will administer or be administered naloxone, the le-
gal situation becomes murky.
US providers voiced strong concerns over uncertain medico-legal sta-
tus and potential liability issues and expressed anxieties about patients
deputation as health care providers when injecting naloxone (Burris
et al., 2001). Around the same time, Australian providers and service
users alike raised concerns about civil or criminal liability (Lenton and
Hargreaves, 2000).
3.1.5. Thinking at the national level
In 2000, THN provision received an early public endorsement by the
UK Advisory Council on the Misuse of Drugs (ACMD, 2000) who stated:
Our view is that, as a matter of principle, naloxone should be made
more widely available (that is beyond hospital, paramedic and ambu-
lance settings) [ ] . The statutory advisory body gave clear direction
on the need for: (1) enhanced attention to effective overdose manage-
ment by emergency medical services, including authorization of lower
grades of ambulance staW to administer naloxone; (2) uniform agree-
ment that an overdose is primarily a medical emergency (which or-
dinarily should not involve police attendance); (3) treatment agencies
to be teaching overdose management, (4) naloxone to be widely given
to friends and partners of drug users, (5) naloxone provision to be ex-
tended to prisons and police stations for use by trained staW.
The vision articulated in the ACMD report would shape the naloxone
policy debate up to the present (see Table 2).
3.2. 2001–2006 circa: modest progress amidst concerns over the safety and
legality of the intervention
Following the pioneering CRA program, early adopters in the United
States included New Mexico, which began THN distribution in early
2001 (Baca and Grant, 2005).
In 2004, the Baltimore Staying Alive Drug Overdose Prevention
Program was launched, sponsored by the Baltimore City Health De-
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Table 2
| Key statements from the 2000 UK ACMD report, as they relate to target audiences in-




We believe that heroin and other opioid users, who are
most likely to be witnesses to their friends' overdoses,
should be given guidance on what to do in those
circumstances. (p. 80)
[N]aloxone should be made more generally available,
for example, to those who are likely to witness opioid
overdoses. This would involve a supply of the drug being
kept at home, and advice being given to friends and
partners of the drug users on its emergency use. (p. 80)
If it was accepted that this wider availability of
naloxone was desirable there would be a need to ensure,
through training, that the drug was administered
correctly and in the right circumstances; that it was seen
only as part of a larger resuscitative response; that fresh
supplies were regularly introduced; and that proper
arrangements were in place for its prescription, including
to whom it might be administered. (p. 81)
Primary care SpeciTc interventions available to primary care include
[ ] response to overdoses (p. 78)
Emergency
Departments
[H]ospitals should satisfy themselves that the
arrangements [for staW training or treatment protocols]
[for treating opioid overdoses] [in A & E departments]
are satisfactory. (p. 79)
[T]he fact that [A&E departments] see overdosers who
have not died and who are subsequently discharged, is
an opportunity which we think must be exploited more
vigorously. Many such attenders are repeat attenders.
(p. 78)
Ambulance/Police Our view is that a call to a person who has overdosed
should be regarded by the ambulance and police services
as a medical emergency in the Trst instance, rather than as
a call to the scene of a crime. It follows that we do not
believe that ambulance services should, as a matter of
course, inform the police when they are called to a drug
overdose. (p. 79)
We think it is probably unrealistic to expect police
forces to give a blanket guarantee that witnesses to an
overdose will not be prosecuted if oVcers attend. On the
other hand, we think that should be the general
presumption. (p. 79)
Police/Prisons [N]aloxone might also be made available to prison
healthcare staW. And it should be kept at police stations
which have custody suites for emergency use by medical
staW and other trained personnel. (p. 80)
Reduction Coalition in New York conducted a pilot, which was ex-
panded to all city-funded Syringe Exchange Programs in 2005 (Heller
and StancliW, 2007).
In Europe, there were reports of THN distribution in Barcelona as
early as 2001 (Trujols, 2001). In mainland UK, THN was Trst introduced
in South London in mid-2001 (Strang, 2001).
3.2.1. Training opioid users and their family members
In the Trst published evaluation of THN training, Seal et al. (2005)
assessed knowledge of overdose management by asking participants
to name risk factors, signs of overdose, and overdose prevention and
management strategies. A significant increase in knowledge was main-
tained at 6-month follow-up (Seal et al., 2005). Despite willingness
to participate in THN training, opioid users also expressed concerns
about THN, such as fear of experiencing withdrawal symptoms, en-
abling further drug use, risk of blood-borne virus infection, and po-
tentially having to manage agitation and hostility in those revived
(Kerr et al., 2008; Seal et al., 2003; Worthington et al., 2006). Ser-
vice users also expressed concerns about the risk of conTscation of
the antidote and its potential role in
escalating already delicate relationships with law enforcement (Seal et
al., 2003; Worthington et al., 2006).
In an England-based postal survey (Strang et al., 2008b), the major-
ity of family members expressed strong interest in THN training.
3.2.2. Providers’ concerns
Support was weak in the drug treatment Teld, where the debate
was dominated by legal and safety concerns. Providers questioned users
competency in naloxone administration and pointed to the risk of unsafe
needle disposal (Ashworth, 2006; Byrne, 2006; Tobin et al., 2005). Even
though an early survey of drug users had found that THN was unlikely
to lead to increased heroin consumption (Strang, 1999), a common con-
cern among providers was potential promotion of drug use (Ashworth,
2006; Tobin et al., 2005). Negative attitudes were revealed in surveys
of Baltimore-based emergency service providers (Tobin et al., 2005)
and physicians throughout the US who were likely involved in treat-
ment of opioid users (Beletsky et al., 2007): most believed THN would
not reduce drug-related deaths and reported they would never consider
prescribing naloxone. A notable exception was a postal survey of New
York-based clinicians of whom over a third were willing to prescribe
naloxone (CoVn Fuller et al., 2003).
3.3. 2006–2011 circa: identiEcation of legal pathways for take-home
naloxone and Erst national and state-wide programs
3.3.1. Responses to legal barriers
Because THN has come about so recently, most medico-legal barri-
ers to it were unintended consequences of prior legislation passed for
other purposes (NPHL, 2016). About ten years after the original THN
proposal, some jurisdictions began to pass laws to facilitate THN imple-
mentation. Policies are typically of two kinds: those that enable nalox-
one access via broad standing orders, or those that amend Good Samar-
itan legislation to extend immunity beyond physicians to Trst respon-
ders, bystanders, or witnesses who extend care in emergency situations.
3.3.1.1. United Kingdom In 2005, naloxone was incorporated into the
Schedule 7 of the UK Medicines Act which allows any member of the
general public to administer naloxone with the aim of saving a life,
thereby placing naloxone alongside glucagon, adrenaline and snake an-
tivenin (Strang et al., 2006). Naloxone could then lawfully be given by
a witness to an overdose victim to whom it was not prescribed, open-
ing doors to naloxone administration by layperson Trst-responders. At
least 16 sites then implemented THN pilots in England (NTA, 2011).
However, naloxone remained a prescription-only medication. Hence
the UK Department of Health Orange Guidelines' (DOH, 2007) stated:
“naloxone […] must be prescribed to named patients or supplied to an indi-
vidual by means of a patient group direction [PGD].”
3.3.1.2. United States Naloxone is a prescription-only-medication at the
federal level, although there is considerable variation due to state-level
legislation and lower-court rulings. New Mexico became the Trst state
to remove legal barriers to THN prescribing and distribution in 2001
(Alcorn, 2014) and to grant legal immunity to bystanders via a Good
Samaritan law in 2007. New York and Connecticut followed with laws
that granted immunity from civil liability to healthcare providers with
prescribing authority (Sporer and Kral, 2007).
Established in 2006, the Massachusetts THN pilot program used a
standing order to enable public health care workers to provide THN
without a prescription (Doe-Simkins et al., 2009). The standing order
model allows a lead physician within a given jurisdiction to issue a writ-
ten order that naloxone can be distributed by designated pharmacists or
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At the end of the 2000s, there were fewer than three dozen THN pro-
grams in the US, but the standing order model would lead to a dramatic
increase in the following years (OSF, 2013).
3.3.2. First national and state-wide programs
In the late 2000s, Trst THN programs expanded coverage from a lo-
cal to a state-wide or national level.
3.3.2.1. Catalonia Following earlier underground distribution of nalox-
one, the public health agencies of Barcelona and the autonomous re-
gion of Catalonia formally launched a THN program in 2008 which al-
lowed staW and clients of participating sites to receive training
(EMCDDA, 2016).
3.3.2.2. Scotland Three local pilots were launched in Glasgow, Lanark
and Inverness during or after 2007 using the authority of PGDs for
nurses and paramedical staW to issue THN (McAuley et al., 2012). In
2011, the Scottish Procurator Fiscal issued a Letter of Comfort , grant-
ing immunity to pharmacists who supplied naloxone without prescrip-
tion to staW working at services with a high rate of overdoses (e.g., hos-
tels) (Angiolini, 2011). These so-called Lord Advocate s guidelines
thus permitted naloxone storage in non-medical facilities for emer-
gency use (ACMD, 2012).
The Scottish National Programme was launched in November 2010
(McAuley et al., 2012) and involves THN distribution in the community
and to prisoners on release. Services can issue THN to staW, persons at
risk of overdose, family members, and peers (with documented consent
of the person at risk). The Scottish government funded the program cen-
trally up until 2016. Over the years, the Scottish National Programme
would distribute over 20,000 THN kits (McAuley et al., 2017) − ap-
proximately 90% in the community and 10% to prisoners on release
(ISD, 2016).
3.3.2.3. Wales Following the 2007 introduction of a THN pilot
(Bennett and Holloway, 2011, 2012), Wales launched a national nalox-
one program in 2011. Between mid-2009 and early 2014, 4579 THN
kits were issued and reportedly used in 375 overdose events
(McDonald et al., 2016).
3.3.2.4. Massachusetts The Massachusetts Department of Public Health
has conducted the most comprehensive US program evaluation to date.
Boston-based harm reduction activists began THN distribution in the
early 2000s without formal approvals and documented the number of
naloxone vials distributed and overdose events reversed in a 2005 let-
ter to the mayor of Boston who facilitated a joint meeting between the
activists and the Department of Public Health. As a result, Boston Pub-
lic Health Commission authorized development of a THN program via
its mobile needle-exchange scheme in 2006. The Massachusetts THN
program was the Trst to involve distribution of intranasal naloxone and
to allow non-medical public health workers to issue naloxone. By 2009,
the Massachusetts Department of Public Health had expanded the pro-
gram to seven more communities, operating out of needle-exchange
sites, methadone clinics, homeless shelters, inpatient detoxiTcation
programs, community meetings, outpatient and residential addic-
tion-treatment programs, and emergency departments. By 2014, the
Massachusetts THN program had trained 4926 drug users, of whom
373 reported administering naloxone (Doe-Simkins et al., 2014).
3.4. 2011–2016 circa: emergence of stronger data, alternative
implementation models, and recent eForts to widen naloxone access
By the 2010s intervention studies typically reported the number of
overdoses reversed with naloxone as a central outcome; high nalox-
one usage rates conTrmed the trainability of heroin users to ade-
quately respond to overdose (Green et al., 2008; Lopez-Gaston et al.,
2009; Markham-Piper et al., 2008; McAuley et al., 2010; Strang et
al., 2008a; Tobin et al., 2009; Wagner et al., 2010). A systematic
review of naloxone usage rates found that, for every 100 opioid users
trained and supplied with THN, 9% of THN kits are likely used for over-
dose reversal within the Trst three months post-training (McAuley et al.,
2015). However, methodological limitations such as small sample sizes,
uncontrolled designs, lack of randomization and systematic follow-up
made it difTcult to quantify the impact of THN provision on overdose
mortality.
3.4.1. A growing evidence base
In 2012, the United Nations Commission on Narcotic Drugs passed
Resolution 55/7 (UNODC, 2012), which identiTed need for more ef-
fective prevention of drug overdose, and [e]ncourage[d] all Member
States to include effective elements for the prevention and treatment of
drug overdose, in particular opioid overdose, in national drug policies,
[ ], including the use of opioid receptor antagonists such as naloxone.
The same year, the Trst large-scale randomized trial of THN (N-ALIVE)
started recruitment (see Section 3.4.3) (Strang et al., 2013).
In 2013, two cost-effectiveness analyses presented modelling data
from the United States and Russia, concluding that THN was cost-ef-
fective even when the cost of naloxone increased and the rate of ob-
served overdoses decreased (CoVn and Sullivan, 2013a; CoVn and
Sullivan, 2013b). Another 2013 study addressed the impact of THN pro-
vision on local overdose rates using an interrupted-time series analysis,
Tnding that Massachusetts-based communities with THN provision had
significantly lower overdose mortality rates than communities without
(Walley et al., 2013).
Regarding the safety of THN, common concerns were whether THN
availability would promote drug use and whether the short half-life of
naloxone would result in rebound overdose after the initial dose wore
oW. A large US retrospective cohort study (n = 4926) concluded that
THN provision did not lead to increased heroin use (Doe-Simkins et
al., 2014). Previously, a Danish study had found that death from (pre-
sumed) rebound overdose toxicity occurred only in 3 out of 3245 cases
of naloxone administration (Rudolph et al., 2011).
A waiting-list randomized trial (Williams et al., 2014) of THN train-
ing demonstrated good improvements in the knowledge and compe-
tence of carers in overdose management, which were maintained at
3-month follow-up − thus conTrming the trainability of potential over-
dose witnesses in the community.
These results were among the key evidence included in a WHO re-
view of community-based naloxone, which led to the November 2014
launch of the WHO Guidelines on the Community Management of Opi-
oid Overdose (WHO, 2014).
The key recommendation was that [p]eople likely to witness an opi-
oid overdose should have access to naloxone and be instructed in its ad-
ministration (WHO, 2014). Subsequently, a BMJ editorial argued that
there is [n]ow enough experience to justify [THN implementation]
(Strang et al., 2014).
Following release of the WHO Guidelines, three systematic reviews
(Clark et al., 2014; EMCDDA, 2015; McDonald and Strang, 2016)
reached similar conclusions. The EMCDDA (2015) concluded: there
is evidence that educational and training interventions with provision
of take-home naloxone decrease overdose-related mortality (p. 11).
Likewise, Clark et al. (2014) found that participation in THN pro-
grams led to improved overdose-related knowledge and appropriate
use and administration of naloxone. However, the authors (Clark et
al., 2014) also reported that the rate of ambulance calls during over-
dose events was below 50% in 6 out of 9 studies, which appeared
to substantiate the concern that THN might discourage users from
calling an ambulance. (This concern was later refuted by McAuley
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from the Scottish National Naloxone Programme found no association
between the supply of take-home naloxone kits and the number of am-
bulance call-outs). The most recent systematic review (McDonald and
Strang, 2016) assessed the safety of THN programs as well as their im-
pact on opioid overdose-related mortality. Evidence from 22 observa-
tional studies was evaluated using the nine Bradford Hill criteria (Hill,
1965), devised to assess a potential causal relationship between pub-
lic health interventions and clinical outcomes when only observational
data are available. The analysis conTrmed that THN programs met all
nine Bradford Hill criteria, reduced overdose mortality among program
participants and in the community, and had a low rate of adverse events
(McDonald and Strang, 2016).
Finally, in April 2016, the United Nations General Assembly Spe-
cial Session on Drugs (UNGASS 2016) included naloxone distribution
to prevent overdose deaths associated with opioid use as example of
evidence-based strategies in its scientiTc summary (UNODC, 2016a).
3.4.2. Dissemination and expansion
3.4.2.1. Australia Despite immediate endorsement of the original THN
proposal by Australian researchers (Darke and Hall, 1997; Fry et al.,
2000; Lenton and Hargreaves, 2000), funding for an early naloxone
trial in Victoria was affected by the 2000 Australian heroin drought
(Dietze, 2016). Intranasal naloxone was explored in ambulance-based
trials (Kelly et al., 2005; Kerr et al., 2009), but THN was halted by
medico-legal concerns.
Following the emergence of Tndings from THN schemes overseas,
Australian researchers reiterated the case for THN (Dietze and Lenton,
2010; Lenton et al., 2009), which ultimately led to the launch of I-EN-
NAACT, the Trst Australian THN program in Canberra, in late 2011.
A preliminary evaluation in late 2014 showed that over 200 inject-
ing drug users had been trained in overdose prevention (including 18
inmates) and reported 57 successful overdose reversals (Dietze, 2016).
Naloxone access in Australia was facilitated by the 2012 addition of the
antidote to the government Pharmaceutical BeneTt Scheme which sub-
sidizes prescription drugs. Australian residents can now obtain nalox-
one at a concession rate of AUD 5.90, rather than the previous AUD
60 (Fowlie, 2013). The Australian Medical Association endorsed THN in
2013 (Anex, 2013). THN scale-up in New South Wales is currently un-
derway (Dietze, 2016).
3.4.2.2. Continental Europe In the early 2010s, several northern Euro-
pean countries launched THN projects: Denmark and Estonia in 2013,
with Norway following in 2014 and Ireland in 2015 (EMCDDA, 2016).
3.4.2.3. United Kingdom In 2012, ACMD urged the Department of
Health to review naloxone s prescription-only status (ACMD, 2012).
Triggered by this request, the Medicines and Healthcare Products Reg-
ulatory Agency (MHRA) released a consultation in 2013, asking for
feedback on a proposal to increase community-based naloxone access
(MHRA, 2013). Thus, new UK legislation was passed in late 2015
which explicitly enabled wider availability to drug users, family mem-
bers, other carers, and staW working in relevant treatment and social
care agencies. New Public Health England (PHE) guidelines exempted
naloxone from the usual prescription requirement when it is supplied
by a drug service commissioned by a local authority or NHS (PHE,
2015).
3.4.2.4. United States Amid growing public support, organizations in-
cluding the US Conference of Mayors, the American Medical Associa-
tion, the American Public Health Association, and the National Associa-
tion of Boards of Pharmacy urged states to remove legal barriers to
THN (Alcorn, 2014; NPHL, 2016). As of June 2016, forty-eight states
had amended laws to relieve provider liability when pre
scribing or dispensing naloxone, and thirty-seven states had passed
Good Samaritan laws (Burris et al., 2001; DOJ, 2014; NPHL, 2014,
2016). Sustainability has been achieved in several states (CDC, 2012).
As of mid-2014, 136 THN programs were providing naloxone kits
to laypersons at 644 sites across the country (CDC, 2015), with pro-
grams operated by community-based organizations, public health de-
partments, and Veterans Health Administration facilities (Humphreys,
2015). Between 1996 and mid-2014, naloxone kits had been supplied to
a total of 152,283 clients who reported 26,463 overdose reversals (CDC,
2015). Among these cases, CRA alone reported training and providing
naloxone kits to a total of 36,708 individuals, with 5767 peer overdose
reversals (CRA, 2014).
3.4.3. Exploration of new settings and workforces
Community-based harm reduction teams have been the default re-
source for THN provision, with users and their primary carers the main
target populations. The CDC survey (2015) of current THN programs
in the US reported that most program participants are people who use
drugs (82%), with friends and family members being the second most
common group (12%). Over the past Tve years, researchers have sought
to study whether expansion of the THN intervention to new settings and
workforces could enhance its impact.
3.4.3.1. Police and EreEghters In the US, several jurisdictions have
passed legal provisions to authorize nonmedical Trst responders to ad-
minister naloxone (Banta-Green et al., 2013). In 2010, Massachusetts
was the Trst state to pioneer equipping TreTghters and police with
naloxone (Davis et al., 2014), and the Obama administration s National
Drug Control Strategy (ONDCP, 2010) urged training of law enforce-
ment professionals and TreTghters in how to recognize an overdose
and [in] how to administer [ ] naloxone.
Law enforcement ofTcers can be successfully trained to respond to
overdose (Saucier et al., 2016; Wagner et al., 2016).
Over 220 law enforcement agencies across 24 U.S. states carry nalox-
one (Davis et al., 2015). Equipping Ohio police with naloxone nasal
spray was associated with a decline in opioid overdose deaths (Rando et
al., 2015). A New York-based program reported over 100 overdose res-
cues within a year (NYAG, 2015).
Law enforcement ofTcers generally expressed willingness to receive
training in overdose management and naloxone administration
(Banta-Green et al., 2013; Ray et al., 2015; Wagner et al., 2016). How-
ever, a Seattle-based study found law enforcement ofTcers' knowledge
of a Good Samaritan law to be low (Banta-Green et al., 2013). Further-
more, training did not impact law enforcement ofTcers' mixed attitudes
toward opioid users (Banta-Green et al., 2013; Wagner et al., 2016).
Geographical disparities have also been revealed, with naloxone equip-
ment of emergency responders being more common in urban than rural
settings (Rando et al., 2015).
3.4.3.2. Primary care Despite extensive contact with opioid users and
favorable attitudes towards wider naloxone availability, many
providers have remained wary of providing THN (Barry et al., 2017;
NPHL, 2014). US primary care providers described insufTcient time
during patient appointments and inability to follow up with patients as
main organizational barriers to THN (Binswanger et al., 2015). Cana-
dian primary care providers considered existing naloxone guidelines in-
adequate and identiTed the lack of user-friendly naloxone devices, suf-
Tcient funding and training as central barriers to THN provision (Leece
et al., 2015). Scottish primary care providers reported low awareness
of the national THN program, pointing to their need for training
(Matheson et al., 2014).
However, a San Francisco-based project of naloxone co-prescrib-
ing for primary care patients receiving long-term opioid pain therapy
established that the intervention was feasible, acceptable to patients
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related emergency department (ED) visits at 1-year follow-up (CoVn et
al., 2016).
3.4.3.3. Emergency care The Massachusetts THN program provides
THN at EDs, and feasibility has recently also been explored elsewhere.
A British Columbia survey of ED patients at risk of opioid overdose
(Kestler et al., 2017) found that two-thirds accepted THN kits when of-
fered to them at the ED, highlighting the potential of this setting for
overdose prevention.
3.4.3.4. Pharmacy-based provision In pharmacy-based THN provision,
pharmacists take on a dual role: a) monitoring patients opioid pre-
scriptions and assessing their risk of opioid use disorder as well as b)
expansion of naloxone access (Green et al., 2015b; Penm et al., 2017).
Since October 2015, UK pharmacies providing supervised opioid substi-
tution treatment can supply THN without prescription to individuals
likely to witness an opioid overdose provided the [naloxone] supply is
suitably recorded (PHE, 2015). As of August 2016, US pharmacists
can prescribe naloxone in 5 states and dispense naloxone via standing
orders in forty-two states (Davis and Carr, 2017). Pharmacy-based pro-
vision has been piloted as a strategy to promote naloxone access in
rural areas (Green et al., 2015b) and increased dramatically in the US
since 2013 (Jones et al., 2016). However, pharmacists willingness to
dispense THN varies (Freeman et al., 2017) and patients and carers re-
port stigma of THN receipt (Green et al., 2017).
3.4.3.5. Peer-led provision Peer-led naloxone supply is becoming more
common. In the UK, (former) service users can be employed or en-
gaged in drug treatment services and supply naloxone to potential
overdose witnesses as of October 2015 (PHE, 2015). A Canadian inter-
view study with peer-trainers identiTed the wish to help others as key
motivation and found psychological beneTts associated with the
peer-trainer role, including a sense of recovery and empowerment
(Marshall et al., 2017).
3.4.3.6. Prison release THN provision on prison release was the focus of
the N-ALIVE randomized trial in England and Wales, which assessed its
impact on overdose mortality in the month post-release (Bird and
Hutchinson, 2003; Farrell and Marsden, 2008; Strang et al., 2013).
N-ALIVE pilot with its target recruitment of 2800 subjects yielded a
marked decrease in opioid-related deaths, a subsequent large-scale trial
involving 28,000 prisoners on release was scheduled. However, the pi-
lot was ended prematurely in December 2014 (total enrolment: 1685
subjects) (Parmar et al., 2017) after the SNNP showed a significant re-
duction in the proportion of opioid-related deaths in the month follow-
ing prison release. Among Scottish prisoners supplied with THN, mor-
tality decreased to 4.7% by 2013, compared with the pooled 2006 10
baseline of 9.8% (ISD, 2014). Since program start in 2011, heroin-re-
lated deaths within 4 weeks of prison release gradually decreased every
year, coinciding with a steady increase in the volume of THN kits (Bird
et al., 2016; Bird et al., 2015). Prison-based THN has also been intro-
duced and studied in New York City, California, and Rhode Island
(Green et al., 2015a; Jordan, 2015; Rosner, 2015).
3.4.4. EForts to widen availability of naloxone
Since 2015, significant developments have widened naloxone access
through a variety of mechanisms, including reformulation of the prod-
uct.
3.4.4.1. Non-injectable naloxone Naloxone s exclusive availability as
formulated for injection is one of the main barriers to wider use, as cer-
tain jurisdictions restrict the administration of injections to medical
professionals (EMCDDA, 2016). Injectable naloxone is not ideal for
layperson use and can present a twofold barrier to THN implementa-
tion: on a clinical level, carriage rates for injectable naloxone have
been found to be below 20% (McAuley et al., 2016). Laypersons who
witness overdose events may be less likely to intervene and
administer an injection for lack of familiarity with needle-and-syringe
assembly or for fear of needle-stick injury and potential risk of contract-
ing blood-borne diseases (e.g., hepatitis C, HIV) (Wermeling, 2013).
Improvised nasal naloxone kits consisting of a 2 mg/2 ml pre-Tlled
syringe with a nasal mucosal atomizer device were Trst provided in the
Massachusetts THN program in 2005 (Doe-Simkins et al., 2009). Since
the preTlled naloxone syringe is approved only for injectable use, the
improvised nasal kits represent oW-label or oW-license use (Strang et al.,
2016b). The improvised nasal kits were later introduced elsewhere in
the United States, Denmark, Norway, and Scotland s Highland region.
The Norwegian THN program distributed 2056 nasal kits between
program start in mid-2014 and late 2015, with 277 overdose reversals
reported (Madah-Amiri et al., 2017). The Danish THN kits are unique in
that they contain both the mucosal atomizer device for nasal adminis-
tration and a needle for intramuscular injection in case of non-response
to the nasal spray (EMCDDA, 2016).
According to a survey of 136 US-based THN programs, 51% pro-
vided only injectable naloxone, 37% provided only improvised nasal
kits, and 12% provided both (CDC, 2015).
In 2012, a step-change occurred in the U.S. with the joint initiative
of the Food and Drug Administration (FDA), Centers for Disease Con-
trol and Prevention (CDC), and National Institute on Drug Abuse (NIDA)
to encourage new non-injectable naloxone formulations, alongside FDA
clariTcation of the regulatory benchmark: one or multiple doses of any
new non-injectable formulation would need result in similar or greater
naloxone exposure than the reference product of intramuscular nalox-
one 0.4 mg (Hertz, 2012). A systematic review identiTed nasal, buccal
and sublingual naloxone delivery as the three viable routes for naloxone
administration in an overdose emergency, of which study of the nasal
route was most advanced (Strang et al., 2016a).
Prior to the 2012 FDA initiative, only one patent application (WO/
2012/156317) for non-injectable naloxone containing human in-vivo
data had been Tled, highlighting very limited investment from phar-
maceutical industry. With injectable naloxone-hydrochloride solution
available as generic and oW-patent medication, naloxone was of limited
commercial value. Moreover, as an antidote, naloxone is only prescribed
for emergency use (unlike e.g., medications for opioid substitution ther-
apy), and its per-patient sales volume limited accordingly.
When NIDA announced that it would fund development of
user-friendly naloxone delivery systems (Volkow et al., 2014), indus-
try interest Tnally appeared. Two companies Tled separate New Drug
Applications for nasal naloxone in 2015, of which only one product
was FDA-approved later that year. This concentrated nasal spray prod-
uct (4 mg/0.1 ml) has a promising pharmacokinetic proTle with good
bioavailability (Krieter et al., 2016). Whether it can improve commu-
nity-based naloxone availability remains to be seen.
3.4.4.2. Over-the-counter naloxone Until recently, Italy was the only
country where naloxone was available without a prescription. In 1996,
the Italian Ministry of Health classiTed naloxone as an over-the-
counter medication, allowing pharmacists to issue naloxone without a
prescription (Senza Obbligo di Prescrizione) (ForumDroghe, 2016, 2017;
Lenton and Hargreaves, 2000; WHO, 2014). However, naloxone cannot
be publicly displayed on shelves to which customers have direct access.
Customers must request naloxone directly from the pharmacist. While
no causal conclusions may be drawn, the 1996 introduction of
over-the-counter status was succeeded by a gradual decline in opioid
overdose mortality rates in Italy, with 470 deaths in 1999, 280 in
2005, and 101 in 2015 (ForumDroghe, 2016, 2017). As of 2016, 57
Italian harm reduction services distribute THN, but there are stark re-
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in the major metropolitan areas (i.e., Rome, Milan, Bologna, Turin,
Naples). Some regions are without THN coverage, which has been
linked to the lack of a national harm reduction policy and insufTcient
investment (ForumDroghe, 2016).
Although THN was only introduced in Australia in 2011, Australia
became the second country to have naloxone formally available
over-the-counter, following the decision of the Therapeutic Goods Ad-
ministration to place naloxone when used for the treatment of opioid
overdose on Schedule 3, thereby approving over-the-counter (OTC) sta-
tus (Lenton et al., 2016). Since early 2016, Australian community phar-
macists have been able to supply naloxone without a prescription.
In Canada, THN programs exist in seven of the 13 provinces and ter-
ritories, with large programs in British Columbia (120 sites, 6389 kits
distributed) and Ontario (22 sites, 2734 kits distributed) (CCSA, 2016).
In 2016, Health Canada approved the previously FDA-licensed nasal
naloxone product and issued an interim order to make the spray avail-
able without a prescription (CBCnews, 2016).
Select U.S. pharmacies in at least 15 states have special practice
agreements allowing pharmacists to sell naloxone (incl. the FDA-ap-
proved nasal spray) without a prescription (EMCDDA, 2016). However,
it is unclear if or how soon formal re-classiTcation of naloxone from pre-
scription-only medicine to over-the-counter status may occur. An earlier
legal analysis suggested this regulatory process might be lengthy and
cost-intensive (Burris et al., 2001), as FDA would require additional data
demonstrating the ability of laypersons without medical training to cor-
rectly diagnose an overdose and administer the formulation (Compton
et al., 2013; FDA, 2012).
In the UK, the 2015 PHE guidelines allow people engaged or em-
ployed in NHS drug treatment services to make THN available to opi-
oid users, family members, and hostel staW without prescription, pro-
vided the naloxone supply is documented accurately (PHE, 2016). Even
though naloxone technically remains a prescription-only medication,
the guidelines reduce the staVng burden for THN as staW without pre-
scribing authority can issue THN for emergency use.
3.4.4.3. Calls for universal THN provision Beyond lack of funding or po-
litical support, low prescriber awareness and commitment persist as
central barriers to wider THN access. Despite evidence of effectiveness
and endorsements from professional organizations (ACMD, 2000, 2012,
2016; AMA, 2012), many providers fail to integrate THN into standard
care for at-risk patients. Dissemination was found to be difTcult even
among addiction treatment staW (Mayet et al., 2011) with the antici-
pated cascade of the train-the-trainer-model occurring at the disap-
pointing pace of one drug user trained per clinician trainee in on aver-
age 11 months.
Providers struggle with competing clinical demands, making opt-in
medical services low priority. A more proactive approach whereby THN
was routinely prescribed to all at-risk patients unless patients declined
( opt-out system) would likely increase coverage.
An international treatment target similar to the UNAIDS (Joint
United Nations Program on HIV/AIDS) 90-90-90 test and treat strat-
egy (introduced to help end the AIDS epidemic) (UNAIDS, 2014) could
potentially improve naloxone access in countries affected by opioid-re-
lated mortality. Researchers estimate that target naloxone distribution
should exceed 100 kits per 100,000 population (Walley et al., 2013) or
at least nine times as many naloxone kits as there are annual opioid-re-
lated deaths to impact opioid mortality (Bird et al., 2015; Madah-Amiri
et al., 2017).
4. Discussion
4.1. Strengths and limitations
This narrative review represents the Trst peer-reviewed attempt to
reconstruct the development of THN from its conception to present.
To allow for the wide scope of this review, a broad search strategy
was applied. While the search strategy was not limited to English-lan-
guage entries, we cannot rule out that relevant international sources
(published in other languages) may have been overlooked. Similarly, it
is possible that the chronological timeline (see also Table 2) may include
inaccuracies.
We present these data as our best estimates that are based on careful
extraction from the referenced source documents. We hope to stimulate
discussion and invite feedback from take-home naloxone users, advo-
cates, prescribers and researchers around the world.
4.2. Questions for future research
Many questions are still unanswered about THN, including about
routes of administration and optimal dose range (especially for overdose
from synthetic opioids) (FDA, 2016), and questions on core elements of
overdose trainings and their potential impact on behavior. Finally, the
question of co-prescription of naloxone for chronic pain patients being
treated with opioids is just now being raised (CoVn et al., 2016) as THN
research has been largely conTned to heroin users.
THN implementation studies have mostly recruited heroin users
via urban harm reduction infrastructures, including needle exchange
schemes. Implementation studies are needed for emerging target groups
such as rural user populations and prescription opioid users (includ-
ing chronic pain patients) whose overdose risk awareness may be low
(Albert et al., 2011; CoVn et al., 2016; Compton and Volkow, 2006;
Paulozzi and Ryan, 2006). The US opioid epidemic has led to a de-
mographic shift in heroin users, from urban minority populations to
predominantly white suburban and rural men and women (Cicero et
al., 2014). Overdose mortality rates (any substance) have increased
among men and women of non-Hispanic white and black ethnicity
(CDC, 2016). It will be important to examine the demographics of pre-
scription opioid users (including chronic pain patients) in greater detail
(CoVn et al., 2016; Ling, 2017; Volkow and McLellan, 2016), particu-
larly considering that the prevalence trends of overdoses from prescrip-
tion opioids and heroin are likely intertwined and indicative of switch-
ing from prescription opioid to heroin use (Unick et al., 2013).
4.2.1. Models for implementation
Implementation research will be necessary as THN programs move
into new settings. One such feasibility study is currently being under-
taken in correctional and reentry settings in California, where stake-
holder interviews and focus groups are being conducted to address THN
implementation barriers (NIH project number: 5R34DA039101-02).
Research is also needed to systematically compare different set-
tings and distribution models for THN to identify those with biggest
reach among target populations. The issue of THN cost also needs to
be considered. For instance, it is unknown how likely potential over-
dose witnesses are to access and obtain naloxone via THN programs
at no cost versus as over-the-counter medication for sale. Availability
of naloxone solely over-the-counter, i.e., without additional free dis-
tribution, may only yield limited community-based coverage. Such is
the case in Italy, where naloxone was reclassiTed to over-the-counter
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based naloxone coverage, presumably because of insufTcient public in-
vestment (ForumDroghe, 2016).
By analogy, in the prevention of sexually transmitted infections
(STIs), a systematic review identiTed cost as barrier to condom use
(Ubrihien et al., 2016). Consequently, recent NICE guidelines recom-
mend free-of-charge condom distribution schemes to target populations
at highest risk of STIs (Iacobucci, 2017; NICE, 2017).
4.2.2. Naloxone coverage
Future studies will need to look at the extent to which widespread
THN provision, as perhaps achieved in Scotland (Bird et al., 2017;
McAuley et al., 2017), Norway (Madah-Amiri et al., 2017) and several
states in the US (Walley et al., 2013), results in reduction in opioid over-
dose mortaliy at state or national level, and what naloxone coverage
rates are required to achieve this effect.
4.2.3. Opioid user engagement
Despite increasing THN provision among (recent) injecting drug
users from 8% (2006 10 baseline) to 51% (2014 2015) (Bird et al.,
2017), the Scottish National Naloxone Programme reported naloxone
carriage rates of only 5 16% (McAuley et al., 2016), highlighting the
need to improve user engagement in take-home programs.
Qualitative research may help shed light onto barriers to THN in-
tervention uptake. While opioid users in Baltimore and Chicago re-
ported predominantly positive interactions with police and paramedics
(Sherman et al., 2008) and expressed interest in THN provision as well
as willingness to share information on overdose emergency manage-
ment with peers and family members (Sherman et al., 2009), nalox-
one experiences likely differ. Qualitative interviews conducted in Scot-
tish cities in 1997 99 (Neale and Strang, 2015) revealed opiate users
negative views of naloxone and accounts of harm caused by its admin-
istration (e.g., acute withdrawal, aggression, self-discharge and further
drug-seeking), even though this was not apparent in observational data.
Similarly, opioid users in New York and Los Angeles reported fear
of withdrawal and police involvement as key concerns associated with
THN distribution (Lankenau et al., 2013; Worthington et al., 2006), and
continued use of folk remedies posed a barrier to THN use (Lankenau et
al., 2013).
Systematic study of lived naloxone experiences is needed to identify
strategies for increasing user engagement in THN programs.
5. Conclusion
Twenty years ago, the very idea of THN was a radical speculative
proposal to extend harm reduction beyond needle and syringe exchange.
Today THN is increasingly accepted as an effective public health strat-
egy to reduce overdose fatalities and is increasingly being considered as
part of routine care and possibly a required standard of care. Nonethe-
less, THN lags behind its full potential, with only modest distribution of
THN relative to the evident (and growing) clinical need. To date, THN
distribution has mostly been made possible by community-based harm
reduction organizations with limited central funding. To tackle the ris-
ing numbers of opioid-related deaths, governments will need to provide
political leadership and perhaps speciTc Tnancial support to improve
the necessary extent of coverage of this potentially life-saving interven-
tion.
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ABSTRACT
Background and Aims Fatal outcome of opioid overdose, once detected, is preventable through timely administration of
the antidote naloxone. Take-home naloxone provision directly to opioid users for emergency use has been implemented
recently in more than 15 countries worldwide, albeit mainly as pilot schemes andwithout formal evaluation. This system-
atic review assesses the effectiveness of take-home naloxone, with two speciﬁc aims: (1) to study the impact of take-home
naloxone distribution on overdose-related mortality; and (2) to assess the safety of take-home naloxone in terms of adverse
events. Methods PubMed, MEDLINE and PsychINFO were searched for English-language peer-reviewed publications
(randomized or observational trials) using the Boolean search query: (opioid OR opiate) AND overdose AND prevention.
Evidence was evaluated using the nine Bradford Hill criteria for causation, devised to assess a potential causal relationship
between public health interventions and clinical outcomes when only observational data are available.Results A total of
1397 records (1164 after removal of duplicates) were retrieved, with 22 observational studies meeting eligibility criteria.
Due to variability in size and quality of the included studies, meta-analysis was dismissed in favour of narrative synthesis.
From eligible studies, we found take-home naloxone met all nine Bradford Hill criteria. The additional ﬁve World Health
Organization criteria were all either met partially (two) or fully (three). Even with take-home naloxone administration, fa-
tal outcome was reported in one in 123 overdose cases (0.8%; 95% conﬁdence interval = 0.4, 1.2). Conclusions Take-
home naloxone programmes are found to reduce overdose mortality among programme participants and in the commu-
nity and have a low rate of adverse events.
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INTRODUCTION
Opioid overdose represents a major cause of premature
death [1] and accounts for the majority of deaths among
injection drug users (IDUs) world-wide [2]. Opioid overdose
deaths are preventable through timely administration of
naloxone, a potent mu-opiate antagonist that rapidly re-
verses opiate-induced respiratory depression.
In 2014, the World Health Organization (WHO)
launched guidelines on the community management of
opioid overdose [3], recommending that ‘people likely to
witness an opioid overdose should have access to naloxone
and be instructed in its administration’ (p. x).
The community-based provision of naloxone rescue
kits to opioid users (‘take-home naloxone’, THN) was
ﬁrst proposed in the 1990s [4]. THN programmes typ-
ically involve training opioid users and/or their family
members or peers in overdose risk awareness, over-
dose emergency management and naloxone adminis-
tration [5]. During the past 15 years, THN
programmes have been implemented in Europe, North
America, Asia and Australia [1]. However, the vast
majority of evaluations have been pilot schemes with
uncontrolled study designs.
The evaluation of THN programmes is challenging:
randomized controlled trials (RCTs) are often considered
the gold standard of scientiﬁc study of clinical impact, but
conducting such trials in this context would often be un-
ethical and fraught with methodological difﬁculties, given
the infrequency and unpredictability of overdose.
© 2016 Society for the Study of Addiction Addiction
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Critics of THN programmes argue that the existing ob-
servational data are not strong enough to infer causation
from naloxone provision to the reduction of overdose
deaths [6,7]. A counter-argument may be that similar res-
ervations initially blocked other harm reduction strategies,
including needle exchange programmes and opioid substi-
tution therapy [8] that are nowevidence-based practice [9]
(andwould still be absent if the precautionary principle had
been strictly applied).
A clearer understanding of the potential beneﬁts and
risks of THN provision is essential. If concerns are valid
they need to be identiﬁed and considered in context, but
mere assertions of hypothetical disadvantages must not
prohibit access to a life-saving medication. A previous sys-
tematic review [10] found that participation in THN
programmes led to improved overdose-related knowledge
as well as appropriate use and administration of naloxone,
but the impact on overdose mortality was not assessed.
Our goal in this review is to assess the effectiveness of
THN programmes by following a well-recognized process
(i.e. Bradford Hill criteria) rigorously to evaluate the data
within eligible studies, addressing the following two aims:
(1) to describe the impact of THN provision on overdose-
relatedmortality in opioid users; and (2) to assess the safety
of THN provision by quantifying adverse events associated
with naloxone administration.
METHODS
A systematic literature search was performed following
PRISMA (Preferred Reporting Items for Systematic Re-
views andMeta-Analyses) guidance (see Fig. 1 for PRISMA
ﬂow diagram and Supporting information, Appendix S1 for
search protocol and excluded studies).
Identiﬁcation of eligible studies
Electronic databases were searched to identify relevant
peer-reviewed papers published between January 1946
and June (third week) 2015. Replicating the search strat-
egy reported by Clark et al. [10], the following Boolean
search query was used: (opioid OR opiate) AND overdose
AND prevention.
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) ﬂow diagram of study selection process
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Electronic database searching generated 1397 records:
150 onMedline, 772 on PsycInfo (both via OVID) and 475
on PubMed. Five studies [11–15] were added after a man-
ual search of the reference lists of recent literature reviews
[10,16,17].
Original quantitative (or mixed-method) studies of
randomized or observational trials of THN programmes
that trained opioid users in overdose prevention AND re-
ported on overdose outcomes were included into the
study. Several exclusion criteria were applied: reporting
on buprenorphine/naloxone; case reports; not reporting
primary research data; not reporting on heroin/opioid
users, naloxone or overdose.
Under supervision of the senior investigator, the ﬁrst
author extracted data using the STROBE (Strengthening
the Reporting of Observational Studies in Epidemiology)
checklist [18], assessed study eligibility and conducted
quality appraisal using an eight-item scale by Jinks et al.
[19], which had been applied previously by Clark et al.
[10] (see Table 4).
All 22 studies that met the inclusion criteria were en-
tered into the analysis. Among these, one was an
interrupted time–series analysis that provided quasi-
experimental data. Sixteen were pre–post studies (nine
with systematic follow-up), three were case series and
two were cross-sectional. None of the studies involved ran-
domization to the intervention (i.e. THN distribution), al-
though two studies were controlled [12,20]. Of the 22
included studies, 15 were carried out in the United States,
two in Canada, four in the United Kingdom and one in the
United Kingdom and Germany (multi-site). Sample sizes
varied from aminimum of 24 to a maximum of 2912 (me-
dian: n = 203).
Analysis
There was large variability in the size and quality of the
THN intervention studies identiﬁed: for example, many
were merely descriptive reports which, while valuable
communications to other practitioners, were neverthe-
less lacking study design or analytical rigour. Moreover,
while nine studies involved systematic follow-up, they
were not considered necessarily representative of the ma-
jority of included studies due to small sample sizes. As a
consequence, narrative synthesis was chosen as the
more appropriate method of analysis in lieu of meta-
analysis.
In this context, the evidence was evaluated using the
Bradford Hill criteria [21], a set of nine criteria (see Table 1)
devised in 1965 by British epidemiologist and statistician
Sir Austin Bradford Hill to assess causality when only cor-
relational data are available: (1) strength of association,
(2) consistency, (3) speciﬁcity, (4) temporality, (5) dose–
response relationship, (6) plausibility, (7) coherence, (8)
experimental evidence and (9) analogy. The Bradford Hill
criteria are considered a standard tool to assess the impact
of broad-based public health interventions where it is not
ethically feasible or operationally impractical to conduct
RCTs.
The Bradford Hill criteria have been applied valuably in
a WHO ‘Evidence for Action’ report [22] on the effective-
ness of needle-exchange interventions in reducing HIV
among IDUs. TheWHO report also considered evidence ac-
cording to ﬁve additional criteria relating to feasibility and
implementation (see Table 2), which we include as supple-
mentary analysis: (10) cost-effectiveness; (11) absence of
negative consequences; (12) feasibility of implementation,
expansion and coverage; (13) unanticipated beneﬁts; and
(14) special populations.
Where summary outcome measures (e.g. number of
naloxone administrations, overdose reversals, adverse
events) were calculated across studies, we sought to
avoid (partial) duplication of samples by including only
the study with the largest participant sample per project
[20,23] for THN projects that had produced more than
one published study (i.e. Boston/Massachusetts, Los
Angeles, New York, San Francisco). Vice versa, if the
time-periods covered by multiple studies from the same
project could be distinguished clearly and did not over-
lap, all project evaluations entered analysis [24–27].
All summary statistics are pooled, unweighted estimates
from the referenced studies. The number of overdose re-
versals is used as proxy for the impact of THN provision
on opioid overdose mortality (aim 1), as a ratio of one
fatal overdose in every 20 overdose events has been de-
scribed in the literature [28], and it is impossible to
ascertain for each overdose event whether, in the
absence of intervention, the outcome would have been
fatal or whether respiratory function would have
recovered.
RESULTS
We now present the ﬁndings from application of the nine
original Bradford Hill criteria [21], followed by consider-
ation of the extra ﬁve criteria added in the WHO report
[22,29].
Consideration according to the original Bradford Hill
criteria
Strength of association
In 21 of the 22 studies, pre-provision of naloxone was
followed by use of the naloxone to reverse opioid overdose.
After exclusion of four studies that possibly contained
duplicate samples [30–33], a total of 2336 THN administra-
tions were found across 17 studies (see Table 3). Due the
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binary outcome (survival/death), the number of successful
overdose reversals can be estimated by deducting the num-
ber of deaths from the number of THN administrations. By
deducting the 20 conﬁrmed deaths (1 + 1 + 2 + 6 + 10)
where overdose victims did not recover following naloxone
administration [12,24,25,34,35], we obtain an upper esti-
mate of 2316 successful overdose reversals.1 If the four
deaths where it was unclear if naloxone had been adminis-
tered [23] and 63 cases (8 + 36 + 14 + 5) of naloxone ad-
ministration with ‘unknown outcome’ [23,24,27,34] are
12316 overdose (OD) reversals = 2336 THN administrations minus 20 deaths (see Table 3).










Bennett 2011 426 426 249 (58%) 2 ≥ 96% 8 NR
Bennet 2012 525 NR 28 (NR) 1 96% NR
Dettmer 2001f 101 101 5 (5%) 0 100% Withdrawal (NR)
Dettmer 2001f 124 124 29 (23%) 0 100% Withdrawal (10)
Doe-Simkins 2009d 385 385 74 (19%) 0 100% Withdrawal (2)
Dwyer 2015d 415 56 6 (11%) 0 100% NR
Enteen 2010 1942 2962 399 (13%) 6 ≥ 89% 36 Vomiting (50),
agitation (36),
seizures (3)
Galea 2006 25 25 10 (40%) 1a 100% 1a None
Lankenau 2013d 30 30 15 (50%) 0 ≥ 97% 1 NR
Leece 2013 209 209 17 (8%) 0 100% None
Lopez-Gaston 2009 70 70 0 (0%) 1a NA NA
Markham Piper 2008 122 122 82 (67%) 0 ≥ 83% 14 NR
Maxwell 2006 1120 3500 319 (9%) 1c 99% Seizures (1),
vomiting (1)
McAuley 2010 41 19 2 (11%) 1a 100% NR
Rowe 2015 2500 2500 702 (28%) 10 99% NR
Seal 2005 24 24 15 (63%) 0 100% NR
Strang 2008 239 239 1 (5%) 1a 100% Withdrawal
Tobin 2009 250 250 22 (9%) 0 100% NR
Tzemis 2014 692 836 85 (10%) 0 100% Withdrawal (55),
agitation (9)
Wagner 2009 66 66 28 (42%) 4b NR 5 Agitation (5),
vomiting (1)
Walley 2013 [20] 2912 2912 327 (11%) 0 100% NR
Walley 2013 [33]d 1553 1553 92 (6%) 0 100% NR
Yokell 2011 120 120 5 (4%) 0 100% NR
aNaloxone not administered; bunclear if naloxone administered; cnon-opioids present; NA: not applicable; NR: not reported; OD = overdose; THN: take-home
naloxone; dnot included in summary measures to avoid (partial) duplication of samples; ewhere applicable, unknown outcomes were counted towards
unsuccessful THN administrations (as indicated by the ≥ symbol); fMulti-site study with two samples: Jersey (n=101) and Berlin (n=124).
Table 2 Additional feasibility and implementation criteria and application to take-home naloxone.
Criterion Take-home naloxone (THN)
Cost-effectiveness Is THN for lay overdose reversal cost-effective compared to treatment as
usual (no intervention)?
Absence of negative consequences Does the distribution of THN to users bear the risk of adverse events?
Feasibility of implementation, expansion,
and coverage
Is it feasible to introduce THN distribution in diverse settings, including
resource-poor settings, and scale up implementation?
Unanticipated beneﬁts Does the distribution of THN to users lead to unanticipated beneﬁts?
Special populations How successful are THN programmes in reaching special populations that
have been identiﬁed as particularly ‘at-risk’ opioid users?
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also counted towards fatalities following naloxone adminis-
tration, a conservative, lower estimate of 2249 successful
overdose reversals2 emerges. In the only study where THN
provision did not lead to overdose reversals [11], nine of
46 programme participants witnessed a total of 16 over-
doses at 6-month follow-up, but none administered nalox-
one to the overdose victims. The main reason for non-
administration was that participants did not have their nal-
oxone supply available.
In summary, there is a strong association between THN
programmes and overdose survival, as evidenced by at
least 2249 successful overdose reversals [96.3%; 95% con-
ﬁdence interval (CI) = 95.5, 97.1] among 2336 THN
administrations.
Temporality
In 21 of the 22 studies, training in overdose prevention
and THN provision preceded overdose reversals. Two of
these studies provide clear evidence in support of the
temporality criterion. Supportive evidence comes from
descriptive accounts of early THN distribution in Chicago
and surrounding Cooks County [35]: after a 135% in-
crease in local overdose deaths from 1996 to 2000, the
introduction of THN in 2001 led to reduction in fatal
overdoses by 20% in 2001, 8% in 2002 and 6% in
2003 (compared to past-year rate). While these data
are indicative of a temporal sequence between THN in-
troduction and reduced overdose mortality, no deﬁnite
conclusion can be drawn, as the lack of control group
means that other causes may have contributed to de-
creasing overdose mortality rates.
Stronger evidence comes from Walley et al. [20] who
conducted an evaluation of a state-funded THN pro-
gramme in Massachusetts. Between 2006 and 2009, the
Massachusetts Department of Public Health used a phased
roll-out to introduce THN in 19 communities, enrolling
2912 individuals in total. To evaluate the impact of THN,
Walley et al. used an interrupted time–series analysis,
where each community served as its own geographic con-
trol and communities without concurrent THN availability
served as time control. For all 19 participating communi-
ties, overdose mortality rates in the time-periods before
and after THN implementation were compared. Overdose
mortality rates were reduced signiﬁcantly in communities
where THN was implemented, compared to pre-
implementation rates and to communities without THN.
Consistency
Overdose reversals by means of THN have been docu-
mented in the selected studies by independent investigators
22249 overdose (OD) reversals = 2336 THN administrations minus 20 deaths minus four unclear cases minus 63 cases with unknown outcome.
Table 4 Included studies: follow-up rate, study design and quality rating.
Study Location n FU FU % FU type Design Score
Bennett 2011 Pittsburg 426 89 21% Non-systematic Pre–post 5
Bennet 2012 Wales 525 28 5% Systematic Pre–post 6
Dettmer 2001a Jersey 101 NR NR Non-systematic Case series 4
Dettmer 2001a Berlin 124 40 32% Non-systematic Case series 4
Doe-Simkins 2009 Boston 385 278 72% Non-systematic Pre–post 5
Dwyer 2015 Boston 415 51 12% Systematic Pre–post 6
Enteen 2010 San Francisco 1942 310 16% Non-systematic Pre–post 6
Galea 2006 New York 25 22 88% Systematic Pre–post 7
Lankenau 2013 Los Angeles 30 NA NA NA Cross-sectional 6
Leece 2013 Toronto 209 NR NR Non-systematic Case series 5
Lopez-Gaston 2009 Birmingham & London 70 46 65% systematic Pre–post 7
Markham Piper 2008 New York 122 NR NR Non-systematic Pre–post 6
Maxwell 2006 Chicago 1120 NR NR Non-systematic Case series 4
McAuley 2010 Lanarkshire 41 17 89% Systematic Pre–post 7
Rowe 2015 San Francisco 2500 613 25% Non-systematic Pre–post 7
Seal 2005 San Francisco 24 24 100% Systematic Pre–post 5
Strang 2008 England 239 186 78% Systematic Pre–post 7
Tobin 2009 Baltimore 250 85 34% Systematic Pre–post 6
Tzemis 2014 British Columbia 692 NA NA NA Cross-sectional 6
Wagner 2009 Los Angeles 66 47 71% Systematic Pre–post 7
Walley 2013 [20] Massachusetts 2912 212 7% Non-systematic ITS 7
Walley 2013 [33] Massachusetts 1553 286 18% Non-systematic Pre–post 6
Yokell 2011 Rhode Island 120 10 8% Non-systematic Pre–post 5
FU: number of follow-up participants; FU%: FU participants as percentage of study sample; ITS: interrupted time–series analysis; NA: not applicable; NR: not
reported; score: summary quality score based on eight-point scale by Jinks et al. [19], modiﬁed from Clark et al. [10] aMulti-site study with two samples (Jersey,
Berlin).
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under different circumstances in at least 15 different cities,
states and countries: in Canada (Toronto and British
Columbia), the United States (Baltimore, Boston/
Massachusetts, Chicago, Los Angeles, San Francisco, New
York, Pittsburgh, Rhode Island), the United Kingdom
(England, Jersey, Scotland, Wales) and Germany (Berlin).
Overdose reversals by THN have also been documented re-
peatedly in New York [26,27] and San Francisco
[14,24,25]. In conclusion, there is substantial support for
the consistency criterion.
Biological plausibility
This criterion addresses the therapeutic effect of naloxone.
Naloxone is a pure opioid antagonist that binds to the μ-
opioid receptor and blocks competing agonists, such as
heroin [36]. All but one study [11] reported on THNadmin-
istration in cases of suspected opioid overdoses, and the
pharmacological effects of naloxone led to at least 2249
overdose reversals. In conclusion, there is strong empirical
support to the biological plausibility criterion.
Coherence
Declining overdose rates in the absence of THN have been
reported in the literature. The Australian heroin drought
constitutes a prominent example, where between 2001
and 2002 overdose-related mortality rates dropped in con-
junction with a shortage in illicit heroin imports. THN
could not have accounted for the decline in mortality, as
it was introduced in Australia only in 2011 [37,38]. How-
ever, the Australian example does not conﬂict with the pre-
sumed effect of THN on reduced overdose mortality. The
cause-and-effect interpretation of our data is consistent
with current understanding of the mechanisms of opioid
overdose, and the 21 studies which reported overdose re-
versals provide strong support for the coherence criterion.
Speciﬁcity
The speciﬁcity criterion relates to efﬁcacy of the interven-
tion (the same as biological plausibility), rather than
population-wide effectiveness. THN exclusively reverses
opioid-induced overdoses, as illustrated by the following
two cases: in the Dettmer et al. study [39], naloxone
had zero effect when administered to a person suffering
from cocaine intoxication. The Chicago Recovery Alli-
ance reported one fatality after naloxone administration
[35] where naloxone failed to revive an overdose victim
with non-opioids in their system. The mooted beneﬁt
from naloxone is speciﬁc to opioid overdose. In practice,
THN may be primarily beneﬁcial for the reversal of over-
doses from heroin and other short-acting opioids. (All 22
studies reported primarily on heroin overdoses, and one
study speciﬁed that the long-acting opioid methadone
was involved in less than 5% of overdose reversals
[33].) Overall, the evidence constitutes strong support
for this criterion.
Dose–response relationship
Researchers estimate that THN distribution can only
achieve maximum impact on overdose reduction if a cer-
tain volume of THN kits is available in the community.
Among the 22 studies, only Walley et al. [20] assessed
the impact of varying degrees of THN availability on over-
dose mortality by splitting the 19 participating communi-
ties into three groups based on volume of THN
distribution: zero implementation, low implementation
(1–100 programme enrolments per 100 000 inhabitants)
and high implementation (>100 enrolments). Both low
and high implementers had signiﬁcantly reduced overdose
mortality rates compared to communities without imple-
mentation, and there was a signiﬁcant implementation
dose-relationship with overdose death rates, with greatest
effect with greatest implementation.
To summarize, there is only this limited empirical evi-
dence for a dose-related impact of THN availability, and
hence this criterion is only partially fulﬁlled.
Experimental evidence
While none of the 22 studies deliver experimental evi-
dence, the interrupted time–series analysis by Walley
et al. [20] provides quasi-experimental evidence in sup-
port of causation. Importantly, even communities with
low-level THN implementation of THN (1–100 partici-
pants, see above) saw a reduction in overdose mortality,
compared to communities without THN distribution.
Interrupted time–series analysis is considered to be the
strongest quasi-experimental research design [40]. The
results of the study by Walley et al. [20] thus provide
preliminary support for the experimental evidence
criterion.
Analogy
THN is analogous to naloxone treatment for the same clin-
ical indication in emergency medical care, and also to the
prescription of other emergency medications (typically an-
tidotes for overdose or poisoning) for peer administration:
THN has been compared to the provision of adrenaline in-
jection kits (e.g. EpiPen) to individuals with severe allergic
reactions for family members to administer in the event
of anaphylactic shock [15] or the provision of glucagon
for insulin overdose [35]. Similarly, THN has been likened
to pre-placement of deﬁbrillators and cardiopulmonary re-
suscitation (CPR) training for lay people likely to witness
cardiac arrest [41]. For all these emergency interventions,
timely delivery is crucial.We conclude that the analogy cri-
terion is fulﬁlled.
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Consideration according to additional feasibility and
implementation criteria
Cost-effectiveness
Separate modelling data from both the United States and
Russia conclude that THN is cost-effective even under con-
servative circumstances, i.e. when the cost of naloxone in-
creases and the rate of observed overdoses decreases
[42,43]. Bearing in mind the potential limitation that both
studies were conducted by the same authors, there is con-
sistent evidence for the cost-effectiveness of THN.
Absence of negative consequences
In ﬁve of the 17 studies that did not contain duplicate sam-
ples, 20 overdose victims did not survive naloxone admin-
istration [12,24,25,34,35]. In addition, Wagner et al.
[23] reported four deaths where it was unclear if naloxone
had been administered. Based on these observations, the
following fatality rates emerge: 20 conﬁrmed deaths per
2336 naloxone administrations (0.9%; 95% CI = 0.5,
1.2) or 24 deaths per 2336 naloxone administrations
(1.0%; 95% CI = 0.6, 1.4) if we include the four fatalities
where it was unclear if naloxone had been administered.
If we limit the study selection to the nine papers with sys-
tematic follow-up, a similar ratio of one conﬁrmed death
per 123 naloxone administrations (0.8%; 95% CI = 0.4,
1.2) was observed.
In six [15,23,24,35,39,44] of the 17 studies, several
adverse reactions were reported in conjunction with a total
of 2336 naloxone administrations: at least 65 instances of
withdrawal symptoms (2.8%), 52 cases of vomiting
(2.2%), 50 cases of agitation (2.1%) and four seizures
(0.1%).
In conclusion, THN programmes have a low rate of ad-
verse events. Where adverse reactions occurred, these
were most frequently symptoms of opioid withdrawal (in-
cluding nausea/vomiting, agitation).
Feasibility of implementation, expansion and coverage
The 22 studies document THN implementation in a variety
of settings across 16 geographical locations, and naloxone
usage rates between 5 and 63% are reported. San
Francisco is an example of rapid expansion, as the volume
of THN kits distributed increased from 24 in 2001 to 2962
kits during the 6-year period between 2003 and 2009 (i.e.
approximately 494 kits/year) [24], and to 2500 kits from
2010 to 2013 (i.e. approximately 833 kits/year) [25]. Out-
side the 22 studies included in this review, implementation
in resource-poor settings has been achieved in Kyrgyzstan
and Tajikistan, with reported naloxone usage rates of 47
and 78%, respectively [45]. These studies suggest that
THN schemes are capable of implementation across a wide
range of settings and cultures.
Unanticipated beneﬁts
Four of the 22 studies reported unanticipated beneﬁts. In
THN programmes in California, 25% of participants in
San Francisco entered treatment within 6-month follow-
up [14] and 53% of participants in Los Angeles reported
decreased drug use at 3-month follow-up [23]. Similarly,
Maxwell et al. reported anecdotal evidence of increased
willingness among THN recipients to be tested for HIV
and hepatitis C virus (HCV) [35]. Strang et al. [15] found
a secondary training effect: within a 3-month follow-up pe-
riod, 28% of THN recipients had trained a family member
or peer.
Special populations
THN provision has been implemented successfully in
programmes targeting special populations with high risk
of overdose: detox patients [11,33], homeless users [23–
25,27,46], methadone patients [33] and prison inmates
[12]. The Massachusetts THN programme [20] also en-
rolled attendees of HIV education centers, and a Los
Angeles-based programme recruited more than 50%
HCV-positive patients. Both represent particularly vulnera-
ble groups due to their comorbid health issues and risk of
blood-borne virus transmission by needle-sharing. From
the perspective of implementation, THN schemes can be
delivered to populations in special need.
Summary of ﬁndings
Empirical evidence from the 22 studies reporting on THN
interventions for opioid users meets all nine Bradford Hill
original criteria. Among these, Sir Austin Bradford Hill
considered the experimental evidence criterion to deliver
the strongest support for causation [21], but only quasi-
experimental evidence from one study [20] is available
here. The robustness of empirical support ranges from
one study per criterion (dose–response, experimental evi-
dence) to 21 studies per criterion (strength of association,
coherence) (see Supporting information, Appendix S1).
With regard to the ﬁve additional criteria assessing feasibil-
ity and implementation, THN fulﬁls fully or partially all ﬁve
criteria. It is found to be cost-effective, and existing projects
were able to access and train high-risk populations that led
to 2336 layperson naloxone administrations (aim 1) with
a low rate of adverse effects (aim 2).
DISCUSSION
Application of the Bradford Hill criteria to the current evi-
dence base on THN supports the causation hypothesis.
While the evidence is sometimes based on only one or
two studies, we nevertheless conclude that this constitutes
support for all nine criteria. THN provision reduced fatal
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outcome of overdose among programme participants
themselves, among fellow opioid users and in the wider
community, as evidenced by public vital statistics records
[14,20]. Alternative explanations for this observation are
unlikely: in control communities that did not implement
THN, opioid overdose mortality was signiﬁcantly higher
[20]. The risk associated with THN programmes is rela-
tively low, especially when the life-threatening nature of
the emergency situation is borne in mind: in studies with
systematic follow-up, one death was reported among 123
overdose victims who were administered THN. Moreover,
there is no empirical evidence to support the concern that
THN programmes might encourage heroin use. Two stud-
ies reported decreased drug use among THN programme
participants at follow-up [14,23], whereas a more recent
study found no overall change in the frequency of heroin
use across THN recipients [47].
This is the ﬁrst published application of the BradfordHill
criteria to assess the international evidence base on THN.
Our ﬁndings extend and substantiate the 2014 WHO
Guidelines as well as the results of the previous systematic
reviews by Clark et al. [10] and the European Monitoring
Centre for Drugs and Drug Addiction (EMCDDA) [17].
Clark et al. (2014) cautiously concluded: ‘participation [in
THN programs] is associated with overdose reversals’ (p.
162), but avoided statements on the effectiveness of THN,
whereas the EMCDDA stated: ‘there is evidence that
educational and training interventions with provision of
take-home naloxone decrease overdose-related mortality’
(p. 11).
There are potential limitations to this analysis, which
need to be borne in mind. Selection bias may have affected
the internal validity of the data included. Among 19 stud-
ies with pre–post and case series designs, 10 relied on un-
systematic follow-up to capture overdose events and
naloxone usage, relying upon spontaneous follow-up, with
THN programme participants asked typically to report
back on naloxone usage when collecting a naloxone reﬁll.
This raises scientiﬁc analytical doubt about data quality
and interpretations: ﬁrst, across these 10 studies, fewer
than a quarter (22.9%; i.e. 1973 of 8602) of THN recipi-
ents returned for reﬁlls after THN use, and information
on the majority of participants was consequently lost. Sec-
ondly, it is possible that users with positive naloxone expe-
riences (e.g. successful overdose reversals) may be more
likely to return for a reﬁll of their THN kit and complete a
follow-up survey, whereas those with negative naloxone
experiences may not be captured in the follow-up. The lack
of systematic follow-up in themajority of studies is reﬂected
in the wide range of follow-up rates attained across all
studies (min. 5%, max. 100%). High levels of dropout can
reduce the external validity and generalizability of results.
A further source of potential bias lies in the fact that, for
21 of the 22 studies, there was an exclusive reliance on
self-report data for overdose outcomes. Only the
interrupted time–series analysis by Walley et al. [20] in-
cluded a public database of vital statistics to calculate over-
dose fatality rates. A further limitation concerns the fact
that the experimental evidence and dose–response criteria
hinge on data from the Walley et al. [20] study. More well-
conducted studies are needed to conﬁrm these results and
assess their applicability to other regions internationally,
in particular low- and middle-income countries. Moreover,
the ﬁndings from the studies do not inform which distribu-
tion model of overdose education and THN distribution is
preferable. Future studies could evaluate the impact of pro-
gramme components formally by providing THN to all sub-
jects and randomizing subjects into different training
conditions (e.g. ‘overdose education’ versus ‘overdose edu-
cation + CPR training’).
Despite these methodological limitations, positive re-
ports of overdose reversals following THN distribution were
reported across 21 studies, regardless of type of follow-up
(systematic versus unsystematic) or data source (self-re-
port versus objective data), suggesting that the ﬁnding is
indeed robust and not an artefact of methodological ﬂaws.
To control for potential publication bias, we additionally
searched the grey literature for documents reporting on
THN initiatives that are not published in the peer-reviewed
journal domain. While this search was probably not ex-
haustive, the data reported in the grey literature are
broadly consistent with the results of the studies included
in our systematic review. For instance, in the Scottish Na-
tional Naloxone Programme, in 2012 and 2013 the per-
centage of opioid-related deaths occurring within
4 weeks of prison release (5.5 and 4.7%) was almost half
that of the pooled 2006–10 baseline indicator (9.8%), sug-
gesting that distribution of naloxone kits on releasemay re-
duce the risk of fatal overdose among (former) prisoners
with history of opioid use [48].
With regard to clinical implications, it needs to be em-
phasized that the vast majority of studies included in this
review reported on heroin overdoses. Consequently, the
generalizability of our ﬁndings to overdoses from long-
acting opioids is unclear. Even when methadone patients
were recruited speciﬁcally into a THN programme [33],
more than 90% of witnessed (and reversed) overdoses were
heroin-induced. The results of this review on the effective-
ness of THN are thus limited to impact on heroin overdoses,
and the effectiveness of the intervention for overdoses from
long-acting opioids (e.g. methadone or many prescription
opioids) needs to be explored in future research.
To conclude, application of the Bradford Hill criteria to
the current evidence base from non-randomized studies
ﬁnds that THN programmes have led to improved survival
rates among programme participants and reduced heroin
overdose mortality rates in the community (aim 1) and
are accompanied by only a low rate of adverse events
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(aim 2). In the absence of RCTs, we conclude that THN dis-
tribution to at-risk users should be introduced as standard
of care for the community-based prevention of heroin over-
dose deaths.
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Clinical provision of improvised nasal naloxone without
experimental testing and without regulatory approval:
imaginative shortcut or dangerous bypass of essential
safety procedures?
John Strang*, Rebecca McDonald*, Basak Tas & Ed Day




Context Take-home naloxone is increasingly provided to prevent heroin overdose deaths. Naloxone 0.4–2.0 mg is licensed
for use by injection. Some clinicians supply improvised nasal naloxone kits (outside lisenced approval). Is this acceptable?
Aims (1) To consider provision of improvised nasal naloxone in clinical practice and (2) to search for evidence
for pharmacokinetics and effectiveness (versus injection). Methods (1) To document existing nasal naloxone
schemes and published evidence of pharmacokinetics (systematic search of the CINAHL, Cochrane, EMBASE and
MEDLINE databases and 18 records included in narrative synthesis). (2) To analyse ongoing studies investigating nasal
naloxone (WHO International Clinical Trials Registry PlatformandUSNIHRePORT databases). Findings (1)Multiple studies
report overdose reversals following administration of improvised intranasal naloxone. (2) Overdose reversal after nasal nalox-
one is frequent but may not always occur. (3) Until late 2015, the only commercially available naloxone concentrations were
0.4 mg/ml and 2mg/2ml. Nasal medications are typically 0.05–0.25ml of ﬂuid per nostril. The only published study of phar-
macokinetics and bioavailability ﬁnds that nasal naloxone has poor bioavailability. Questions for debate (1) Why are phar-
macokinetics and bioavailability data for nasal naloxone not available before incorporation into standard clinical practice? (2)
Does nasal naloxone have the potential to become a reliable clinical formulation? (3) What pre-clinical and clinical studies
should precede utilization of novel naloxone formulations as standard emergency medications? Conclusions The addictions
treatment ﬁeld has rushed prematurely into the use of improvised nasal naloxone kits. Evidence of adequate bioavailability and
acceptable pharmacokinetic curves are vital preliminary steps, especially when effective approved formulations exist.
Keywords Death, emergency, heroin, naloxone, nasal, opioid, overdose, unlicensed.
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INTRODUCTION
Naloxone undoubtedly saves lives by reversing respiratory
depression caused by heroin/opioid overdose. Analogous to
the pre-provision of EpiPens for the peer-based emergency
management of anaphylactic shock, practitioners in Chicago
[1] and in a few locations in Europe [2] ﬁrst began prescrib-
ing take-home naloxone for emergency use to heroin users
(and family/peers) in the late 1990s in order to prevent over-
dose deaths from heroin or other opiates [3]. Take-home nal-
oxone has been implemented by early adopters, but has
become more mainstream only in the last 5 years, with the
introduction of the ﬁrst state-wide scheme in Massachusetts
in 2008 [4] and ﬁrst national schemes in Scotland andWales
in 2011 [5]. Take-home naloxone is now available in at least
a dozen countries world-wide [6].
Systematic reviews conclude that pre-provision of nal-
oxone is effective [7,8], and recentWHOGuidelines [9] rec-
ommend that anyone likely to witness an opioid overdose
should have access to the antidote. Naloxone is approved
for intravenous (i.v.), intramuscular (i.m.) or subcutaneous
injection for treatment of heroin/opiate overdose [9].
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Additionally, in the US, a new concentrated naloxone nasal
spray was approved in Novemeber 2015 [10]. The recom-
mended initial dose for the injection is 0.4 mg, which may
then be increased to 2 mg, according to response, and may
be repeated thereafter in extremis [9].
The notion of nasal naloxone is unquestionably
attractive. It is quick to administer and reduces risk of
needle-stick injury. However, until late 2015, naloxone for
intranasal (i.n.) administration was not licensed anywhere
in the world – neither for addiction or overdose treatment
nor for any other indication. In November 2015, the situa-
tion changed with FDA approval (US only) of a naloxone
nasal spray [10].
In this ‘For Debate’ paper, we consider we the wide-
spread provision, by some services (parts of the US; parts
of Australia; Norway; Denmark; parts of Scotland), of an
improvised nasal naloxone kit (atomizer attached to pre-
ﬁlled syringe) for take-home naloxone [11,12]. This
follows a practice used by some ambulance teams that
administer naloxone off-licence as nasal spray [13].
However, the context of emergency care is fundamentally
different from emergency care from a family member or
peer with a nasal spray naloxone kit. In the ambulance
context, the paramedic teams can give a naloxone
injection when the nasal spray fails. However, no fallback
treatment exists in the community setting for the family
member or carer with only the nasal spray.
This ‘For Debate’ exploration neither condemns nor con-
dones the pragmatic provision of improvised nasals spray by
public health initiatives, particularly in communities where
the distribution of injectable naloxone is politically not feasi-
ble. Rather, our aim is to stimulate discussion on the unli-
censed use of new drug formulations in the addictions
treatment ﬁeld. Can we justify bypassing product testing
and efﬁcacy when licensed naloxone products already exist?
METHOD
The objectives for this examination are twofold: ﬁrst, to
report the practice of provision of nasal naloxone in clinical
practice, and secondly to examine available published
evidence of pharmacokinetics and effectiveness of naloxone
by nasal administration (versus injection).
Search strategy
Replicating an earlier peer-reviewed search strategy [14],
the CINAHL, Cochrane, EMBASE and MEDLINE databases
were searched to identify relevant peer-reviewed English-
language papers published between January 1946 and
January (4th week) 2015 using the terms: ‘naloxone.mp’
or ‘exp naloxone’, ‘narcan.mp.’ or ‘exp.Narcan’ and ‘exp
administration, intranasal/or intranasal.mp’ or ‘nose.mp’.
Two raters (B.T., R.M.) conducted the initial data searches,
screened papers for eligibility and extracted data under the
supervision of the senior investigator (J.S.). A total of 388
papers were retrieved and screened for original research
(including case reports) reporting on pharmacokinetics,
safety or effectiveness data of i.n. naloxone administration
in healthy volunteers or patients with suspected opioid
overdose. Eighteen records matched our search criteria
[4,13,15–30] (see Table 1 and Fig. 1).
In addition, the WHO International Clinical Trials Reg-
istry Platform and US NIH RePORT database were
searched for ongoing studies investigating nasal naloxone.
FINDINGS
Is i.n. naloxone already being prescribed in clinical
practice?
Ambulance use
Nasal naloxone for treatment of opioid overdose was intro-
duced as regular clinical practice (although without licence
approval for this route) into ambulance services in parts of
the United States (Denver, Colorado; Fresno, California;
among others) in the 2000s [13,15,25], and in several
National Health Service (NHS) Ambulance Service Trusts
in the United Kingdom (including South Western, Great
Western and East Midlands).
Take-home supply
Take-home naloxone as nasal spray only (i.e. without
supplementary needle for i.m. injection) was ﬁrst in-
troduced in the United States in Boston, Massachu-
setts [4]. In 2013, 51 US organizations reported
providing only i.n. naloxone [12]. In Europe, the Nor-
wegian take-home naloxone scheme began providing
only i.n. naloxone in 2014 [31]. At the time of writ-
ing, it is also proposed that the nasal spray will be
the only form of naloxone provided in parts of Scot-
land (Inverness and surrounding regions Highland,
Argyll and Buke) [11] and in France [32].
What is the evidence-base for i.n. naloxone?
No systematic review exists on nasal naloxone to date, but
there is growing evidence of i.n. administration of naloxone
reversing opioid overdose: at least 327 overdose reversals
using nasal naloxone kits were reported in the Massachusetts-
based take-home naloxone scheme [4,29,30]. In ambulance
and hospital-based trials, the time from dose administration
to clinical response often took longer for nasal admin-
istration compared to injectable routes [19,25,26].
However, for the comparison of i.n. and i.v. routes, this
time difference disappeared when measuring the time
from patient contact to clinical response due to the
time saved for having to establish i.v. access [25].
Similarly, the time to clinical response was no different
2 John Strang et al.
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from i.m. administration when a more concentrated
nasal spray formulation (2 mg/ml) was used [20].
However, with concerns as summarized below, there
remains a lack of information about how adequately and
reliably naloxone is absorbed intranasally.
Lack of simple pharmacokinetics
Progress with basic pharmacokinetic study of i.n. nalox-
one has been slow. The only published pharmacokinetic
study [17] reported extremely poor bioavailability (4%)
for nasal naloxone (although the authors acknowledged
that the dilute solution probably resulted in post-nasal
loss or nasal leakage). Despite reports of replication
studies (e.g. by pharmaceutical companies), no new
pharmacokinetics data have yet been published in the
peer-reviewed domain.
Non-response rate
The results from ambulance-based studies in Australia
[18,19] and the United States [12,14,23,26] indicate that
not all opioid overdose victims respond to nasal naloxone,
with some needing a rescue dose of i.m. or i.v. naloxone
(see also Table 1). An ambulance-based randomized trial
in Australia compared i.n. to i.m. naloxone: in a moderate
proportion of instances the i.n. initial dose was not sufﬁ-
cient. Furthermore, it was not equal—the i.n. group was
twice as likely to require rescue naloxone [26% i.n. group
versus 13% i.m. group; P = 0.056; odds ratio (OR) = 2.4;
95% conﬁdence interval (CI) = 1.0–5.7) [18]. In a replica-
tion trial with a more concentrated nasal spray formula-
tion (2 mg/ml), 18% of the i.n. group still needed rescue
naloxone, which was signiﬁcantly higher than the
i.m. group (5%) [19]. This rate is broadly consistent with
Figure 1 Flowchart of study selection
For debate 5
© 2016 Society for the Study of Addiction Addiction
16% of i.n. non-responders in a Denver-based observa-
tional trial [13]. Other studies have reported non-
response rates between 9 and 23% [15,24,27].
Ongoing research
Clinical trials are currently being conducted in the ambu-
lance setting in Cincinnati, USA, and in a supervised
injecting clinic in Sydney, Australia.
Pharmacokinetic exploration of i.n. formulations is
ﬁnally under way by two groups in the United States and
one in Norway: however, no results are yet published.
Other potential non-injectable routeswarrant consider-
ation. Rectal suppositories would almost certainly be effec-
tive, but probably with poor acceptability to family and
peers. The oral cavity is the obvious alternative: however,
sublingual naloxone had poor bioavailability with marked
intersubject variability in an opioid-using sample [33]. In
contrast, the buccal route was found to have high nalox-
one bioavailability in rodents [34], and has been successful
with other emergency medications; for example, buccal
midazolam is now licensed for family use for interim
management of seizures or status epilepticus [35]. We are
currently examining the pharmacokinetics of buccal
naloxone (EudraCT: 2014–001 802–16).
Reasons for caution
The concerns raised in this paper relate to the use of impro-
vised nasal sprays based on dilute solutions of naloxone
developed for injection and not examined for suitability or
efﬁcacy as nasal spray. A recent step-change, in November
2015, was the licensing by FDA in the US of a naloxone
nasal spray [10] which evidently met their pre-speciﬁed
criteria of comparability of effect to injectable naloxone.
Another application for a naloxone nasal spray was unsuc-
cessful because it was found not to be absorbed sufﬁciently
rapidly [36]. In our opinion, there remain the following
crucial considerations:
First, non-response rates of between 9 and 26% have
been reported for nasal naloxone [13,15,19,20,24,27]. As
noted in the Introduction section, there is an inherent safety
in the use of nasal naloxone in the ambulance or hospital
context, where a naloxone injection can be administered in
the event that the initial nasal naloxone does not reverse
overdose. However, in the recently introduced take-home
naloxone schemes that provide naloxone only for i.n. use
[4], the absence of a back-up injection is a crucial difference.
In this situation the failure of effect of i.n. naloxone, forwhat-
ever reason, can delay the time to naloxone injection until
an ambulance arrives. In the emergency management of
opioid-induced respiratory depression, time is of the essence.
Secondly, there is still uncertainty about dose adequacy
and comparability of nasal naloxone. For the improvised
nasal spray, the only commercially available injectable
formulations have concentrations of either 0.4mg/ml or
1mg/ml (adult formulations). Drug administration via nasal
spray typically involves giving 0.1 ml per nostril, with
0.25 ml considered the maximum, as any greater volume
is probably lost post-nasally (and then swallowed and conse-
quently inactivated) or by nasal drip (and thereby lost) [17].
Some consideration of the practical administration of
the naloxone as nasal spray is warranted. The most con-
centrated formulation available of naloxone is 2 mg/2 ml.
If this concentration of naloxone is administered at
0.25 ml per nostril, then, even if we discount the reported
nasal bioavailability of 4% [17] and assume optimistically
that 40% of naloxone is absorbed, the effective i.n. dose
would be only 0.2 mg, i.e. equivalent to only half the lower
recommended injectable dose. The remainder would be lost
as nasal drip or as post-nasal drip (and inactivation).
Given the small dose that is probably absorbed, reported
beneﬁt from improvised nasal devices (see Table 1) is
puzzling: this should prompt challenge to assumptions
about naloxone dose–response. Dose-ranging studies with
dependent volunteers could explore this sensitively.
Thirdly, at a practical level, uncertainties about the
effectiveness of a nasal spray include: the need for a spray
device to function in horizontal position, the impact of
compromised nasal mucosa (e.g. chronic ulceration from
drug snorting [37]) and the risk of nasal obstruction from
opioid-induced vomit. Any factors which reduce or delay
the absorption of naloxone may lessen the overdose
victim’s chance of survival.
QUESTIONS FOR DEBATE
What data should be available on nasal naloxone
formulations?
If we are considering introduction of a novel non-
injectable formulation of naloxone, then we have a re-
sponsibility to be conﬁdent that the non-injectable form
is absorbed equivalently or to a sufﬁcient extent so as to
produce the life-saving reversal of opioid effect (for which
emergency reason it is being given). It is not obvious that
nasal administration would be equivalent in healthy
volunteers, and even less clear when administered in an
emergency situation to an overdose victim whose drug
use may include damage to nasal mucosa and structure
and also whose crisis overdose may have resulted in vom-
itus or secretions in the nasal cavity. These challenges
need to be examined and addressed. Pharmacokinetics
and study of bioavailability need to be undertaken and
published showing acceptable availability and reliability
before incorporation into standard clinical practice: until
such data are presented publicly, clinicians should not
consider a hypothetical new route of administration as
necessarily reliable.
6 John Strang et al.
© 2016 Society for the Study of Addiction Addiction
Can we list the probable necessary speciﬁcations for an
acceptable non-injectable formulation of naloxone?
We can already list some of the proﬁle of what we would
expect an acceptable nasal naloxone formulation to look
like. In view of the emergency context of the resuscitation
and the probably unconscious state of the overdose vic-
tim, the nasal device would need to be functional in all
orientations (i.e. not just when held vertically, as with
many nasal sprays). If 0.25 ml of ﬂuid can be absorbed
per nostril, and if we put to one side the Dowling ﬁnding
of 4% bioavailability and assume a more optimistic 40%
bioavailability for nasal naloxone, then a more concen-
trated solution is required—perhaps between 4 mg/ml
up to 20 mg/ml. Fortunately, naloxone is highly soluble,
so this should not be a problem, provided that there are
no adverse local effects. It also needs to be established that
the speed of onset of effect is sufﬁcient. It needs to be more
than simply evidence of adequate absorption with a good
area under the curve (AUC) because, for this emergency
situation, it is essential that the absorption occurs rapidly.
We suggest a rapid onset of action with detectable effect
within 5 minutes and good effect within 10 minutes.
Measures of Tmax (i.e. the time at which the maximum
blood serum concentration of naloxone is observed) may
not capture the shape of onset of effect, and so we suggest
also measuring T50% (by which we mean the time taken
to achieve blood levels of 50% of those subsequently re-
corded as Cmax). (There may also be value in measuring
Wmax to examine length of time before blood level drops
below 50% of the value achieved as Cmax).
Clinical experimental studies should be conducted with
opiate-dependent volunteer subjects as well as with healthy
volunteer subjects
A distinct advantage of experimental study of non-
injectable naloxone formulations with dependent volun-
teers is that the rate of absorption of naloxone and the
onset of brain effect can be detected very sensitively
(alongside blood levels), as the naloxone will be detectable
immediately through onset of opiate withdrawal symp-
toms. While this may be distressing to the dependent
volunteer subjects (and while the ethics and the informa-
tion and discussion will need careful discussion and explo-
ration), this is the most powerful experimental approach
to testing such proposed alternative naloxone products.
A current example of a clinical trial in dependent volun-
teers is the Australian randomized, double-blind clinical
trial comparing i.n. versus i.m. naloxone in clients of the
Sydney Medically Supervised Injecting Centre (currently
in progress). Furthermore, if the relative bioavailability of
a novel nasal formulation is high, there may be implica-
tions for the safety proﬁle [38], which would not be
detected in healthy volunteers.
Implications of the prior existence of an approved licensed
injectable naloxone
Some consideration needs to be given to why a clinician
would prescribe naloxone for use by an unlicensed route,
when a highly effective, licensed injection is already in
their armamentarium. Perhaps the nasal spray relieves
ayperson anxiety about giving an i.m. injection. However,
families of patients with other disorders overcome this fear
successfully (e.g. EpiPen, glucagon). Training in technique
is necessary, but this can be conducted efﬁciently and
bolsters the conﬁdence of family and peers to intervene
[39]. In jurisdictions where laypeople (including family
members) are prohibited from administering emergency
medications by injection, there should be urgent challenge
of this obstacle. We posit that, wherever possible, clinicians
should prescribe medications for use by the approved route
of proven effectiveness.
Medico-legal risks considerations
It also needs to be borne in mind that medico-professional
and medico-legal risks may arise when naloxone is pre-
scribed for use by unlicensed route, especially when licensed
naloxone products are applicable. If death were to occur
following nasal administration, what reason would justify
having provided naloxone for use by an unlicensed route?
Cost considerations
The pricing of novel naloxone products is currently un-
certain and possibly variable. Affordability relative to
existing injectable products will be crucial, particularly
for the proposed population-wide provision of emer-
gency naloxone, as articulated by the World Health
Organization [9].
CONCLUSION
There are good reasons to want a non-injectable naloxone
preparation for treating opioid overdose to work. However,
wishing for a product is not the same as demonstrating
efﬁcacy and effectiveness. The benchmark for any non-
injectable naloxone product, if considered for wider com-
munity use, should be that it is, in general terms, at least
as effective and reliable as the licensed injection.
Description of use of improvised nasal formulations
should not be accepted as evidence of effectiveness. Actual
data need to be published and need to report not only on
whether it is effective in some subjects, but also whether
it is effective in all subjects. If no injectable comparator
existed, then a new overdose resuscitation medication that
was effective for many subjects would be valued, even if it
was not effective for all subjects. However, as an established
licensed injectable naloxone with proven efﬁcacy and good
For debate 7
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safety proﬁle already exists, the expectations for a potential
new naloxone formulations are at a higher bar.
In the US, in November 2015, the FDA granted
approval to a naloxone nasal spray [10] which we under-
stand to be a concentrated nasal spray delivering a 4mg
naloxone dose in a 0.1ml volume through what appears
to be an Aptar single-dose liquid nasal spray device [40].
This approval was issued while this ‘For Debate’ was in
press, but we have had opportunity to add brief consider-
ation. This FDA approval only applies to US territory, and
is as a prescription-only medicine, although special local
arrangements allow pharmacists to sell naloxone without
a prescription in at least 15 US states. A competitor nasal
spray product was denied FDA approval [36]. This prompts
us to offer the following additional observations, for debate.
Firstly it is awelcome development to see the appearance of
a tested and approved naloxone nasal spray. At present this
is only available in the US although we anticipate it will be
submitted for consideration in other countries in the near
future. We look forward to seeing more PK information
on the new approved nasal spray. Secondly the denial of
approval for the competitor nasal spray was because of
insufﬁciently rapid absorption (relative to the injectable
naloxone reference). This accords with the concerns
described above.We need proper examination and scrutiny
of proposed use of medications outside their tested and
licensed routes of administration. For example, the relative
bioavailability of the improvised nasal spray (which we
consider above) was found to be only approximately 10%
compared to relative bioavailability of 30-40% for the
new concentrated nasal spray. Thirdly clinicians need this
information on relative bioavailability and extent of inter-
individual variability so that they canmake correct clinical
decisions on dose adjustment for the new nasal spray
(relative to the established injectable formulations for
which dose guidance has been developed).
To conclude, outside clinical trial contexts, clinicians
should prescribe take-home naloxone only as one of its
licensed formulations, since it remains uncertain how ade-
quately and reliably the improvised nasal spray is absorbed.
Or, if clinicians choose to prescribe the improvised naloxone
nasal spray off-licence, then they should include a needle in
the naloxone kit to allow for a back-up injection if the nasal
spray is insufﬁcient.
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a  b  s  t  r  a  c  t
Introduction:  Deaths  from  opioid  overdose  can  be prevented  through  administration  of  the  antagonist
naloxone,  which  has  been  licensed  for injection  since  the  1970s.  To support  wider availability  of  naloxone
in  community  settings,  novel  non-injectable  naloxone  formulations  are  being  developed,  suitable  for
emergency  use  by  non-medical  personnel.
Objectives: 1)  Identify  candidate  routes  of  injection-free  naloxone  administration  potentially  suitable
for  emergency  overdose  reversal;  2)  consider  pathways  for developing  and  evaluating  novel naloxone
formulations.
Methods:  A  three-stage  analysis  of candidate  routes  of  administration  was  conducted:  1)  assessment  of  all
112  routes  of administration  identiﬁed  by  FDA  against  exclusion  criteria.  2)  Scrutiny  of  empirical  data  for
identiﬁed  candidate  routes,  searching  PubMed  and  WHO  International  Clinical  Trials  Registry  Platform
using  search  terms  “naloxone  AND  [route  of administration]”.  3)  Examination  of  routes  for feasibility  and
against  the inclusion  criteria.
Results: Only  three  routes  of  administration  met  inclusion  criteria:  nasal,  sublingual  and  buccal.  Products
are  currently  in development  and  being  studied.  Pharmacokinetic  data  exist  only  for  nasal  naloxone,  for
which  product  development  is more  advanced,  and  one  concentrated  nasal  spray  was granted  licence  in
the  US  in  2015.  However,  buccal  naloxone  may  also  be  viable  and may  have  different  characteristics.
Conclusion: After  40 years  of injection-based  naloxone  treatment,  non-injectable  routes  are  ﬁnally  being
developed.  Nasal  naloxone  has  recently  been  approved  and  will soon  be  ﬁeld-tested,  buccal  naloxone
holds  promise,  and  it is  unclear  what  sublingual  naloxone  will  contribute.  Development  and  approval
of  reliable  non-injectable  formulations  will facilitate  wider  naloxone  provision  across  the  community
internationally.
©  2016  Elsevier  Ireland  Ltd.  All  rights  reserved.ontents
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. Introduction
.1. An excess of deaths
Heroin/opioid  overdose deaths represent a major international
ublic health concern (UNODC/WHO, 2013). Even in countries with
ow prevalence of opioid use relative to consumption of other illicit
rugs, opioids contribute disproportionately to overdose fatali-
ies (Degenhardt et al., 2011; WHO, 2014). In the United States
US), there has been a greater than fourfold increase in overdose
eaths from prescription opioids since 1999, accounting for 16,651
eaths in 2010 alone (CDC, 2012; Volkow et al., 2014), as well as
 simultaneous rise in heroin overdose deaths from 2007 onwards
Calcaterra et al., 2013). In the United Kingdom (UK), a 64% rise
n heroin/morphine deaths was recorded for England and Wales
etween 2012 and 2014 (ONS, 2015).
.2. Wider provision of naloxone
In response, there are increasing calls for wider access to the opi-
id antagonist naloxone (ACMD, 2012; UNODC/WHO, 2013). The
orld Health Organization (WHO) launched new guidelines on the
revention of opioid overdose deaths in 2014, recommending that
people likely to witness an opioid overdose should have accesss
o naloxone” (p. x) (WHO, 2014).
In the US, the National Institute on Drug Abuse (NIDA) made
unding available for the development of novel injection-free
aloxone products (Volkow et al., 2014) and, in November 2015,
he US Food and Drug Administration (FDA) gave approval to a
ew nasal spray of concentrated naloxone solution (FDA, 2015),
hereby giving the ﬁrst regulatory product approval worldwide for
 non-injectable naloxone product.
.3. The promise of non-injectable naloxone
The notion of non-injectable formulations of naloxone is attrac-
ive: naloxone without needles would have many advantages.
irstly, medications which need to be injected are intimidating for
ay persons to use in non-medical settings (Beletsky et al., 2012).
econdly, with use of naloxone by injection, there is the risk of
eedle-stick injury and contraction of blood-borne diseases (e.g.,
epatitis C, HIV), which are highly prevalent among this patient
roup. Thirdly, non-injectable naloxone could more easily be pro-
ided to a much wider intervention workforce (e.g., hostel staff,Please cite this article in press as: Strang, J., et al., Naloxone without the
naloxone for opioid overdose reversal. Drug Alcohol Depend. (2016), h
utreach workers, police, etc.).
New methods of delivery for naloxone need to be suitable for
mergency use by non-medical personnel in community-based set-
ings. Furthermore, formulations should be developed with longer . . . .  . .  .  .  . . .  . .  .  . . . . . . .  . . . . .  . . .  . .  . . . . . .  . .  .  . . .  .  .  . .  . . .  .  .  .  . .  .  .  .  .  . . . .  . . . . .  .  . .  .  .  .  . .  00
shelf-life,  especially in view of the pre-placement of these nalox-
one products to community and families and other non-hospital
settings. Naloxone also needs to be absorbed rapidly, given the
emergency situation, in quantity sufﬁcient to effect quick reversal
of opioid-induced respiratory depression.
The reference for any candidate non-injectable routes is
injectable naloxone, administered by the licensed intramuscular
(IM), intravenous (IV), and subcutaneous (S/C) routes (WHO, 2014).
When administered by the IM or S/C routes, naloxone typically
reverses opioid action within 3–7 min; whereas the effect from IV
administration has an onset typically within 2 min  (UNODC/WHO,
2013). With long-standing approval for, and experience with,
naloxone in injectable form, this sets the standard against which
possible non-injectable formulations need to be measured (Hertz,
2012). In this review, we  examine the options for non-injectable
naloxone with potential application for wider community-based
opioid overdose reversal.
2.  Material and methods
A  three-stage approach has been taken (see Fig. 1). The ﬁrst
stage was  an examination of all 112 routes of drug administration
listed by the US Food and Drug Administration (FDA, 1992) updated
2014). For each of the 112 possible routes of administration, we
considered the potential applicability as a viable non-injectable
route for emergency naloxone delivery by non-medical personnel
(see Supplementary Material). We  thus identiﬁed routes as unsuit-
able according to ﬁve exclusion criteria:
i) If the drug administration is by injection (or similar invasive
procedure);
i)  If the route is only relevant to medical procedures or requires
medical training;
i) If the route is not publicly acceptable for administration by non-
medical  bystanders (e.g., rectal or vaginal administration);
v) If the route does not produce adequate systemic drug concen-
trations;
v) If the route does not produce sufﬁciently rapid drug absorption
relative to parenteral administration (Hertz, 2012).
The second stage was  to systematically search PubMed and the
WHO International Clinical Trials Registry Platform for the poten-
tial candidate routes of administration that had emerged from the
ﬁrst stage. The search term “naloxone AND [route of administra- needle − systematic review of candidate routes for non-injectable
ttp://dx.doi.org/10.1016/j.drugalcdep.2016.02.042
tion]” (e.g., “naloxone AND (nose OR nasal OR intranasal)”) was
used for each route across the electronic databases (see Supplemen-
tary Material for search protocol). R.M. conducted the search and
assessed retrieved studies for eligibility under supervision of J.S.
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iFig. 1. Selection process of c
elevant original research studies that were published in English
anguage and reported on the outcomes of in vivo naloxone admin-
stration (e.g., overdose reversals, pharmacokinetics/-dynamics
ata)  in humans or animals were included in our analysis (see Fig. 2
or PRISMA diagram).
The  third stage, for remaining potential non-injectable routes
f administration, comprised a more rigorous examination of the
vidence against the inclusion criteria (see also Table 1):
i)  The route is suitable for overdose emergency situation.
i) The route does not bear major risk of compromise from overdose
complication.
For the ﬁrst and third stage, R.M. and J.S. used the speciﬁedPlease cite this article in press as: Strang, J., et al., Naloxone without the 
naloxone for opioid overdose reversal. Drug Alcohol Depend. (2016), h
xclusion and inclusion criteria to independently screen all relevant
outes of administration for potential inclusion. When the review-
rs reached different decisions, B.F. acted as the ﬁnal arbitrator for
nclusion or exclusion of a route.te routes of administration.
3.  Results
3.1. Shortlisting potential non-injectable routes from analysis of
all routes of administration
From  examination of all 112 listed routes of administration
(FDA, 1992), four were excluded on the basis that they held no
analytic relevance (‘unassigned’, ‘unknown’, ‘other’ and ‘not appli-
cable’). From the remaining 108 categories, a further 102 were
excluded according to the criteria listed in ‘Method’ (see determi-
nation in Supplementary Material). For instance, enteral delivery
(through the gastro-intestinal mucosa) was excluded because of
insufﬁcient systemic absorption, since naloxone is poorly bioavail-
able if swallowed due to high ﬁrst-pass metabolism (Fishman
et al., 1973). After this process, six non-injectable candidate routes
remained to be considered further (see Table 1).
We  then removed two of these six routes (see bottom of Table 1)needle − systematic review of candidate routes for non-injectable
ttp://dx.doi.org/10.1016/j.drugalcdep.2016.02.042
on the basis that they were overarching categories of routes already
being considered. Thus ‘oropharyngeal’ was removed as substan-
tially overlapping with ‘buccal’ and ‘sublingual’, and ‘transmucosal’
ARTICLE IN PRESSG ModelDAD-5969; No. of Pages 8














IFig. 2. PRISMA ﬂow diag
as removed and considered under the speciﬁc mucosa (‘buc-
al’, ‘intranasal’, ‘sublingual’). With regard to the wider range of
ossible transmucosal routes, rectal delivery, which has replaced
dministration by injection for several emergency medications in
aediactric care (Lyon and McIntosh, 1985; NICE, 2009), was  specif-
cally not included for further consideration since it is unlikely to
e acceptable to family and peers for community-based naloxone
mergency administration to overdose victims.
.2. Fuller examination of the four shortlisted potential
on-injectable routesPlease cite this article in press as: Strang, J., et al., Naloxone without the
naloxone for opioid overdose reversal. Drug Alcohol Depend. (2016), h
We  next examined more fully these four potential routes (buc-
al, nasal, sublingual, respiratory/inhalation) based on the litera-
ure retrieved from the electronic databases. According to the WHO
nternational Clinical Trials Registry Platform, nasal naloxone is study selection process.
currently being investigated in clinical trials by the Norwegian Uni-
versity of Science and Technology (NCT02307721, NCT01939444),
in the US by the University of Cincinnati (NCT01912573) and Light-
lake Sinclair Ltd. (NCT01567670), in Jordan by Mitovie Pharma Ltd.
(NCT01622504), and in Australia at the Sydney Medically Super-
vised Injecting Centre (ACTRN12611000852954). Buccal naloxone
is currently being studied at King’s College London in the UK
(EudraCT 20140001802-16 & 2016-000582-23; see below). No
database entries were found for study of naloxone via the sublin-
gual or respiratory/inhalation routes.
We then consider each of these in turn: needle − systematic review of candidate routes for non-injectable
ttp://dx.doi.org/10.1016/j.drugalcdep.2016.02.042
3.2.1. Respiratory (inhalation). We  excluded the ‘Respiratory
(Inhalation)’ route as not being suitable for further consideration
because the victim might no longer be breathing (or breathing only
very shallowly). Further, current portable devices for drug delivery
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Table  1
Third  stage of selection of potential routes of administration: inclusion criteria.
Inclusion criteria
Name Deﬁnition FDA Code Suitable for overdose crisis
situation
No  risk of compromise from
overdose complication
Buccal Administration directed toward the cheek,
generally from within the mouth
030  X X
Nasal  Administration to the nose; administered by
way of the nose
014 X Possible impairment due to
O/D vomit or secretions
Sublingual Administration beneath the tongue 024 X Possible impairment due to
O/D vomit or secretions or due
to closed mouth
Respiratory  (inhalation) Administration within the respiratory tract by
inhaling orally or nasally for local or systemic
effect
136 Not viable as O/D victim
not  breathing or only
shallowly
X









































(Oropharyngeal  Administration directly to the mouth and
pharynx
Transmucosal Administration across the mucosa 
o the lungs could not be used reliably in an emergency situation
y non-medical personnel (spray or aerosolized naloxone is better
onsidered under the ‘nasal’ category).
.2.2. Sublingual. For the sublingual route, PubMed identiﬁed one
harmacodynamics study in opioid-dependent volunteers, where
ublingual naloxone precipitated withdrawal symptoms in 5 out
f 9 participants (Preston et al., 1990). Apart from separate work
n buprenorphine/naloxone combination, no further investigative
ork for sublingual was identiﬁed.
.2.3. Nasal. PubMed search yielded 18 studies reporting in vivo
dministration of intranasal naloxone. Preclinical data from rodent
tudies showed complete absorption of nasal naloxone (bioavail-
bility relative to IV: F% = 101%; Hussain et al., 1984). In ﬁrst
n-human trials, nasal naloxone was found to elicit withdrawal
ymptoms in opioid-dependent volunteers (Loimer et al., 1992,
994). Since the early 2000s, nasal naloxone has been used off-label
y ambulance personnel (Barton et al., 2005, 2002; Belz et al., 2006;
elly et al., 2005; Kerr et al., 2009; Merlin et al., 2010; Robertson
t al., 2009; Weber et al., 2012) and in the emergency department
Sabzghabaee et al., 2014). More recently, improvised nasal kits
consisting of a pre-ﬁlled naloxone syringe and an atomizer which
ts onto the syringe to generate a nasal spray) have been pro-
ided to opioid users, peers, and families in take-home naloxone
rials (Doe-Simkins et al., 2009; Dwyer et al., 2015; Walley et al.,
013a, 2013b), and succesful overdose reversals using improvised
asal kits have also been reported for police ﬁrst responders (Rando
t al., 2015). However, the only published pharmacokinetics study
n humans found intranasal naloxone (2 mg/5 mL)  had a relative
ioavailability of only 4% (Dowling et al., 2008).
.2.4. Buccal. PubMed search identiﬁed two preclinical studies on
uccal naloxone. In rodents, buccal naloxone administration led to
igh bioavailability (F% = 69–71%) and a Tmax of 24 min  (Hussain
t al., 1987, 1988), whereas in dogs, despite buccal Tmax at 18 min,
ioavailability was low (16%) (Hussain et al., 1988).
Consequently, only three routes of administration are carried
orward for full consideration as candidate routes of administrationPlease cite this article in press as: Strang, J., et al., Naloxone without the 
naloxone for opioid overdose reversal. Drug Alcohol Depend. (2016), h
or emergency naloxone by non-medical personnel: nasal, sub-
ingual and buccal. We  now compare all three routes more fully
gainst the FDA-identiﬁed reference route (injectable naloxone)
Hertz, 2012).0 Absorption likely to be too
slow
Possible impairment due to
O/D vomit or secretions
2 - As for buccal -
3.3. Testing requirements for potential new routes of
administration (nasal, sublingual and buccal)
For all three identiﬁed candidates non-injectable routes (nasal,
sublingual and buccal), investigators and manufacturers need to
consider the FDA guidance on development of novel naloxone for-
mulations for outpatient use (Hertz, 2012). The FDA proposed this
strategy mindful of the good safety proﬁle of naloxone: while nalox-
one blocks opiate receptors, it has no pharmacological effect in
individuals who are not opiate-dependent and do not have any opi-
oids in their system. Moreover, as it has no potential of abuse due to
lack of euphoriant effect (Brunton et al., 2010), the pharmacokinet-
ics of novel naloxone formulations can be safely tested in healthy
volunteers. According to the FDA guidance (Hertz, 2012), pharma-
cokinetic studies will need to “[e]valuate the relative bioavailability
of at least two  different doses compared to parenteral injection of
naloxone (IM, IV or SC). [Studies should] [c]ompare a parenteral
dose of naloxone of at least 0.4 mg  to dose(s) of the new product
that would be expected to result in similar or greater drug exposure.
Target plasma naloxone levels [should be] detectable in all subjects
for a meaningful duration comparable to approved product.”
The  FDA guidance (Hertz, 2012) outlines the following key ques-
tions concerning the bioavailability and usability of a new product:
1) “If the relative bioavailability is low, will there be adequate efﬁ-
cacy?  If the relative bioavailability is high, are there implications
for  the safety proﬁle?”
2) “Can the product be used by the intended population, i.e. [is]
administration by someone other than the patient [possible]?”
For all potential non-injectable naloxone products, it will be
important to focus on absorption within the ﬁrst 20–30 min. For
emergency overdose applications, any novel naloxone product will
need to be absorbed rapidly into the bloodstream and thence across
the blood-brain barrier. This is plausible for the nasal, buccal and
sublingual routes, since they all involve absorption across a mucous
membrane outside the gastro-intestinal tract. They drain to the
peripheral circulation rather than the hepatic portal vein, thus
avoiding the hepatic portal system and ﬁrst-pass metabolism in
the liver.
The nasal route is characterized by high blood perfusion ofneedle − systematic review of candidate routes for non-injectable
ttp://dx.doi.org/10.1016/j.drugalcdep.2016.02.042
the nasal mucosa which facilitates transmucosal absorption, and
drainage mainly occurs into the facial veins (Dale et al., 2006;
Standring, 2015). The buccal route (from the oral vestibular cav-
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ein via the facial veins, and thence rapidly to the brain (Standring,
015).
For nasal administration, Ehrick et al. (2013) identify three
echanisms as signiﬁcant (inertial impaction, gravitational sedi-
entation, and Brownian diffusion) of which they identify inertial
mpaction as the most important mechanism, with absorption
nderstood to take place primarily in the posterior/respiratory zone
f the nasal cavity (Ehrick et al., 2013). Additionally, a nose-to-brain
N2B) connection has been hypothesized. It is mooted that drugs
ould be transported directly into the cerebrospinal ﬂuid via the
lfactory and trigeminal nerves (Djupesland et al., 2014) through
he olfactory epithelium (on the roof of the nasal cavity) projecting
irectly into the olfactory bulb. However, human evidence of direct
rug transport from the nose to the cerebrospinal ﬂuid is currently
till lacking (Djupesland et al., 2014; Merkus et al., 2003).
In  addition to these anatomical and pharmacological factors,
e need to consider the context of emergency overdose reversal
e.g., devices need to be portable, accessible, easy to use and also
perational on an unconscious supine overdose victim) as well as
he physical health of the target population, including potential
amage to, or obstruction of, the relevant mucosa.
.3.1. Intranasal. Clinical reports describe use of improvised nasal
aloxone kits which indicate life-saving beneﬁt in many situations
see Results 3.2). However, for non-concentrate nasal kits, there
emains uncertainty with regard to the formulation’s bioavailabil-
ty and reliability of clinical effectiveness (Strang et al., 2016).
or example, Dowling et al. (2008) found that non-concentrate
asal naloxone spray (2 mg/5 mL)  had a bioavailability of only
%, although the authors themselves acknowledged that the poor
bsorption was likely due to the insufﬁciently concentrated formu-
ation.
In two ambulance-based clinical trials, intranasal naloxone had
 substantial non-response rate: among opioid overdose victims,
6% (using 2 mg/5 mL  nasal formulation; Kelly et al., 2005) and
8% (using 2 mg/mL  nasal formulation; Kerr et al., 2009) required
 second rescue dose of naloxone (the second dose given IM).
For  a purpose-developed nasal naloxone spray, a more concen-
rated formulation of naloxone should be used, e.g., at least 5–10×
urrent concentrations, a) to overcome the drug loss associated
ith administration of excessive volumes to the nasal cavity and
) to administer naloxone across the recommended dose range (i.e.
ioequivalent to 0.4–2 mg  IV or IM).
A  signiﬁcant positive development in this regard is the recent
DA approval of a new nasal spray formulation of a concentrated
aloxone solution (US territory only) (FDA, 2015). Pharma-
okinetics data (including dose-equivalence and constancy) on
oncentrated naloxone nasal spray will hopefully become available
nd it will be important to ﬁeld-test the new product to assess the
otential signiﬁcance of practical obstacles, e.g., inter-individual
ariability, impact of airway blockage or apnea, impact of vomitus
n the nasal passages or mouth, impact of nasal mucosal dam-
ge from drug abuse. This is necessary because drug users may
ave damaged nasal mucosa − for example, ulceration, scarring
nd loss of tissue from repeated cocaine use (Peyrière et al., 2013).
bsorption may  consequently vary substantially between individ-
als, making it difﬁcult to achieve systemic drug levels rapidly
nd reliably. There is also the possibility of interference with nasal
bsorption from vomiting associated with the overdose, thereby
endering the nasal cavity compromised.
.3.1. Sublingual. An FDA product application was submitted inPlease cite this article in press as: Strang, J., et al., Naloxone without the
naloxone for opioid overdose reversal. Drug Alcohol Depend. (2016), h
015 for a sublingual naloxone spray (FDAnews, 2015). If the
aloxone were to be absorbed rapidly and efﬁciently, then this
ould be viable. However, there are several concerns regarding the
uitability of the sublingual route for the emergency administra- PRESS
pendence xxx (2016) xxx–xxx
tion  of naloxone. Access to the mucosa under the tongue may  be
obstructed if the mouth of the overdose victim is closed and/or
if vomiting has occurred. A sublingual spray would be difﬁcult to
administer, as liquid may  be lost to swallowing. Sublingual tablets
are typically small and would be hard to position. Furthermore,
signiﬁcant inter-subject variability of sublingual naloxone delivery
and effect was observed in a pharmacodynamics study in opioid
users (Preston et al., 1990).
3.3.2.  Buccal. Despite lack of human in vivo data for buccal nalox-
one, we see merit in exploration of the option of a solid-form
rapid-dispersal buccal tablet formulation. Working between the
Addictions Department and the Institute of Pharmaceutical Science
at King’s College London, we have developed a working proto-
type lyophilised tablet of naloxone, suitable for application to the
buccal mucosa with rapid drug release for absorption (e.g., within
30 s; Alqurshi et al., in press). Approval has been received from the
Medicines and Healthcare products Regulatory Agency (MHRA) in
the UK for a ﬁrst-in-human CTIMP to investigate buccal delivery of
naloxone (EudraCT number 2014-001802-16), and the Phase-I trial
will generate pharmacokinetics data of naloxone absorption from
the buccal cavity in healthy volunteers. This ﬁrst study is examin-
ing absorption of a buccal liquid, and a subsequent study (EudraCT
number 2016-000582-23) will examine absorption from the buccal
lyophilized formulation of naloxone which we have developed and
manufactured (Alqurshi et al., in press) and whose pharmacokinet-
ics will be compared to those with IV and IM injection of the existing
licensed naloxone. In this way, we will explore dose comparabil-
ity and draw a comparison between absorption of buccal naloxone
from solution and from the new lyophilized formulation.
4. Discussion
The development of non-injectable formulations of naloxone
is of major importance because of the potential for administra-
tion by non-medical people in emergency situations. Injectable
routes work well and are ﬁt for purpose for use by medical
staff in hospital settings or by ambulance personnel attending a
community emergency overdose scenario. However, the consid-
eration is different for emergency administration by the general
public (i.e. without medical training). While family members can
be trained and are regularly given such training and emergency
injectable medications for other potential medical crises (e.g.,
adrenaline/epinephrine for allergy anaphylaxis, insulin for diabet-
ics, etc.), there would nevertheless be greater ease of distribution
and comfort with emergency administration if an effective and reli-
able non-injectable formulation of naloxone was  available.
Examination of the extensive list of more than 100 different
routes of administration identiﬁed three plausible non-injectable
routes − nasal, sublingual and buccal − which warrant proper
study. If successful, all three routes could become viable, cost-
effective future alternatives to the licensed naloxone injection and
could facilitate effective bystander response to opioid-overdose
while minimizing associated risk.
Consideration and investigation of nasal naloxone is the more
advanced area. After a decade of community provision of impro-
vised naloxone nasal spray, several pharmaceutical companies
have recently been developing and testing purpose-made naloxone
nasal sprays.
In  November, 2015, FDA approved a ﬁrst concentrated naloxone needle − systematic review of candidate routes for non-injectable
ttp://dx.doi.org/10.1016/j.drugalcdep.2016.02.042
nasal spray (FDA, 2015) and granted fast-track review to a new drug
application for a subligual naloxone spray (FDAnews, 2015). In the
US at least, the new concentrate nasal product is expected to replace
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r evidence of bioavailability − had been introduced in growing
umbers since the late 2000s.
Sublingual medications have been used in medicine to great
eneﬁt in emergency situations, such as glyceryl trinitrate (GTN)
ublingual tablets or spray as acute treatment of angina or myocar-
ial infarct. However, the sublingual route may  be compromised if
here is vomit or secretions.
No  human data exist for buccal naloxone to date, and study
f the buccal route for naloxone administration is less advanced.
owever, the buccal route has been successfully used to develop
on-injectable versions of other medications previously available
s injection only. Buccal midazolam (‘Buccolam’) produces rapid
nset of action and its bioavailability (80%) is slightly superior
o nasal midazolam (73–75%; Dale et al., 2006; Knoester et al.,
002; Schwagmeier et al., 1998; Taylor et al., 2008). Buccolam is
ow a licensed treatment that parents can administer while await-
ng professional medical care (MHRA, 2011). There have also been
romising experimental results with buccal naltrexone delivery in
umans (Paderni et al., 2013).
With regard to feasibility of the three candidate routes (see also
able 1), we consider the nasal route to be strong if concentrated
olutions are used and provided dose-titration schedules can be
ade possible. We  consider the sublingual route to be weakest,
iven that access to the sublingual mucosa may  be obstructed in at
east two scenarios: a) if the mouth of the overdose victim is closed
nd/or b) if vomiting has occurred. We  consider the buccal route
o hold real potential if rapid absorption and good stability can be
chieved.
The main strength of this review lies in the methodological
pproach of its exhaustive consideration of all FDA-recognized
outes of administration. However, we cannot rule out the pos-
ibility that other non-injectable routes that may  in future prove
easible for naloxone administration due to technological advances.
he scope of this review is further limited by the lack of empirical
ata from pre-clinical or clinical studies, which reﬂects the lack of
nvestment in naloxone product development by science and by
he pharmaceutical industry. A particular current failing is the dis-
onnect between clinical innovation and the need for evidence of
ioavailability and clinical safety (Strang et al., 2016).
With regard to clinical safety, we suggest that the risk of adverse
eactions should be studied for novel formulations. The dosage of
ny new formulation will need to strike a balance between revers-
ng opioid action without causing severe adverse reactions (Hertz,
012). Reports of the harm caused by naloxone over-antagonism
ave been described, and high-dose naloxone formulations with
ncreased risk of over-antagonism may  also result in negative atti-
udes from drug users, as previously reported (Neale and Strang,
015). Similar to testing of the maximum tolerated dose in cancer
reatment, there may  be merit in experimental study conducted
ith opioid-dependent volunteers in order to establish, in a pop-
lation closer to the relevant target population, the non-response
ate, dose adequacy and the speed with which the novel naloxone
ormulation reverses central opioid action.
At least one study has been conducted using a vulnerable
opulation (i.e. opioid-dependent prisoners) to assess the phar-
acodymanics of nasal naloxone (Loimer et al., 1992). However,
tmost importance is necessary in design and conduct of studies in
pioid-dependent volunteers with attention to the informed con-
ent procedure to ensure that all interested subjects are properly
nformed and sufﬁciently protected from potential harm. Com-
unity consultation with service user groups has already been
nitiated to discuss what potential study designs would be feasiblePlease cite this article in press as: Strang, J., et al., Naloxone without the 
naloxone for opioid overdose reversal. Drug Alcohol Depend. (2016), h
nd ethically sound.
At  a minimum, any licensed new naloxone product should be
arefully monitored for potential side effects and non-response
ate once it enters the market, and take-home naloxone recipients PRESS
pendence xxx (2016) xxx–xxx 7
should  be actively encouraged to report any adverse reactions that
may  occur.
To  conclude, deaths from opioid overdose can be prevented
through prompt administration of naloxone, and there is increas-
ing pre-provision of naloxone for emergency use by non-medical
personnel. However, worldwide, provision is held back by reliance
on injectable formulations. From application of the FDA criteria and
review of all 112 categories for routes of administration, we identify
only three routes of possible non-injectable naloxone administra-
tion which meet the FDA criteria: nasal, sublingual and buccal.
Improvised nasal naloxone kits have been distributed in many
cities, and a ﬁrst concentrate nasal spray was granted FDA  approval
in November, 2015, although pharmacokinetic data are still not
available in the peer-reviewed domain and inter-individual dose
variability needs to be studied. The buccal route may  have a differ-
ent pharmacokinetic proﬁle and may  have the advantage of ease
of carriage and administration as well as not being obstructed by
opiate-induced vomiting. After 40 years of opioid overdose treat-
ment by naloxone injection, non-injectable naloxone products are
ﬁnally being explored, and nasal, sublingual and buccal routes of
delivery warrant proper exploration and testing.
Author contributions
JS  and RM drafted the manuscript. RM conducted the database
analyses. AA, BF, DT, and PR contributed to the overall work and
further development of the manuscript. All authors approved of
the ﬁnal draft of the manuscript.
Funding
No  speciﬁc funding was  sought or secured for the study reported
in this paper.
Declaration of interests
JS  declares that he is a researcher and clinician who has worked
with a range of types of treatment and rehabilitation service-
providers. JS is supported by the National Institute for Health
Research (NIHR) Biomedical Research Centre for Mental Health at
South London and Maudsley NHS Foundation Trust and King’s Col-
lege London. He has also worked with a range of governmental and
non-governmental organisations, and with pharmaceutical com-
panies to seek to identify new or improved treatments (including
naloxone products) from whom he and his employer (King’s College
London) have received honoraria, travel costs and/or consultancy
payments. This includes work with, during past 3 years, Martindale,
Reckitt-Benckiser/Indivior, MundiPharma, Braeburn/MedPace and
trial medication supply from iGen. His employer (King’s College
London) has registered intellectual property on a novel buccal
naloxone formulation with which all authors are involved. JS has
also been named in a patent registration by a Pharma company
as inventor of a concentrated nasal naloxone spray. For a fuller
account, see JS’s web-page at http://www.kcl.ac.uk/ioppn/depts/
addictions/people/hod.aspx.
DT  is supported by the National Health Service (NHS), the
NIHR Mental Health Research Network (MHRN), the Department
for Transport (DfT), and the Driver and Vehicle Licensing Agency
(DVLA). He serves as Advisory Board Member of Lundbeck, Servier,
and Sunovion. DT has received research funding from BMS, Janssen,needle − systematic review of candidate routes for non-injectable
ttp://dx.doi.org/10.1016/j.drugalcdep.2016.02.042
and Lundbeck as well as honoraria for lectures from Janssen,
Otsuka, Servier, Lundbeck.
RM,  AA, BF, and PR have no interests to declare except that King’s



































implementation of overdose education and nasal naloxone distribution in
Massachusetts: interrupted time series analysis. BMJ  346, f174.
Weber, J.M., Tataris, K.L., Hoffman, J.D., Aks, S.E., Mycyk, M.B., 2012. Can nebulized
naloxone be used safely and effectively by emergency medical services forARTICLEAD-5969; No. of Pages 8
 J. Strang et al. / Drug and Alco
roperty on a novel naloxone formulation with which JS, RM,  AA,
F, PR, and DT are involved.
ppendix  A. Supplementary data
Supplementary data associated with this article can be found, in
he online version, at http://dx.doi.org/10.1016/j.drugalcdep.2016.
2.042.
eferences
CMD, 2012. Consideration of Naloxone. The Stationery Ofﬁce, Home Ofﬁce,
London, England.
lqurshi, A., Kumar, Z., McDonald, R., Strang, J., Buanz, A., Ahmed, S., Allen, E.,
Cameron, P., Rickard, J., Sandhu, V., Holt, C., Stansﬁeld, R., Taylor, D., Forbes, B.,
Royall, P., in press. Amorphous formulation and in vitro performance testing of
instantly disintegrating buccal tablets for the emergency delivery of naloxone.
arton, E.D., Ramos, J., Colwell, C., Benson, J., Baily, J., Dunn, W.,  2002. Intranasal
administration of naloxone by paramedics. Prehosp. Emerg. Care 6, 54–58.
arton, E.D., Colwell, C.B., Wolfe, T., Fosnocht, D., Gravitz, C., Bryan, T., Dunn, W.,
Benson, J., Bailey, J., 2005. Efﬁcacy of intranasal naloxone as a needleless
alternative for treatment of opioid overdose in the prehospital setting. J.
Emerg. Med. 29, 265–271.
eletsky,  L., Rich, J.D., Walley, A.Y., 2012. Prevention of fatal opioid overdose. JAMA
308, 1863–1864.
elz, D., Lieb, J., Rea, T., Eisenberg, M.S., 2006. Naloxone use in a tiered-response
emergency medical services system. Prehosp. Emerg. Care 10, 468–471.
runton, L., Chabner, B., Knollman, B. (Eds.), 2010. Goodman & Gilman’s The
Pharmacological Basis of Therapeutics. McGraw Hill, New York.
DC, 2012. CDC grand rounds: prescription drug overdoses — a U.S epidemic.
MMWR 61, 10–13.
alcaterra,  S., Glanz, J., Binswanger, I.A., 2013. National trends in pharmaceutical
opioid related overdose deaths compared to other substance related overdose
deaths: 1999–2009. Drug Alcohol Depend. 131, 263–270.
ale,  O., Nilsen, T., Loftsson, T., Tønnesen, H.H., Klepstad, P., Kaasa, S., Holand, T.,
Djupesland, P.G., 2006. Intranasal midazolam: a comparison of two delivery
devices in human volunteers. J. Pharm. Pharmacol. 58, 1311–1318.
egenhardt,  L., Bucello, C., Mathers, B., Briegleb, C., Ali, H., Hickman, M.,  McLaren, J.,
2011. Mortality among regular or dependent users of heroin and other opioids:
a  systematic review and meta-analysis of cohort studies. Addiction 106, 32–51.
jupesland, P.G., Messina, J.C., Mahmoud, R.A., 2014. The nasal approach to
delivering treatment for brain diseases: an anatomic physiologic, and delivery
technology overview. Ther. Deliv. 5, 709–733.
oe-Simkins, M.,  Walley, A.Y., Epstein, A., Moyer, P., 2009. Saved by the nose:
bystander-administered intranasal naloxone hydrochloride for opioid
overdose. Am.  J. Public Health 99, 788–791.
owling, J., Isbister, G.K., Kirkpatrick, C.M., Naidoo, D., Graudins, A., 2008.
Population pharmacokinetics of intravenous intramuscular, and intranasal
naloxone in human volunteers. Ther. Drug Monit. 30, 490–496.
wyer,  K., Walley, A.Y., Langlois, B.K., Mitchell, P.M., Nelson, K.P., Cromwell, J.,
Bernstein, E., 2015. Opioid education and nasal naloxone rescue kits in the
emergency department. West. J. Emerg. Med. 16, 381–384.
hrick,  J.D., Shah, S., Shaw, C., Kulkarni, V., Coowanitwong, I., De, S., Suman, J., 2013.
Considerations for the development of nasal dosage forms. In: Kolhe, P., et al.
(Eds.), Sterile Product Development, Advances in the Pharmaceutical Sciences
(AAPS Series 6). American Association of Pharmaceutical Scientists, http://dx.
doi.org/10.1007/978-1-4614-7978-9 5.
DA, 1992. Route of Administration (accessed on 10.5.15.). http://www.fda.gov/
Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/
ElectronicSubmissions/DataStandardsManualmonographs/ucm071667.htm.
DA,  2015. FDA Moves Quickly to Approve Easy-to-use Nasal Spray to Treat Opioid
Overdose (accessed on 11.18.15.). http://www.fda.gov/NewsEvents/
Newsroom/PressAnnouncements/ucm473505.htm.
DAnews, 2015. FDA Grants Fast Track to Insys Therapeutics’ Naloxone (accessed
on 2.1.16.). http://www.fdanews.com/articles/173913-fda-grants-fast-track-
to-insys-therapeutics-naloxone.
ishman,  J., Roffwarg, H., Hellman, L., 1973. Disposition of naloxone-7, 8-3H in
normal and narcotic-dependent men. J. Pharmacol. Exp. Ther. 187, 575–580.
ertz, S., 2012. Naloxone for Outpatient Use: Data Required to Support an NDA
(accessed on 05.30.14.). http://www.fda.gov/downloads/Drugs/NewsEvents/
UCM300874.pdf.
ussain, A., Kimura, R., Chong-Heng, H., Kashihara, T., 1984. Nasal absorption of
naloxone and buprenorphine in rats. Int. J. Pharm. 21, 233–237.
ussain,  M.A., Aungst, B.J., Kearney, A., Shefter, E., 1987. Buccal and oral
bioavailability of naloxone and naltrexone in rats. Int. J. Pharm. 36, 127–130.
ussain, M.A., Aungst, B.J., Koval, C.A., Shefter, E., 1988. Improved buccal delivery
of opioid analgesics and antagonists with bitterless prodrugs. Pharm. Res. 5,
615–618.Please cite this article in press as: Strang, J., et al., Naloxone without the
naloxone for opioid overdose reversal. Drug Alcohol Depend. (2016), h
elly, A.-M., Kerr, D., Dietze, P., Patrick, I., Walker, T., Koutsogiannis, Z., 2005.
Randomised trial of intranasal versus intramuscular naloxone in prehospital
treatment for suspected opioid overdose. Med. J. Aust. 182, 24–27.
err, D., Kelly, A.M., Dietze, P., Jolley, D., Barger, B., 2009. Randomized controlled
trial comparing the effectiveness and safety of intranasal and intramuscular PRESS
pendence xxx (2016) xxx–xxx
naloxone for the treatment of suspected heroin overdose. Addiction 104,
2067–2074.
Knoester, P.D., Jonker, D.M., van der Hoeven, R.T.M., Vermeij, T.A.C., Edelbroek,
P.M., Brekelmans, G.J., de Haan, G.J., 2002. Pharmacokinetics and
pharmacodynamics of midazolam administered as a concentrated intranasal
spray. A study in healthy volunteers. Br. J. Clin. Pharmacol. 53, 501–507.
Loimer, N., Hofmann, P., Chaudhry, H.R., 1992. Nasal administration of naloxone for
detection of opiate dependence. J. Psychiatr. Res. 26, 39–43.
Loimer,  N., Hofmann, P., Chaudhry, H.R., 1994. Nasal administration of naloxone is
as effective as the intravenous route in opiate addicts. Int. J. Addict. 29,
819–827.
Lyon, A., McIntosh, N., 1985. Rectal aminophylline in the management of apnoea of
prematurity. Arch. Dis. Child. 60, 38–41.
MHRA, 2011. Buccal Midazolam (Buccolam): New Authorised Medicine for
Paediatric Use—care Needed when Transferring from Unlicensed Formulations
(accessed on 12.2.14.). http://www.mhra.gov.uk/Safetyinformation/
DrugSafetyUpdate/CON131931.
Merkus, P., Guchelaar, H.-J., Bosch, D.A., Merkus, F.W., 2003. Direct access of drugs
to the human brain after intranasal drug administration? Neurology 60,
1669–1671.
Merlin, M.A., Saybolt, M.,  Kapitanyan, R., Alter, S.M., Jeges, J., Liu, J., Calabrese, S.,
Rynn, K.O., Perritt, R., Pryor 2nd, P.W., 2010. Intranasal naloxone delivery is an
alternative to intravenous naloxone for opioid overdoses. Am.  J. Emerg. Med.
28, 296–303.
NICE, 2009. Epilepsy − Scenario: Managing a Seizure (accessed on 12.02.14.).
http://cks.nice.org.uk/epilepsy#!scenario:1.
Neale, J., Strang, J., 2015. Naloxone—does over-antagonism matter? Evidence of
iatrogenic harm after emergency treatment of heroin/opioid overdose.
Addiction 110, 1644–1652.
ONS,  2015. Statistical Bulletin: Deaths Related to Drug Poisoning in England and




Paderni,  C., Campisi, G., Schumacher, A., Gottsche, T., Giannola, L.I., De Caro, V.,
Wolff, A., 2013. Controlled delivery of naltrexone by an intraoral device:
in vivo study on human subjects. Int. J. Pharm. 452, 128–134.
Peyrière,  H., Léglise, Y., Rousseau, A., Cartier, C., Gibaja, V., Galland, P., 2013.
Necrosis of the intranasal structures and soft palate as a result of heroin
snorting: a case series. Subst. Abuse 34, 409–414.
Preston, K.L., Bigelow, G.E., Liebson, I.A., 1990. Effects of sublingually given
naloxone in opioid-dependent human volunteers. Drug Alcohol Depend. 25,
27–34.
Rando, J., Broering, D., Olson, J.E., Marco, C., Evans, S.B., 2015. Intranasal naloxone
administration by police ﬁrst responders is associated with decreased opioid
overdose deaths. Am.  J. Emerg. Med. 33, 1201–1204.
Robertson, T.M., Hendey, G.W., Stroh, G., Shalit, M.,  2009. Intranasal naloxone is a
viable alternative to intravenous naloxone for prehospital narcotic overdose.
Prehosp. Emerg. Care 13, 512–515.
Sabzghabaee, A.M., Eizadi-Mood, N., Yaraghi, A., Zandifar, S., 2014. Naloxone
therapy in opioid overdose patients: intranasal or intravenous? A randomized
clinical trial. Arch. Med. Sci. 10, 309–314.
Schwagmeier, R., Alincic, S., Striebel, H., 1998. Midazolam pharmacokinetics
following  intravenous and buccal administration. Br. J. Clin. Pharmacol. 46,
203–206.
Standring, S., 2015. Gray’s Anatomy. Elsevier Health Sciences, Amsterdam.
Strang, J., McDonald, R., Tas, B., Day, E., 2016. Clinical provision of improvised nasal
naloxone without experimental testing and without regulatory approval:
imaginative shortcut or dangerous bypass of essential safety procedures?
Addiction,  http://dx.doi.org/10.1111/add.13209.
Taylor,  D., Okocha, C., Paton, C., Smith, S., Connolly, A., 2008. Buccal midazolam for
agitation on psychiatric intensive care wards. Int. J. Psychiatry Clin. Pract. 12,
309–311.
UNODC/WHO, 2013. Opioid Overdose: Preventing and Reducing Opioid Overdose
Mortality (accessed on 5.30.14.). http://www.unodc.org/docs/treatment/
overdose.pdf.
Volkow, N.D., Frieden, T.R., Hyde, P.S., Cha, S.S., 2014. Medication-assisted
therapies—tackling the opioid-overdose epidemic. N. Engl. J. Med. 370,
2063–2066.
WHO, 2014. Community Management of Opioid Overdose (accessed on 11.11.14.).
http://apps.who.int/iris/bitstream/10665/137462/1/9789241548816 eng.
pdf?ua=1&ua=1.
Walley, A.Y., Doe-Simkins, M.,  Quinn, E., Pierce, C., Xuan, Z., Ozonoff, A., 2013a.
Opioid overdose prevention with intranasal naloxone among people who take
methadone. J. Subst. Abuse Treat. 44, 241–247.
Walley, A.Y., Xuan, Z., Hackman, H.H., Quinn, E., Doe-Simkins, M.,
Sorensen-Alawad,  A., Ruiz, S., Ozonoff, A., 2013b. Opioid overdose rates and needle − systematic review of candidate routes for non-injectable
ttp://dx.doi.org/10.1016/j.drugalcdep.2016.02.042
suspected opioid overdose? Prehosp. Emerg. Care 16, 289–292.
COMPREHENSIVE REVIEW
International patent applications for non-injectable naloxone for opioid




REBECCAMCDONALD1 , ØYVIND DANIELSSON GLENDE2,3, OLA DALE2,4 &
JOHN STRANG1
1National Addiction Centre Institute of
Q6
Psychiatry Psychology and Neuroscience, King’s College London, London, UK,
2Department of Circulation and Medical Imaging, NTNU-The Norwegian University of Science and Technology, Trondheim,
Norway, 3Apotek 1 Nardo, Trondheim, Norway, and 4St. Olav’s Hospital, University Hospital of Trondheim, Trondheim,
Norway
Abstract
Q7 Issues. Non-injectable naloxone formulations are being developed for opioid overdose reversal, but only limited data have been
published in the peer-reviewed domain. Through examination of a hitherto-unsearched database, we expand public knowledge of
non-injectable formulations, tracing their development and novelty, with the aim to describe and compare their pharmacokinetic
properties. Approach. (i) The PatentScope database of the World Intellectual Property Organization was searched for relevant
English-language patent applications; (ii) Pharmacokinetic data were extracted, collated and analysed; (iii) PubMed was searched
using Boolean search query ‘(nasal OR intranasal OR nose OR buccal OR sublingual) AND naloxone AND pharmacokinetics’.
Key Findings. Five hundred and twenty-two PatentScope and 56 PubMed records were identiﬁed: three published international
patent applications and ﬁve peer-reviewed papers met eligibility criteria. Pharmacokinetic data were available for intranasal,
sublingual and reference routes (intramuscular, intravenous and subcutaneous). Highly concentrated formulations (10–
40 mg mL!1) had been developed and tested. Sublingual bioavailability was very low (F = 1%; relative to intravenous). Non-
concentrated intranasal spray (1 mg mL!1; 1 mL per nostril) had low bioavailability (F = 11%). For concentrated intranasal
spray formulations (≥10 mg mL!1), bioavailability ranges were F = 21–42% and FIM = 26–57% (relative to intramuscular),
with peak naloxone concentrations (dose-adjusted Cmax = 0.8–1.7 ng mL!1) reached in 19–30 min (tmax). Implications.
Exploratory analysis identiﬁed intranasal bioavailability as associated positively with dose and negatively with volume.
Conclusion. PatentScope is a valuable data source but rarely explored. From data integration from different naloxone patent
applications, we ﬁnd consistent direction of development of intranasal sprays to high-concentration, low-volume formulations with
bioavailability in the 20–60% range. These have potential to deliver a therapeutic dose in 0.1 mL volume. [McDonald R,
Glende ØD, Dale O, Strang J. International patent applications for non-injectable naloxone for opioid overdose
reversal: Exploratory search and retrieve analysis of the PatentScope database. Drug Alcohol Rev 2017;00:000-000]
Key words: intranasal, naloxone, pharmacokinetics, opioid, drug overdose.
Introduction
Q8
On 18 November 2015, the US Food and Drug
Administration (FDA) gave regulatory approval for a
concentrated intranasal (IN) naloxone spray by Adapt
Pharma [1], which constitutes the ﬁrst-ever licensed
non-injectable naloxone product. Regulatory approval
in Canada followed in October 2016 [2]. The FDA and
Health Canada decisions have opened up the possibility,
for North America at least, of wider access to naloxone in
light of the rising death toll from opioid overdoses [3]. At
an estimated 106 000 deaths per annum [4], opioid
overdose deaths are also a growing international public
health concern. To date, globally, no other
non-injectable naloxone formulation has been licensed.
Rebecca McDonald MSc, PhD Student, Øyvind Danielsson Glende MSc, Pharmacy Manager, Ola Dale MD, Professor, John Strang MD, Professor.
Correspondence to Professor Sir John Strang, National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College
London, 4 Windsor Walk, London SE5 8BB, UK. Phone: + 44 (0)20 7848 0438. E-mail: john.strang@kcl.ac.uk
Received 9 November 2016; accepted for publication 21 April 2017.
© 2017 Australasian Professional Society on Alcohol and other Drugs










































































































































Effective non-injectable naloxone products would
remove the risk of needle-stick injury in medical and
community settings. Non-injectable naloxone may offer
a particular implementation advantage for take-home
naloxone (THN) programs, that is, the pre-placement
of naloxone kits with opioid users, families, peers,
community police and staff at treatment services, drop-
in centres and hostels, where it would likely reduce
regulatory obstacles and the current requirement of
training laypersons in needle-and-syringe assembly and
administration [5]. First proposed in 1996 [6], THN
has increasingly been introduced in the past decade,
and recent World Health Organization (WHO)
guidelines and a UN declaration have called for naloxone
access for ‘anyone likely to witness an overdose’ [7,8]. In
response, the FDA, the US Centers for Disease Control
and Prevention, National Institute on Drug Abuse and
Ofﬁce of the Assistant Secretary for Health and Human
Services sponsored a 2012 stakeholder meeting where
key criteria for any novel non-injectable naloxone
product were proposed [9,10].
According to the FDA [9], one or more standardised
doses of a novel non-injectable naloxone formulation
would need to result in plasma naloxone levels (i.e. area
under the curve; AUC) comparable with a parenteral
doseof at least 0.4mg. If the bioavailability [(F= ‘absolute
bioavailability’, relative to intravenous; FIM = ‘relative
bioavailability’, relative to intramuscular (IM)] of the
new product compared with the approved injection is
low, then it is unclear if adequate efﬁcacy can be reached.
Vice versa, if the bioavailability is unexpectedly high, then
this may have implications for the safety proﬁle of the
novel formulation. Furthermore, the bioavailability
compared with injection would need to be reasonably
constant between different individuals. In the emergency
situation of opioid overdose, naloxone needs to be
absorbed rapidly. Absorption would thus need to be at
least as rapid as IM injection, whereby onset of effect
starts within 3 to 7 min of administration [8]. The key
pharmacokinetic (PK) parameters for a non-injectable
naloxone formulation are typically the maximum
observed plasma concentration (Cmax) and the time
from dosing to peak concentration (Tmax), in addition
to bioavailability.
A recent systematic review [11] applied the FDA
criteria to the peer-reviewed literature and identiﬁed
three candidate routes of administration for injection-
free naloxone delivery: IN, sublingual and buccal.
However, at the time of the FDA approval of the ﬁrst
nasal spray, no results from clinical trials on the new
nasal spray were published, and human PK data were
only reported in one peer-reviewed publication for an
improvised IN naloxone spray formulation (2 mg
5 mL!1), with extremely low bioavailability (F = 4%)
[12]. While improvised IN spray devices (administered
by attaching a mucosal atomiser device to a pre-ﬁlled
2 mg 2 mL!1 naloxone syringe) are commonly used
in THN programs in some countries (US Centers for
Disease Control and Prevention) and a signiﬁcant
number of overdose reversals have been reported
[13,14], uncertainties regarding their efﬁcacy have been
considered and primarily concern their potential
non-response rate and lack of safety data [15–17].
Time lag between research and development activity
in the pharmaceutical industry and the publication of
relevant data in the peer-reviewed literature is not
new: Indeed, more than ﬁve decades ago, the discovery
and original synthesis of naloxone was ﬁrst reported in a
1961 patent application [18] before a conference
abstract [19] and a full journal article [20] followed in
subsequent years.
This exploratory review attempts to close the existing
gap in the literature by examining published international
patent applications of non-injectable naloxone
formulations and contributory PK data. The aims are
threefold: (i) to trace the concept and product
development by route of administration; (ii) to describe
the non-injectable naloxone formulations for which
human in vivo data are available; and (iii) to compare
human PK data reported in the patent applications.
Methods
A three-stage approach has been taken.
Stage 1
The PatentScope database of the World Intellectual
Property Organization (WIPO), which contains 58
million patent documents including 3 million published
international patent applications [21], was searched for
patent applications for non-injectable naloxone
formulations. PatentScope was searched for English-
language patent applications (‘Language: EN’) that
were registered with any international patent ofﬁce
(‘Ofﬁce(s): all’) and contained the search term
‘naloxone’ within their First Page (default). Only patent
applications for non-injectable naloxone that contained
human PK data were eligible for inclusion in the
analysis [Aims (ii) and (iii)].
Stage 2
The pharmaceutical properties of the non-injectable
naloxone formulations and human PK data were
extracted from patent applications and summarised. To
improve comparability between formulations, dose-
adjusted values per 1 mg were generated.
2 R. McDonald et al.















































































































Stage 3. To supplement and cross-check the data
obtained in Stages 1 and 2, we also searched PubMed for
human PK data for non-injectable naloxone using the
Boolean search query ‘(nasal OR intranasal OR nose
OR buccal OR sublingual) AND naloxone AND
pharmacokinetics’ (see Table S1 for search protocol).
These three routes of administration were chosen based
on the systematic review [11].
For all three stages, R.M. and Ø.D.G. conducted the
PatentScope and PubMed searches, assessed retrieved
records for eligibility and extracted relevant information
under supervision of the senior authors (O.D. and J.S.).
Results
Stage 1. A PRISMA ﬂow diagram of the selection
process of patent applications is shown in FigureF1 1.
Five hundred and twenty-two PatentScope records
were identiﬁed using the search term ‘naloxone’ for
front-page matches. At this stage, a cross-check was
made for known patent applications, and it was found
that no entry for the FDA-approved Adapt IN spray
product had been captured. We thus additionally
searched PatentScope for ‘Adapt OR Lightlake’-related
entries. In late 2014, Adapt Pharma had bought the
global license from Lightlake Therapeutics Inc. to
develop and commercialise their IN naloxone spray
[22]. After matching for the search term ‘Lightlake’
(front-page search, English language, all patent ofﬁces),
this additional search yielded ﬁve patent applications,
which had not been captured using the search term
‘naloxone’ because Lightlake had not included the
word ‘naloxone’ on the front page. Consequently, we
manually added these ﬁve Lightlake patent applications
(n.b. in the following, we denote these as ‘Lightlake’
unless we refer directly to the licensed Adapt nasal
spray product).
Of the 47 records that remained after removing 480
irrelevant records, 10 were excluded based on their
abstract (e.g. active ingredient other than naloxone).
The remaining 37 records were downloaded for full-text
review and screened for human PK data. Of the 14 patent
applications that contained relevant PK data, 11 were
excluded for the following reasons: ﬁve reported only
animal data, and six were duplicates (earlier or later
versions of patents containing the same PK data but
different patent claims or country of publication). Three
published international patent applications were
identiﬁed as eligible for inclusion: WO/2015/136373,
WO/2015/095644 and WO/2012/156317.
Figure 1. PRISMA diagram of PatentScope search. PK, pharmacokinetic; WIPO, World Intellectual Property Organization.
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A timeline of the publication of all 37 patent
applications (including excluded records) is provided in
Table S2 of the Online Appendix. The timeline shows
that the concept of non-injectable naloxone (drops,
spray, solution, suspension, ointment or gel) was ﬁrst
being explored at the University of Kentucky, with ﬁrst
animal data reported in 1982. The 1990s showed no
activity for IN naloxone except for the patent application
of a spray dispenser by Britannia Pharmaceuticals in
2000 (n.b. the same spray device as in the 2015 FDA-
approved Adapt naloxone spray). In 2005, an IN
naloxone powder was proposed by the Chinese PLA
Academy of Military Science. The ﬁrst human PK data
for IN naloxone were ﬁled by Euro-Celtique in 2012
(WO/2012/156317).
The ﬁrst patent application describing the concept of
sublingual or buccal naloxone was published by the
Israeli company Pentach Pharmaceuticals in 2004, and
patent applications covering sublingual naloxone (spray,
dripping pills) by two Beijing-based companies followed
in 2007 and 2011. In 2012, Euro-Celtique included
sublingual PK data in its patent application on
concentrate IN naloxone spray. In June 2015, INSYS
Pharma submitted two patent applications for sublingual
naloxone spray (no PK data) and was granted FDA fast-
track review later that year [23].
Stage 2: Description of intranasal pharmacokinetic data
We now describe the IN PK data reported in the
published international patent applications WO/2015/
136373 (Lightlake Therapeutics), WO/2015/095644
(AntiOp) and WO/2012/156317 (Euro-Celtique). The
pharmaceutical properties of the naloxone formulations
tested by AntiOp (10 mg mL!1) and Lightlake (10, 20
and 40 mg mL!1) are described in detail in Table S4 of
the Online Appendix; Euro-Celtique only reported the
concentration of their formulations (20 mg mL!1,
40 mg mL!1 Naloxone HCl).
All PK data were obtained using cross-over study
designs, although sample sizes differed from 7 to 35
subjects per arm. For a full summary of the PK data
(including reference routes), please see TableT1 1.
AntiOp described two studies, which are hereby
referred to as ‘Trial 1 (Pilot)’ and ‘Trial 2’. AntiOp tested
a 10 mg mL!1 IN formulation administered as 0.1 mL
into one and two nostrils, as well as 0.2 mL per nostril
(0.1 + 0.1 mL with 5 min interval). Trial 1 (Pilot) also
tested non-concentrate 1 mg mL!1 naloxone, with
mucosal atomiser device attached to a syringe, thus
replicating the improvised IN naloxone distributed
off-label in several countries.
Lightlake presented results from two studies: Study 1
assessed a 10 mg mL!1 formulation, whereas Study 2
tested 20 and 40mgmL!1 formulations, all administered
as 0.1 mL into one and two nostrils (total volume:
0.2 mL).
Euro-Celtique tested IN doses of 8 mg (0.2 mL per
nostril; 20 mg mL!1 concentration) and 16 mg (0.2 mL
per nostril; 40 mg mL!1 concentration). Euro-Celtique
also included a sublingual arm (16 mg mL!1 solution),
but this route is not described here in detail, as its
absolute bioavailability was only 1%.
For IN administration, we present F as well as FIM, as
neither measure was reported across all three patent
applications. (Euro-Celtique only provided F, whereas
the more recent AntiOp and Lightlake patent
applications reported FIM in accordance with guidance
from the FDA).
F: For the Euro-Celtique data, we calculated F values
of 22% (20 mg mL!1, administered as 0.2 mL per
nostril) and 21% (40mgmL!1; 0.2 mL per nostril) using
AUC0-∞ data listed in the PK data appendix of the
patent application. We were unable to obtain the higher
F values of 32% (20 mg mL!1 formulation) and 27%
(40 mg mL!1), which Euro-Celtique cited in-text for
lower doses (1.2 and 1.6 mg, dose-adjusted from 8 and
16mg) in the body of the patent application. AntiOp only
reported FIM, but included an IV reference in Trial 1
(Pilot), which allowed us to determine the following F-
values for comparison: 36% (0.1 mL, one nostril only)
and 42% (0.1 mL per nostril) for the 10 mg mL!1
formulation, and 11% for non-concentrate naloxone
(1 mg mL!1 per nostril).
FIM: Lightlake achieved the highest FIM values
across all three patent applications, with 0.1 mL of the
10 mg mL!1 formulation administered into both
nostrils (FIM = 57%). FIM was lower (48%), when
the volume of the same formulation was doubled
(0.2 mL per nostril). For the 20 mg mL!1 formulation,
FIM was 54% (0.1 mL, one nostril only) and 55%
(0.1 mL per nostril). The 40 mg mL!1 formulations
achieved 49% and 45% when administered into one
and both nostrils, respectively. AntiOp reported the
following FIM values for a 10 mg mL!1 formulation:
34% (0.1 mL, one nostril only), 31–39% (0.1 mL per
nostril) and 26% (0.1 mL per nostril, with
re-administration after 5 min; i.e. total volume of
0.2 mL per nostril). Non-concentrate naloxone
(1 mg mL!1 per nostril) had an FIM of 10%.
t1/2: The terminal half-life (t1/2) is the time it takes for
the blood concentration of a pharmacological agent to
decrease by 50%, which usually translates into the loss
of half of its pharmacological activity. Euro-Celtique
reported the longest terminal half-lives (t1/2) for IN
administration, with 9.1 (40 mg mL!1) and 9.5 h
(20 mgmL!1), although data were only available for four
subjects. In the AntiOp and Lightlake patent
applications, t1/2 fell in the range of 1.2–2.1 h.
4 R. McDonald et al.















































































































tmax: IN tmax was 0.27 h (i.e. 16 min) for non-
concentrated spray (AntiOp, 1 mg mL!1, 1 mL per
nostril) and ranged from 0.31 to 0.50 h (i.e. 19–30 min;
AntiOp 10 mg mL!1, 0.1 mL into one nostril and
Lightlake 40 mg mL!1, 0.1 mL into one nostril) across
concentrated spray formulations.
AUC and Cmax:Dose-adjusted Cmax values (per mg)
were highest for the Lightlake 20 mg mL!1 formulation
administered as 0.1 mL per nostril
(Cmax = 1.66 ng mL!1). The same treatment arm
achieved AUC0-∞ = 2.48 ng * h mL!1. The
Euro-Celtique 20 mg mL!1 formulation reached the
highest AUC0-∞ value (2.76 ng*h mL!1) and a per mg
Cmax of 1.60 ng mL!1. The 1 mg mL!1
non-concentrate AntiOp treatment (administered as
1 mL per nostril) had the lowest values
(AUC0-∞ = 0.45 ng * h mL!1; Cmax = 0.27 ng mL!1).
Additional exploratory analyses: In order to examine the
potential inﬂuence of spray concentration on IN
absorption, we plotted AUC, Cmax, and tmax values
against volume (adjusted by dose for AUC and Cmax)
and dose (Figure F33). For both AUC and Cmax, the plots
indicate a positive association with dose and a negative
association with volume of the IN spray. The graphs do
not suggest a clear association for tmax.
Stage 3
The PubMed search generated 56 matches, with zero
duplicates (see Figure F22 for PRISMA diagram). Forty-
six papers were excluded based on title and abstract
(no primary research data from human-subject
naloxone studies).
The 10 remaining records were then downloaded for
full text, with ﬁve papers excluded for the following
reasons: one was a review article, and four did not
include naloxone PK data (see Table S3 for list of
excluded studies). The remaining eligible ﬁve papers
included human PK data in two papers for IN
naloxone [12,24] and three papers for sublingual
naloxone [25–27]. None of the papers contained
human PK data for buccal naloxone.
Table 1. Pharmacokinetic properties of patent formulations
Study n Conc.(mg mL!1) Nostrils# Dose (mg)/volume (mL) F% FIM% tmax(h)
IV AntiOp Trial 1 13 0.4 0.4/1.0 0.03 ± 0.1
Euro-Celtique 11 1 1.0/1.0 0.85 ± 1.6
IM AntiOp Trial 1 13 NA 1.0/NA 1061, 4 0.33 ± 0.5
AntiOp Trial 2 34 0.4 0.4/1.0 0.17 (0.1, 1.0)
Lightlake 1 14 0.4 0.4/1.0 0.34 ± 0.1
Lightlake 2 28 0.4 0.4/1.0 0.42 (0.1, 2.0)
SQ AntiOp Trial 1 13 NA 1.0/NA 991, 4 941, 4 0.17 ± 0.3
IN AntiOp Trial 1* 13 10 2 2.0/0.2 421, 4 391, 4 0.42 ± 0.3
AntiOp Trial 1* 13 10 1 1.0/0.1 361, 4 341, 4 0.50 ± 0.2
AntiOp Trial 1 7 1 2 2.0/2.0 111, 4 101, 4 0.27 ± 0.1
AntiOp Trial 2* 33 10 2 2.0/0.2 311, 4 0.33 (0.3, 0.8)
AntiOp Trial 2* 35 10 2+23 4.0/0.4 261, 4 0.42 (0.2, 1.0)
Lightlake 1 14 10 2 2.0/0.2 57 0.33 ± 0.1
Lightlake 1 14 10 2 4.0/0.4 48 0.31 ± 0.1
Lightlake 2 28 20 1 2.0/0.1 54 0.33 (0.3, 1.0)
Lightlake 2 28 20 2 4.0/0.2 55 0.33 (0.1, 0.5)
Lightlake 2 28 40 1 4.0/0.1 49 0.50 (0.2, 1.0)
Lightlake 2 28 40 2 8.0/0.2 45 0.33 (0.2, 1.0)
Euro-Celtique 11 20 2 8.0/0.4 22)1, 4 0.34 ± 0.2
Euro-Celtique 12 40 2 16.0/0.4 (21)1, 4 0.39 ± 0.2
SL Euro-Celtique 11 16 16.0/1.0 (1)1, 4 3.91 ± 10.6
Annotations:Values for tmax,Cmax, AUCand t1/2 denotemean±SD, except for values in italics. Values in italics denotemedian ± SD
or median (min, max). Inconsistent information between the patent and the PK data whether the formulation contained10 mg mL!1
naloxone HCl dihydrate or 10 mg mL!1 Naloxone HCl. Dose-adjusted values (per mg) in table are based on Naloxone HCl.
1calculated values;
2harmonised mean;
3re-administration after 5 min;
4calculated F and FIM values based on AUC0-∞;
5sample size = 3;
6sample size = 4. AUC, area under the curve; IM, intramuscular; IN, intranasal; IV, intravenous;NA, not available; SQ, subcutaneous;
SL, sublingual.
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Divergent bioavailability values have been reported
for IN naloxone. One healthy volunteers study
(n = 6) assessed a non-concentrate formulation of IN
naloxone (2 mg 5 mL!1) and reported an absolute
bioavailability of only 4%, which the authors attributed
as possibly because of the dilute solution (and high
volume) used [12]. Higher absorption was reported in
a study [24] with recreational prescription opioid users
(n = 10) where absolute bioavailability of IN
administration of crushed buprenorphine/naloxone
(4:1 ratio) of two concentrations (0.5 and 2 mg
naloxone) was 24% and 30%, respectively.
Systemic uptake after sublingual naloxone
administration was generally found to be low. In
one healthy volunteers study, naloxone doses of 1.4
and 2 mg were administered in combination with
buprenorphine, resulting in a median tmax of 0.8 h
and peak naloxone plasma concentrations below
0.4 ng mL!1 for both doses [26]. A second study
in non-dependent opioid users (n = 8) [27] assessed
escalating naloxone doses (1, 2 and 4 mg) and found
that dose-effect comparisons were impossible, as
many naloxone plasma concentrations were below
the level of quantiﬁcation (0.050 ng mL!1). The
highest individual AUC reported was
0.55 ng * h mL!1.
A third study [25] suggested that sublingual
naloxone bioavailability is negatively associated with
healthy liver functioning. A sublingual 0.5 mg naloxone
tablet (in combination with 2 mg buprenorphine) was
administered to 43 subjects stratiﬁed by hepatic
impairment (mild, moderate or severe), HCV diagnosis
without hepatic impairment and healthy volunteers.
Across all groups, the median tmax ranged from 0.8
to 1.1 h, with mean t1/2 from 1.9 to 5.5 h. However,
the AUC0-last data revealed an approximate 3 to
14-fold increase in total naloxone exposure in subjects
with moderate and severe hepatic impairment.
Likewise, the naloxone Cmax was 3 to 11 times higher
in subjects with hepatic impairment.
Table 1. Pharmacokinetic properties of patent formulations




(ng * h mL!1)
AUC0-last
(ng * h mL!1)
Cmax(ng mL!1) AUC0-∞
(ng * h mL!1)
AUC0-last
(ng * h mL!1)
IV 1.28 ± 0.2 3.87 ± 2.7 1.67 ± 0.5 9.681 4.181
0.89 ± 0.15 17.9 ± 29.9 12.6 ± 12.45 10.5 ± 7.2 17.91 12.61 10.51
IM 1.41 ± 0.3 2.54 ± 1.0 4.43 ± 1.2 2.541 4.431
1.38 ± 0.3 1.05 ± 0.4 1.67 ± 0.4 2.631 4.181
1.21 ± 0.2 0.77 ± 0.2 1.42 ± 0.3 1.38 ± 0.3 1.911 3.551 3.451
1.192 0.91 ± 0.3 1.83 ± 0.4 1.79 ± 0.4 2.26 ± 0.7 4.57 ± 1.1 4.481
SQ 1.59 ± 0.6 2.72 ± 0.8 4.15 ± 1.1 2.721 4.151
IN 1.53 ± 0.2 1.95 ± 1.1 3.47 ± 0.8 0.981 1.741
1.41 ± 0.3 0.84 ± 0.5 1.52 ± 0.5 0.841 1.521
1.64 ± 0.3 0.53 ± 0.2 0.90 ± 0.2 0.271 0.451
1.37 ± 0.3 1.78 ± 1.0 2.63 ± 1.3 0.891 1.321
1.41 ± 0.3 3.06 ± 1.6 4.42 ± 2.2 0.771 1.111
1.19 ± 0.1 2.32 ± 1.0 3.44 ± 1.0 3.41 ± 1.0 1.161 1.721 1.71
1.22 ± 0.1 4.55 ± 2.9 5.68 ± 1.6 5.63 ± 1.6 1.141 1.421 1.41
1.702 3.11 ± 1.1 4.86 ± 1.5 4.81 ± 1.5 1.56 ± 0.6 2.43 ± 0.7 2.41
2.092 6.63 ± 2.3 9.91 ± 2.7 9.82 ± 2.7 1.66 ± 0.6 2.48 ± 0.7 2.46
2.002 5.34 ± 2.4 8.87 ± 3.3 8.78 ± 3.3 1.34 ± 0.6 2.22 ± 0.8 2.20
1.912 10.3 ± 4.0 16.1 ± 3.8 15.9 ± 3.8 1.29 ± 0.5 2.01 ± 0.5 1.99
9.48 ± 3.96 12.8 ± 4.5 22.0 ± 4.26 20.1 ± 4.9 1.601 2.761 2.511
9.09 ± 2.76 18.3 ± 7.5 42.8 ± 10.66 32.8 ± 10.2 1.141 2.671 2.051
SL 1.13 ± 0.26 0.90 ± 0.4 1.50 ± 0.46 2.67 ± 1.8 0.061 0.091 0.171
Annotations:Values for tmax,Cmax,AUC and t1/2 denotemean±SD, except for values in italics. Values in italics denotemedian ±SD
or median (min, max). Inconsistent information between the patent and the PK data whether the formulation contained10 mg mL!1
naloxone HCl dihydrate or 10 mg mL!1 Naloxone HCl. Dose-adjusted values (per mg) in table are based on Naloxone HCl.
1calculated values;
2harmonised mean;
3re-administration after 5 min;
4calculated F and FIM values based on AUC0-∞;
5sample size = 3;
6sample size = 4. AUC, area under the curve; IM, intramuscular; IN, intranasal; IV, intravenous; NA, not available; SQ, subcutaneous;
SL, sublingual.
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Human PK data for purpose-made non-injectable
naloxone formulations had not been reported in peer-
reviewed scientiﬁc papers at the time of the FDA-
approval of the ﬁrst IN naloxone spray [28]. However,
published international patent applications by the
companies AntiOp, Euro-Celtique and Lightlake contain
data on concentrated sublingual and IN spray
formulations in the range 10–40 mg mL!1. Through
integration of data from WIPO PatentScope and
scientiﬁc publications retrieved via PubMed, this
exploratory review charts R&D activity over the past
two decades (particularly 2012–present) and provides
an assessment of the current status of non-injectable
naloxone development relative to pre-deﬁned regulatory
criteria [9,10].
Statement of principal ﬁndings
Across all concentrate IN naloxone formulations,
bioavailability was 21–42% relative to IV and 26–57%
relative to IM. We plotted AUC0-∞ and Cmax values
and found a moderately linear relationship with dose
(higher dose ➔ higher AUC0-∞, Cmax) and a negative
association for volume (lower volume ➔ higher AUC0-
∞, Cmax). The highest IN bioavailability (FIM = 57%)
was reached when 0.1 mL of a 10 mg mL!1
formulation was administered into both nostrils. For
the same formulation, FIM decreased to 48% when
volume doubled to 0.2 mL per nostril. Volume clearly
matters. Also, dose-concentration linearity is evident.
We identify the importance of (low) volume with IN
bioavailability drastically lower (F = 11%) when a
non-concentrate formulation of 1 mg mL!1 was
administered into both nostrils. This conﬁrms previous
reports of low bioavailability (F = 4%) for dilute IN
spray (0.4 mg mL!1) [12].
Sublingual naloxone administration of a concentrate
solution (16 mg mL!1) had very low bioavailability
(F = 1%). This is below the range of 7–9% identiﬁed by
Chiang et al. in their review of sublingual
buprenorphine–naloxone formulations [29]. We
conclude that sublingual is unlikely to be a route of
administration of clinical value.
Strengths and weaknesses of the review
This is the ﬁrst review of non-injectable concentrate
naloxone formulations in the peer-reviewed literature.
It includes examination of public-domain information
from patent applications. A core strength of this
exploratory review lies in the integration of empirical
evidence from PubMed and WIPO PatentScope
databases, capturing both academic and pharmaceutical
industry advances in the ﬁeld.
The validity of our comparison of IN PK data across
different patent applications is strengthened by the
similarity of the IN spray formulations used. While
Euro-Celtique only disclosed dose concentrations, all
formulations all formulations by Lightlake and AntiOp
with provided PK data are characterised by absence of
absorption enhancers (which increase membrane
permeation) and viscosity-increasing agents (which
increase the residence time of naloxone to the nasal
mucosa and thus contributes to better absorption) (see
Table S4 in Online Appendix).
Potential limitations need to be considered. Firstly, not
all research and development activity leads to registration
of intellectual property or to journal publication, and
non-signiﬁcant or negative results have low likelihood of
getting published.
Secondly, our exploratory WIPO PatentScope
database search was unlikely exhaustive. Considering
that our search initially failed to capture the Lightlake
patent applications, we cannot rule out the possibility of
other false-negatives. We conducted the default ‘First
Page’ search, which identiﬁed any patent document with
the search term (‘naloxone’)mentioned on its cover page,
Figure 2. Q9PRISMA diagram of PubMed search. PK, pharmacokinetic.
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generating 522 matches. Had we conducted the more
comprehensive ‘Full Text’ search (‘naloxone’mentioned
in any full-text patent document), PatentScope would
have identiﬁed over 19 000 matches, which would have
exceeded our capacity for manual screening. Compared
with online literature databases such as PubMed or
Embase, the functionality of the PatentScope interface
is less advanced, in that users cannot export full search
results to a citation manager. For every PatentScope
entry, we thus had to download associated documents
individually to assess eligibility for inclusion in our
review. We considered supplementing our PatentScope
search with additional query of all national and regional
patent ofﬁces for which our PatentScope ‘naloxone’
search had yielded relevant entries (Canada, China,
European Union, Germany, Great Britain, Israel,
Russia, Singapore, South Africa and United States; see
Online Supplement 2). However, we concluded that this
was not feasible due to their different search and output
formats that are not always compatible with PatentScope:
for instance, the British online database Ipsum of the UK
Intellectual Property ofﬁce only permits search by
application or publication number (i.e. not by keyword,
e.g. ‘naloxone’) [30], and the United States Patent and
Trademark Ofﬁce offers two separate search modes:
one for patent applications (Patent Application Full-Text
and Image Database, AppFT) and one for issued patents
(Patent Full-Text and Image Database; PatFT) [31],
whereas PatentScope does not provide such distinction.
The third limitation concerns the quality of the data
retrieved: we did not have access to raw data, and our
analysis was reliant upon summary data provided by the
patent applicants. Consequently, the comparability of
the PK results was limited by different analytical methods
and result formats used in the individual studies included
in the patent applications (e.g. bioavailability reported as
F vs. FIM; central tendency expressed as mean vs.
median). For instance, for no apparent reason, we were
unable to replicate the F-values that Euro-Celtique cited
in-text when we used the PK values listed in the data
appendix. Similarly, we remain uncertain about the
actual concentration of the AntiOp formulation
(10 mg mL!1 Naloxone HCl or 10 mg mL!1 Naloxone
HCl dihydrate), which could have affected calculation
Figure 3. AUC0-∞, Cmax and Tmax plotted by volume and dose. AUC, area under the curve; Cmax, maximum observed plasma concentration; Tmax;time
from dosing to peak concentration.
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of dose-adjusted values in Table 1. There was also
variability in the sampling periods (8–36 h), which may
have impacted AUC-dependent measures (e.g. F%,
FIM%). In terms of reliability of the mean values
reported inTable 1, it also needs to be borne inmind that
the cross-over studies (which comprised pilot and
registration trials) differed substantially in sample sizes
(7–35 subjects per treatment arm).
Meaning of the review: possible mechanisms and implications
for clinicians or policy-makers
These ﬁndings have multiple implications for clinicians
and policy-makers.
IN naloxone. Low spray volume and high
concentrations lead to better IN naloxone absorption.
Concentrated IN naloxone spray is thus a potentially
valuable non-injectable formulation for opioid overdose
reversal. This is likely relevant both in medical settings
and in the community (THN programs). This
conclusion accords with the ﬁrst FDA-approval of an
IN naloxone spray product [1], at 4 mg 0.1 mL!1
naloxone hydrochloride (i.e. 40 mg mL!1
concentration). However, further examination is
required of the full PK curve and the resulting clinical
effect because, for all doses of the 40 mg mL!1
formulations tested (4–16 mg), we found Cmax
(5.34–18.3 ng mL!1) was much higher than for IM
references (Cmax = 0.77–1.05 ng mL!1).
Consequently, while clinical efﬁcacy of concentrated
IN sprays is likely, there is the risk of inducing acute
opioid withdrawal in overdose victims [32]. A recent
qualitative analysis of heroin/opioid overdose reversals
found instances of apparent excessive naloxone dosing
and consequent ‘over-antagonism’, sometimes
triggering discharge and active further drug-seeking
[33]. Hepatic impairment also increases naloxone
bioavailability, particularly relevant when larger
fractions of buccal/sublingual or IN naloxone are
swallowed [25], potentially causing severe distress and
adverse events from naloxone over-antagonism in
dependent patients.
The poor IN bioavailability of non-concentrated
naloxone using the mucosal atomiser device also raises
important questions [15–17]. From a scientiﬁc
perspective, how can such low absorbed doses be
effective if they are indeed succeeding in reversing
overdose? Also, the continued use of improvised (i.e.
dilute) IN naloxone kits needs review.
Sublingual naloxone. In October 2015, INSYS
Therapeutics announced that its sublingual naloxone
spray (formulation unknown) had been granted fast-track
review by the FDA. Considering the low bioavailability
reported by the Euro-Celtique study, it seems unlikely
that sublingual naloxone will be clinically useful.
Unanswered questions and future research
Unanswered questions around non-injectable naloxone
remain. All PK data reported in the referenced patent
applications were from healthy volunteers. It remains
unclear how these ﬁndings relate to the heroin/opioid
users where non-response rates (i.e. response judged by
ambulance personnel to need supplementary injected
dose) around 18–26% have been reported for IN
naloxone [34,35].
Secondly, there are limitations in our current
understanding of the PKs and pharmacodynamics of
naloxone. While this review largely focuses on the
bioavailability of non-injectable naloxone relative to
parenteral injection, the absolute naloxone plasma
concentration range required to reverse opioid overdose
remains unknown. This needs sorting. Because
naloxone is a competitive antagonist, the therapeutic
dose will likely differ by route of administration
alongside inter-individual variability. Moreover, the
naloxone dose required to reverse the effects of a
speciﬁc opioid agonist will depend on the opioid
agonist dose and its pharmacological properties,
particularly its potency, duration of action and receptor
afﬁnity [36].
An ongoing Australian double-blinded randomised
clinical trial at the Sydney Medically Supervised
Injecting Centre (trial ID: ACTRN12611000852954)
compares IN (0.8 mg mL!1) versus IM (0.8 mg mL!1)
naloxone treatment and assesses the proportion of
suspected opioid overdose cases (by treatment group)
needing a second naloxone dose (both groups:
0.8 mg 2 mL!1 IM) for overdose reversal. The
results of this trial will likely shed light on the
question of therapeutic dose.
The 2014 WHO guidelines note that a 0.4–0.8 mg
parenteral naloxone dose is effective in most cases to
reverse opioid overdose. However, given that the
duration of naloxone is shorter than that of many opioids,
repeat doses of naloxone may need to be given [37]. The
WHO guidelines advise that initial naloxone doses above
0.8 mg increase the likelihood of signiﬁcant withdrawal
symptoms [8]. For any therapeutic drug, dose-related
adverse effects (i.e. opioid withdrawal symptoms in the
case of naloxone) often occur around Cmax [38],
suggesting that novel naloxone formulations with Cmax
above that of a 0.8 mg parenteral naloxone injection
may pose elevated risk of adverse effects. Future studies
should systematically monitor and assess reports of
naloxone-related adverse effects (from the medical or
Patent records for non-injectable naloxone 9















































































































community setting) in relation to the naloxone dose and
formulation used.
Thirdly, while the PK data from the patent
applications indicated a negative relationship between
volume and naloxone uptake, they did not allow us
to determine a cut-off for IN spray volume (volume
above which naloxone is lost to pre or post-nasal
drip). Deﬁnition of the maximum volume will affect
repeat administrations of IN naloxone spray. This
too needs resolution.
Finally, we present a new analytical method of
synthesis of public patent data from the WIPO
PatentScope database. The limitations discussed earlier
illustrate that this exploratory method will require
optimisation and would beneﬁt from enhanced
functionality of the PatentScope interface, so that review
of a greater volume of patent documents would become
manageable. A ‘Patent Crawler’ software has been
trialled as a search tool that combines analysis of
medication and patent databases [39]. Future open-
source editions of such software may potentially help
academics, clinicians and members of the general public
retrieve medication-related information across patent
databases and the peer-reviewed medical literature. If
such open-source software becomes available, we hope
that our search protocol provided in Table S1 of the
Online Appendix will allow researchers to replicate our
exploratory analysis with added capture capability. When
replicating our search in the future, researchers might
also ﬁnd it helpful to work together with patent experts
who will be familiar with the functionality of patent
databases and the legal language of (the often broad)
patent claims.
In the future, such syntheses would also be more
valuable if data were presented uniformly: this would
require investigators of non-injectable naloxone
formulations (including pharmaceutical companies) to
publish their data even if ﬁndings are negative (see e.g.
AllTrials.net) [40].
Conclusions
Over the past 15 years, IN naloxone sprays have been
tested in humans, but no product was licensed and
commercially available until late 2015 [1]. With an
ongoing epidemic of prescription-opioid overdose
deaths alongside a more recent rapid rise in heroin
deaths, an IN naloxone spray is ﬁnally available to
prevent overdose deaths in opioid users—a target
population vastly underserved for decades. This ﬁrst
licensed non-injectable naloxone marks a signiﬁcant
milestone towards wider naloxone access and more
effective prevention of opioid overdose deaths. High-
concentrate IN naloxone has good bioavailability
although, thus far, formal product testing has only
involved healthy volunteers. It remains possible that
high-concentrate formulations may provoke naloxone
over-antagonism in opioid-dependent patients. Options
for dose-titration and alternative routes (e.g. buccal)
also need exploration. We call for proper publication
of PK data on naloxone products: only then can there
be properly informed consideration of different
naloxone products by the clinical, policy and scientiﬁc
communities.
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ABSTRACT (293 words) 
 
Background and Aims: Lack of non-injectable naloxone formulations has impeded 
widespread take-home provision for the prevention of heroin/opioid overdose deaths. For 
non-injectable formulations that are finally being investigated, rapid onset of action and 
sufficient bioavailability will be vital. We present analysis of data from a study of 
concentrated naloxone nasal spray formulations. Our aims are: to assess 1) 
pharmacokinetic properties and 2) suitability for overdose reversal in terms of naloxone 
absorption within 30 minutes post-dosing.  
 
Design and interventions/comparator: Open-label, randomized, 4-way crossover Latin-
square pharmacokinetic study of naloxone administration by three routes: intranasal at two 
doses (8mg/0.4mL, 16mg/0.4mL) versus sublingual (16mg/mL) versus intravenous reference 
(1mg/mL). 
 
Setting: Clinical Pharmacology Unit at The Ohio State University (Columbus, Ohio, USA). 
 
Participants: 12 healthy volunteers (age 20-41; 7 female). 
 
Measurements: From blood plasma naloxone concentrations, 1) standard pharmacokinetic 
parameters, including maximum plasma concentration (Cmax) and mean absolute 
bioavailability (F%, relative to intravenous injection), were determined; as well as 2) partial 
area under the curve (AUC) values, tmax (time to maximum plasma concentration), and 
T50% (time to 50% of maximum plasma concentration) as measures of early absorption. 
 
Findings: 1) Bioavailability was F%=25-28% for intranasal naloxone. Sublingual had low 
bioavailability (F%=2%) and was not considered further. Mean Cmax values for 8mg 
(12.83ng/mL) and 16mg (18.25ng/mL) intranasal exceeded 1mg intravenous (9.64ng/mL) 
naloxone. 2) Following intranasal administration, T50% was reached within 8 minutes and 
tmax within 20 minutes. Mean naloxone absorption from dosing to 30 minutes (AUC30) was 
greater following 8mg (4.17h*ng/mL) and 16mg (5.91h*ng/mL) intranasal than following 1mg 
intravenous (1.70h*ng/mL) administration.  
 
Conclusions:  
Concentrated naloxone nasal spray has a promising pharmacokinetic profile, with substantial 
bioavailability. Its early absorption time-course suggests that concentrated nasal naloxone is 
 This article is protected by copyright. All rights reserved. 
suitable for emergency administration in the community, where rapid restoration of 
respiratory function is essential for opioid overdose reversal. 
 
1. Introduction: 
Opioid overdose constitutes a major international public health problem (1). Overdose 
deaths from heroin and other opioids can be prevented through timely administration of the 
antagonist naloxone.  
 
Naloxone was, until recently, only licensed as injection. Regulatory criteria for non-injectable 
naloxone have been proposed (2) and, in 2015/16, a first naloxone nasal spray (4mg/0.1mL) 
was approved in the US (3) and Canada (4), with 44-47% mean bioavailability relative to 
intramuscular injection (5).  
 
Some opioid overdoses have insidious onset, while others occur rapidly. Darke and Duflou 
(6) recently analysed the time course of opiate metabolites post-mortem and concluded that 
heroin overdose death occurred within 20-30 minutes of injecting in 43% of cases, 
suggesting the time window for naloxone administration may be very narrow (7). Hence, 
analysis of naloxone pharmacokinetics in the first 20-30 minutes is particularly important.  
 
In this new analysis of previously unpublished data from a 2004 pharmacokinetic study of 
naloxone nasal spray (which investigated abuse liability of an oral oxycodone/naloxone 
formulation), we consider the potential of the studied high-concentration intranasal (IN) 
naloxone formulations from the different perspective of overdose reversal, with two aims: to 
assess 1) their pharmacokinetic properties and 2) naloxone absorption in the clinically-




2.1. Study design:  
We report data from a pharmacokinetic study with healthy volunteers conducted in 2004 by 
Purdue Pharma LP (US). Ethics approval was granted by the Western Institutional Review 
Board (Olympia, WA, US). Its key features (eligibility criteria, etc.) are summarised in the 
web-appendix. Participants received naloxone in four dose/route combinations (one per 
session) in a 4-way crossover Latin square design. The four naloxone sessions compared 
1mg/mL intravenous (IV) reference with 16mg/mL sublingual (SL) administration and two IN 
doses: 8mg/0.4mL from 20mg/mL and 16mg/0.4mL from 40mg/mL solution.  
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Naloxone hydrochloride 10mg/10mL vials for 1mg/mL IV bolus injection were obtained from 
Bristol-Meyers Squibb (USA). The SL dose (16mg/mL; prepared from naloxone-
hydrochloride powder (Mallinckrodt Pharmaceuticals, USA) in 0.9% sodium-chloride 
solution) was administered by having subjects retain the solution under the tongue for 5 
minutes. IN solution was prepared by dissolving naloxone-hydrochloride powder (see above; 
11.0g for 20mg/mL; 22.0g for 40mg/mL solution) in sodium-citrate stock solution (9.35g for 
20mg/mL; 20.9g for 40mg/mL) and brought up to 500mL volume using 0.9% sodium-chloride 
solution. IN solution was atomized using metered dose nasal spray devices (comprising a 
pump spray assembly threaded onto small amber glass bottle), with two 0.1mL aerosol 
actuations delivered per nostril, for a 0.2mL total volume per nostril. Subjects were required 
to remain upright (seated or standing) with the head tilted slightly forward from dosing until 4 
hours post-dosing. Pharmacokinetic blood samples were drawn into tubes containing the 
anticoagulant K2EDTA. Blood was collected pre-dosing and at minutes 1, 2, 4, 10, 30, 40; 
and hours 1, 2, 4, 6, 8, 12, 16, 24.  
Bioanalysis was conducted by Purdue Pharma L.P. (Ardsley, NY, USA). Naloxone plasma 
concentration was determined by a validated liquid extraction method using liquid 
chromatography–mass spectrometry (LC-MS/MS). The range of quantification was 0.01-




2.2. Outcome measures for this new analysis 
Our interest was the potential of IN naloxone for opioid overdose reversal, and consequently 
we focused on the pharmacokinetics within the first half-hour, examining plasma naloxone 
sample concentrations from dosing to 30 minutes.  
Partial area-under-the-curve (AUC) values were determined for these sampling points using 
Phoenix WinNonlin 6.4. AUC values are expressed as h*ng/mL, i.e. hour(s) times 
nanograms per millilitre, representing naloxone exposure over time.     
We also introduced the exploratory parameter T50%, defined as time from dosing to 
concentration equal to 50% of maximum plasma concentration (Cmax) (8). 
 
2.3. Statistical analysis: 
Inferential statistics were calculated using SPSS Statistics 23. Analysis of variance (ANOVA) 
was conducted to determine differences in naloxone absorption by treatment arm. Following 
WHO guidance (9), dose-dependent AUC data were log-transformed to allow for normal 
 This article is protected by copyright. All rights reserved. 
distribution in the ANOVA. Tukey's HSD test was used for post-hoc comparisons, with 
significance level at p<.05. 
3. Results: 
3.1. Study participants and sensitivity analysis 
Twelve eligible healthy subjects were entered into the study, which is within the FDA 
recommendation of 6-36 subjects (10); 5 were males (age 20-41 years, height 165-193cm, 
weight 74-106kg) and 7 females (19-48 years, 157-168cm, 51-83kg). Subject 12 did not 
attend the final 8mg IN session, and Subject 7 failed to attend the 16mg SL and 1mg IV 
sessions. These three sessions were handled as missing data. The plasma naloxone 
concentration from Subject 3 was clearly anomalous at 20 minutes following IV 
administration, being 5-9 times greater than adjacent time points (10, 30 minutes) with an 
AUCt-value (26.85h*ng/mL) four times greater than the group median (6.64h*ng/mL). We 
have excluded all IV data for this individual. Consequently, values reported below refer to 
sample sizes of n=10 (1mg IV), n=11 (8mg IN, 16mg SL), and n=12 (16mg IN), unless 
otherwise specified.  
 
3.2. Pharmacokinetics: 
Plasma naloxone concentrations over the first 6 hours are displayed in Figure 1 (left-hand 
graph) and with expanded depiction of the first 30 minutes (right-hand graph). IV 
administration (1mg) was characterized by rapid uptake and subsequent decline; whereas 
SL administration (16mg) showed minimal absorption. Both IN administrations (8mg, 16mg) 
had similar time profiles, reaching peak concentrations in less than 30 minutes post-dosing. 
(The 12 subjects’ individual plasma-concentration curves are provided as web-appendix).  
 
 
Pharmacokinetic parameters are shown in Table 1. The two IN administrations (8mg, 16mg) 
displayed similar uptake, with rapid median tmax of 20 minutes (0.33 h) for both doses. 
T50% was 7-8 minutes for both IN doses (8mg IN: x =0.12h; 16mg IN: x =0.13h), and hence 
slower than from IV administration (4 minutes; x =.06h,). Cmax values following 8mg IN 
(x =12.83ng/mL) and 16mg IN (x =18.25ng/mL) were greater than those following 1mg IV 




Dose-adjusted AUC data (per mg) from IN and SL administrations were compared against 
the 1mg IV reference. Since comparisons were not possible for missing and excluded 
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sessions (see Section 3.1), absolute bioavailability was determined for sample sizes of n=9 
(8mg IN) and n=10 (16mg IN, SL).  
The mean absolute bioavailability (F%) from dosing to last measureable concentration 
(AUCt) was 2.0% for SL naloxone; hence it was not considered further. IN administration 
had F% of 27.7% (8mg) and 24.6% (16mg; see Table 2).  
Mean bioavailability values for partial AUC at 1, 2, 4, 10, 20, and 30 minutes post-dosing are 
reported in Table 2, with similar increase over time for both IN doses (8mg, 16mg): >5% at 4 
minutes, ≥13% at 10 minutes, ≥20% at 20 minutes. 
 
 
3.4. AUC30 and nasal dose equivalent to 1mg IV bolus 
Observed AUC30 values following 8mg IN (x =4.17h*ng/mL) and 16mg IN (x =5.91h*ng/mL) 
were greater than following 1mg IV (x =1.70h*ng/mL; see Table 1).  
These AUC30 values were dose-adjusted, log-transformed and compared in a one-way, 
between-subjects ANOVA. AUC30 values differed significantly as a function of naloxone 
treatment [F(3,40)=255.11, p<0.001].  Post-hoc tests showed that dose-adjusted, log-
transformed AUC30 was significantly higher with IV (x =3.21, SD=0.15) versus both IN 
concentrations (8mg IN: x =2.68, SD=0.19; 16mg IN: x =2.53, SD=0.18). However, there was 
no significant difference between both IN concentrations (p=0.230), suggesting naloxone 
absorption was proportional to IN dose administered.  
Hence, with dose-adjusted AUC30 values for 8mg (x =0.52 h*ng/mL per mg) and 16mg IN 
(x =0.37 h*ng/mL per mg) and 1mg IV (x =1.70 h*ng/mL) (from above observed values), we 
calculate, for AUC30, the IN-dose equivalent to 1mg IV would be 3.3mg IN (20mg/mL 
formulation) and 4.6mg IN (40mg/mL).  
 
3.5. Safety 
No serious adverse events occurred. Side effects reported after naloxone administration 
included fainting (3 cases; one each after 8mg IN, 16mg IN, 1mg IV), headache (2 cases) 
and gastrointestinal symptoms (5 cases). These 10 cases were distributed by treatment as 
follows: 8mg IN (3 cases); 16mg IN (5 cases); 16mg IN (0 cases); 1mg IV (2 cases).  
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4. Discussion: 
Recent WHO guidelines (11) recommend that, similar to adrenaline/epinephrine for the 
treatment of allergic shock (12), naloxone should be offered to anyone in the community 
likely to suffer or witness an opioid overdose (‘take-home naloxone’, THN). However, the 
lack of licensed non-injectable naloxone formulations until late 2015 (which continues 
outside North America) has hindered widespread THN (13-17). Once non-injectable 
solutions exist, naloxone may be provided more widely. 
 
Our analysis identifies a promising pharmacokinetic profile for concentrated naloxone nasal 
spray. In 2008, Dowling et al. (18) reported only 4% absolute bioavailability with a nasal 
spray adaptation of a commercially-available concentration of naloxone (2mg/5mL), although 
the authors suggested the extremely low bioavailability may be a result of excessive volume 
at the nasal membrane. In sharp contrast, we now report that, at much higher concentrations 
(8mg/0.4mL, 16mg/0.4mL), there is a mean absolute bioavailability between 25-28%. Even 
though originally studied for different reasons, we conclude that concentrated solutions of 
naloxone administered as nasal spray have bioavailability adequate for overdose reversal.   
We also report that, crucially, half of the maximum observed concentration (T50%) was 
reached within 8 minutes and maximum concentration (tmax) within 20 minutes of IN 
administration. This time profile suggests that concentrated naloxone nasal spray may be 
suitable for the reversal of overdoses from heroin and other short-acting opioids (e.g. 
fentanyl), where rapid restoration of respiratory function within 30 minutes of opioid use may 
be essential (6).  
 
These results are broadly consistent with the recent paper by Krieter et al. (19) who reported 
a Cmax of 10.3ng/mL for a 8mg/0.2mL IN dose as well as tmax values of 18-30 minutes and 
bioavailability of 44-54% (relative to intramuscular reference) for 0.1-0.2mL of 20mg/mL and 
40mg/mL IN formulations. However, absence of an intramuscular reference in this study 
means that a direct bioavailability comparison between the studies is not possible. 
 
We did not find a significant difference between the two nasal formulations in their dose-
adjusted naloxone absorption (AUC30). This allowed us to estimate an IN dose-equivalent 
that would deliver the same naloxone exposure within 30 minutes as the reference (1mg/mL 
IV bolus injection). We calculate that a nasal dose of 3.3mg (at 20mg/mL) and 4.6mg 
(40mg/mL) will provide, over the clinically-critical initial 30-minute period, the same AUC over 
30 minutes as 1mg/mL IV.  
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Algorithms exist for injectable naloxone to guide correct initial and repeat dosing (20) but 
have yet to be developed for IN naloxone. The T50% data suggest that initial IN absorption 
is delayed compared to the IV bolus, with IN administration taking 7-8 minutes to attain half 
of the peak concentration (versus 4 minutes for IV), and IN absolute bioavailability only 
surpassing 10% between 4-10 minutes (see Table 2). If this finding is robust, then lay 
responders may need to be advised to wait some minutes before administering a second IN 
dose to avoid risk of precipitating over-antagonism. 
 
Several limitations need to be borne in mind. Some averages were based on low subject 
numbers (see Table 1). There was also variability in the tmax values for IV administration 
(median: 4 minutes), due to two outliers at 4 hours. It is unclear if the low SL bioavailability 
resulted from subjects possibly swallowing the solution. For the nasal route, only a 0.2mL-
volume per nostril was tested in this study, meaning that a volume-absorption relationship 
cannot be determined. Finally, while it is generally assumed that atomization at a droplet 
size greater than 10µm increases nasal absorption (21), the droplet size distribution was not 
characterized in this study, and its potential impact on nasal deposition cannot be 
determined. 
 
We should also give consideration to how quickly the nasal spray versus injectable naloxone 
can be administered, which then needs to be considered alongside pharmacokinetics-
derived speed of onset. For example, in a Vancouver ambulance study, differences in time-
to-recovery comparing IV versus subcutaneous naloxone, disappeared when the greater 
time to establish IV access was accounted for (22). 
 
This data analysis focuses on the clinically relevant first 30 minutes, and it also introduces 
the measure of T50%. Also, while our findings support good bioavailability in healthy 
subjects, concentrated naloxone nasal spray has yet to be formally tested in the target 
population of opioid users. 
 
The emergence of supportive pharmacokinetic data for concentrated IN naloxone, along with 
approval of a first nasal naloxone spray in North America (3)(4), constitutes a significant 
advancement for the field, after concerns over off-label use of injectable naloxone-
hydrochloride solution as nasal spray sparked a lively debate in early 2016 (8).  
 
The time-lag between the original study conducted thirteen years ago (with its results 
subsequently archived) and this new analysis warrants concern. This new analysis identifies 
the potential of concentrated naloxone nasal spray for overdose reversal (hence authorship 
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of this research report is across academia and industry). There has recently been 
considerable public investment to conduct healthy volunteer studies of nasal naloxone (19): 
the field could have progressed faster if there had been awareness of the above data. In 





Concentrated naloxone nasal spray appears to be a feasible formulation with adequate 
speed of onset and acceptable bioavailability in the concentrated form. This appears directly 
relevant to prevention of opioid overdoses in medical settings and in the community (THN). 
The above data find concentrated nasal spray solutions (at 20mg/mL and 40mg/mL) to have 
acceptable bioavailability and plasma levels over the clinically-critical first 30 minutes, with 
moderate uptake from 4-10 minutes onwards. Further examination is required (and is in 
progress) and dose-titration protocols and repeat-dosing guidance will need development, 
especially for wider distribution to non-medical persons (family members, peers, drug users 
themselves). We conclude that concentrated naloxone nasal sprays hold real promise, may 
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Table 1: Pharmacokinetic parameters (mean, SD) 
 
Parameter n Unit 1mg IV 8mg IN  16mg IN 16mg SL 
AUC20 10-12 h*ng/mL 1.24 (0.62) 2.50 (1.35) 3.58 (2.25) 0.11 (0.09) 
AUC30 10-12 h*ng/mL 1.70 (0.62) 4.17 (1.68) 5.91 (0.30) 0.22 (0.11) 
AUCt 10-12 h*ng/mL 8.83 (4.90) 20.07 (4.93) 32.81 (10.22) 2.67 (1.78) 
Cmax 10-12 ng/mL 9.64 (12.66) 12.83 (4.47) 18.25 (7.50) 0.90 (0.37) 
T50% 10-12 h 0.06 (0.05) 0.12 (0.06) 0.13 (0.07) 0.24 (0.10) 
Tmax^ 10-12 h 0.07        
(0.03, 4.00) 
0.33        
(0.07, 0.50) 
0.33       
(0.07, 0.67) 
0.67       
(0.50, 36.00) 
Annotations: AUC20 = partial area under the curve (AUC) from dosing to 20 minutes; AUC30 = partial 
AUC from dosing to 30 minutes; AUCt = AUC from dosing to last measurable time point; Cmax = 
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Table 2: Absolute bioavailability (F%) based on partial AUCs (1-30 min. post-dosing) & AUCt 
 AUC1 AUC2 AUC4 AUC10 AUC20 AUC30 AUCt 
8 mg IN 3.4% 2.4% 6.2% 17.5% 27.6% 33.1% 27.7%  
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Figure 1 | Mean naloxone plasma profiles within 6 hours (left) and expanded depiction of first 30 
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Appendix C. Buccal Naloxone Tablet Patent  
 







































